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Abstract
Species differences exist in the induction response o f CYP3A genes to xenobiotics, 
and these are proposed to be due, in part, to host cell differences. These host cell 
effects were investigated functionally by trans-species transfections o f alkaline 
phosphatase reporter genes containing -1 .5  kb o f the CYP3A23 or CYP3A4 5’ 
flanking regions into human HepG2 and rat FaO and H4IIEC3 hepatoma cells.
HepG2 and FaO cells were demonstrated to support induction o f  the activity o f  both 
CYP3 A constructs by 50 \xM dexamethasone but H4IIEC3 cells could not. The 
receptor mRNA complement (CAR, G Ra, HNF4a, PXR and R X R a) o f the rat and 
human cell lines were characterised in comparison to rat and human liver using 
semi-quantitative RT-PCRto identify any differences. Principal component analysis 
(PCA) o f the receptor mRNA levels was scattered indicating that rat liver does not 
resemble human liver and that hepatoma cell lines do not resemble their liver 
counterparts in terms o f individual receptor mRNA levels.
Increasing knowledge o f nuclear receptor interactions with response elements led to 
consideration that response to xenobiotics may be due to relative receptor abundance 
in the cells, as opposed to individual receptor expression levels. PCA on comparison 
ratios showed clustering of human and HepG2 receptor ratios, supporting the 
observation that CYP3 A reporter gene induction responses in HepG2 cells mimic 
those in vivo. From this data we hypothesise that relative receptor expression levels 
are key to determining CYP3A responsiveness to xenobiotics. However this 
hypothesis could not be further examined at the protein level, as Western blotting 
experiments were equivocal.
The latter hypothesis was further examined through the use o f TaqMan, expanding the 
receptor cohort to include COUPTFI and RXRs (3 and y, plus CYP3 A mRNA 
expression levels. In addition the effects o f xenobiotics, dexamethasone, rifampicin, . 
PCN and phénobarbital at a range o f concentrations, were tested. The hepatoma cell 
lines did not have the same endogenous CYP3 A mRNA expression or induction 
profiles as liver.
The TaqMan results suggested that in human CYP3A regulation, the relative 
abundance o f PXR heterodimerisation partners or accessory factors were more 
important than the level o f PXR, whereas in rats, PXR was dominant in determining 
induction o f CYP3A, indicating a further species difference. In conclusion, host cell 
effects on CYP3A regulation are dependent on receptor abundance and interactions, as 
well as differential receptor activation.
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1 Introduction 
l.lT h e Function of Drug Metabolism
Drug metabolism is described as the overall disposition o f a drug and includes 
biotransformation o f the drug into metabolites and their excretion (Gibson and Skett, 
2001). Biotransformation consists o f two phases; Phase I functionalisation reactions, 
uncover or add functional groups, onto which Phase II conjugation occurs. This 
increases the polarity o f  the metabolites, facilitating their excretion and hence 
inactivation (Gibson and Skett, 2001). However it should be noted that metabolism o f  
xenobiotics can bioactivate inert compounds producing reactive intermediates. These 
can cause toxic effects, such as mutations, cell damage, carcinogenesis and cell death 
if  not further detoxified (Gibson and Skett, 2001).
The microsomal mixed function oxidase system (MFO) dominates the catalysis o f 
many phase I reactions (Gibson and Skett, 2001). In these reactions, one atom of 
oxygen is incorporated into the substrate, increasing the overall chemical reactivity 
and allowing further phase II metabolism to occur. Phase two enzymes include 
glutathione-S-transferase and UDP-glucuronyltransferase (Gibson and Skett, 2001). 
There are also phase III reactions that involve the further processing o f phase II 
metabolites (Gibson and Skett, 2001). Together these enzymes form a drug 
metabolising system capable o f catalysing virtually every chemical reaction that a 
compound can undergo. The reaction type depends on the substrate, the enzymes 
available within the tissue and the availability o f cofactors (Gibson and Skett, 2001).
1.2 The Cytochrome P450 Superfamilv
1.2.1 The structure and location of cytochrome P450
Cytochrome P450 is a superfamily o f heme-thiolate proteins present in prokaryotes 
and eukaryotes (Nelson et al., 1996). The proteins were named cytochrome P450 
because they exhibited a spectral absorbance o f 450 nm when complexed with carbon 
monoxide in a reduced form, unlike most haemoproteins that absorb at 420 nm. The 
unusual spectral properties were attributed to a thiolate cysteinyl sulphur atom bound 
to the haem iron in the fifth co-ordination site.
W ith the exception o f some bacterial P450s, the P450 enzymes are intrinsically 
membrane bound and the majority are situated within the endoplasmic reticulum 
(Nelson et a l, 1996). They are present in all mammalian tissues with the highest 
concentration in liver endoplasmic reticulum, where they act as mono-oxygenases as 
part o f  the microsomal mixed function oxidase system (MFO) (Gibson and Skett, 
2001).
1.2.2 The role of cytochrom e P450 in the  mixed function oxidase system 
The complete MFO system consists o f  cytochrome P450, NADPH-cytochrome P450 
reductase and lipid. During the MFO reaction, reducing equivalents derived from 
NADPH + H*’, by NADPH-cytochrome P450 reductase, are consumed and one atom 
o f oxygen is incorporated into the substrate while the other oxygen is reduced to 
water. The equation to represent this reaction is as follows,
NADPH + H^ + O2  + R H ------------► NADP^ + H 2 O + ROH (1)
where RH represents the substrate and ROH is the oxidised product. P450 is both the 
substrate and oxygen-binding locus in the MFO reaction. The key feature o f the 
catalytic cycle is the oxidation / reduction reaction o f the P450 haem iron. The 
catalytic cycle begins with the drug binding to the oxidised form o f P450. This is 
followed by haem reduction using an electron derived from NADPH + H^ and 
transferred by flavoprotein NADPH-cytochrome P450 reductase in the following 
manner.
NADPH + H^ ------► (FAD — ► FM N ) ► P450 (2)
Oxygen binding, electron rearrangement, oxygen insertion and product release follow 
this (Gibson and Skett, 2001).
P450 enzymes also have a role in the biosynthesis and degradation o f endogenous 
compounds such as steroids, fatty acids, prostaglandins, leucotrienes and vitamins 
(Nebert and Gonzalez, 1987).
1.2.3 T he nom enclature of the cytochrom e P450 superfam ilv 
The P450 superfamily is divided into clans, families and subfamilies depending on 
sequence similarity and substrate specificity (Nelson et al., 1996; Nelson, 1999). At 
present 17 mammalian P450 gene families encode about 60 distinct P450 forms in any 
given species. The sequencing o f the human genome indicates that there are 
potentially 56 human P450s, not including non-expressed pseudogenes 
(http://drnelson.utmem.edu/CytochromeP450.html). Members o f one gene family are 
usually defined as having greater than 40 % amino acid sequence identity. Subfamily 
members are often found clustered on a chromosome. GYP clusters are found 
scattered throughout the human genome. In mammals there is greater than 55 % 
amino acid sequence similarity between subfamily members. Table 1.1 provides a 
general overview o f the P450 families and subfamilies and their enzyme functions in 
various species.
Table 1.1 Exam ples of the functions of P450 families
P450 Fam ily Function
CY Pl Dioxin (TCDD) inducible, metabolism o f polycyclic aromatic 
hydrocarbons, halogenated and heterocyclic hydrocarbons and 
aromatic amines
CYP2 Metabolism o f drugs and environmental chemicals
CYP3 Metabolism o f drugs and environmental chemicals
CYP4 Fatty acid hydroxylases
CYP5 Thromboxane synthase
CYP6 Metabolism o f insecticides (e.g. pyrethroid) and toxic natural plant 
products
CYP7A Cholesterol 7a-hydroxylase
CYP7B Unknown functions
CYP8 Prostacyclin synthase
C Y P ll Cholesterol side-chain cleavage, steroid Ilp-hydroxylase, 
aldosterone synthase
CYP17 Steroid 17a-hydroxylase
CYP19 Aromatization o f androgens
CYP21 Steroid 21-hydroxylase
CYP24 Steroid 24-hydroxylase
CYP27 Steroid 27-hydroxylase
CYP51 Steroid biosynthesis
CYP52 Alkane hydroxylases
CYP73 Cinnamic acid hydroxylase
(Adapted from Kasai et al., 1996; Nelson et al., 1993 and Nelson et al., 1996)
1.2.4 Cytochrome P450 Regulation
Som eP450s are highly inducible; for example C Y PlA l is elevated one hundred fold 
or more in liver and extrahepatic tissues following exposure to
2,3,7,8-tetrachlorodibenzo-/?-benzodioxin (TCDD) (Waxman and Azaroff, 1992). 
CYP4A is induced by peroxisome proliferators, such as clofibrate, in rat liver and 
kidney (Aldridge et al., 1995; Miyamoto et al., 1997). CYP2A, 2B and 2C are induced 
by phénobarbital in rat liver and rat hepatoma cells (Agrawal and Shapiro, 1996;
Shaw et al., 1993). Phénobarbital also induces the CYP3 A subfamily, as does 
dexamethasone and other structurally unrelated chemicals (Waxman and Azaroff, 
1992). The mechanism o f  this induction is unclear and will be fiarther discussed in 
section 1.3.6.2. The aforementioned P450s are pretranscriptionally induced via 
nuclear receptor interaction with specific nucleotide sequences within the genes. 
However, there are other mechanisms for P450 induction including mRNA and 
protein stabilisation (Eliasson et al., 1994). Table 1.2 details some P450 inducers and 
their mechanisms o f action.
P450 enzymes can also be inhibited or suppressed by a wide variety o f  different 
structural substrates. For example, troleandomycin (TAO), mentioned in Table 1.2 as 
an inducer due to its protein stabilisation properties, is metabolised by CYP3 A to a 
nitroso-derivative which in turn binds to the haem-iron core o f P450 and inactivates 
CYP3A (Iribarne et a l, 1997; Pessayre et a l, 1980). The broad substrate specificity o f  
P450s allows many drugs to act as competitive inhibitors, such as the calcium channel 
blocker nifedipine and the antifungal ketoconazole which inhibit CYP3 A4 in human 
liver microsomes, which creates the potential for clinically significant drug-drug 
interactions (Guengerich, 1991; Iribarne et a l, 1997). Endogenous molecules, such as 
interferons, and some xenobiotics are capable o f down regulating P450 expression 
(Delaporte et a l, 1993; Martini et a l , 1997). For example, human interleukin 6 down 
regulates C Y P lA l and 1A2 at a transcriptional level (Fukada et a l , 1992).
Thus total P450 activity is influenced by both endogenous and exogenous chemicals 
in several different ways, including induction, inhibition and repression. Some 
substrates have the ability to both induce and /or inhibit the enzymes, for example, 
TAO (Pessayre et a l, 1980).
The net effect o f this ability o f many compounds, both endogenous and xenobiotics, 
to influence P450 activity raises the potential for clinically significant drug-drug (e.g. 
midazolam metabolism is inhibited by coadministration o f Ca^^ channel antagonists 
causing increased sedation) or drug-environment (e.g. grapefruit juice increases the 
systematic bioavailability o f terfenadine due to inhibition o f intestinal CYP3A4) 
interactions to exist (Benton et al., 1996; Kane and Lipsky, 2000; Thummel and 
Wilkinson, 1998). It is hence important to dissect the molecular mechanisms 
underlying these induction effects, so as to enhance risk assessment and allow the 
dose schedules for new compounds to be accurately made.
T able 1.2 P450 induction m echanisms
P450 Exam ple of Inducer P rim ary  induction mechanism
lA l 3-methylcholanthrene Transcriptional activation via AhR
1A2 3-methylcholanthrene mRNA stabilisation
2B1,2B2 Phénobarbital Transcriptional activation
2E1 Ethanol Protein stabilisation
3A1 Dexamethasone Transcriptional activation (not via 
classical glucocorticoid receptor 
pathway)
3A1 Troleandomycin Protein stabilisation
4A1 Clofibrate Transcriptional activation via PPAR
(Adapted from Waxman and Azaroff, 1992)
1.2.5 The m aio r d rug  m etabolising P450s
In each mammalian species, there are four major families o f P450 enzymes, with a 
total o f approximately 2 0  members that are able to metabolise a wide array o f 
xenobiotics (Lewis et al., 1998). These are CY Pl, 2, 3 and 4 and exhibit broad but 
overlapping substrate and product specificities that may vary between corresponding 
forms from different species (Guengerich, 1997; Nelson et al., 1996). Among them, 
the CYP3A enzymes are the most abundant P450s in humans and are involved in the 
metabolism o f two thirds o f xenobiotics (Lewis et al., 1998).
1.3 Cytochrome P450 3A Subfamily
1.3.1 In troduction  to the CYP3A Subfamily
CYP3A gene products are among the most abundant o f monoxygenases in 
mammalian liver and intestine, and thus play a major role in drug metabolism. In 
humans, CYP3A4 is involved in the metabolism o f  many xenobiotics, including 
approximately 60 % of drugs in clinical usage that undergo oxidation, as well as 
endogenous substances such as steroids (Maurel, 1996). At present 50 different 
CYP3A genes have been characterised at the level o f the gene, cDNA or protein, 
across all species studied (Nelson et al., 1996). These are listed in Table 1.3, along 
with their trivial names, used prior to the introduction o f a standard nomenclature for 
P450S.
Table 1.3 A list of the known CYP3A family forms
CYP3A form Trivial names Species
CYP3A1 pcnl, PCNa, 6(3-4, pIGC2 , p450p Rat
CYP3A2 pcn2, PCNb/c, PB -1 , 6(3-1/3 Rat
CYP3A4 HLp, nf-25, nf-10, hPCN l, P450NF Human
CYP3A5 HLp3, hPCN3 Human
CYP3A5P1 Human
CYP3A5P2 Human
CYP3A6 LM3c, 3 c Rabbit
CYP3A7 HLp2, HFLa, HFL33, hPCN5, Human
CYP3A8 MKnf2 Monkey
CYP3A9 olf3 Rat
CYP3A10 Hamster
C yp3all IIIAm lm Mouse
CYP3A12 PBD-1 Dog
Cyp3al3 IIIAm2 Mouse
CYP3A14 Guinea pig
CYP3A15 Guinea pig
Cyp3al6 Mouse
CYP3A17 Guinea pig
CYP3A18 Rat
CYP3A19 D warf goat
CYP3A20 Guinea pig
CYP3A21 Marmoset
CYP3A22 Miniature pig
CYP3A23 cDEX, RL33, 6(34 Rat
CYP3A form Trivial nam es Species
CYP3A24 Sheep
Cyp3a25 Mouse
CYP3A26 Dog
CYP3A27 Rainbow trout
CYP3A28 Bovine
CYP3A29 v l-4  Pig, v5 Mini pig
CYP3A30 Teleost {Fundus heteroclitus)
CYP3A31 Syrian hamster
CYP3A32 Minke whale
CYP3A33 Dali’s porpoise
CYP3A34 Steller sealion
CYP3A35 Spotted seal
CYP3A36 Ribbon seal
CYP3A37 Chicken
CYP3A38 Medaka fish
CYP3A39 vl-4  Pig
CYP3A40 Medaka fish
Cyp3a41 Mouse
CYP3A42 Ball/Royal python
CYP3A43 Human
Cyp3a44 Mouse
CYP3A45 Rainbow trout
CYP3A46 vl-2  Pig
CYP3A47 Pufferfish
CYP3A48 Pufferfish
CYP3A49 Pufferfish
CYP3A50P Pufferfish
(Adapted from Nelson et a l, 1993, 1996 and http://drneIson.utmem.edu/CytochromeP450.html)
1.3.2 R a t CYP3A forms
As can be seen from Table 1.3, the rat CYP3A subfamily is currently known to 
contain five genes, CYP3A1, 3A2, 3A9, 3A18 and 3A23 (Nelson et al., 1996). These 
enzymes are closely related at the cDNA level, sharing up to 98 % identity (Table 
1.4).
Table 1.4 cDNA sequence identity  of ra t CYP3A form s
CYP3A1 CYP3A2 CYP3A9 CYP3A18
CYP3A1
CYP3A2 90%
CYP3A9 71.3 % 70.2 %
CYP3A18 69 % 6 6 % 70.2%
CYP3A23 98.4% 86.3 % 71.3% n.d.
Percentage similarity o f cDNA sequences o f known rat CYP3A forms, n.d. = not 
determined. (Gonzalez et al., 1986; Gushchin et al., 1999; Ribeiro and Lechner, 1992; 
Wang et al., 1996)
Rat CYP3 A enzymes are located in a number o f organs within the body and in 
leucocytes, but most notably in the centrilobular region o f the liver (Debri et al., 1995; 
Mahnke et al., 1996; Wang et al., 1996; Wright et al., 1997). The developmental 
expression o f rat CYP3A mRNA forms is shown in figure 1.1.
1.3.2.1 CYP3A1
Ribeiro and Lechner (1992) demonstrated that CYP3A1 mRNA was present in both 
male and female rat liver from birth. This is in contradiction to the earlier work o f 
Gonzalez et al. (1985) who detected CYP3A1 only after treatment with inducers, 
reflecting improved sensitivity in measuring CYP3A1 mRNA, underscoring the low 
level o f expression o f this gene (Figure 1 . 1 ). CYP3A1 protein was also detected at 
low levels in small intestine, kidney and clara cells o f the lung (Debri et al., 1995).
In common with all CYP3A enzymes, CYP3A1 has a wide substrate profile, but can 
be extremely stereo-specific and regio-specific for certain substrates, such as 
testosterone (Namkung et al., 1988).
Hence, CYP3A1 activity is commonly characterised by the stereospecific 2(3, 6(3,15(3 
and 16p-hydroxylation o f testosterone (Namkung et al., 1988).
1.3.2.2 CYP3A2
CYP3A2 mRNA is constitutively expressed in both male and female rats from soon 
afterbirth (Gonzalez et al., 1986; Ribeiro and Lechner, 1992). CYP3A2 exhibits sex- 
dependent expression, with protein levels increasing until twelve weeks o f  age in both 
sexes and then female expression ceases (Gonzalez et al., 1986; Ribeiro and Lechner,
1992; Wright et al., 1997) (Figure 1.1).
1.3.2.3 CYP3A9
CYP3 A9 shows relatively low cDNA identity to other rat CYP3 As (approximately 
70 %, refer to table 1.4) but 91.6 % identity with mouse Cyp3al3 (Wang et al., 1996).
This suggests an earlier evolutionary divergence than other members o f the family.
However, identity is still sufficiently high for this gene to be considered part o f the |
CYP3A subfamily, CYP3 A9 is the major CYP3 A mRNA in rat brain and may be 
involved in the N-demethylation o f the tricyclic antidepressant imipramine in the 
brain (Wang et al., 1996). CYP3A9 mRNA is also expressed in the liver, small 
intestine, spleen, kidney and lung (Robertson et al., 1998). The expression in the liver 
and brain is age and sex dependent, being only expressed in adult rats, at higher levels 
in females than males due to female uniform, rather than pulsatile, growth hormone 
secretion patterns (Mahnke et al., 1997; Robertson et al., 1998; Wang and Strobel,
1997) (Figure 1.1).
CYP3A9 induction differs from that o f the other rat CYP3 A mRNA forms as 
phénobarbital is a more effective inducer than dexamethasone, clotrimazole or PCN, 
possibly reflective o f its earlier divergence resulting in a slightly different substrate 
profile (Mahnke et al., 1997).
1.3.2.4 CYP3A18
CYP3A18 is a sex dependent P450, with mRNA and protein expressed predominantly 
in male rats at all stages o f development but at higher levels post puberty due partially 
to gonadal androgens and partially to male growth hormone secretions (Kawai et al., 
2000; Mahnke et al,, 1997; Shimada et al., 1997; Strotkamp et al., 1995) (Figure 1.1). 
CYP3A18 mRNA is predominantly expressed in the liver and small intestine, with 
low levels in the brain, kidney, lung and spleen (Robertson et al., 1998).
Dexamethasone is an effective inducer of CYP3A18, whereas phénobarbital can 
marginally induce CYP3A18 expression (‘t Hoen et al., 2000; Mahnke et al., 1997).
1.3.2.5 CYP3A23
Kirita and Matsubara (1993) identified a second CYP3A inducible by dexamethasone 
in both W istar and Sprague Dawley rats, originally termed cDEX. Comparison to the 
published CYP3A1 cDNA sequences o f  Gonzalez et al. (1985) and Ribeiro and 
Lechner (1992) showed a high degree o f identity, 97.8 % and 98.4 % respectively. As 
cDEX was found in both Wistar and Sprague Dawley rats, ruling out the possibility o f 
it being a strain-specific allelic variant o f CYP3A1, it was named CYP3A23 (Kirita 
and Matsubara., 1993; Ribeiro and Lechner, 1992). While CYP3A1 mRNA is at low 
levels in rat liver, CYP3A23 mRNA is present at higher concentrations, indicating 
that it is the major rat liver CYP3A (Brown et al., 1997; Kirita and Matsubra, 1993) 
(Figure 1.1).
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Figure 1.1 Developmental Expression of Rat CYP3A mRNA Forms in Rat Liver
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Mahnke et al. (1997) measured the mRNA expression o f  CYP3A2, 9, 18 and 23 by 
quantitative RT-PCR in terms o f  CYP3A mRNA/ p actin mRNA. This data was 
adapted to include data from slot-blot hybridisation analysis o f  CYP3A1 and CYP3A2 
mRNA by Ribeiro and Lechner (1992) and shown in relative amounts o f  each CYP3A 
mRNA in this figure. Solid lines represent female CYP3 A forms. Broken lines 
represent male CYP3A forms.
1.3.3 H um an CYP3A forms
There are four identified human CYP3A enzymes, CYP3A4, 3A5, 3A7 and 3A43 
(Domanski et al., 2001; Nelson et al., 1996). The cDNA identity o f these forms is 
shown in Table 1.5.
Table 1.5 cDNA sequence identity o f hum an CYP3A forms
CYP3A4 CYP3A5 CYP3A7
CYP3A4
CYP3A5 83%
CYP3A7 95 % 89%
CYP3A43 84% 83% 82%
Percentage similarity o f  cDNA sequence o f  known human CYP3A forms. 
Data taken from Hashimoto et al., 1993; Kolars et al., 1994; Saito et al., 2001; 
Schuetz et al., 1994; Westlind et al., 2001.
11
The CYP3 A family is the major cytochrome P450 in human liver at all stages o f 
development, and is also expressed in a number o f other human tissues. CYP3A4 
protein is the major CYP3 A form in the liver and the small intestine whereas 
CYP3A5 protein is the main form in the stomach and human colon (Gervot et al., 
1996; Kolars et al., 1994). CYP3A5 protein appears to be constitutively expressed in 
the adult kidney, while CYP3 A4 protein is polymorphically expressed in 14 % o f 
adult kidneys (Jounaidi et al., 1994; Schuetz et al., 1992). CYP3A7 mRNA has only 
been detected in the liver (Kolars et al., 1994). CYP3A43 mRNA is a newly identified 
member o f  the CYP3A subfamily, which is highly expressed in human prostate 
(Gellner et a l ,  2001).
1.3.3.1 CYP3A4
Cytochrome P450 3 A3 and 3 A4 are very similar, differing in only eleven out o f five 
hundred and three amino acids (Schuetz et a l, 1994). They have almost identical 
catalytic activities and expression patterns. CYP3 A3 is now suspected to be a 
sequencing artefact o f  CYP3 A4 and will not be considered further (Nelson et a l ,
1996; Schuetz et a l, 1994; http://drnelson.utmem.edu/human.p450s. html, 1998).
CYP3 A4 mRNA is undetectable in fetal liver but rapidly appears in neonatal liver to 
become the major adult liver P450, comprising up to 30 % of the total P450 content 
(Schuetz et a l , 1994; Wrighton et a l ,  1989). CYP3 A4 enzyme is responsible for the 
metabolism o f over 60 % o f clinical pharmaceuticals, which undergo oxidation, and is 
therefore an important enzyme with respect to the action and duration o f dmgs and 
their metabolites (Cholerton et a l, 1992). Because CYP3A4 can be induced or 
inhibited by many o f  its substrates, it may also play a role in drug-drug interactions 
(Lucey et a l ,  1990; Pichard et a l, 1989).
Li et al. (1995) evaluated a total o f 32 chemicals belonging to different structural 
classes that were substrates o f CYP3 A4, demonstrating metabolic pathways including 
N-oxidation, C-oxidation, N-dealkylation, 0-dealkylation, nitro-reduction, 
dehydration and C-hydroxylation. Shou et al. (1994) proposed the active site o f 
CYP3 A4 to be very large, explaining the broad substrate selectivity and ability to 
metabolise very large substrates (e.g. rifampicin).
1 2
Although CYP3 A4 can accommodate a wide variety o f structurally diverse 
compounds, it exhibits regio- and stereo-selectivity similar to rat CYP3A1. For 
example CYP3A4 catalyses the 2p, 6(3 and 15 (3-hydroxy lation o f  testosterone as does 
CYP3A1 (He et ah, 1997; Komori et ah, 1988).
1.3.3.2 CYP3A5
CYP3 A5 is a polymorphically expressed enzyme, found within 25 % o f livers in the 
adult human population and in a statistically higher percentage o f children and 
adolescents compared to the rest o f the population (Gervot et ah, 1996; Wrighton et 
ah, 1990). CYP3A5 mRNA is also expressed in foetal liver (Schuetz et ah, 1994). 
CYP3A5 appears more limited in its metabolic capacity than CYP3 A4, being roughly 
five fold less active and not induced or suppressed by prototypical CYP3 A inducers, 
such as PCN (Jounaidi et ah, 1994; Schuetz et ah, 1993a).
1.3.3.3 CYP3A7
CYP3A7 is the major CYP3A mRNA expressed in human fetal liver and is also 
polymorphically expressed in 54 % o f adult livers, albeit at relatively low levels 
(Gervot et al., 1996; Kitida et ah, 1985; Shuetz et ah, 1994). CYP3A7 may protect the 
fetus from the effects o f  endogenous steroids as it can metabolise both testosterone 
and progesterone (Komori et ah, 1988; Schuetz et ah, 1993b). CYP3A7 activity in 
fetal livers is replaced by other CYP3As after birth, most notably CYP3 A4 (Kitida et 
ah, 1985). Wrighton et ah (2001) investigated the relative catalytic activities o f 
CYP3A4, 5 and 7 and found CYP3A7 to have the lowest catalytic activity.
1.3.3.4 CYP3A43
CYP3A43 mRNA is expressed at comparatively low levels in adult and foetal liver, 
kidney, pancreas, skeletal muscle, testes and prostate; hepatic expression o f CYP3A43 
mRNA is approximately 0.1 and 2  % that o f CYP3A4 and CYP3A5, respectively 
(Domanski et ah, 2001; Westlind et ah, 2001). Initial studies suggest the CYP3A43 
catalytic activity to be low, but this remains to be fully clarified (Wrighton et ah, 
2001). This low activity may be potentially explained by six amino acid mismatches 
in the substrate recognition site compared to CYP3 A4 protein, resulting in a reduced 
testosterone 6 p-hydroxylase activity (Domanski et ah, 2001).
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1.3.4 Regulation of CYP3A
The regulation o f the CYP3A subfamily is complex and there has been large amounts 
o f work undertaken to identify CYP3A inducers and inhibitors. Investigations into the 
role o f receptors are beginning to clarify the mechanisms o f regulation, but there is 
more to be learned. Possible mechanisms o f  induction include increasing the rate o f 
gene transcription, increasing CYP3 A mRNA or protein stability or enhancing the 
rate o f mRNA translation (Eliasson et al., 1994).
13.4.1 Inducers
The first inducer identified was pregnenolone 16a-carbonitriIe, which provided the 
earlier name for this subfamily, P 4 5 0 p c n  (Lu et al., 1972). Since its identification as 
an inducer, a wealth o f evidence has accrued on the PCN-mediated induction o f 
CYP3A. Characteristic CYP3 A metabolic activity and CYP3 A protein has been shown 
to increase in various strains o f mature rats, o f both sexes both in vivo and in vitro 
after treatment with PCN (Eberhart et al., 1992; Lu et al., 1972; Shimada and 
Guengerich, 1985; Sonderfan et al., 1987; Williams et al., 1987).
Although CYP3As were originally described as PCN-inducible P450s, Shimada and 
Guengerich (1985) described dexamethasone as the most effective inducer o f CYP3A 
enzyme activity in rat liver microsomes. Dexamethasone induces CYP3 A4 protein 
and mRNA, both in vivo and in vitro in human hepatocytes (Fukuda et al., 1992; 
Schuetz et al., 1993a; Watkins et al., 1985). Other endogenous glucocorticoids but not 
sex steroid hormones or mineralocorticoids also stimulate the induction o f CYP3A 
protein synthesis (Schuetz and Guzelian, 1984). It should be noted that since then, 
more efficacious CYP3A inducers have been described, such as troglitazone, 
lovastatin and simvastatin (El-Sankary et al., 2001). Several o f these, plus other 
classical CYP3 A inducers are listed in table 1.6. It can be seen that they belong to a 
wide range o f xenobiotic classes used for different pharmacological reasons.
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1.3.4.2 Species difTerences in induction
There are marked species differences in response to CYP3 A inducers, as shown in 
figure 1.2 (Williams et al., 1994). For example, rifampicin has been identified as one 
o f  the most potent inducers o f  CYP3 A4 expression and activity and is also a potent 
inducer o f  CYP3 A 6  protein or activity in rabbits, but has no induction effect on 
CYP3A1 protein or activity in vivo or in vitro (Kocarek et al., 1995; Lange et al., 
1984; Sonderfan et al., 1987; Williams et al., 1994; Wrighton et al., 1985).
PCN induces CYP3 A l mRNA and protein but fails to induce CYP3A6 mRNA or 
protein in rabbits (Kocarek et al., 1995; Wrighton et al., 1985). It has been reported 
that CYP3 A4 mRNA is induced by PCN in some, but not all human liver hepatocytes 
(Barwick et al., 1996; Kocarek et al., 1995). This may indicate two human hepatocyte 
populations, one expressing CYP3A4 responsive to PCN, like rats, and the other a 
non-responsive CYP3A4, like rabbits. These differences in CYP3A4 inducibility by 
PCN are unlikely to be due to allelic differences and are more likely to be due to 
differences in receptor or liver transcription factor availability, cultured hepatocyte 
viability or polymorphisms in the CYP3A4 5’ flanking region.
Figure 1.2 Species differences in CYP3A inducers
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> ^P C N ,
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Barwick et al. (1996) investigated these differences by trans-species gene transfer o f 
the 5’ flanking sequences o f CYP3A2, CYP3A4, CYP3A5, CYP3A6, CYP3A7 and 
CYP3A23 coupled to a chloramphenicol acetyltransferase (CAT) reporter gene.
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Rifampicin increased the CAT activity o f all the CYP3A promoter driven reporter 
genes transfected into rabbit hepatocytes but not in rat hepatocytes. This indicated that 
in addition to gene structure, host cellular environment dictates the pattern o f CYP3 A 
inducibility. CAT activity was increased in rat hepatocytes but was not affected by 
PCN treatment in rabbit hepatocytes. Dexamethasone treatment increased CAT 
activity in both rabbit and rat hepatocytes (Barwick et al., 1996). In general, the 
human CYP3A4 induction profiles resemble most closely those o f  rabbit CYP3A6. 
However selected inducers, including spironolactone, cyproterone acetate and 
clotrimazole have been reported to induce both rat and human CYP3 A mRNA and 
protein but not rabbit (Kocarek et al., 1995). Therefore it would appear that neither rat 
nor rabbit can completely duplicate human CYP3A induction profiles.
Even hormonal regulation shows species differences, for example, thyroid hormone 
attenuates rifampicin induction o f CYP3 A mRNA in human hepatocytes whereas it 
had no effect on phénobarbital induction o f CYP3A1 mRNA in rat hepatocytes and 
suppressed CYP3A2 mRNA expression in vivo in rat liver (Schuetz et al., 1993a). 
There are striking interspecies differences in the apparent rank order o f efficacy o f 
inducers. For example, SR12813 is a strong inducer o f CYP3A4 and CYP3A6 mRNA 
but only weakly induces CYP3A1 mRNA (Kocarek et al., 1995; Wrighton et al., 
1985). There appear to be many interspecies differences in induction that may be 
transcriptional, pharmacokinetic or pharmacodynamic, which indicate that there are 
different regulation mechanisms between species. These species-dependent regulatory 
aspects need to be fully dissected to allow proper testing and assessment o f new 
compound entities.
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1.3.5 CYP3A Nucleotide Sequence Analysis
CYP3A expression varies with age, sex, species and strain and can be induced by 
various endogenous and exogenous chemicals at the transcriptional level (Barwick et 
al., 1996; Debri et al., 1995; Hunt et al., 1992; Larsen et al., 1994; Oinonen and 
Lindros, 1995; Pereira and Lechner, 1995; Ribeiro and Lechner, 1992; W right et al., 
1997). This has lead to investigations into the nucleotide sequence o f  the 5’ flanking 
regions o f these genes, in an attempt to identify regulatory elements within these areas 
and the transcription factors/receptors that interact with them, to control CYP3A 
expression. The investigations into the major rat and human CYP3 A promoter regions 
will be discussed in the following sections.
1.3.5.1 CYP3A1 promoter
Burger et al. (1992) analysed 1.5 kb o f the 5’ flanking region o f CYP3A1 gene from 
adult male Sprague Dawley rats (nucleotide sequence is shown in figure 1.3). A 164 
bp fragment (-220 to -5 6  bp) was found to confer dose-dependent dexamethasone and 
PCN responsiveness, independent o f its orientation (Burger et al., 1992). This 
fragment did not contain a classical glucocorticoid response element (GRE), but 
putative GREs similar to the TGTYC motif o f the GRE consensus half palindrome 
(Burger et al., 1992). Two regions (-936 to -797  and -219 to -146) contained GRE- 
like sequences in close proximity to motifs known to bind transcription factors that 
interact with the glucocorticoid receptor (GR) such as nuclear factor 1 (N Fl), octamer 
factor and CACCC box binding factor (Burger et al., 1992). These experiments 
indicated that CYP3A1 induction involves either a classical GR interacting with 
altered GREs or a GR-like receptor with similar binding properties (the then termed 
PCN receptor). The PCN receptor has since been identified as a human orphan 
nuclear receptor termed the pregnane X receptor (PXR) and will be discussed in 
section 1.3.6 (Kliewer et al., 1998; Lehmann et al., 1998).
This earlier work was confirmed by Quattrochi et al. (1995) who identified a 165 bp 
fragment, approximately 2 0 0  bp upstream from the transcriptional start site o f 
CYP3A1, containing two extensively protected regions, FP l (-135 to -117) and FP2 
(-108 To -85) (Quattrochi et al., 1995).
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Only fragments containing F P l, independent o f orientation, were responsive to 
dexamethasone and PCN at a similar magnitude to endogenous CYP3A1 induction 
(Quattrochi et al., 1995). F P l contained a palindromic sequence ATGAACTTCAT 
that overlaps one o f two direct repeats o f ATGAACT separated by 2 nucleotides 
(Quattrochi et al., 1995). A 6  bp portion o f these 7 bp repeated sequences, on the 
opposite strand AGTTCA, represents a high affinity binding site for the N R II family 
o f nuclear receptors including peroxisome proliferator activated receptors, retinoic 
acid receptors and PXR, known as a DR3 (Quattrochi et al., 1995).
In addition to FP l and FP2, Ogino et al., (1999) also identified a protected site 
between -145 and -164 known as 6|3B-C. The factor(s) binding to 6 PB-C have not 
been identified, but may bind to an imperfect inverted repeat o f AGGTCA, separated 
by 6  nucleotides (an ER 6  element, TTAACTcaaaggAGGTCA) (Ogino et al., 1999). 
FP 2 /6 PB-A was shown to be an H N F4a binding site required for basal CYP3A1 
activation (Ogino et al., 1999). FP1/6PB-B was shown to contain a DR3 element to 
which PXR/RX Ra heterodimers bound. However ARPl and EAR3 (COUPTFs) 
could also bind to this site and inhibit H N F4a mediated activation o f CYP3A1 
preventing clear delineation o f the molecular mechanisms (Ogino et al., 1999). The 
three binding sites previously detected are conserved within the CYP3A2 promoter 
and bind the same factors the same way; this probably reflects the importance o f  these 
sites in control o f  rodent CYP3A expression and / or induction (Miyata et al., 1995).
Pereira et al., (1998) identified two G R a protected sites in the distal CYP3A1 5’ 
flanking region from -1960 to -1982 bp and -1986 to -2001 bp respectively. 
Mutation o f the former abolished both binding and transcriptional activation by 
dexamethasone, whereas mutation o f the latter site decreased binding but had no 
effect on the transcriptional activation by 50 to 1 0 0  nM dexamethasone. Putative 
binding sites for Spl and E tsl were identified downstream of the G R a sites and these 
factors have previously been shown to co-operate with G R a in regulating gene 
transcription (Espinas et al., 1994; Zhao et al., 1995).
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1.3.5.2 CYP3A23 promoter
Huss et al. (1996) examined the regulation o f CYP3A23 by dexamethasone using a 
CYP3A23 promoter driven luciferase reporter gene construct. The nucleotide 
sequence o f this region the proximal promoter can be seen in figure 1.4. DNasel 
footprinting identified three sites o f protection within the region o f -167  to -6 0  bp 
(Huss et al., 1996).
Site A (-91 to - 1 1 0 ) shared 80% identity with an HNF4 consensus element and could 
bind both H N F4a and U SFl as it contains both HNF4 and E box consensus binding 
motifs (Huss et al., 1996, 1999). The sites B (-118 to -136) and C (-144 to -169) were 
necessary for maximum dexamethasone induction in a co-operative manner, but 
neither contained a glucocorticoid response element.
Site B (also called DexRE-2) contained a repeated ATGAACT sequence (DR3) 
which, was also found in CYP3A1 and CYP3A2 proximal promoter sequences. 
PXR/RX Ra heterodimers bind to the DR3 and activate the CYP3A23 gene.
COUPTFl homodimers can also bind to this site (Huss and Kasper, 1998; Huss et al., 
1999; Kliewer et al., 1998). Site C (also called DexRE-1) contained an imperfect 
AGGTCA direct repeat (ER 6 ) (Huss et al., 1996; M iyata et al., 1995; Quattrochi et 
al., 1995). This ER 6  in site C is imperfect due to one mismatch in the upstream 
hexamer, suggesting PXR/RXRa binding to this site is too weak to directly mediate 
ligand activation (Huss and Kasper, 2000). Site C also binds COUPTFs and a 
complex B, containing unidentified 45 kDa protein(s) (Huss and Kasper, 1998; Huss 
et al., 1999).
2 1
Figure 1,4 The nucleotide sequence of the proximal promoter of the CYP3A23 
gene
The blue, red and black underlined sequences represent site-A, site-B and site-C 
respectively. Site A shares 80 % identity with HNF-4 consensus element.
Sites B and C contain direct repeats, which are the sequences coloured red and green, 
respectively. DR3 is located in site B, ER 6  is located in site C and is indicated in bold. 
The TATA box is boxed. (Huss et al., 1996)
-303TGAAGATTTGAATGAAGTCAGCCTTGGTGAGAGATTATTT
-263 TATATTATCGAATTTGCTTGAATTTCTGATAGAAACAAAC
-223TAAGAAACnTGGTCTTACTTATATGGCACTGTTGTTCAC
ER6 binds COUPTFs and complex B 
-183 TGACGCCACCCAGAATGTTAACTCAAAGGAGGTCAAAATA 
DR3 binds PXR/RXRa HNF4
-143 GGCTGTAGATGAAC1TCATGAACTGTCTAGGGGAAGAGAG 
E box
-103 TACCAAAGTCCACGTGAGGCAGAGGTGATCCATCTACTGG
-63 CTGGATCCCTGGTGCCACCCATCTTTCCAGCA TATAA GTA
-23 CTGCAGGCTGGCCTCAGTGCAGCAGTGTGGGCAGAAAGGA
1.3.5.3 Relationship between the CYP3A1 or CYP3A23 promoters
CYP3A23 cDNA was first isolated by Kirita and Matsubara (1993). CYP3A23 
showed 98 and 97% identities with the CYP3A1 nucleotide and amino acid 
sequences, with the divergence localised to CYP3A23 amino acids 107 to 230 
(Gonzalez et al., 1985; Komori and Oda, 1994). The high similarity indicated that 
CYP3A23 may be an allelic variant o f CYP3AL However both CYP3A23 and 
CYP3A1 mRNA were detected in Sprague Dawley rat liver, thus eliminating them as 
allelic variants (Kirita and Matsubara, 1993). When a rat CYP3A cDNA library was 
constructed and probed with a CYP3A23 oligonucleotide probe, CYP3A23 was found 
to represent over 70 % o f  the total CYP3A mRNA in rat liver, whereas CYP3A1 and 
CYP3A2 were found to comprise only a small percentage o f the total CYP3 A mRNA 
signal (Komori and Oda, 1994).
The nucleotide sequence o f  the 5’ flanking region o f  CYP3A23 is completely 
identical with that o f  the genomic clone o f  CYP3A1 isolated by Burger et al. (1992) 
(Komori and Oda, 1994). Therefore when the CYP3A1 promoter driven reporter gene 
construct designed by Burger et al. (1992) was used in transfection experiments by 
Barwick et al. (1996), the construct was renamed CYP3A23.
2 2
CYP3 A l mRNA is reported to be expressed at low levels in rat liver whereas 
CYP3 A23 mRNA is present at higher concentrations, suggesting differential 
regulation o f expression o f the two forms (Ribeiro and Lechner, 1992; Komori and 
Oda, 1994; Mahnke et al., 1997). Despite this, Mahnke et al. (1997) measured the 
expression and inducibility o f  CYP3A23 mRNA and stated that their results were also 
anticipated for CYP3A1, which they indicated was an allelic variant, because they did 
not detect CYP3 A1 mRNA. This indicates the current lack o f clarity in this area, 
including published papers using the term CYP3A1 when referring to CYP3A23 and 
most CYP3A1 specific cDNA probes or PCR primers also detecting CYP3A23 (Brown 
et al., 1997; Gushchin et al., 1999).
1.3 5.4 CYP3A2 promoter
M iyata et al. (1995) identified c/5 -acting elements in the CYP3A2 proximal promoter 
region o f -165 to -73 nucleotides. Rat nuclear extract interacts with three sites within 
this region. These were identified as 6 pA-A (-106 to -87), 6 PA-B (-140 to -119) and 
6 PA-C (-163 to -145) as shown in figure 1.5 (M iyata et al., 1995). These sites contain 
the same putative response elements as the A, B, C and 6 PB sites in the CYP3A23 and 
CYP3A1 promoters respectively, which may explain why many inducers act on both 
CYP3A1, 3A2 and 3A23 (Huss and Kasper, 1998; Huss et al., 1996, 1999; Ogino et 
al., 1999; Quattrochi et al., 1995).
A substituted base was identified in the E box in Site 6 PA-A o f the CYP3A2 promoter 
compared to that in site A o f CYP3A23. This prevented U SFl binding, probably 
contributing to the lower basal activity o f CYP3A2 (Huss et al., 1999). Site 6 PA-B 
contained two base mismatches compared to site B/DexRE-2 in the CYP3A23 
promoter, which contributed to the lower induction o f CYP3A2 promoter driven 
reporter gene activity by dexamethasone. However no obvious differences in binding 
o f PXR/RX Ra heterodimers or COUPTFl homodimers to the two sites were 
observed (Huss et al., 1999).
The binding o f COUPTFs to the CYP3A2 6 pA-C site was more extensive than 
binding to the CYP3A23 C/DexRE - 1  site.
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Binding o f  complex B to 6 PA-C was undetected, unlike its high affinity binding to 
DexRE-1 in the CYP3A23 promoter (Huss et al., 1999). These differences in complex 
B binding have been proposed to be due to two base mismatches in the CYP3A2 6 pA- 
C compared to the CYP3A23 DexRE-1 and it is believed that these are responsible for 
the lower inducibility o f  CYP3A2 compared to CYP3A23 promoter driven reporter 
gene activities (Huss et al., 1999). Furthermore, the CYP3A2 6 PA-C ER 6  upstream 
hexamer contains a base mismatch, compared to CYP3A23 DexRE-1, which 
obliterated PXR/RXRa binding (Huss and Kasper, 2000).
Figure 1.5 The nucleotide sequence o f the proximal promoter of the CYP3A2 
gene
The blue, red and black underlined sequences represent 6 PA-A, 6 PA-B and 6 pA-C 
respectively which are regions with which rat nuclear extract interacted. The green 
and red sequences are direct repeats similar to the consensus sequence o f  nuclear 
receptors such as the retinoic acid receptor and the thyroid receptor. The blue 
sequence resembles the HNF4 binding sequence. The TATA box is boxed. (M iyata et 
al., 1995).
_lgQ ER6 binds COUPTFs
GATGCCACACAGAATGTTAGCTCAAGAAGGTCAAAGAAGCTGTAGATGAACTTTATGAAC
-120 HNF4
TGTTTAGGGGAAGAGAGTACCAAAGTCCAGGTGAGCCAGAGGTGATCCATCTACTGGTTG 
-60
GATCCCTGGTGCCACCCATCTTTCCAGCA^ ATA/ GTACTGCAGGCTGGCCTCAGTGCAGC
1.3.5.5 CYP3A9 and CYP3A18 promoters
To my knowledge, the promoter regions o f  rat CYP3A9 and CYP3A18 have not been 
sequenced or characterised and therefore will not be discussed fiirther.
1.3.5.6 Summary of Rat CYP3A Promoters
From the rat CYP3A promoters investigated to date, there are three major sites 
involved in CYP3A regulation (Huss et al., 1999; M iyata et al., 1995; Ogino et al., 
1999; Quattrochi et al., 1995). Site A (FP2, 6 PA-A, 6 PB-A) binds HNF4, which 
regulates basal CYP3A expression and is required for maximal glucocorticoid 
responsiveness (Huss et al., 1999). Site B (FP l, 6 pA-B, 6 pB-B) contains a perfect 
DR3 m otif to which, PXR/RXRa heterodimers bind (Kliewer et al., 1998). COUPTFs 
also compete for binding to the aforementioned site (Ogino et al., 1999).
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Site C (6 p A-C, 6 pB-C) contains an imperfect ER 6  motif, but the proteins that bind to 
this site have yet to be identified (Huss et al., 1999). Base pair mismatches in the sites 
between the CYP3A forms alter receptor binding affinities thus determining the 
differential CYP3A form expression (Huss et al., 1999).
1.3.5.7 CYP3A4 promoter
Computer analysis suggested that the CYP3A4 5’flanking region contains both a basic 
transcription element (BTE) and a TATA box (Hashimoto et al., 1993). There are also 
putative binding sites o f  transcriptional regulatory factors such as octamer binding 
protein (Oct-1), CCAAT binding protein (CP-1), activator protein 3 (AP-3), estrogen 
receptor (ER), progesterone/glucocorticoid receptor (PR/GR), hepatic nuclear factors 
4 and 5 (HNF-4, HNF5) and p53 (Hashimoto et al., 1993). Basic transcription 
element binding protein and similar factors have been found in both fetal and adult 
human liver and as such may play a role in the transcription o f CYP3A4 (Hashimoto et 
al., 1993). The 5’ flanking region nucleotide sequence o f CYP3A4 is shown in figure 
1. 6 .
The CYP3A4 promoter region was investigated using deletion mutants linked to CAT 
reporter genes and indicated that nucleotides -362 to -94  o f the CYP3A4 gene possess 
promoter properties when transfected into HepG2 cells (Hashimoto et al., 1993). 
Barwick et al. (1996) located an AT G A AT site in this region which corresponded to a 
DR3 half-site in CYP3A23 5’ flanking region. It also contains a second hexamer 
(AGGTCA), associated with group II orphan receptor binding, six nucleotides 
downstream from the DR3 half-site (Barw ick et al., 1996). Members o f  the N R II 
nuclear receptor family preferentially bind this everted repeat ER 6  m otif (Savas et al., 
1999a).
A  cz5 -acting element in the region from nucleotides -2900 to -445 bp appears to 
repress transcription, and one site in the region -445 to -254 bp is required for 
efficient transcriptional activity o f CYP3 A4 promoter driven reporter gene constructs 
in HepG2 cells (Hashimoto et a l ,  1993). The latter region contains both the P 4 5 0 n f -  
specific element (NFSE) and CAAT, a known ‘cis’-acting element for the 
enhancement o f transcription (Hashimoto et a l, 1993).
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The NFSE is a characteristic segment that exists in the CYP3 A4 promoter but not in 
the CYP3A7 promoter (Hashimoto et ah, 1993). It has no known regulatory function. 
N o enhancement o f CAT activity was observed during the transfection o f the same 
deletion mutant promoter driven CYP3A4 reporter genes into human amnion cells 
(FL), indicating the liver specific factors required for CYP3 A4 gene transcription are 
present inH epG 2  cells (Hashimoto et al., 1993).
Saito et al. (2001) identified binding sites for C /EBPa and Y Y l (a transcriptional 
repressor) at -139  to -126  and -120  to -104 bp respectively in the CYP3A4 promoter. 
N F l is proposed to bind to the C/EBPa motif and activate the CYP3A4 promoter 
driven reporter gene by interfering with the repressive action o f Y Y l (Saito et al., 
2001). The C/EBP motif can also bind C/EBPa and activate the CYP3A4 gene (Ourlin 
et al., 1997). This activation is potentiated by HNF3y due to chromatin remodelling 
effects (Martinez-Jiménez et al., 2001; Rodriguez-Antona et al., 2001). HNF3 has 
been shown previously to co-operatively interact with N Fl to activate transcription o f 
genes in the liver, therefore this may be responsible for the observed synergy (Saito et 
al., 2001). Saito et al., (2 0 0 1 ) also identified an E  box at -7 9  to -7 4  in the CYP3A4 
promoter, which bound U SFl and activated expression o f luciferase from the CYP3A4 
promoter driven reporter gene construct.
The role o f the CYP3A4 promoter is augmented by a distal enhancer module, located 
at -7607 to -7836 bp in the CYP3A4 5’ flanking region (Goodwin et al., 1999a). This 
region contained three ER 6  binding sites -7738 to -7715, -7698 to -7682 and -7290 
to -7270 bp and cotransfection o f hPXR with reporter constructs containing these 
sites, substantially increased rifampicin inducibility (Goodwin et al., 1999a). This 
distal element co-operates with the c/.y-acting elements o f the CYP3A4 proximal 
promoter. The distal enhancer contains two further protected sites FP l (-7811 to -  
7770 bp) and FP2 (-7763 to -7740 bp) but their roles have still to be elucidated. FP l 
contains overlapping recognition sequences for R O R al (-7783 to -7771 bp) and 
C0UPTF/HNF4 (-7783 to -7772 bp), whereas FP 2  shows significant identity to a 
CCAAT/enhancer binding protein a  m otif (Goodwin et al., 1999a). Martinez-Jimenez 
et al. (2001) also identified a functional C/EBP motif in the -9418 to -6954 bp region 
o f the CYP3A4 distal enhancer, which was potently activated by C/EBP (3 /  LAP.
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1.3.5.8 CYP3A5 prom oter
Jounaidi et al. (1994) reported isolation o f the 5’ flanking region and first exon o f 
CYP3A5, which shares 60 % and 59 % similarity with the corresponding regions o f 
CYP3A4 and CYP3A7 respectively. However, the 5’ genomic sequences o f CYP3A4 
and CYP3A7 appeared to be more closely linked than CYP3A5, suggesting a gene 
modification event, such as a gene conversion with a non CYP3 A gene, a large 
deletion or a large insertion, has occurred in CYP3A5 upstream from -700  bp. A 
recent study on the sequencing o f  the entire human CYP3A locus revealed that 
Jounaidi et al. (1994) had isolated the 5’ flanking region o f a CYP3A5 pseudogene 
(Gellner et al., 2001). Iwano et al. (2001) have now isolated the 5’ flanking region o f 
CYP3A5. A positive regulatory region was identified between -9 0  and -4 0  bp o f the 
CYP3A5 gene, that contained an inverted CCAAT box and a BTE shown in figure 1.7 
(Iwano et al., 2001).
The CCAAT box is recognised by the NF-Y transcription factor, whereas Spl and 3 
interact with the BTE o f the CYP3A5 gene. Mutations in either o f these elements 
caused a 80 to 90 % decrease in transcriptional activity o f a CYF3A5 promoter driven 
luciferase construct, whereas mutations in both elements lowered transcriptional 
activity further, to 4 % o f the wild type CYP3A5 promoter driven luciferase activity 
(Iwano et al., 2001). Therefore transcription o f the CYP3A5 gene is co-operatively 
regulated by the CCAAT box and BTE, involving NF-Y and Spl. In comparison, the 
CYP3A5 pseudogene sequence published by Jounaidi et al. (1994) contains mutations 
in both the CCAAT box and the BTE. These mutations may reduce the NF-Y and Sp 
family member binding affinity for the sites, which may explain the low 
transcriptional activity o f a CYP3A5P promoter driven reporter gene in HepG2 cells 
that was observed by Schuetz et al. (1996).
There is also an ER 6  between -120 and -109  in the CYP3A5 proximal promoter, but 
the presence o f response elements for other receptors and transcription factors have 
not been reported yet (Iwano et al., 2001).
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1.3.5.9 CYP3A7 promoter
Hashimoto et al. (1993) compared the 5’ flanking region o f  CYP3A7 with that o f 
CYP3A4, There was a 91 % identity between the two sequences up to -1  kb, but each 
had a characteristic segment, P450HFu-specific element (HFLaSE) and P 4 5 0 n f -  
specific element (NFSE) respectively (Hashimoto et al., 1993). HFLaSE was between 
nucleotides -737 and -729  CYP3A7. As shown in figure 1.8, all o f  the response 
elements in the CYP3A4 proximal promoter are present in the CYP3A7 promoter. 
There was debate over the functionality o f the CYP3A7 proximal promoter ER 6  motif, 
which had been reported to contain 3 mutations that disrupted both half-sites 
(Blumberg et al., 1998; Itoh et al., 1992; Yang et al., 1994). However resequencing o f 
the CYP3A7 promoter resolved the debate, as no mutations were found in the CYP3A7 
ER 6  m otif and PXR could bind to this site and transactivate CYP3 A7-ER6 driven 
luciferase in the presence o f human PXR ligands (Pascussi et al., 1999). A C /EBPa 
site at -129  to -120  bp in a CYP3A7 promoter driven CAT construct can be 
transactivated by C/EBPa and the transactivation is enhanced by HNF3y, as in 
CYP3A4 regulation (Ourlin et al., 1997; Rodriguez-Antona et al., 2 0 0 1 ).
Putative binding sites for HNF3 and N F l, and an E box like element were also 
identified in the CYP3A7 proximal promoter at -129 to - 1 2 0 , -131 to -117  and -7 9  to 
-7 4  bp respectively (Saito et al., 2001). HNF3p can bind and activate the CYP3A7 
promoter driven reporter gene. Binding o f U SFl to the E box and /  or Spl or Sp3 to 
the BTE enhanced this activation. U SFl or SPl or 3 alone could also bind and 
activate the CYP3A7 promoter driven reporter gene (Saito et al., 2 0 0 1 ).
Saito et al. (2001) also identified aNFicB-like element, in the distal CYP3A7 5’ 
flanking region from -2326 to -2297, that confers transcriptional activation o f a 
CYP3A7 promoter driven reporter gene. A 1 bp mismatch in this region in CYP3A4 is 
responsible for the lower activation o f  CYP3A4 than CYP3A7 promoter driven 
reporter genes in HepG2 cells. The mismatch allows Spl and 3 to bind to and activate 
the CZP5/17 NFKB-like element but not the CYP3A4 element (Saito et al., 2 0 0 1 ). This 
distal NFicB-like element co-operates with the proximal promoter HNF3 element, the 
E  box and the BTE to regulate CYP3A7 expression (Saito et a l, 2001).
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A distal enhancer region corresponding to the distal CYP3A4 XREM has been 
identified in the CYP3A7 gene, approximately - 8  kb upstream o f the proximal 
promoter (Bertilsson et al., 2001). All three distal PXR binding sites in the CYP3A4 
XREM  are conserved in the CYP3A 7 distal enhancer, with only two substitutions that 
do not appear to affect their function in the PXR dependent induction o f CYP3 A7 
promoter driven reporter gene assays. CAR is also a strong activator o f CYP3A7, but 
only in the presence o f the XREM (Bertilsson et al., 2001; M oore et al., 2000).
1.3.5.10 CYP3A43 prom oter
To my knowledge, the promoter region o f human CYP3A43 has not been sequenced 
or characterised and therefore will not be discussed further.
1.3.5.11 Sum m ary o f H um an CYP3A Prom oters
The CYP3A4 and CYP3A7 promoters are 91 % identical up to 1 kb and all o f the 
response elements are conserved between the two promoters (Hashimoto et al., 1993). 
Both promoters contain an ER 6  motif that binds PXR/RX Ra heterodimers and also an 
imperfect DR3 m otif (Barwick et al., 1996; Pascussi et al., 1999). A C/EBPa site has 
been identified in both promoters, that can bind C/EBPa and this activation is 
potentiated by HNF3 (Ourlin et al., 1997; Saito et al., 2 0 0 1 ). However N Fl can also 
bind to this site in the CYP3A4 promoter and interferes with Y Y l repressor protein 
action, thus promoting its reporter gene expression. CYP3A7 contains a NFicB-like 
element that is able to bind Spl or 3, which activate CYP3A7 promoter driven 
reporter gene expression (Saito et al., 2 0 0 1 ). Both CYP3A4 and CYP3A7 have distal 
enhancer regions, approximately 8  kb upstream of the proximal promoter, which 
contain 3 ER 6  motifs that enhance CYP3A induction by xenobiotics by PXR-mediated 
gene activation (Goodwin et al., 1999a; Bertilsson et al., 2001). However CYP3A5 is 
not as similar as the other human CYP3A forms discussed here in. It is believed to be 
regulated by the binding o f NF-Y and Spl to a CAAT box and BTE, but also contains 
an ER 6  m otif (Iwano et al., 2001).
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1.3.6 The Role of Receptors and Transcription Factors in CYP3A Induction
W ithin the 5’ flanking regions o f the CYP3 A subfamily, there are various motifs, 
similar or identical to the sequences to which regulatory or transcription factors bind. 
These are illustrated in figures 1.9 and 1.10. Table 1.7 describes the functions o f these 
various motifs.
Because CYP3A is inducible by glucocorticoids such as dexamethasone, an important 
regulatory factor would logically be the steroid hormone receptor, the glucocorticoid 
receptor (GR) (Evans, 1988). However it has been claimed that the classical GR 
signalling pathway does not explain the xenobiotic induction profile o f CYP3A 
enzymes (Schuetz and Guzelian, 1984). The concentration o f glucocorticoid required 
for CYP3A induction exceeds full GR occupancy and GR antagonists, such as PCN, 
also induce CYP3A (Schuetz and Guzelian, 1984; Schuetz et al., 1984; Wright and 
Paine, 1994).
The discovery o f the orphan nuclear receptor PXR by Kliewer et al. (1998) provided a 
clarification o f the CYP3A induction mechanism. This is because PXR preferentially 
binds to  DR3, DR4 and ER 6  motifs found in the proximal promoters o f CYP3 A genes 
(Savas et al., 1999a). These motifs are shown in Table 1.8. However it is important to 
note that other receptors may be involved in the regulation o f CYP3A, such as the 
constitutively activated/androstane receptor (CAR). CAR mediates the induction o f 
CYP2B by phénobarbital and phenobarbital-Iike inducers, and high concentrations o f 
phénobarbital can also induce CYP3A. Smirlis et al. (2 0 0 1 ) showed that CAR and 
PXR /R X R a heterodimers can bind to the same response elements (DR4 in the PBRE 
or DR3 in the PXRE) but activation o f CYP2B1 and CYP3A1 reporter gene 
expression is ligand dependent. CAR activates both genes in response to barbituates, 
whereas PXR activates both genes in response to synthetic steroids (Smirlis et al., 
2001).
The la ,  25-dihydroxyvitamin D 3 receptor can also stimulate CYP3A expression, 
possibly by binding to DR3 elements (Schmiedlin-Ren et al., 2001; Waxman, 1999).
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In CaCo-2 cells that express CYP3 A4 at a basal level, PXR ligands were unable to 
induce CYP3 A4 but l a ,  25-dihydroxyvitamin D 3 could induce CYP3 A4 mRNA and 
protein expression (Schmiedlin-Ren et a l ,  2001). CaCo-2 cells may lack PXR 
expression, indicating that induction o f  CYP3A4 by a,25-dihydroxyvitamin D 3  is 
unlikely to involve PXR but may involve the vitamin D 3  receptor (VDR). There are 
possible roles for liver enriched transcription factors, HNF3, HNF-4 and HNF-5 
whose response elements are found in many CYP3 A proximal promoters.
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Table 1.7 P utative r e g u la te m o t i f s  and transcrip tion  factors p resen t in the 
upstream  region of the CYP3A genes
R egulatory  m otif Function
AP-3 Consensus sequence tliat is recognised by tlie gene activating factor, 
Activator Protein-3. Involved in tlie activation of many proto­
oncogenes and growth factor genes in response to protein kinase C.
BTE The basal transcription element is involved in maintaining basal levels 
of transcription in many genes, possibly tlnough the BTE binding 
protein (BTEB) wltich has been located in tlie liver. Binds Sp 
transcription family members
CAAT Box A consensus sequence tliat is present in many genes. Binds tlie liver 
specific protein C/EBP (CCAAT/ Enliancer binding protein) and the 
ubiquitous transcription factor CPI (CCAAT-protein-1), amongst 
others, to increase tiunscription. It lias a dominant role in determining 
the efficiency of the promoter.
CACCC box Found upstream from CAAT box, it is tliought to be involved in 
transcriptional initiation. Known to bind Sp-1.
DRn A direct repeat witli n bp spacing (AGTTCA-n-AGTTCA) tliat binds 
PXR/RXR and otlier nuclear receptor heterodimers to activate gene 
transcription
ER6 Two everted copies of tlie AG(G/T)TCA motif separated by 6 
nucleotides. Binds PXR/RXR and other nuclear receptor heterodimers, 
such as CAR/RXR, to activate gene transcription.
ERE/PRE/GRE Response elements witli similar consensus sequences. The binding of 
tlie receptors ER, PR and GR are involved in both positive and 
negative regulation of gene transcription in response to estrogens, 
progestins and glucocorticoids.
HNF-3 Regulatory motif that binds tlie liver-enriched transcription factor, 
HNF-3 (hepatocyte-specific nuclear transcription factor-3). Involved 
in tlie regulation of many liver-specific genes, such as transthyretin 
and a  1-antitrypsin genes.
HNF-4 Regulatory motif tliat binds tlie liver-enriched transcription factor, 
HNF-4 (hepatocyte-specific nuclear transcription factor-4). Involved 
in the regulation of many liver-specific genes, such as CYP2 family 
genes.
HNF-5 Regulatoiy motif that binds tlie liver-enriched transcription factor, 
HNF-5 (hepatocyte-specific nuclear transcription factor-5). Involved 
in tlie regulation of many liver-specific genes, such as tlie human 
transferrin genes.
Octamer m otif A consei’ved motif present in many genes, such as CY PlA l and binds 
members of the Octamer factors family in order to eitlier up or down 
regulate gene transcription. For example, Oct-1 activates liistone H2B 
genes.
p53 Consensus sequence tliat binds tumour suppressor protein p53, P53 is 
a repressor protein tliat can inliibit or activate genes involved in cell 
proliferation, apoptosis, DNA repair and angiogenesis. P53 mutations 
that prevent tliis binding have been detected in many forms of cancer
E box Target motif for members of the basic helix-loop-helix factors in tlie 
liver, tlie most predominant being USF. Involved in tlie regulation of 
many liver-specific genes, such as tlie human |3-globulin gene.
TATA box Found in most eulcaryotic genes, tliis promoter is necessary for 
transcription. It is recognised by the TATA binding protein (TBP).
et a l , 2001; Savas et a l 1999a; Voet and Voet, 1995)
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1.3.6.1 The Role of P regnane X R eceptor in CYP3A induction
PXR was cloned from a mouse liver cDNA library searched for sequences showing 
high identity with the ligand binding domains (LBD) o f a number o f nuclear receptors 
(Kliewer et al., 1998). PXR orthologues have subsequently been cloned from a variety 
o f  species including human (also known as PAR and SXR), rat, rabbit, frog and fish 
(Bertilsson et al., 1998; Blumberg et al., 1998; Jones et al., 2000; Lehmann et al., 
1998; Moore, 2001; Zhang et al., 1999). A splice variant o f human PXR, PXR2, 
contains a deletion o f 111 nucleotides corresponding to 37 amino acids in the putative 
ligand binding domain (Dotzlaw et al., 1999). PXR2 has a diminished inductive 
ability due to impaired ligand binding (Hustert et al., 2001). This is similar in function 
to the mouse PXR2 variant, indicating splice variants may be common among 
mammalian PXRs (Kliewer et al., 1998).
PXR is expressed most abundantly in the liver o f most o f the aforementioned species, 
but differences exist in the extrahepatic tissue expression and in transcript mRNA or 
protein size, as shown in table 1.9 (Bertilsson et al., 1998; Hustert et al., 2001; Jones 
et al., 2000; Kliewer et al., 1998; Lehmann et al., 1998; Zhang et al., 1999). In 
addition to the tissues in table 1.9, human PX R l and 2 have been shown to be 
expressed in normal and neoplastic breast tissue and rat PXR is expressed in the 
ovary, placenta and uterus (Dotzlaw et al., 1999; Masuyama et al., 2001).
A  wide range o f structurally diverse xenobiotics, many o f which have been shown to 
be CYP3A inducers, can activate PXR. However species differences have been 
observed in their activation profiles (Table 1.10). For example rifampicin is a potent 
activator o f human and rabbit PXR but does not activate rodent PXR, in a similar 
manner to the species differences observed in CYP3A induction (Jones et al., 2000; 
Kliewer et al., 1998; Kocarek et al., 1995; Lehmann et al., 1998; Zhang et al., 1999).
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Table 1.9 Tissue expression and transcript or protein size of PXR orthologues
Species Liver Intestine Kidney Stomach Lung Transcript 
or protein 
size
Reference
M ouse +  + 4-4- 4- 4- 2.6, 1.9, 4.4 kb Kliewer et al., 
1998
Human +  + 4-4- 2.6, 4.3, 5 kb Lehmann et al., 
1998
Human
(PAR)
+  -f 4- ■+■ 3.4, 4.9, 6.6 kb Bertilsson et al., 
1998
Rat 4-4- 4-4- 4- 4- 4- 51, 58,42 kDa Zhang et al., 
1999
Rat 4—h 4- -t* 4- 4- Jones et al., 
2000
Rabbit "4- 4- "H -f- 4-4- 2.6, 4.5, 5 kb Jones et al., 
2000
+ + abundant, + detected at lower levels, - not detected, blank box not tested. The first transcript size 
(emboldened) is tlie most abundant witli tlie second and tliird being expressed in lower amounts.
Rodent PXRs exhibit higher sequence identity with each other (-90  %) than with 
hPXR (-80  %) at both nucleotide and amino acid levels, whereas rabbit PXR is 
roughly equi-divergent from the human and rodent forms (Jones et al., 2000; Kliewer 
et al., 1998; Lehmann et al., 1998; Zhang et al., 1999). As shown in table 1.11, the 
DNA binding domain o f PXR is 95 % conserved across the species, supporting their 
interaction with the same or similar response elements. However the ligand binding 
domains are more divergent, with only 78 % identity, suggesting the orthologs may 
have different ligand specificity (Jones et al., 2000).
Elucidation o f  the PXR ligand binding domain crystal structure identified that it was 
largely hydrophobic with a binding cavity volume substantially larger than many o f 
the other nuclear receptors to allow binding o f the structurally diverse CYP3A 
inducers that act via PXR. Five polar residues that interacted with SRI 2813 were 
identified in the cavity, four o f these residues differed between human and mouse 
PXR and were responsible for direct rifampicin interaction with hPXR LBD but not 
m PX RLBD  (Kliewer et al., 1998, 1999; Lehmann et al., 1998; Watkins et al., 2001).
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When these four residues were mutated, they conferred a human like activation profile 
on mouse PXR, indicating that PXR selectivity is affected by change in only a few 
polar residues in the ligand binding cavity (Watkins et a l , 2001). Therefore small 
differences in the ligand binding domain appear to be responsible, in part, for the 
species differences observed in PXR activation and thus much o f the cross species 
variability in CYP3A regulation may be accounted for at the level o f PXR activation.
Table 1.10 Species Differences in PX R  A ctivation (Adapted from Savas et a l, 1999b)
X enob iotic M ouse R at R abb it H um an Reference
5p pregnane- +  4- - - 4- -t- Savas et al 1999a
3,20-dione 4- 4* 4- 4- 4- 4- -}- Jones et al 2000
PCN 4* 4- 4- 4- - " Savas et al 1999a
4-
n.d.
4-4-
n.d.
4- 4- 
n.d. 4-
Jones et al 2000 
Lehmann et al 1998
Rifampicin - - + 4- Jones et al 2000
Clotrimazole - - 4- 4- 4- Savas et al 1999a
Troglitazone - - 4- 4- Jones et al 2000
Phénobarbital 4- 4- -t- -f -f- -4- Jones et al 2000
Cyproterone
acetate
4- 4- -4- 4- 4- Jones et al 2000
Spironolactone 4- 4- -j- - Jones et al 2000
Trans-nonachlor - 4- -f 4- Jones et al 2000
SR12813 4- 4- •4- 4- 4- 4- Jones et al 2000
TCPOBOP 4- n.d. n.d. 4- 4- Moore et al 2000
The agonist profiles for each receptor were determined by cotransfection of expression vectors for 
mouse (Kliewer et al., 1998; Lelunaiui et al., 1998, Jones et a l, 2000; Moore et a l, 2000), rat (Savas et 
al., 1999a; Zhang et al., 1999; Jones et al., 2000), rabbit (Savas et al., 1999a; Jones et al., 2000) or 
human (Bertilsson et al., 1998, Blumberg et al., 1998; Lelunann et al., 1998; Jones et al., 2000; Moore 
et al., 2000) PXR with eitlier a DR-3 or ER-6 reporter construct. Because different reporter constructs 
and different cell lines were used in tliese transfection assays only qualitative descriptions are used to 
compare the responses:
Strong activator ++, moderate activator +, not efficacious -, not determined n.d.
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Table 1.11 Amino acid sequence sim ilarity  of PXR between species
R at M ouse R abb it H um an
R at 100 92.5 95.5
M ouse 96.6 92.5 95.5
R abbit 76.6 78.3 94.0
H um an 75.9 77.3 82.0
DNA binding domain percent amino acid identities in rec Ligand binding domain
percent amino acid identities in blue. Adapted from Jones et a l, 2000
This has led to the suggestion that PXR is involved in mediating the induction o f  
CYP3A, and is novy generally accepted as true. Gel mobility shift assays confirmed 
that PXR bound to the CYP3A1/23 DR3 and the everted repeat m otif (ER6) found in 
CYP3 A4 proximal promoter, as a non permissive heterodimer with cis-9 retinoic acid 
receptor (RXR) (Bertilsson et a l ,  1998; Jones et a l ,  2000; Kliewer et a l ,  1998; 
Lehmann et a l ,  1998). This binding was found to be functional and could induce gene 
expression o f a reporter plasmid containing either DR3 or ER6 when treated with 
various CYP3A inducers as shown in table 1.8 (Jones et a l ,  2000; Kliewer et a l ,
1998; Lehmann et a l ,  1998; Schuetz et a l ,  1998; Zhang et a l , 1999).
Goodwin et a l ,  (1999a) demonstrated PXR/RXR heterodimers bound to an imperfect 
DR3 and an ER6 m otif within their distal xenobiotic enhancer module (XREM) o f  the 
CYP3A4 5’ flanking region. This binding could induce gene expression o f  a 
luciferase-XREM-proximal promoter construct when treated with various CYP3A 
inducers and could co-operate with the proximal promoter to enhance induction o f  the 
construct, although the precise mechanisms o f  this co-operativity remain to be 
clarified (Goodw in et a l ,  1999a). Overall there is good correlation between PXR 
activation and CYP3A induction and thus provides strong evidence that PXR is the 
key regulator o f  CYP3A transcription. This is supported by the abolition o f  CYP3A 
induction in PXR-nuU mice by prototypic rodent inducers such as dexamethasone and 
PCN (Xie et a l ,  2000a). PXR can also bind to and activate DR4 elements in the 
phénobarbital response elements in CYP2B6 and CYP2B1 in the presence o f  PXR 
activators such as rifampicin and PCN (Drocourt et a l , 2001; Geick et al., 2001; 
Smirlis et a l ,  2001). The ER6 element in the CYP3A4 and CYP3A7 promoters 
encompasses a DR4 element (Sueyoshi et a l ,  1999).
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Therefore in addition to being promiscuous in terms o f ligand activation, the 
PXR/RX Ra heterodimers also show a great deal o f flexibility in terms o f their DNA 
binding activity (Smirlis et al., 2001).
Recent studies in primary rat hepatocytes transfected with hPXR allowed induction o f 
a CYP3A23 promoter driven reporter gene by human specific inducers, such as 
rifampicin and phénobarbital, thus converting the induction response profile o f  the 
hepatocytes from rat to human (Xie et al., 2000a). This provides a possible 
explanation for the host cell dependent species differences observed in the induction 
o f CYP3A promoter driven reporter genes by Barwick et al. (1996). In vivo evidence 
for PXR determining the species specific CYP3A induction was provided by studies in 
transgenic mice, expressing hPXR, producing “humanised” CYP3A induction 
responses to human-specific inducers such as rifampicin (Xie et al., 2000a). Thus the 
presence, both qualitative and quantitative, of PXR forms in selected cell lines may 
determine the induction o f reporter gene constructs. Cotransfection experiments with 
different PXR forms may help to further elucidate their role in species differences.
PXR also has an indirect impact on CYP3A regulation by xenobiotics. PXR regulates 
other areas o f drug metabolism including the expression o f the ATP binding cassette 
(ABC) transporters, such as M D R l, which codes for p-glycoprotein, MRP3 and 
0A TP2 and phase II drug metabolising enzymes, such as glutathione S-transferase A2 
(Falkner et al., 2001; Geick et al., 2001; Müller, 2000; Schuetz et al., 2001;
Staudinger et al., 2001; Synold et al., 2001). For example, cells with higher levels o f 
p-glycoprotein, require higher concentrations o f rifampicin to induce CYP3A (Müller, 
2000).
1.3.6.2 The Role of Constitutively Active R eceptor in CYP3A induction 
CAR is the constitutively activated /androstane receptor, highly expressed in the liver, 
that mediates the induction o f CYP2B by xenobiotics (Baes et al., 1994; Honkakoski 
et al., 1998). CAR is also expressed in the intestine, heart, lung and muscle (Choi et 
al., 1997). CAR interacts stereo specifically with two steroids, androstanol and 
androstenol that inhibit its transcriptional activity by causing the dissociation o f the 
nuclear receptor coactivator SRC-1 (Forman et al., 1998; Moore et al., 2000).
43
It is believed that PB-like inducers abolish androstane binding, de-repressing CAR 
transcriptional activity. PB can promote translocation o f CAR to the nucleus without 
direct binding, so PB may activate CAR through an indirect mechanism involving 
translocation to the nucleus (Kawamoto et al., 1999; Moore et al., 2000; Tzameli et 
al., 2000). Okadaic acid, a phosphatase inhibitor, can inhibit CAR nuclear 
translocation, suggesting that PB activates a protein phosphatase, such as PP2A-C, 
that controls the translocation o f CAR into the nucleus (Kawamoto et al., 1999; 
Negishi, 2001). Once in the nucleus, CAR binds as a heterodimer with RX Ra, 
preferentially to DR4 and DR5 elements (Choi et al., 1997; Sueyoshi et al., 1999).
Initially due to the high concentration o f PB required to induce CYP3A compared to 
CYP2B1, it was suggested that PB mediated induction o f CYP3A via a different 
regulatory pathway than PXR (Kocarek et al., 1990). It was found that CAR could 
activate CYP3 A4-(ER6)3-tk-CAT and CYP3 A4 promoter driven luciferase activity in 
HepG2 cells via a DR4 element encompassed within the ER6, suggesting that CAR 
mediates CYP3A induction by PB (Goodwin et al., 1999b; Sueyoshi et al., 1999). This 
role is supported by PB induction o f Cyp3all in PXR null mice but not in CAR null 
mice (Wei et al., 2000; Xie et al., 2000a). It has since been found that CAR can also 
activate CYP3A4 and CYP3 A7-XREM driven reporter genes in CV-1 (Monkey 
kidney) and C3A (HepG2 derived) cells respectively (Bertilsson et al., 2001; M oore et 
al., 2000). Smirlis et al. (2001) investigated the promiscuity o f PXR and CAR by 
transfection o f  the receptors with either C YP3 A 1 -(PXRE)4-tk-C AT or CYP2B1- 
(PBRE)-SV40-luciferase into primary rat hepatocytes and in vivo rat liver. CAR 
appeared to mediate barbituate activation o f  CYP3A via the same response elements 
as PXR activation in response to synthetic steroids, such as the DR3 in CYP3AJ and 
DR4 in CYP2B1. Therefore CAR is extremely promiscuous with respect to DNA but 
not ligand binding (Smirlis et al., 2001).
Another indicator o f the preferential control by CAR of all P450 induction by 
phénobarbital was the poor induction o f CYP2B and CYP3A in response to 
phénobarbital in obese Zucker rats, which have low CAR expression levels (Zelko 
and Negishi, 2000). Whereas PB induced CYP2B and CYP3A in lean Zucker rats with 
normal CAR expression levels (Zelko and Negishi, 2000).
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Despite the ligand preference o f CAR for phénobarbital, there are significant amino 
acid differences in the LBDs o f mouse and human CAR (72 % amino acid similarity) 
(Baes et al., 1994; Choi et al., 1997; Negishi and Honkakoski, 2000). Thus the 
activation profiles o f human and mouse CAR may differ in a similar manner to the 
species differences observed in PXR activation (Jones et al., 2000). For example, 
clotrimazole is an efficacious deactivator o f hCAR but not mCAR (Moore et a l, 
2000). The PB-like xenobiotic TCPOBOP causes the translocation o f both human and 
mouse CAR to the nucleus but only directly binds to and activates mouse CAR 
(Kawamoto et al., 1999; M oore et al., 2000; Sueyoshi and Negishi, 2001). In contrast, 
sp  pregnane-3,20-dione increases the interaction o f hCAR with SRC-1, thus 
activating the human receptor, but only weakly activates mCAR (Moore et al., 2000). 
Therefore like PXR, CAR may also play a role in determining the species differences 
observed in CYP3Â induction, especially by barbituates.
1.3.6.3 The Role of Glucocorticoid Receptor in CYP3A induction
The glucocorticoid receptor can activate or down regulate gene transcription (Pascussi 
et al., 2000a, b; Schweizer-Groyer et al., 1997; Subramaniam et al., 1999). The 
binding o f  glucocorticoid to the receptor promotes dissociation from heat shock 
protein 90 (HSP90). The GRs then dimerise and translocates to the nucleus where 
they interact with glucocorticoid response elements (GRE) in the DNA o f 
glucocorticoid responsive genes. The consensus sequence o f GRE is 
GGTACAnnnTGTTCT (Beato, 1989). Putative GREs have been recognised in the 5’ 
flanking regions oïCYP3Al, 3A4, 3A5 and 3A7 (Burger et al., 1992; Hashimoto et al., 
1993; Jounaidi et al., 1994; Perlera et al., 1998; Schuetz et al., 1996). It is still unclear 
if  and how the GR is involved in the regulation o f CYP3A and may function by direct 
or indirect mechanisms.
Recent work in the Molecular Toxicology laboratory (University o f Surrey) indicated 
that the GR was involved for at least some inducers o f CYP3A4, such as PCN, 
rifampicin, phenytoin and phenobarbitone because the fold induction was enhanced 
by cotransfection o f a vector expressing GR with CYP3 A4-CMV-pSPAP promoter 
driven reporter gene construct into HepG2 cells (Ogg et al., 1999).
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Enhancement was also observed when GR was cotransfected with PXR and the 
CYP3 A4-CMV-pSPAP promoter driven reporter gene construct compared to PXR 
alone (El-Sankary et al., 2000). Steven Kliewer and colleagues have observed that 
dexamethasone is always a more efficacious inducer o f CYP3A in vivo than PCN, 
suggesting the involvement o f GR (S .Kliewer, personal communication).
The activated GR may bind to its target sequence, modify the local chromatin 
structure and then leave the site accessible to another factor. This “hit and run” 
mechanism o f  transcriptional activation has previously been observed in the rat TAT 
gene with glucocorticoid-dependent HNF5 binding (Rigaud et al., 1991). A HNF5 
m otif is located in the CYP3A4 5’ flanking region (Hashimoto et al., 1993).
However Patrick Maurel and his colleagues suggests that dexamethasone acts through 
the classic glucocorticoid receptor pathway to induce hPXR and hCAR mRNA which 
then potentiates the induction by rifampicin and other xenobiotics (Pascussi et al., 
2000a & b) (figure 1.11). Interleukin-6 (IL6) down regulates PXR and CAR 
expression, thus reducing rifampicin and PB mediated induction o f CYP2 and CYP3 A 
mRNA forms (Pascussi et al., 2000c). IL6 transiently activates the NFicB pathway up- 
regulating the p65 subunit, which can physically interact with GR, repressing 
activation or induction o f genes regulated by the classical GR pathway, including 
PXR and CAR (Assenât et al., 2001; Pascussi et al., 2001). It is this repression that 
decreases CYP3 A  mRNA induction. Therefore the involvement o f GR in CYP3 A 
mRNA induction is at least partially due to its regulation o f PXR and CAR.
46
Figure 1.11 Cross talk between GR, PXR and RXR a in Human Hepatocytes
Adapted from Patrick Maurel lecture DMW/ISSX 2000 and Huss and Kasper, 2000
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1.3.6.4 The Role o f cis-9 Retinoic Acid Receptor Family in CYP3A induction
The retinoid X receptor family o f  nuclear receptors act as heterodimerisation partners 
for many o f  the nuclear receptors, including PXR, CAR, VDR and PPAR, during their 
binding to their cognate response elements (Keller et al., 1993). RXRs also bind to 
hormone response elements as homodimers, binding preferentially to D Rl motifs and 
activating genes such as the cellular retinol binding protein type II (CRBPII) gene 
(M angelsdorf et al., 1991). RXRs are activated solely by 9-cis retinoic acid (Heyman 
et al., 1992; Levin et al., 1992). However due to conversion o f  trans-retinoic acid to 9- 
cis retinoic acid, high concentrations (10"^-10'^ M) o f  trans-retinoic acid can also 
activate gene transcription in cells transfected with RXRs (M angelsdorf et al., 1990, 
1992).
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There are three known forms o f RXR, namely RX Ra, P and y. RXRP was initially 
referred to as RcoR-1 and exhibits 95 % identity with the DNA binding domain 
(DBD) o f R X R a and greater than 90 % identity with R X Ra LBD (Yu et al., 1991). 
R X R a and P have a widespread expression pattern, with the level o f  R X R a especially 
high in the adult liver (Jiang et al., 1999; M angelsdorf et al., 1992; Mano et al., 1993). 
The presence o f both ligand and receptor in the liver, indicates that R X R a is likely to 
play a significant role in controlling liver-specific gene expression and hepatocyte 
phenotype in vivo. This is supported by the R X R a null mouse foetus having an under­
developed liver (Sucov et al., 1994). Knock outs o f R X R a also had ocular and cardiac 
malformations resembling those found in foetal vitamin A deficiency syndrome, 
whereas RXRp knock outs had aberrant lipid metabolism in Sertoli cells (Kastner et 
al., 1994, 1996; Sucov et al., 1994). This indicates specific roles for R X R a in retinoid 
signalling including interactions with VDR, and in the PPAR signalling pathway for 
RXRP (Keller et al., 1993). Interestingly RXRP is expressed at low levels in tissues 
where R X R a is well expressed (M angelsdorf et a l, 1991).
In contrast, RXRy has a more restricted distribution; liver, skeletal muscle, heart, 
kidney, lung, brain, sensory epithelia o f the visual and auditory system and in the 
thyrotropes o f the pituitary (Dollé et a l ,  1994; Liu and Linney, 1993; M angelsdorf et 
a l ,  1992; Mano et a l, 1993; Sugawara et a l, 1995). Knock out RXRy mice lacked 
apparent defects, which was surprising considering its tissue specific expression 
pattern (Krezel et a l, 1996). The evolutionary conservation o f RXRy indicates that it 
must confer some selective advantage, which may be fine tuning the functioning o f 
certain tissues rather than in the control o f major developmental and/or physiological 
events. This is supported by dual knock outs o f either R X R a and y or RXRp and y, 
which show the same defects as the single R X R a or p mutants (Krezel et a l ,  1996). 
R X R a or p alone are sufficient for completion o f a number o f developmental RXR 
functions, indicating the existence o f functional redundancy amongst RXRs. A 
further indicator o f this is an RXR triple null mouse, with only one R X R a allele and 
no p or y, is essentially normal, displaying only growth deficiency and male sterility 
(Krezel et a l, 1996). This shows that a single allele o f R X R a can therefore perform 
most o f the developmental RXR functions.
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The expression o f the RXR forms is differentially regulated by retinoic acid (RA) in 
different cell types, for example R X R a is up-regulated by RA in F9 teratocarcinoma 
cells but down regulated in Hep3B cells (Wan et a l, 1994, 1998). Thyroxine also 
differentially regulates RXR, increasing transcription o f  RXRP and decreasing 
RXRy by mRNA destabilisation and having no effect on R X R a in the heart and brain 
(Mano et a l, 1993, 1994). In Hep3B cells, R X R a levels also increase as the cells 
reach confluence (Wan et a l , 1998). From this it appears that ligands can regulate 
their receptor expression because thyroid receptor (TR) and retinoic acid receptor 
(RAR) require RXR heterodimerisation partners.
Apart from the information provided by transgenic mice, it is difficult to elucidate 
specific roles for the R X R a and P forms because both are capable o f heterodimerising 
with TR, RAR and VDR enhancing their DNA binding and transcriptional function on 
their respective response elements (Yu et a l, 1991). However the rat CRBPII gene is 
differentially regulated by R X R a compared to RXRp. Transient transfection of 
R X R a into NIH3T3 fibroblasts yields a high level o f  9-cis retinoic acid-dependent 
transcription o f a CRBPII reporter gene construct compared to RXRP, suggesting that 
the two molecules perform distinct but overlapping roles in vivo (Hallenbeck et a l, 
1996). This effect was cell type dependent, as both receptors elicited comparable 
transcriptional activation o f the same reporter in P I 9 embryonal carcinoma cells 
(Hallenbeck et a l, 1996). Cell type specific transcriptional regulation may be due to 
co-operation or interaction with other cell-specific factors such as receptor-associated 
coactivator-3 (RAC3) and GRIPl (Issa et a l, 2001).
RXR interactions with cofactors are ligand dependent, and therefore may be 
dependent upon the conformation o f the LBD (Leong et a l, 1998). RXRs can also 
interact with TFIIB via their carboxyl region to regulate target genes (Leong et a l ,
1998). Nuclear receptor RXR heterodimers can either enhance, inhibit or have no 
overall effect on target gene expression in the presence o f ligand (Depoix et a l, 2001; 
Hallenbeck et a l, 1993; Wan et a l, 1998; Yoshikawa et a l, 2001). The transcriptional 
response may depend on the structure and /or sequence o f the response element 
(Hallenbeck et a l, 1993).
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Once RXRs heterodimerise, their ligand dependent activation function is usually 
silenced. However synergistic activation o f target genes by PPARa/RX R 
heterodimers in the presence o f both their cognate ligands has been reported (Baes et 
al., 1995; Keller et a l, 1993). In terms o f CYP3A induction, 9-cis-retinoic acid is not 
required for maximum PXR/RX Ra mediated activation o f CYP3A genes. The type o f 
ligand present determines whether heterodimerisation occurs, for example in the 
presence o f  RAR agonists, RAR/RXR heterodimers form, whereas RAR antagonists 
inhibit heterodimerisation (Depoix et a l , 2001).
There is no direct evidence whether RXRp or RXRy can heterodimerise with PXR or 
CAR. However Honkakoski et al. (1998) reported a dramatic increase in CAR,
R X R a and RXRP binding to N R l in the CYP2B10 promoter after PB treatment, 
suggesting co-operation o f CAR and RXRp during gene activation may occur. 
Disruption o f the mouse R X R a gene specifically in hepatocytes, reduced the 
expression o f hepatic CYP2B10 and CYP3A1 mRNA, 10 and 4 fold respectively, 
indicating that the basal activity o f  pathways in adult liver involving class II nuclear 
receptors is compromised in the absence o f R X R a (Wan et a l, 2000). The functional 
redundancy observed between R X R a and RXRp suggest that RXRP heterodimerise 
with PXR and CAR and these heterodimers are responsible for the remaining 
CYP2B10 and CYP3A1 mRNA expression in the R X R a null hepatocytes (Krezel et 
a l ,  1996; Wan et a l, 2000). Wan et a l (2000) reports that all three RXRs are able to 
heterodimerise with any o f the class II nuclear receptors, but that there may be 
preferences for distinct forms in vivo, which in the case o f PXR and CAR appears to 
be R X R a (Chiba et a l, 1997). Interactions o f PXR and CAR with RXRp or RXRy 
may be competitive with R X R a and/or form functionally inactive or permissive 
heterodimers. The abundance o f R X R a in the liver supports its role as the major 
heterodimerisation partner in CYP3A regulation, however in other tissues CYP3A 
induction may require the alternate forms. Therefore with regard to CYP3A induction 
the roles o f the different RXR forms requires further investigation.
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1.3.6.5 The Role of Hepatic Nuclear Factor 4 in CYP3A regulation
HNF4 is a liver-enriched transcription factor that participates in the restricted 
expression o f liver genes (Cereghini, 1996; Kuo et ah, 1992). HNF4 was first 
identified by its interaction with the cis sequence GGGTCAAAGGTCA in the 
transthyretin and a  1-antitrypsin promoters (Costa et ah, 1989). HNF4 is classed as a 
member o f  the nuclear receptor subfamily due to a zinc finger region and a highly. 
hydrophobic carboxy-terminal region, similar to the dimérisation and LBD o f other 
nuclear receptors such as R X R a (Sladek, 1994). However no specific ligand for 
HNF4 has been identified and hence it remains classed as an orphan receptor. HNF4 
exists as stable homodimers in solution, resides primarily in the nucleus and binds to 
the consensus sequence presented above, an almost perfect D R l m otif (Jiang et ah, 
1995). HNF4 therefore competes for binding sites with other nuclear receptors such as 
COUPTF and RXR homodimers and RXR nuclear receptor heterodimers (Makover et 
ah, 1989; Mietus-Snyder et ah, 1992; Nakshatri and Chambon, 1994). There are 
several binding sites that are specific for HNF4 binding, being present in the H N Fl 
and al-antitrypsin  promoters (Sladek, 1994).
In adults HNF4 has a limited tissue distribution in the liver, intestine and kidney at 
high levels (Sladek et ah, 1990). HNF4 is crucial for the expression o f the HN Fl 
gene, activating transcription by facilitating the assembly o f the preinitiation complex 
intermediate via direct physical interactions with TFIIB (Viollet et ah, 1997). The 
importance o f HNF4 in gene regulation is demonstrated by the embryonic death o f 
HNF4 null mice (Chen et ah, 1994). HNF4 is essential for liver development and 
function, and has been proposed to be responsible for the final commitment for cells 
to differentiate into hepatocytes (Nagy et ah, 1994).
HNF4 is phosphorylated at tyrosine, serine and threonine residues, so various 
stimulators and inhibitors o f protein kinase pathways modify the HNF4-mediated 
transcriptional activation (Cereghini, 1996). For example, cAMP activates protein 
kinase A, which phosphorylates HNF4 near to its DBD, converting it into an inactive 
form unable to bind to DNA. This is the mechanism responsible for the down 
regulation o f phosphoenolpyruvate carboxykinase (PEPCK) expression by 
glucocorticoids (Viollet et ah, 1997).
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However tyrosine aminotransferase (TAT) expression is induced by cAMP as 
COUPTF replaces HNF4 on the DNA and interacts with cyclic adenosine 3’,5’- 
monophosphate response element binding protein (CREB) to activate the gene 
(Schweizer-Groyer et a l, 1997; Viollet et al., 1997). Therefore regulation via HNF4 is 
not just due to direct phosphorylation or dephosphorylation but due to interaction with 
various corepressors or coactivators.
The COUPTF family o f  transcription factors can negatively regulate HNF4 
transactivation (described further in section 1.3.6.6). HNF4 has also been shown to 
interact with CREB binding protein (CBP) in a ligand-independent manner on the 
hepatocyte growth factor-like protein (HGFL) promoter, which initiates chromatin 
alteration to recruit components o f the basal transcription machinery (Muraoka et al.,
1999).
HNF4 can also act negatively to repress gene transcription. For example, the 
mitochondrial HMG-CoA synthase gene is repressed by HNF4 binding to a hormone 
response element within the promoter, in competition with PPAR/RXR heterodimers 
and COUPTF, which induce the expression o f the gene (Rodriguez et a l ,  1998). This 
may involve interaction with a corepressor.
In terms o f  CYP3A regulation, the regulatory role o f HNF4 in basal CYP3A1, CYP3A2 
and CYP3A23 expression was described in sections 1.3.5.1 and 1.3.5.2 via a site A, 
6pB-A, 6pA-A in the respective proximal promoters. HNF4 is also required for 
maximal induction response o f the aforementioned genes (Huss et a l, 1999; Huss and 
Kasper, 1998, 2000; Ogino et a l, 1999). Putative binding sites for HNF4 are present 
in CYP3A4 and CYP3A 7 proximal promoters, but their precise role in human CYP3A 
regulation has still to be elucidated (Hashimoto et a l, 1993). In human hepatocytes 
transfected with HNF4 antisense RNA, there is a dose dependent down regulation o f 
CYP3A4 and CYP3A5 mRNA indicating that HNF4 may play a similar role in 
regulating human CYP3A basal expression compared to the rat (lover et a l, 2001).
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1.3.6.6 Chicken Ovalbumin Upstream Promoter Transcription Factors and their 
role in CYP3A regulation
COUPTFs are so-called after human COUPTF 1 was discovered bound to  the COUP 
element, which regulated transcription o f the ovalbumin gene (Wang et al., 1989a). 
COUPTF 1 is also known as Ear3 after being independently cloned as v-ErbA-related 
protein 3 (M iyajima et al., 1988). A second human family member COUPTFII was 
cloned as apoliopoprotein regulating protein-1 (ARP-1). These factors belong to the 
NR2F nuclear receptor subgroup and have since been detected in numerous species 
from humans toÆ  laevis, D. malanogaster and C.elegans (Pereira et al., 2000). 
Human COUPTFI and II differ by a single amino acid in the DBD and are 97 % 
identical in their C terminals, but diverge from one another in the N  terminal regions 
(Butler and Parker, 1995; R itchie et al., 1990). There is also third human COUPTF, 
Ear2, which is less conserved than the other forms in the LBD and DBDs (Avram et 
al., 1999; Escriva et al., 1997; Tsai and Tsai, 1997).
In different species COUPTF DBDs are almost identical and the LBDs have 99.6 % 
identity amongst vertebrates and even 90 % between human and fly LBD (Tsai and 
Tsai, 1997) (Table 1.12). This suggests that these domains are critical for the 
biological function o f COUPTFs and have thus been conserved throughout evolution. 
The importance o f these factors is supported by the lethality o f COUPTFI or II null 
mice. COUPTFI null mice have defects in the central and peripheral nervous system, 
whereas COUPTFII null mice have malformed hearts and blood vessels suggesting 
distinct roles for the different forms despite their similarity (Pipaon et al., 1999).
COUPTFI and II exhibit overlapping but distinct expression patterns in all three germ 
layers during mouse development, with high expression o f COUPTFI in the nervous 
system and o f  COUPTFII in the mesenchyme o f internal organs, which continues into 
adulthood (Pereira et al., 1995; Qiu et al., 1994). This indicates a role for COUPTF in 
development and differentiation.
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Table 1.12 Amino acid sequence similarity of COUPTF forms between species
hCOUP
TFI
mCOUP
TFI
xCOUP
TFI
hCOUP
TFII
mCOUP
TFII
xCOUP
TFII
xCOUP
TFIII
dSVP hEAR2
hCOUPTFI 100 100 100 98 98 98 95 95 n.d.
mCOUPTI 100 100
xCOUPTFI 100 100 100
hCOUPTFII 96 96 96 100
mCOUPTFII 96 96 96 100 100
xCOUPTFII 96 96 96 100 100 100
xCOUPTFIII 90.6 90.6 90.6 91.5 91.5 91.5 100
dSVP 89.8 89.8 89.8 91.0 91.0 91.0 88.1 100
hEAR2 71.0 71.0 71.0 71.0 71.0 71.0 69.3 69.3 100
DNA binding domain percent amino acid identities in red. Ligand binding domain 
percent amino acid identities in blue. n.d. indicates not determined. (Avram et al., 
1999; Butler and Perker, 1995; Escriva et al., 1997; Ritchie et al., 1990; Tsai and Tsai, 
1997)
The COUPTFs exist in solution as stable homodimers, capable o f binding with high 
affinity to direct repeats o f  the nuclear receptor half site AGGTCA o f  various 
spacings, with preference to direct repeats separated by one nucleotide (D R l) 
(Cooney et al., 1992). COUPTF homodimers can also bind to everted repeats or 
palindromic sequences but with lower affinity than direct repeats (Cooney et al., 
1992). The COUPTF dimer forms contacts with both half sites and undergoes 
structural adaptation to accommodate binding to these spatial variants, either by one 
o f  the DBDs rotating 180® w ith respect to the other, or both DBD rotating 90® 
maintaining dimérisation through a single interface (Cooney et al., 1992).
This promiscuous affinity for direct repeats allows COUPTF to compete for the same 
hormone response elements as other nuclear receptors and thus negatively regulate 
genes activated by these receptors. For example COUPTF represses transcription o f 
the hRXRy-2 gene by competing with R X R a homodimers for binding to the yRXRE 
(Barger and Kelly, 1997; M iyata et al., 1993). COUPTF can also compete for HNF4 
binding sites and thus often negatively regulates HNF4 activated genes, such as the 
angiotensinogen gene (Qiu et al., 1996; Yanai et al., 1999).
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There are other mechanisms by which COUPTF negatively regulates gene 
transcription, including heterodimerisation with common nuclear receptor 
dimérisation partner RXRa. COUPTF and R X R a can form stable heterodimers in 
vitro and on D R l motifs, fully repressing RXR mediated activation (Kliewer et al.,
1992). COUPTFs can also heterodimerise with other nuclear receptors such as 
TRp, AhR, E R a  and RAR via their LBDs (Berrodin et al., 1992; Klinge et al., 1997, 
2000; Leng et al., 1996; Tran et al., 1992). However this formation o f functionally 
inactive heterodimers is unlikely to be the general repression mechanism o f  COUPTF, 
because Butler and Parker (1995) reported that COUPTFII homodimers were formed 
in preference over TRp, RAR or R X R a heterodimers (Cooney et al., 1993). The C 
term inal domain o f COUPTF is an active silencing or repression domain (Achatz et 
al., 1997; Leng et al., 1996). This domain interacts with cellular corepressors such as 
NCoR, SMRT and Rip 13 to silence a variety o f transactivators, possibly by 
recruitment o f hi stone deacetylases (Bailey et al., 1997; Klinge, 1999; Pipaon et al., 
1999; Shibata et al., 1997, 1998). A fourth method o f repression by COUPTF, 
transrepression, has been proposed. Transrepression involves COUPTF interacting 
with a nuclear receptor already bound to DNA and repressing general transcription 
factors within the complex, such that the repression domain o f  COUPTF is recruited 
to DNA by heterodimerisation with other nuclear receptors (Achatz et al., 1997; Leng 
et al., 1996). COUPTF can interact with TFIIB, possibly freezing it in an inactive 
conformation and thus blocking basal transcription (Leng et al., 1996).
COUPTF is widely regarded as a negative transcriptional regulator, however it can 
also activate genes including its namesake the ovalbumin gene. This positive 
regulatory function can occur by numerous mechanisms: COUPTF homodimers can 
bind to direct repeats and directly transactivate genes (Fernandez-Rachubinski and 
Fliegel, 2001). COUPTF can act as an accessory factor during glucocorticoid 
induction o f the PEPCK gene (Hall et al., 1995; Scott et al., 1996). COUPTF can also 
act as a coactivator through DNA-bound HNF4 to transactivate the H N Fl gene 
(McNair et al., 2000). However variant H N Fl (vHNFl) is activated by COUPTF in 
the absence o f HNF4, via interaction with Oct transcription factor family members 
(McNair et al., 2000). COUPTFI can also interact with Spl, using it as a docking 
protein to mediate NGFI-A gene transcription (Pipaon et al., 1999).
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The same region o f the COUPTF protein (184 to 423 amino acids) is responsible for 
all the above activation mechanisms and the association o f G RIPl, SRC-1 and p300 
which potentiate COUPTFI activity (Pipaon et a l, 1999; Sugiyama et a l ,  2000). 
Therefore COUPTF may be responsible for coactivator recruitment for nuclear 
receptor transactivation, as COUPTF also enhances the interaction o f  R A R a with 
CBP, its coactivator (Lin et a l , 2000). The importance o f coactivators and 
corepressors in the role o f COUPTF gene regulation suggest that their availability 
may be responsible in part for the different actions of COUPTF.
COUPTF expression is also regulated by all trans retinoic acid and cAMP, indicating 
a role for phosphorylation in the regulation or activity o f COUPTF (Pereira et a l , 
2000; Soosaar et a l, 1996). Brodie et a l (1996) observed that COUPTF binding to 
DNA correlated with TCDD and RA induced phosphorylation. The direction o f 
COUPTF regulation o f genes, either positive or negative, will most likely, depend on 
numerous factors including the organisation o f the DNA binding site, promoter 
architecture, cell context and the ratio o f COUPTF to other receptors, coactivators and 
corepressors (Qiu et a l, 1996).
As described in sections 1.3.5.1 and 1.3.5.2, COUPTF is involved in the expression o f 
CYP3A23 and CYP3A2 by competition with complex B and PXR/RX Ra heterodimers 
for binding to an imperfect ER6 and a perfect DR3 respectively. In CYP3A2, where 
COUPTF binding affinity was greater than in CYP3A23 due to mismatches in the 
DexRE-1 and 2 elements, glucocorticoid responsiveness was reduced, indicating that 
COUPTF acts as a transcriptional repressor in CYP3A23 and CYP3A2 induction (Huss 
et a l, 1999). It has also been suggested that COUPTF competition for binding to the 
imperfect ER6 in DexRE-1 may repress HNF4 mediated basal CYP3A expression 
(Quattrochi and Guzelian, 2001). HNF4 mediated activation o f a CYP3A1 promoter 
driven reporter gene at DexRE-2 has also been suppressed by recombinant ARP-1 and 
Ear3 (COUPTFII and I respectively) w ithout competition with H N F4a at site A, 
again indicating a negative role for COUPTF in rat CYP3A regulation (Huss et a l, 
1999; Ogino et a l ,  1999).
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There are also COUPTF binding sites located in the CYP3A4 and CYP3A7 distal 
enhancer regions, but the role of COUPTF in human CYP3A regulation is unclear 
(Bertilsson et al., 2001; Goodwin et al., 1999a). Rodrigues et al. (2001) proposed that 
dynamic heterodimers o f COUPTF/PXR regulate adult induction o f  CYP3A1 by 
glucocorticoids because cotransfection o f COUPTFI with a CYP3 A1 promoter 
reporter gene, in human HuH7 cells, increased transcriptional activation by PXR. The 
positive action o f COUPTF on CYP3A1 in HuH7 cells, compared to the negative 
regulation o f CYP3A23 and CYP3A2 expression in Cosl and H4IIEC3 cells, may be 
due to cell type differences. COUPTF can be differentially regulated in different cell 
types, and as mentioned previously, species differences in CYP3A regulation have 
been proposed to be due to host cell effects (Barw ick et al., 1996; Qiu et al., 1996; 
Soosaar et al., 1996). This may therefore indicate a positive role for COUPTF in the 
regulation o f human CYP3As.
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1.3.7 The Role of H ost Cell E nvironm ent in CYP3A Regulation
Species differences in CYPSA regulation have been proposed to be due to host cell 
effects (Barw ick et al., 1996). These host cell effects have now been proposed to be 
due to differences in receptor activation profiles in different species. As explained in 
section 1.3.6.1, human PXR is activated by rifampicin but mouse and rat PXR are not, 
due to differences in the amino acid residues in their ligand binding cavities. However 
gene regulation is complex, involving different receptors in different species binding 
to different promoters and therefore it is unlikely to be determined purely by receptor 
activation, but by the interaction o f these activation factors such as receptor-ligand 
competition and receptor-DNA competition.
The major receptors discussed in section 1.3.6 can interact with a variety o f 
coactivators and corepressors, some o f which overlap (Masuyama et al., 2001; 
M uraoka et al., 1999; Shibata et al., 1997, 1998). For example, the extent o f CAR 
interaction with SRC-1 determ ines the potency o f many CAR activators, whereas the 
promotion o f interaction o f PXR with SRC-1 and GRIP, plus the ability to displace 
the repressor SMRT, determines the activity o f a ligand with PXR (Moore et al.,
2000; Ourlin et al 1997; Synold et al., 2001).
SRC-1 is a common coactivator for PXR, CAR, G Ra, COUPTF and HNF4, 
indicating that competition for SRC-1 may occur between the regulatory pathways in 
which it is involved (Kino et al., 1999; M oore et al., 2000; Pipaon et al., 1999; 
Sugiyama et a l, 2000; Synold et a l, 2001; Wang et a l, 1998). Therefore unless 
coactivators and corepressors are unlimited within cells, competition o f  nuclear 
receptors for them may have a limiting effect on gene regulation. Therefore the 
balance and availability o f these coactivators and corepressors within the cellular 
environment may also effect CYPSA regulation (Kamei et a l, 1996).
Receptors can also compete for binding at the same response elements, for example 
COUPTF represses HNF4 mediated transcription by competition for D R l elements 
(Qiu et a l, 1996; Yanai et a l, 1999).
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PXR/RXR and CAR/RXR heterodimers compete for binding to the DR3 in rat 
CYPSA, DR4 in CYP2B6 and CYP2B1 and ER6 in human CYPSA promoters (Baes et 
a l ,  1994; Bertilsson et a l, 2001; Moore et a l, 2000; Smirlis et a l ,  2001; Xie et a l, 
2000b). This competition will also affect CYPSA regulation and thus the relative 
abundance o f  the nuclear receptors will determine the level o f  cross talk and the 
dominant regulatory pathway. For example in the regulation o f CYPSA, PXR is 
usually the dominant regulator over CAR. This conclusion is based on the fact that 
even with a 50 fold excess o f hCAR to hPXR expression plasmids cotransfected with 
a CYP3 A4 promoter driven reporter gene into CV-1 cells, the negative effects o f 
clotrimazole and androstanol on hCAR were neutralised by their positive effects on 
hPXR (Moore et a l, 2000). Also at a 20 fold excess o f hCAR to hPXR, there was a 
net activation o f XREM-CYP3 A4-luciferase reporter activity in response to 
clotrimazole (Moore et a l, 2000).
The expression o f a nuclear receptor is often regulated by other nuclear receptors, 
such as PXR, CAR and RX Ra, which are all regulated by GR (Pascussi et a l , 2000a 
and b). In HepG2 cells stably transfected with mCAR, the gene hEar2 (hCOUPTFIII) 
is up regulated (Sugatani et a l , 2001). This may indicate an autoregulatory role for 
CAR or its involvement in the regulation o f other factors in the CYPSA regulatory 
pathways such as PXR and HNF4 that are known to compete with COUPTFs for 
binding sites (Huss et a l, 1999; Sugatani et a l, 2001).
The presence o f  inactive forms o f receptors may also affect CYPSA regulation. For 
example, a human GRp form with a unique LBD is widely expressed but is unable to 
bind dexamethasone or RU486 and so is transcriptionally inactive (Kino et a l , 2001; 
Oakley et a l , 1996, 1999). It is primarily located in the nucleus and as such does not 
require translocation like G R a (Kino et a l, 2001). GRp is therefore able to compete 
for DNA binding sites or heterodimerise with G R a thus inhibiting gene activation by 
G R a (Kino et a l , 2001; Oakley et a l , 1996, 1999). Splice variants o f PXR with 
truncated LBDs are also expressed but are transcriptionally inactive (Dotzlaw et a l, 
1999; Hustert et a l, 2001; Kliewer et a l, 1998). Therefore the levels o f  these 
receptors within cells, will also determine the level o f CYPSA response to inducers.
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Further factors such as cell origin, cell age and level o f differentiation have to be 
considered when examining CYPSA regulation in different cell types or cell lines. 
Many o f  the transcription factors involved in CYPSA regulation are liver enriched and 
therefore may not be available in non liver cells or their role may have been replaced 
by an alternate factor. For example, C /EBPa can transactivate CYP3 A4, 5 and 7 
promoter driven reporter genes in both liver (HepG2) and non-liver (HeLa, a cervical 
carcinoma cell line) cells but HNF3y can only enhance their activation in liver 
(HepG2) cells (Rodriguez-Antona et al., 2001).
Therefore the origins o f the cells in which induction is taking place, may determine 
the regulatory pathway, especially in tissues where a major regulator is not expressed; 
such as PXR which is not expressed in human lung but CYP3A5 protein is (Pascussi 
et al., 2001). CYP3A7 mRNA is expressed in foetal liver, whereas CYP3 A4 protein is 
expressed in adult liver (Schuetz et al., 1994). The levels o f receptors and 
transcription factors alter during development, in part due to hormonal signals. There 
is little difference between CYPSA7 and CYPSA4 5’ flanking region, therefore it 
appears the availability o f  transcription factors determines which form is expressed 
(Bertilsson et al., 2001; Hashimoto et al., 1993; Saito et al., 2001). For example Spl 
recognises the NFxB-like enhancer in the CYPSA7 gene but not in the CYPSA4 gene 
due to a 1 bp mismatch (Saito et al., 2001). Spl has been reported to be expressed at a 
higher level in foetal livers, compared to adult human livers (Saffer et al., 1991).
So it appears that the cellular environment is a delicately balanced mixture o f receptor 
forms, coactivators, corepressors and other regulatory proteins. Alterations to any one 
o f these factors may switch the functional orientation o f a ligand from an inducer to 
an inhibitor, and thus may be another determining factor in species differences.
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1.4 Experimental Approaches to Investigate Species Differences in 
CYP3A Induction
1.4.1 CYPSA promoters
Human CYP3 A4 and rat CYP3A23 promoter driven reporter gene constructs were 
developed and used to compare the regulation o f rat and human CYPSA genes by 
xenobiotics. Previously in the Molecular Toxicology laboratory (University o f 
Surrey), a CYP3 A4 reporter gene had been developed using approximately 1 kb (- 
1087 to “ 57 bp) o f the CYPSA4 regulatory region coupled to the reporter gene for 
secretory placental alkaline phopsphatase (SPAP) (Ogg, 1998; W illiams, 1997). The 
plasmid was transfected into HepG2 cells, which were then treated with known 
inducers o f CYPSA4 and the levels o f  SPAP measured by chemiluminescence (Ogg et 
al., 1999). This system was used for the human element o f this investigation.
A similar system has been developed, in this investigation, for a rat CYPSA gene. On 
consideration o f the literature on rat CYPSA, it appeared that CYPSA2S was more 
advantageous in an investigation o f xenobiotics in rats. The reasons for this were; 
CYP3A23 is the major constitutive CYP3A mRNA expressed in rat liver. CYP3A23 
mRNA does not appear to be affected by sex differences unlike CYP3A2 mRNA 
which is found at high levels in adult male rats but not in adult females (Gonzalez et 
al., 1985; Ribeiro and Lechner, 1992). In addition, there was more information 
available in the literature on the CYPSA2S 5’ flanking sequence than the CYPSA2 
sequence. Also, most CYPSA inducers preferentially induce CYPSA2S compared to 
CYPSA2 by ratios ranging from 3 to 400 fold (Ghosal et al., 1996). Therefore I 
considered it more appropriate to use CYPSA2S in an investigation o f induction.
1.4.2 Reporter Genes
Genetic manipulation has been used frequently to elucidate the regulatory 
mechanisms o f P450 expression and a variety o f reporter gene vectors had been used 
including chloramphenicol acetyltransferase and (3-galactosidase. Each has 
advantages and disadvantages but secretory placental alkaline phosphatase (SPAP) 
was selected for my studies. Although this is an eukaryotic gene, its expression is 
limited to the placenta (Bronstein et al., 1994).
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SPAP is extremely heat stable compared to other eukaryotic alkaline phosphatases, so 
endogenous enzyme can be specifically inhibited by heating to 65 °C (Bronstein et al., 
1994). SPAP is secreted from the cells into the culture medium, so it can be measured 
using intact cells, so the cultures may be used in other studies such as RNA and 
protein analysis, unlike CAT when the cells must be lysed. SPAP can be accurately 
quantitated using either a standard colourmetric, a bioluminescence-based or a 
chemiluminescence-based AP assay (Berger et al., 1988; Bronstein et al., 1994). To 
enhance sensitivity, SPAP activity in the cell culture medium was assessed using the 
Aurora alkaline phosphatase chemiluminescent assay kit (ICN) in 96 well plates. 
There is also a wide range o f  knowledge and experience o f this system in the 
Molecular Toxicology laboratory (El-Sankary, 2000; El-Sankary et al., 2000; 2001).
1.4.3 H epatom a Cell L ines
The reporter gene constructs are transfected into hepatoma cell lines. These were 
selected because they offer several advantages over primary hepatoctyte cultures for 
an in vitro system. They show good reproducibilty, are easy to obtain and culture and 
provide the possibility o f detecting anti-proliferative or long term effects (Ferro et al.,
1993). However primary hepatocyte cultures are used as a model for metabolism 
mediated toxicity because they maintain a range o f P450 activities whereas 
established cell lines are generally considered to be dedifferentiated (Donato et al., 
1998; Ferro et al., 1993; Jacobs et al., 1999).
The most widely used human liver-derived cell line, HepG2 is often used to study 
P450s (Ferro et al., 1993). HepG2 cells were selected for use in this investigation 
because although they have some drawbacks, so do other cell lines such as Hep3B 
cells which contain integrated hepatitis B genome (Aden et al., 1979). The possible, 
low level, CYP3 A protein expression in HepG2 cells would not interfere with the 
investigation o f  CYPSA regulation because it was the reporter gene expression that 
was measured rather than CYP3 A content (Fukuda et a l, 1992; Schuetz et a l, 1993a). 
The CYP3 A4-CMV-pSPAP construct was transfected into HepG2 cells, so for a 
relevant comparison, the CYP3A23 promoter driven reporter construct was 
transfected into the same cell type.
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However Barw ick et al. (1996) demonstrated that CYP3A2 and CYP3A23 promoter 
driven reporter constructs lost their characteristic non-induction by rifampicin when 
cotransfected into rabbit hepatocytes, so a rat cell line was also selected for use.
Rat H4IIEC3 cells were selected because they had been used previously within the 
Molecular Toxicology laboratory and they maintain a number o f liver specific 
functions (Descharette and Weiss, 1974). Rat FaO cells were selected because they 
are a well-differentiated hepatoma cell line widely used in industry (Chevalier and 
Roberts, 1999; Passilly et al., 1999). They have been used successfully in human and 
rat drug response comparisons, using the peroxisome proliferator ciprofibrate 
(Passilly et al., 1996).
Once the conditions for transfection o f both reporter gene constructs were optimised, 
the system was tested with various known CYPSA inducers and this allowed 
comparisons to be made between the induction o f CYP3A23 and CYP3 A4 promoter 
driven reporter gene activity in both rat and human cells.
1.4.4 Cell Characterisation
1.4.4.1 Semi-quantitative RT-PCR
The indication that host cell effects determine the species differences in CYPSA 
induction meant the cell lines used should be characterised. The nuclear receptors 
believed to be involved in induction o f the major rat and human CYPSAs were 
measured in each cell line, previously used for transfections, by semiquantitative 
reverse transcription polymerase chain reaction. RTPCR was selected to measure 
basal mRNA levels because unlike other methods o f RNA analysis including 
Northern blotting, RTPCR does not require large sample concentrations and it is a 
rapid technique. The mRNAs were measured semi-quantitatively because 
development and optimisation o f competitor fragments or internal controls would 
have been too time consuming for this project. The semi-quantitative RTPCR 
provided an indication that some o f the differences in induction observed were due to 
the availability o f receptors in the regulatory pathways. It also indicated that the 
relative abundance o f these receptors play a role in determining the induction 
response.
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1.4.4.2 Western Blotting
mRNA requires translation into protein before the receptors can exert their effects. 
Therefore if  there were any differences in the translation rates or mRNA stability o f 
the receptors, intra or intercellular, the relative abundance o f the receptors would be 
different at a protein and functional level compared to those observed at an RNA 
level. Therefore the expression o f the same receptors were measured at a protein level 
by W estern blotting. Western blotting was selected because it is a relatively simple, 
inexpensive and highly specific technique.
1.4.4.3 Real Time PCR
I f  the relative abundance o f  receptors partially determined the host cell effects 
observed in CYPSA promoter driven reporter gene induction, expanding the genes 
investigated, to include a wider range o f receptors and transcription factors possibly 
involved in CYPSA regulation, would provide support for this theory. Pascussi et al. 
(2000a, b) demonstrated that dexamethasone can induce PXR and CAR, thus 
potentiating their induction o f CYPSA genes. Therefore xenobiotics could alter the 
relative abundance o f receptors compared to the basal levels, which could effect the 
induction o f CYPSA genes. Therefore real time quantitative PCR was used to measure 
the expression o f rat and human CYPSA forms and a selection o f receptors and 
transcription factor mRNAs, both basally and after a range o f dose concentrations o f 
dexamethasone, rifampicin, PCN and phénobarbital, in the three hepatoma cell lines 
used previously for transfection.
Each xenobiotic was selected to target a different receptor, for example PCN for rat 
PXR and rifampicin for human PXR. The range o f doses incorporated both 
pharmacological and physiological concentrations. TaqMan® was the method o f 
choice because it had been used in the literature to measure CYP3A1 mRNA and 
other P450 forms and nuclear receptors such as RXRa. TaqMan® is highly sensitive 
and as such, capable o f detecting genes present at low copy numbers. Also the 
TaqMan® method is very rapid in comparison to semi-quantitative RTPCR allowing 
analysis o f a large number o f genes in a large number o f samples in a short time.
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1.4.4.4 Data Analysis
The amount o f data generated from the semi-quantitative RT-PCR and real time PCR 
required a method to summarise the data and assist in the interpretation. Principal 
component analysis was selected because it reduces the dimensionality o f multivariate 
data, by an eigenanalysis o f  a covariance matrix, calculated on the original data. 
(Calvo et al., 2000). This can be thought o f graphically, as a rotation o f the data points 
in a multidimensional space so that the longest axis (the axis with greatest variance) is 
the first PCA axis, the second longest axis perpendicular to the first is the second PCA 
axis, and so forth. Thus these PCA axes should encompass the greatest amount o f 
variation in the data set. Eigenvalues are produced which indicate the amount o f 
variance accounted for by each PCA axis
(http://www.kovcomp.co.uk/mvsp/mvspwbro.html). The first two axes in the PCAs 
performed here in, represented eigenvalues o f 60 to 80 %.
Each variable is then assigned a variable loading which indicates the relative 
importance o f  that variable. These can be used to identify key variables or groups o f 
variables that control the system under study
(http://obelia.jde.aca.mmu.ac.uk/resdesgn/arsham/opre330.html). In analysis o f the 
semi-quantitative RT-PCR data, the variables were the receptor mRNA levels and the 
mRNA types were the cases. This dimensional reduction permitted graphical 
representation o f the data, in the form o f case scores allowing relationships between 
the cell lines and their liver counterparts to be drawn
(http://www.statsoft.com/textbook/stfacan.html). In analysis o f the real time PCR data 
for each xenobiotic in each cell line, the variables were the receptor mRNA levels and 
the xenobiotic concentrations were the cases. This allowed identification o f the key 
receptors in terms o f their cumulative variability (Calvo et al., 2000).
In summary, the overall experimental work utilised a wide range o f techniques to 
compare the basal and xenobiotic induced regulation of rat and human CYPSA at both 
functional and molecular levels.
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1.4.5 Aims of the Project
My project is designed to highlight the similarities and differences in CYPSA 
expression and regulation between humans and rats, indicating whether rats are a 
suitable model for drug screening for induction and may increase our ability to 
evaluate induction data from relevant non-human pharmacological model systems 
with respect to humans. M ore importantly it will help to elucidate the regulatory 
pathways o f CYP3 A, helping to provide long awaited answers and thus aiding design 
o f further drug screens for induction.
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2 Materials and Methods 
2.1 Reporter Gene Construct Development
2.1.1 Genomic DNA Extraction
DNA was extracted from flash frozen male Wistar rat liver using the Stratagene® 
RecoverEase™ DNA Isolation kit. The protocol for DNA isolation from liver tissue 
samples in the manufacturer’s technical manual was followed. The method involved 
homogenisation and filtration o f  the tissue, followed by isolation o f the cell nuclei via 
centrifugation. The cellular proteins were digested and the resulting peptides removed 
by dialysis leaving fully hydrated purified high molecular weight DNA. The 
concentration o f DNA was measured by spectrophotometry as described in section 
2.1.13.
2.1.2 Primer Design
The published sequence for the 5’ flanking region of CYP3A23 (M86850, Burger et 
al., 1992) was imported into the primer design programme Vector NTI 4.0 (InforMax 
Inc.) from the NCBI Genbank database. The parameters for primer design were set at 
product length 300-600 bp, percentage GC o f 45-60 % and primer length 17-23 bp. 
The primers used in this section are shown in table 2.1.
Upon receipt, lyophilised primers (Gibco BRL, MG Biotech) were resuspended in 
nuclease-free water to a stock concentration o f 100 pmol/pl. The stock primers were 
stored at -20  ®C. The stock primers were diluted with nuclease-free water to a 
working concentration o f 50 pmol/pl. The working primer stocks were stored at 4 °C.
2.1.3 Polymerase Chain Reaction
The volumes indicated in Table 2.2 were used for the PCR reactions. In the 
amplification o f CYP3A23 5’ flanking region four reactions were prepared in thin 
walled 0.5 ml Gene Amp reaction tubes (Perkin Elmer). Duplicate tubes containing the 
CYP3A23 A and CYP3 A23B primers and 200 ng o f extracted genom ic DNA were run 
in parallel with a DNA positive control tube containing control primers P5 and P I 1.
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A  PCR positive control, containing 1 \x\ control DNA (calf thymus DNA 100 ng/p.1) 
plus 2 p,l o f control primer (Advantage® 2 PCR Enzyme system, Clontech) was also 
run to check the PCR technique. The PCRs were performed in a Peltier Thermal 
Cycler (MJ-Research PTC-200, DNA-Engine). Cycle parameters can be seen in table 
2.3. PCR products were visualised by separation in a 1 % agarose gel containing 
ethidium bromide (Section 2.1.12)
Table 2.1 P rim er Sequences Used W ithin  the  Section 2.1.
Enzym e Foi*ward 
/  Reverse
P rim er nam e P rim er sequence
CYP3A23 Forward KES3A23A 5 ’-TACAACGG ATCTGGGAAAGCC-3 ’
CYP3A23 Reverse KES3A23B 5 ’-ATCCCTGCAGGTCTGTCAGCAA-3 ’
CYP3A23 Forward KES3A23MID 5 ’-TCTTCCCTTGGCTCCTCTGCA-3 ’
Human P-lyase Forward P5* 5’-GCTCTTCCGCCAACCC-3 ’
Human p-lyase Reverse p i r 5 ACTC AAAG AGG ATCTCTGCG-3 '
pSEAP Forward PSEAP4790A" 5 ’-CTAGCAAAATAGGCTGTCCC-3 ’
pSEAP Reverse PSEAP34B' 5’-GAGATGCAGATCGCAGATCT-3 ’
* Primers designed and optimised by Dr. N. Plant prior to the commencement o f this 
project using the same method as above.
Table 2.2 Volumes used for PC R
R eagent Volume (p.1) W orking concentration
Advantage 2 
polymerase mix (5OX)
1 2X
Primers 1 (of each o f the primer pair) 2 pmol/pl
dNTPs (5 mM) 1 200 pM
Buffer (lOX) 2.5 IX
M gCl2(1 .5mM ) 1.5 90 pM
DNA 200 ng 8 ng/pl
Nuclease-free water Make up reaction volume to 25 pi
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Table 2.3 Optimised cycle parameters for PCR
T em peratu re  (®C) Time (secs)
94 120
94 10
60 30
72 120
72 300
35 cycles (CYP3A23)
2.1.4 T O PO  TA Clon ing and One Shot T ransform ation
The amplified CYP3A23 5’ flanking region was cloned into the pCR®2 .1-T0P0- 
vector using the Invitrogen TOPO-TA Cloning kit. Refer to appendix 9.1 for relevant 
plasmid maps. The protocol in the manufacturer’s technical manual was followed. 
Three tubes were set up as shown in Table 2.4.
Table 2.4 TO PO  Cloning Reactions.
R eagent CYP3A23 Negative control Positive control
DNA 1 pi PCR product 1 pi control DNA
Sterile water 2 pi 3 pi 2 pi
pCR®2.1-TOPO-vector I p l 1 pi 1 pi
The TOPO TA clones were transformed into competent TOPI OF’ E. Coli cells using 
the Invitrogen One Shot Transformation kit. The protocol in the manufacturer’s 
technical manual was followed. The method involved mixture o f the DNA with the 
competent cells on ice before a brief heat shock, followed by incubation at 37 °C in 
SOC medium (Invitrogen).
The transformed cells were plated out onto LB agar plates containing 0.1 mg/ml 
ampicillin, 0.012 mg/ml 5-bromo-4-chloro-3-indolyl-P-D-Galactopyranoside (X-Gal) 
and 10 mM 367-93-1 isopropyl-P-D-thiogalactopyranoside (IPTG) and incubated 
overnight at 37 ®C.
69
White colonies (producing incomplete p-galactosidase due to the insert in the gene) 
from the CYP3A23 plate were stabbed and cultured in 5 ml LB containing 0.1 mg/ml 
ampicillin overnight at 37 °C. A blue colony was also cultured as a negative control.
2.1.5 Midipreparation of plasmid DNA
Plasmid DNA o f pSV40-SEAP and pCR®2.1-TOPO-vector-CYP3A23 was isolated 
from TOPI OF’ competent Æ coli cells using the QIAGEN midiprep kit. The protocol 
in the manufacturer’s technical manual was followed. The DNA concentration was 
measured by spectrophotometry as described in section 2.1.13.
2.1.6 DNA extraction from agarose gels
2.1.6.1 Phenol chloroform extraction and ethanol precipitation
The CYP3A23 insert and pSV40-SEAP vector bands on the gel o f approximately 
1600 bp and 5500 bp respectively were cut out and the DNA was extracted from the 
agarose fragments by phenol chloroform extraction and ethanol concentrated. Phenol 
chloroform extraction involved melting the agarose fragments in 100 pi IxTE at 
75 ®C and then adding one volume o f phenol chloroform iso-amyl alcohol (lAA) and 
vortexing for 1 minute. The aqueous layer was collected by centrifugation at 16210 xg 
for 5 minutes. One volume o f diethylether was added to this aqueous layer and 
vortexed and centrifuged to collect the DNA in the bottom layer. The DNA was 
ethanol concentrated by the addition o f two volumes o f absolute ethanol and 0.1 
volume 4 M  ammonium acetate to 1 volume o f the DNA containing fraction, which 
was incubated for 30 minutes at -20  ®C. The DNA was centrifuged for 25 minutes at 
16210 xg, 95 % o f the liquid was replaced with 80 % ethanol and the DNA 
centrifuged again for 10 minutes at 16210 xg. The DNA pellet was air dried and 
resuspended in 20 pi o f nuclease-free water. The DNA concentration was measured 
by spectrophotometry as described in section 2.1.13.
2.1.6.2 Promega Wizard PCR Preparation for DNA purification
The amplified human RXRa^^^ and CAR^^  ^DNA (Section 2.4.2.3) were cut from 2 % 
low melting point agarose gels and the DNA was extracted from the gel slices using 
Promega Wizard PCR Preps DNA Purification kit.
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The protocol in the manufacturer’s manual was followed. The method included 
melting the agarose with resin, drawing the resin onto a mini column, drying, washing 
and then eluting the DNA with hot water.
2.1.7 Restriction digest
Restriction enzymes, that would produce two fragments o f distinguishable sizes for 
diagnostic purposes or would isolate the fragment o f DNA required for cloning, were 
selected using restriction maps produced by Vector NTI. The reagent volumes shown 
in table 2.5 were used for digests requiring two enzymes. I f  a single enzyme was 
required, an extra 0.5 pi o f nuclease-free water was added instead o f the second 
enzyme. M aster mixes containing the reagents for multiple reactions were used 
whenever possible to minimise pipetting inaccuracies introduced when aliquoting 
small volumes. The buffer used was dependent on the enzymes used, both can be seen 
in table 2.6.
Table 2.5 Reagents for restric tion digests
R eagent Volume (pi)
Enzyme 1 0.5
Enzyme 2 0.5
Buffer 2
BSA 0.5
Nuclease-free water 11.5
DNA (Wizard Plus SV Miniprep) 5
The digests were allowed to proceed for 1.5 to 2 hours at 37 ®C. The results were 
visualised by electrophoresis on a 1 % agarose gel containing ethidium bromide 
(Section 2.1.12).
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2.1.8 L igation
The CYP3 A23 5’ flanking region inserts were ligated into the cut pSV40-SEAP using 
the volumes shown in table 2.7, producing ligation mixtures with 1:10 and 1:20 vector 
insert ratios. The ligations were incubated overnight at 4 °C. The ligated CYP3A23- 
SV40-pSEAP were transformed into TOPI OF’ competent Æ Coli cells using the 
Invitrogen One Shot Transformation (Section 2.1.4).
Table 2.7 R eagent volumes for ligation
Vector:Insert 1:10 (pi) 1:20 (pi)
DNA insert 3 6
Vector 1 1
Buffer 1 1
T4 DNA Ligase 1 1
Water 4 1
2.1.9 Phenol C hloroform  Cell Lysis
Rapid screening o f colonies was carried out using phenol:chloroform lysis (Ohyama 
et al., 1997). One hundred microlitres o f  culture was vortexed with 100 pi o f  
biophenol/chloroform/IAA. Twenty microlitres o f orange G load dye was added and 
pulsed in a centrifuge. The products were visualised by electrophoresis on a 1 % 
agarose gel (Section 2.1.12). The presence o f an insert was confirmed by comparison 
with a colony containing no insert.
2.1.10 W izard  Plus SV M iiiiprep Plasm id P reparation
Plasmids were isolated from the cultures using the Promega Wizard Plus SV Miniprep 
kit. The protocol from the manufacturer’s technical manual was followed. The 
method involved lysis o f  the cells and breakdown o f proteins followed by 
centrifugation on the miniprep spin column and elution o f the DNA. The DNA 
concentration was measured by spectrophotometry as described in section 2.1.13.
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2.1.11 Sequencing
During sequencing, four different fluorescent dye labels were incorporated into DNA 
extension products using 3’-dye labelled dideoxynucleotide triphosphates (dye 
term inators). Thus the growing chain was simultaneously terminated and labelled 
with the dye that corresponded to that base. An ABI Prism 377 sequencer detected 
fluorescence at different wavelengths from the four different dyes that were used to 
identify the A, G, C and T extension reactions in a single acrylamide gel lane.
Sequencing was carried out at GlaxoSmithKline (The Frythe, Welwyn) by their 
Safety Assessment group. 400 ng m iniprepped DNA in 5 pi was sent for each 
sequencing reaction. Sequencing o f the pCR-TOPO clones used universal primers,
M l 3 forward and reverse, whereas sequencing o f the pSEAP clones used 
pSEAP4790A and pSEAP34B primers. The CYP3 A23 pCR-TOPO clones were also 
sequenced using the KES3A23MID primer (Section 2.1.2).
2.1.12 Agarose Gel Electrophoresis
2.1.12.1 Agarose Gel Electrophoresis
M ost o f the gels within this project utilised 1 % agarose gels containing ethidium 
bromide. The gels were prepared by dissolving 1 g SeaKem® LE agarose (FMC) per 
100 ml IxTAE (1 1 lOxTAE (484 g Tris, 200 ml 0.5 M EDTA, 114.2 ml Glacial 
acetic acid, made up to 10 litres with MilliQ water) plus ethidium bromide buffer (0.5 
mg/1 in IxTAE), by heating. Once set, the gel was placed in a gel electrophoresis tank 
filled with IxTAE buffer. Two percent agarose gels were prepared in the same 
manner using 2 g LE agarose (FMC) per 100 ml IxTAE. One percent low melting 
point agarose gels were prepared in the same manner using 1 g SeaPlaque® agarose 
(FMC).
Samples were prepared by adding 1 pi o f Orange G load dye per 4 pi o f sample. The 
total volume o f sample used depended on the well size and ranged from 10 to 20 pi. 
Ten microlitres o f 1 Kb DNA ladder (100 pg/ml, Promega) was added to 90 pi 
nuclease free water and 30 pi Orange G load dye, and 6 pi o f  this ladder mixture was 
run in the outer lanes o f each gel.
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The gel was am  at approximately 3 volts/cm at room temperature until the dye had 
moved % of the length o f the gel. The bands were visualised using a 302 nm medium 
wavelength ultra-violet transilluminator (Genetic Research Instrumentation Ltd.) or 
using FTI-500 thermal imaging system (Pharmacia Biotech).
Low intensity bands were visualised by rerunning the samples on ethidium bromide 
free agarose gels which were then over-stained with SYBR®-Green nucleic acid gel 
stain (30pl SYBR®-Green in 300ml IxTAE) for 60 minutes at room temperature.
2.1.12.2 Photographic Visualisation
Gels were photographed through an orange filter using a Kodak camera and Polaroid 
type 677 positive only film, exposed for 1 second with an aperture o f 11, or the FTI- 
500 thermal imaging system (Pharmacia Biotech).
2.1.13 Measurement of Nucleic Acid Concentration
The concentration o f DNA and RNA were measured by spectrophotometry using the 
Genequant IIRN A/DN A calculator (Pharmacia Biotech). One absorbance at 260 nm 
correlates to 50 pg/ml o f double stranded DNA or 40 pg/ml o f single stranded RNA. 
The RNA/DNA calculator also provided an estimate o f the purity o f DNA or RNA 
with respect to contaminants that absorb in the UV, such as proteins or components o f 
the extraction buffers. This estimate is in the form o f the ratio between the absorbance 
readings at 260 nm and 280 nm (A 2 6 0 /A 2 8 0 ). Pure DNA has an A2 6 0 /A 2 8 0  ratio o f  1.7 to
1.9 and pure RNA has an A2 6 0 /A2 8 0  ratio o f 1.9 to 2.1 in 10 mM Tris.Cl at pH 7.5. 
However the total RNA (Section 2.6.3) and miniprepped plasmid DNA (Sections
2.1.7.2 and 2.1.11) were eluted in water which is not buffered, whereas midi- and 
maxi-prepped plasmid DNA (Sections 2.1.6 and 2.3.1) were eluted with TE at pH 8, 
so the ratios may have varied due to differences in pH rather than contamination 
(W ilfmger et al., 1997).
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2.2 Cell Culture
Cells were stored frozen in 91 % foetal bovine serum (PCS) and 9 % 
dimethylsulfoxide (DMSO), in liquid nitrogen. To begin culturing the cells, a 1ml 
vial o f  cells was thawed at 37 °C and added to 10 ml o f  medium. The cells were 
centrifuged for 5 mins at 150 xg and then resuspended in 10 mis o f fresh medium.
The cell suspension was added to 10 ml o f  medium in a 75 cm^ vented tissue culture 
flask (Nunclon^'', Nunc Brand products). The cells were incubated in a 4 % CO2  cell 
incubator at 37 °C. The medium was replaced after 24 hours to remove any dead cells.
Cells were passaged every four days, or when they achieved >90 % confluence. This 
involved aspiration o f the medium and washing with 10 ml o f phosphate buffered 
saline (PBS, 1 tablet in 100 ml milHQ water). The cells were then incubated at 37 °C 
w ith 1 ml o f  Trypsin EDTA (TE, IX) until the cells had detached from the flask 
surface. The TE was neutralised by the addition o f 9 ml o f medium containing 10 % 
PCS. The cells were resuspended with a pipette and for a 1:2 split, 3.3 ml o f  cell 
suspension was added to 16.7 ml o f fresh medium in a fresh flask. The cells were 
incubated in a 4 % CO2 cell incubator at 37 °C. The medium and split ratio used was 
dependent on the cell type as is described in the following sections.
2.2.1 HepG2 cell culture
The HepG2 cell line was originally isolated from a liver biopsy o f a 15 year old male 
Caucasian with a well differentiated hepatocellular carcinoma (ECACC). HepG2 cells 
were cultured in Earles minimum essential medium with phenol red containing 10 % 
foetal bovine serum (PCS), IX  L-glutamine, IX  non essential amino acids (NEAA) 
and 50 g gentamycin (Gibco BRL). HepG2 cells were split every four days in the ratio 
o f  1:2.
2.2.2 H4IIEC3 cell culture
The H4IIEC3 cell line was derived from the H-35 Reuber hepatoma cell line, which 
was originally derived from a rat liver hepatoma (ECACC). H4IIEC3 cells were 
cultured in Earles minimum essential medium with phenol red containing 10 % PCS, 
IX  L-glutamine, IX  NEAA and 50 g gentamycin (Gibco BRL). H4-II-EC3 cells were 
split every four days in the ratio o f 1:5.
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2.2.3 FaO  cell culture
The FaO cell line is a differentiated line derived from the H4IIEC3 cell line 
(ECACC). FaO cells were cultured in a 1:1 mixture o f Nutrient mixture FIO (HAM) 
with L-Glutamine and Dulbecco’s modified eagle medium (with phenol red and L- 
Glutamine) containing 5 % PCS and 50 g gentamycin (Gibco BRL). The cells were 
split every four days in the ratio o f 1:3.
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2.3 Transfection Methods
The transfection method varied in terms o f transfection reagent, cell type, reporter 
gene constructs and drug, as described below, but a standard schema was followed.
On Day 0 cells were split to produce an actively dividing cell population (Section 
2.2). On Day 1 cells were seeded into 96 well plates (Nunclon™, Nunc Brand 
Products) using 40 \x\ o f  a 6x10^ cells/ml suspension and 80 |il medium (with phenol 
red) so there were 2.4x10'* cells/well. The plates were incubated for 24 hours at 37 °C 
in a 4 % CO2  cell incubator. All incubations o f 96 well plates were performed in 
humidified chambers to prevent evaporation affecting the small volumes in the plates. 
The cells were transfected on day 2 (Section 2.3.2- 8) and incubated for 24 hours at 
37 in a 4 % CO2  cell incubator. On Day 3 the medium was removed and used to 
produce basal measurements using the alkaline phosphatase assay (Section 2.3.10). 
The cells were then dosed (Section 2.3.9) and incubated for 48 hours at 37 °C in a 4 % 
CO 2  cell incubator. On Day 5, the medium was removed and used to produce dosed 
measurements with the alkaline phosphatase assay (Section 2.3.10).
2.3.1 Endotoxin-free maxipreparation of DNA
The reporter gene vectors were isolated from TOPI OF’ competent E. Coli cells using 
the QIAGEN Endofree^" maxiprep kit. The protocol in the manufacturer’s technical 
manual was followed, with adaptations as detailed in appendix 9.2. The method 
involved a modified alkaline lysis procedure followed by the use o f an endotoxin 
removal buffer which prevented endotoxin binding to the QIAGEN anion-exchange 
resin with the DNA. RNA, proteins, dyes and low molecular weight impurities were 
removed by a medium salt wash before elution o f the DNA in a high salt buffer.
The DNA was concentrated and desalted by isopropanol precipitation. The DNA 
concentration was measured by spectrophotometry as described in section 2.1.13.
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2.3.2 Calcium phosphate precipitate transfection method
The calcium phosphate transfection protocol was based on Jordan et al. (1996) and 
Ogg et al. (1999), The transfection mixture was prepared on ice in 3 stages as shown 
in table 2.8. Eighty microlitres o f this transfection mixture was added per well o f the 
96 well plate. This was overlaid with 40 |il o f medium (without phenol red).
Table 2.8 Preparation of calcium phosphate precipitate transfection mixture
Stage 1 The following reagents were mixed: 
25 pg endotoxin free DNA 
100 pi 2 M  CaCL
Made up to 1ml with O.lxTE (pH 8)
Stage 2 1 ml 2x HBS (pH 7.05)was added 
Mix was incubated for 1 minute on ice
Stage 3 Made up to 6.6 ml with phenol red free medium
2 M CaClz (10.8 g CaCh.ôHzO, 20 ml distilled water), O.lxTE pH 8 (1 mM Tris.CI, 0.1 mM EDTA)
2 X HEPES buffered saline pH 7.05 (1.6 g NaCl, 0.074 g KCl, 0.027 g Na2HP0^.2H20, 0.2 g dextrose,
1 g HEPES, 100 ml distilled water)
2.3.3 DQSPER transfection method
Boehringer Mannheim’s DOSPER transfection reagent is a polycationic liposomal 
reagent that interacts spontaneously with DNA, due to its positively charged spermine 
head groups, resulting in liposome polycationic complexes. These were non- 
specifically adsorbed onto the negatively charged cell surface and the cells acquire the 
DNA. The method suggested in the manufacturer’s technical manual was followed. 
This involved replacement o f culture medium with 60 pi o f medium one hour before 
transfection. Diluting 2.5pg o f DNA with HBS produced a final volume o f 50 pi and 
this was added to 10 pi o f DOSPER also diluted to a final volume o f 50 pi with HBS. 
The transfection complex was incubated for 15 mins before 3.6 pi was added 
dropwise to each well. After incubation for 6 hours at 37 ^C, the cells were overlaid 
with 60 pi medium. The medium was replaced after 24 hours.
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2.3.4 DOTAP transfection method
Boehringer M annheim’s DOTAP transfection reagent is a similar cationic liposomal 
reagent to DOSPER, which interacts with negatively charged DNA to form stable 
complexes. These are non-specifically adsorbed onto the negative charged cell surface 
and the cells acquire the DNA. The method suggested in the manufacturer’s technical 
manual was followed. Diluting 2.5 pg o f DNA with HEPEs buffer to a final volume 
o f 25 pi and this was added to 15 pi DOTAP in a final volume o f 50 pi HEPEs buffer. 
The transfection mix was incubated for 15 mins, then mixed with 2.5 ml o f  M EM  
before 112 pi was added to each well. After incubation for 6 hours at 37 °C, the 
transfection mix was replaced with 120 pi MEM.
2.3.5 Effectene™ transfection method
QIAGEN’s Effectene™ reagent was used for transfection following the method 
suggested in the manufacturer’s technical manual. The method involved condensation 
o f DNA by interaction with an enhancer. The Effectene™ reagent, a propietary non- 
liposomal lipid, formed micelle structures, that, when added to the condensed DNA, 
coated the DNA forming complexes. The Effectene-DNA complexes were mixed 
with medium and added to the cells. The method diluted 0.1 pg DNA to a volume o f 
30 pi with buffer EC. To this, 0.8 pi o f enhancer was added, vortexed and incubated 
at room temperature for 2-5 mins before pulse centrifugation. Effectene transfection 
reagent (2.5 pi) was added and vortexed before incubation for 5-10 mins at room 
temperature. One hundred microlitres o f  medium was added to each well and 33.3 pi 
o f  the transfection complex was added dropwise onto the cells.
2.3.6 SuperFect™ transfection method
QIAGEN’s SuperFect™ activated dendrimer reagent was used to transfect cells 
following the suggested protocol in the manufacturer’s technical manual. The method 
involved diluting 0.5 pg DNA to a volume o f 30 pi with medium free o f serum and 
antibiotics. SuperFect™ reagent (2.5 pi) was added, mixed and incubated for 5-10 
mins at room temperature. One hundred and fifty microlitres o f medium was added to 
the transfection mix and the whole volume was transferred onto the cells.
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The cells were incubated for 3 hours at 37 °C before the medium was replaced with 
medium containing 10 % FCS and gentamycin.
2.3.7 TransFast™ transfection method
Promega’s TransFast™ is a liposomal transfection reagent, consisting o f a mixture o f a 
synthetic cationic lipid molecule and L-dioleoylphosphatidyethanolamine (DOPE) 
which forms mulitlamellar vesicles that associate with nucleic acids. DOPE facilitates 
endosomal disruption releasing liposome complexes into the cytoplasm. Cells were 
transfected following the suggested method from the manufacturer’s technical 
manual. The amount o f positive charge contributed by the cationic lipid component 
must exceed the amount o f negative charge contributed by phosphates on the DNA 
backbone to produce a net positive charge on the vesicles associating with DNA.
This positive charge presumably facilitates the interaction o f the vesicles with the 
negatively charged cell surface. A charge ratio o f 3:1 was used. For 10 wells, 1 pg 
DNA was made up to 400 pi volume with serum-free medium and 4.5 pi TransFast™ 
reagent was added and incubated for 15 mins. Forty microlitres o f transfection mix 
was added to each well and incubated at 37 °C for 1 hour. The cells were then 
overlaid with 80 pi o f medium containing 10 % FCS.
2.3.8 Tfx -10 and Tfx - 50 transfection methods
Promega’s Tfx™ reagents are a mixture o f a synthetic cationic lipid molecule and L- 
dioleoylphosphatidyethanolamine (DOPE) which form mulitlamellar vesicles that 
associate with nucleic acids. Tfx™-10 and Tfx™-50 contain the same amount o f 
cationic lipid but differ in the amounts o f neutral lipid component DOPE. The 
protocol in the manufacturer’s technical manual was followed using a 3:1 charge 
ratio. The procedure was the same as that detailed for TransFast™ transfection 
(Section 2.3.7).
2.3.9 Dosing transfected cells
A lOOOX stock solution o f xenobiotic was prepared for dosing transfected cells. For 
example, 20 pi o f 50 mM dexamethasone (Sigma) was made up to a volume o f 20 ml 
w ith medium producing 50 pM  dexamethasone.
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One hundred and twenty microlitres o f drug was added per well. Cells not dosed with 
drug were dosed with vehicle containing 0.1 % DMSO in medium.
2.3.10 A lkaline phosphatase assay
Alkaline phosphatase (AP) activity was measured using the AURORA™ AP 
Chemiluminsecent Reporter Gene Assay kit (ICN). The protocol in the 
manufacturer’s technical manual was scaled down and adapted as follows. Twenty 
five microlitres o f  medium was diluted with 45 pi o f dilution buffer in an OptiPlate™- 
96 polystyrene microplate (Packard) and incubated for 1 hour at 65 °C to denature any 
endogenous AP. The plate was then incubated with 60 pi o f  assay buffer at room 
temperature for 5 mins. The assay buffer contains a mixture o f differential AP 
inhibitors to reduce endogenous AP activity. StarLight™ chemiluminescent substrate 
was diluted to Ix with reaction buffer and 60 pi was added to each well and incubated 
at room temperature for 10 mins. The chemi luminescence was read using the 
LumiCount™ luminometer and the Plate Reader Version 2.10 for Windows software 
(Packard Instrument Co. Inc.).
2.3.11 D ata Analysis
The day 5 data was normalised using the day 3 values, to allow for any proliferative 
or cytotoxic effects o f the drugs. This involved selecting the highest 
chemiluminescence (relative light units) from the mean day 3 values and dividing this 
by the other day 3 mean values, thus producing normalisation factors. These factors 
were then used to multiply the mean day 5 chemiluminescent measurements to 
calculate the normalised day 5 values. Fold induction was then calculated from the 
normalised mean day 5 values in the ratio o f (dosed 3A:dosed control):(vehicle 
3 A:vehicle control), as described by Ogg et al. (1999). Fold induction values greater 
than two were considered notable, because statistical analysis can not be performed 
on ratios.
Specific chemical effect (SCE) is defined as the change in gene expression due to 
chemical action on the region o f DNA under study in the reporter gene construct, 
removing any non-chemical effects during the calculations.
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SCE values can be produced using a formal mathematical model based on the 
previous fold induction calculation method. This method is explained in Plant et al. 
(2000). However due to the variability discussed in section 3.5.3.1, this method 
produced statistically unviable values. W ork was focussed on reducing inter- and intra 
experiment variability to allow statistical analysis, but until this is achieved, this 
report presents fold induction values to allow trends to be identified and discussed.
Fold induction values greater than two were chosen as notable because it has been 
shown previously that there is a good correlation between statistically significant SCE 
values and fold induction values greater than two, using data produced by Dr. M. Ogg 
and Dr. W. El-Sankary (University o f Surrey) during the development o f the formal 
mathematical model.
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2.4 Cell Characterisation at the RNA Level
Understanding the regulation o f gene expression requires a method for determining 
quantities o f mRNA species in cells, such as measurement o f mRNA induction in 
response to endogenous stimuli. The absolute amount o f a specific mRNA can be 
quantitated by co-amplifying or detecting dilutions o f a synthetic sense strand RNA 
with the endogenous target. The sense RNA creates a concentration curve to which 
the endogenous expressed message is compared, to obtain an absolute measurement 
o f  the transcript under study. This method o f quantitation can be applied to northern 
blotting, nuclease protection assays or RT-PCR. Northern blotting lacks the sensitivity 
o f the alternate techniques and RPAs are easy to use and do not require the extensive 
optimisation o f RT-PCR. However RT-PCR is the most sensitive method for 
detecting low abundance targets (http://www.ambion.com/techlib/tb/tb_165.html). 
This high sensitivity is advantageous for use in mRNA quantitation but this has 
proved difficult to achieve due to the need to establish the linear phase o f the 
exponential generation ofPC R  product (Figure 2.1). This means that any small 
variation in any o f several parameters (annealing temperature, number o f cycles, 
concentration o f  reagents, and primer design) can affect the efficiency o f 
amplification and thus alter the product yield (Foley et al 1993, Gilliland et al 1990, 
Zimmermann and Mannhalter 1996). Also the amount o f product plateau’s in the 
latter stages o f the reaction as reagents such as nucleotides and primers become 
limiting and inhibitory pyrophosphate molecules are generated (Siebert and Larrick 
1992, Gilliland et al 1990).
Early approaches to quantitation compared the amount o f PCR product after different 
numbers o f cycles or different amounts o f target molecules with a standard curve 
(Larrick 1992). However the most promising approach was the inclusion o f internal 
standards. These can be in the form o f unrelated sequences from endogenous genes 
which may be co-amplified with the target RNA or amplified in a separate reaction, 
or competitive quantitation where synthetic mRNA is co-amplified with the target 
sequence using the same primers (Bloch 1991, Kellogg et al 1990, Larrick 1992). 
Competitive quantitative RT-PCR was pioneered by Gilliland et al (1990), whose 
method involved addition o f a known amount o f control RNA which was co- 
amplified with the target sequence.
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The use o f the same primers for both sequences minimised differences in 
amplification efficiency. Internal controls currently used are either identical to the 
target sequence except for a restriction site or a site-directed mutagenesis base 
deletion, or non-homologous synthetic RNA containing the same primer sites to the 
target, PCR mimics. These controls should amplify at equal rates to the target 
sequence while being distinguishable from it (Gilliland et al 1990, Foley et al 1993, 
Schneeberger & Zellinger 1996, Siebert and Larrick 1993, Souazé et al 1996, Wang 
et al 1989b), Competitive PCR has the advantage that it can be used to quantitate 
after the plateau o f the PCR reaction (Siebert and Larrick 1993, Zimmermann and 
Mannhalter 1996),
The traditional methods o f  mRNA analysis, including Northern blots, in situ 
hybridisation, RNA slot or dot blots can also be used semi-quantitatively but require 
large sample concentrations and are time consuming. The method o f semi- 
quantitative RT-PCR involves the co-amplification o f endogenous “housekeeping” 
genes that can act as an internal control for sample to sample variation, allowing 
target RNA levels to be normalised. Once normalised, target RNA levels from 
different samples can be directly compared. Housekeeping genes are those coding for 
ubiquitously expressed genes such as metabolic enzymes or ribosomal enzymes, for 
example actin or P-globin. However their levels o f expression have been seen to 
alter, especially in activated cells and so the control should be chosen carefully 
(Horikoshi et al 1992, Foley et al 1993, Zimmermann and Mannhalter 1996). Another 
limitation to the technique is that the internal standard should be present in similar 
amounts to the target RNA so that they are amplified equally. This is often difficult 
to achieve with mRNAs o f low expression, as housekeeping genes are often abundant 
within the cell, which means that the exponential phases o f the two genes may not 
coincide. This technique is suitable for measuring changes in the level o f a specific 
RNA, but is less appropriate for quantitative comparison o f relative or absolute 
amounts o f different mRNAs, since the amplification efficiency, either o f the target 
gene, control gene or both, may be affected by multiple sets o f primers (Foley et al 
1993, Siebert and Larrick 1992).
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It is important to quantitate during the exponential phase because the amplification 
efficiency decreases during the plateau phase and the relative concentrations o f  the 
genes begins to vary (Kellogg et al 1990) (Figure 2.2). The exponential phase o f each 
sequence can be determined by terminating the reaction at sequential cycles, 
commonly known as a log phase (Foley et al 1993). The number o f cycles can then 
be standardised within the protocol.
This section utilises a semi-quantitative approach which avoids the problems o f  co­
amplification by amplifying the endogenous control sequence in a separate tube to 
the target sequence allowing each reaction to be individually optimised and 
performed within its exponential phase. It is based on the suggestion o f Horikoshi et 
al (1992) that if  an internal mRNA standard is expressed at the same level in two 
samples, the ratio o f PCR products generated from the target and standard should 
indicate the relative expression level o f the target mRNA in those samples (Horikoshi 
et al 1992).
In summary, it can be seen that RT-PCR is a highly sensitive method o f amplification 
o f mRNA which provides many opportunities for quantitation. The various 
quantitation techniques have advantages and disadvantages associated with them and 
the method o f choice will depend on the application. In this project semi-quantitative 
RT-PCR incorporating a separate endogenous standard was utilised in relative 
comparisons o f gene expression in different RNA samples.
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Figure 2.1 Relationship between product amplification and number of cycles.
During PCR an exponential relationship occurs initially which progresses into a 
plateau effect where increases in cycle number result in smaller increases in product.
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2.4.1 M essenger RNA E xtraction
Messenger RNA was extracted from male Wistar rat liver and HepG2, H4IIEC3 
(passage 8) and FaO (passage 7) cell lines using the PolyATract® System 1000 
(Promega). The protocols for mRNA isolation from tissue samples and from cell 
cultures in the manufacturer’s technical manual were followed. Both methods 
involved hybridisation o f a biotinylated oligo(dT) probe to the poly-A sequence o f the 
mRNA molecules in homogenised liver or hepatoma cells. The hybridised mRNA 
molecules were then captured with streptavidin paramagnetic particles (SA-PMPs). 
The mRNA was eluted from the SA-PMPs twice using nuclease-free water (Promega) 
to produce two mRNA fractions. Table 2.9 lists the reagent volumes used to extract 
mRNA from 100 mg of rat liver and 1x10^ hepatoma cells.
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Table 2.9 Reagent volumes used to extract mRNA from lOOmg of rat liver and 
1x10^ hepatoma cells by the PolyATract® System 1000
Reagent 100 mg 1x10^ cells
GTC Extraction buffer 800 pi 200 pi
Dilution buffer 800 pi 400 pi
Oligo(dT) probe 100 pmol 30 pmol
SA-PMP 1.2 ml 500 pi
SSC 0.5X solution 1.2 ml 500 pi
Nuclease-ffee water 200 pi 100 pi
The concentration o f mRNA was measured by spectrophotometry as described in 
section 2.1.13. Twenty micro litres o f extracted second mRNA fraction was added to 5 
j L i l  o f Orange G load dye. This was electrophoresed at 90 V on a 2 % agarose gel 
containing ethidium bromide to check the quality o f the mRNA (Section 2.1.12.1).
The RNA quality was also checked by RT-PCR using primers for albumin, with an 
annealing temperature o f 55 °C for 35 cycles (Section 2.4.2.3).
2.4.2 Primer Design and Optimisation
The primers for rat PXR, RX Ra, GRa, CAR, HNF4, ER a, ER(3 and CYP3A23 and 
the primers for human RXRa, CAR, HNF4a, ERa, ER|3 and actin were designed and 
optimised as below. The following method also applies to the primers for rat albumin 
(designed and optimised by Dr. J. Rockett), the primers for rat actin (designed and 
optimised by Dr. N. Plant) and the primers for human PXR, GRa, SRC-1 and CYP3 A 
(designed by Dr. M. N. Vahaditi). All the primers used for RT-PCR in this section are 
shown in Table 2.10.
2.4.2.1 Target Gene Sequences
The National Institute o f Health (NIK) GenBank database was used to search for the 
human and rat mRNA/cDNA sequences.
8 8
The genomic sequences were also used to provide the location o f the exons, which 
enabled the primers to be designed to cross an intron exon boundary so that any 
amplification o f genomic contaminants would differ in size to the mRNA derived 
products.
2.4.2.Z P rim er Design
Primers for human CYP3 A, human PXR, human SRC-1 and human glucocorticoid 
receptor a  were previously designed, by Mr. N. Vahaditi, using the primer design 
programme Vector NTI 4.0. These crossed intron exon boundaries and were used to 
design the rat CYP3 A, PXR and glucocorticoid receptor a  primers, for which no 
genomic sequence could be found. Gene Jockey (Biosoft) was used to align the 
receptor forms and areas o f similarity were avoided during primer design. The 
parameters for primer design in Vector NTI 4.0 were set at product length 300-600 
bp, percentage GC of 45-60 % and primer length 17-23 bp.
Upon receipt, lyophilised primers (MG Biotech) were resuspended in nuclease-free 
water to a stock concentration o f 100 pmol/|il. The stock primers were stored at 
-2 0  °C. The stock primers were diluted with nuclease-free water to a working 
concentration o f 50 pmol/pl. The working primer stocks were stored at 4 °C.
2.4.2.3 O ptim isation of Signal
The optimal cycle parameters for amplification depend upon the target sequence and 
the primer pair. Initially rat liver luRNA extract and an HepG2 mRNA extract were 
used for the rat and human primer pair optimisation, respectively.
Ready to Go RT-PCR beads (Amersham Pharmacia Biotech) and the volumes from 
the manufacturer's protocol indicated in table 2.11 were used for the rat RT-PCR 
reactions. The Access RT-PCR system (Promega) and the volumes from the 
manufacturer's protocol indicated in table 2.12 were used for the human RT-PCR 
reactions. M aster mixes containing the reagents for multiple reactions were used 
whenever possible to minimise pipetting inaccuracies introduced when aliquoting 
small volumes.
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Table 2.11 The volumes for one Ready to Go RT-PCR reaction
Reagent Volume for one reaction (pi) Final Concentration
Bead 1
mRNA Sample 100 ng cell lines & rat liver
1 ng human liver Poly A+
Upstream Primer 1 50 pmol
Downstream Primer 1 50 pmol
Nuclease-Free Water malte up to 50 pi
Table 2.12 The volumes fo r one Access R T -PC R  reaction
Reagent Volume for one reaction (pi) Final Concentration
AMV/Zy? 5X Reaction Buffer 10 IX
dNTP mix (10 mM of each dNTP) 1 0.2 mM
Upstream primer (50 pmol/pl) 1 1 pM
Downstream primer (50 pmol/pl) 1 1 pM
25 mM MgS04 2 1 mM
AMY Reverse Transcriptase 1 0.1 u/pl
Tfl DNA Polymerase 1 0.1 u/pl
mRNA Sample 100 ng cell lines & rat liver
1 ng human liver Poly A+
Nuclease-Free Water make up to 50 pi
One microlitre o f each o f the upstream and downstream primers were added to 48 p.1 
o f the master mix in thin walled 0.5 ml Gene Amp reaction tubes (Perkin Elmer) and 
the reaction performed in the Peltier Thermal Cycler (MJ-Research PTC-200, DNA- 
engine). The initial cycle parameters can be seen in table 2.13 and the annealing 
temperature and cycle number were varied in subsequent reactions until a strong 
intensity signal with no non-specific bands or smearing was seen. The optimised RT- 
PCR conditions for each target gene can be seen in table 2.14.
Table 2.13 The initial R T-PC R  cycle param eters
* The annealing temperature and cycle number were varied during optimisation o f the 
different primer pairs.
Step Temperature Duration Number of Cycles
First strand cDNA synthesis
Reverse transcription
Inactivation of AMV reverse transcriptase
48*^0 
94 °C
45 min 
2 min
1
PCR amplification
Dénaturation
Annealing
Extension
94 °C 
Variable* 
72 °C
30 sec 
30 sec 
1 min
Variable*
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Table 2,14 The optimised RT-PCR conditions for each primer set
Gene Annealing temperature ("€) Cycle number range Mid-exponential cycle number
h albumin 58 12-32 20
li P actin 58 22-40 20
h CAR( )^ - - -
h CAR^ *^ 58 22-40 28
h ERa(^) 60 21-38 -
h ERa^^ 58 - -
hERP 55 28-48 30
hGAPDH 55 18-36 24
hG R a 58 20-40 24
h HNF4a 60 18-36 24
h HNF4y - - -
hPXR 55 22-40 30
h RXRa^') 55 40-22 -
h RXRa^ )^ 58 20-40 28
h SRC-1 58 20-40 28
r albumin 55 10-17 13
r p actin 55 - 20
rCAR 55 21-35 25
r ERa 55 - -
rERp 55 - -
rGAPDH 52 22-40 26
r GRa 55 21-35 21
r HNF4a 55 21-35 22
r HNF4y - - -
rPXR 55 21-35 21
r RXRa(') 58 26-44 26
r RXRa^ )^ 55 - 30
rRXRP 55 - 30
rRXRy 55 - 30
CYP3A23 55 11-30 16
hCYP3A 58 22-44 24
Including the range o f cycle numbers tested for each primer set during log phase 
experiments
2.4.2.4 RT-PCR Product Verification
Once a clear signal was obtained, the product was sequenced to verify that the correct 
gene was being amplified. The appropriate gene specific primers were used to prime 
the sequencing reaction (Section 2.1.11).
2.4.3 Determination of linear log phase
Fifteen identical rat or 10 identical human RT-PCR reactions were prepared using a 
master-mix containing the reagents listed in tables 2.11 & 2.12. The optimum 
annealing temperature was used for each reaction as shown in table 2.14.
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The reactions were performed in parallel and a tube was removed from the thermal 
cycler, after every sequential cycle for the rat reactions and after every alternate cycle 
for the human reactions, over a selected range o f cycles. Ranges o f cycles spanning a 
cycle number known to produce a clear signal were used. The amplified RT-PCR 
products were analysed on a 2 % agarose gel containing ethidium bromide (section
2.1.12.1). I f  the sequential reactions demonstrated signals identical in intensity, a 
lower range o f cycle numbers were used until the signal intensities were observed to 
gradually increase and then plateau.
A cycle number in mid-exponential phase was selected for use in quantitation, 
according to the signal intensities on the gels. This would allow the signal to remain 
in the exponential phase despite any increases or decreases in the differing cell types. 
Table 2.14 shows the range o f cycle numbers tested for each target gene and the 
selected mid-exponential cycle number.
2.4.4 Semi-quantitative RT-PCR
For each rat primer pair, the mRNA from the FaO and H4IIEC3 cells was compared 
to the rat liver mRNA extracts. For each human primer pair, the mRNA from the 
HepG2 cells was compared to the human liver Poly mRNA. Each reaction was 
performed in triplicate. One hundred nanograms o f rat liver, FaO, H4IIEC3 and 
HepG2 extracts or 1 ng human liver Poly A"*" mRNA were added to the volumes o f 
reagents from tables 2.11 & 2.12 in 0.5 ml Gene Amp tubes.
The reactions were performed in a Peltier thermal cycler using the cycle parameters in 
table 2.13 and the optimum annealing temperature and mid-exponential phase cycle 
number for the target gene (table 2.13). The samples were stored at -20 °C until gel 
analysis.
All the rat gene products or all the human gene products were run on the same gel. 
Initially 2 % agarose containing ethidium bromide gels were used and if  the signal 
intensity was too low for densitometry, the gene products were rerun and overstained 
with SYBR -Green nucleic acid gel stain (FMC Bioproducts) (Section 2.1.12.1).
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2.4.5 PensitometiT
The relative density o f the bands on the gel photographs were measured using the 
Pharmacia Biotech thermal imaging system FTI-500 and Liscap capture software 
(version 1) to capture the image and analysed using ImageMaster Total Lab software 
(version 1.00, Amersham Pharmacia Biotech).
Each band was transformed into a peak of intensity by the software. These peaks 
were integrated to produce numerical values o f density.
2.4.6 Statistical Analysis
The densitometric results were analysed for significant differences between the 
human cell line and its liver counterpart using a paired two tailed t-test (InStat® 
version 3.05, GraphPad Software Inc). The densitometric results were analysed for 
significant differences between the rat cell lines and their liver counterpart using a one 
factor ANOVA with Bonn Feronni Dunn post hoc test (SuperANOVA, version 1.11, 
Abacus Concepts). Principal component analysis (PGA) was also performed on the 
results both on mRNA levels o f the receptors and on receptor ratios calculated from 
Latin square tables using the Multi Variate Statistical Package (MSVP version 3.12f, 
Kovach Computing Services).
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2.5 Cell Characterisation at the Protein Level
Western blotting was selected to characterise the protein levels in the hepatoma cell 
lines because it is relatively simple, inexpensive and highly specific. The procedure 
consists o f three stages (Hayes et al., 1989). Stage 1 is separation o f proteins from a 
complex mixture by electrophoresis. Stage 2 involves transfer and immobilization o f 
the protein onto a suitable membrane to allow access o f the probe to the proteins.
Stage 3 is detection o f the protein by the binding and visualisation o f a specific probe. 
The selection o f methods and reagents for these stages deteimines the sensitivity o f 
the procedure.
Polyacrylamide gel electrophoresis is the most popular method o f protein separation 
and the most widely used is SDS-PAGE when uniformly negatively charged 
denatured proteins are separated according to their size (Lammli, 1970).
Once separated, proteins can be transferred to a membrane by diffussion, capillary 
action or drawing by a vacuum (Egger and Bienz, 1994). However electrophoretic 
mobilization (electroblotting / electrotransfer) o f the proteins from the gel matrix onto 
the membrane, as described by Towbin et al. (1979) and named “Western blotting” by 
Burnette (1981) has been widely adopted due to its speed and virtually complete 
transfer o f proteins from gel to membrane. The choice o f buffer used for the 
electrotransfer depends on the gel type, the membrane type and the molecular weight 
o f the proteins to be eluted (Egger and Bienz, 1994). A Tris-glycine buffer, 
supplemented with 20 % methanol was used. The methanol increased binding o f 
proteins to the membrane, reduced gel swelling and aided cooling during transfer 
(Egger and Bienz, 1994; Gershoni and Palade, 1982; Lissilour and Godinot, 1990). 
However methanol can constrict the pores o f the gel and is also capable o f removing 
SDS from the proteins leading to their precipitation, both o f which can reduce the 
elution o f the proteins (Egger and Bienz, 1994; Harper et al., 1988; Lissilour and 
Godinot, 1990; Perides et al., 1986). Addition o f low level SDS to the buffer can 
counteract these effects, however SDS interferes with protein binding to the 
membranes and can adversely affect subsequent immunoreactivity and so was omitted 
from the transfer buffer utilised in this project (Birk and Koepsell, 1987).
95
The key step in Western blotting procedure is the selection o f the protein binding 
membrane. The most commonly used blotting membrane is nitrocellulose because it 
produces reliable and reproducible results, however it has comparatively low 
mechanical strength, especially when dry (Towbin et al., 1979). Nylon membranes 
avoid the fragility o f nitrocellulose but are difficult to stain due to their positive 
charge and require rigourous blocking (Gershoni and Palade, 1982). So 
polyvinylidene difluoride (PVDF) was chosen for this project due to its greater 
mechanical strength and good staining properties (Pluskal et a l, 1986).
Before immunodetection o f specific proteins was performed, free protein binding sites 
were blocked to prevent non-specific adsorption o f probe molecules. The most 
commonly used blocking agent, non-fat milk powder was utilised in this project 
because it was less expensive than ovalbumin or BSA and it produced a lower 
background than Tween-20 (Baettiger et a l, 1982; Johnson et a l , 1984). Staining o f 
the membrane prior to immunodetection was not performed in this project because 
this can reduce the immunoreactivity o f the proteins by bound stain, blocking 
antibody binding to the protein (Tracy et a l, 1987). The molecular weight markers 
were instead visualised in the same manner as the sample proteins, by 
immunodetection (Carlone et al. 1986).
Immunodetection was achieved by an indirect method, using polyclonal antibodies 
directed against the target protein (primary antibodies) and a labelled antispecies 
antibody (secondary antibody). Polyclonal antibodies were selected because o f their 
high binding affinity and because monoclonal antibodies may not recognise proteins 
in their denatured form (Harper et a l, 1990). The secondary antibody could be radio-
125or chromogenic-1 abel 1 ed. The most common radiolabel is I but preference is now 
given to non radioactive detection methods, for reasons o f speed and safety, where the 
secondary antibody is labelled with an enzyme, such as AP or HRP, and the 
precipitation o f a coloured or chemiluminescent reaction product can be used to locate 
the bound antibody (Crisp and Dunn, 1994). Chemiluminescence was utilised in this 
project because it is more sensitive than chromogenic detection.
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The enhanced CL plus system consists o f cyclic diacylhydrazide, which is excited by 
HRP in the presence o f hydrogen peroxide and then decays releasing light (Crisp and 
Dunn, 1994). The inclusion o f compounds such as phenols in the ECL kits can 
increase the emission o f light up to one thousand fold, allowing less than one 
picogram of protein to be detected (Crisp and Dunn, 1994). The light signal is then 
recorded on photographic film, allowing densitometric quantitation o f  the exposed 
and developed film.
2.5.1 Protein Extraction from Hepatoma Cell Lines
HepG2, FaO and H4IIEC3 cells (passage 10) were washed twice with 4 ml ice cold 
phosphate buffered saline (PBS) containing protease inhibitors (PMSF x400,
Aprotinin AxlOOO, Leupeptin xlOOO). Cells were scraped into 50 ml Beckman 
centrifuge tubes and a sample taken for counting cell numbers using a 
haemocytometer. The cells were centrifuged for four minutes at 350 xg at 4 °C. The 
supernatant was discarded and the pellets were resuspended in 200 p,l o f SDS lysis
buffer, containing protease inhibitors, per 1x10^ cells. The tubes were incubated for 
10 minutes on ice and then centrifuged for 45 minutes at 130000 xg. The supernatant / 
cytoplasmic fraction was transferred to 1.5 ml eppendorf tubes. The nuclear pellets 
were resuspended by homogenisation in 1 ml SDS lysis buffer containing protease 
inhibitors.
2.5.2 Measurement of Protein Concentration
The protein concentration was measured using a modified Lowry method as described 
in Stoscheck (1990). This colourmetric assay was chosen due to its increased 
sensitivity to low levels o f protein. Duplicate 10 pi aliquots o f the unknown samples 
were diluted to 400 pi with MilliQ water and mixed by vortexing with 400 pi o f 
freshly prepared 2x Lowry reagent (1 ml 2 % copper sulphate, 1 ml 1 % sodium 
potassium tartrate, 13 ml 10 % sodium carbonate, 5 ml 1 % SDS and 5 ml 1 M 
sodium hydroxide). The samples were incubated at room temperature for 10 minutes, 
then 200 pi o f 0.2 N  Folin-C iocalteu’s phenol reagent was added dropwise while the 
sample was vigourously vortexed.
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The solution was incubated at room temperature for a further 30 m inutes and the 
absorbance at 750 nm determ ined using a UVIKON spectrophotometer.
Duplicate BSA standards (up to 200 pg/mi), as shown in table 2.15, were run in 
parallel and used to construct a standard curve. The standard curve was then used to 
calculate the unknown protein concentration.
Table 2.15 Bovine Serum Albumin standards for Lowry protein concentration 
measurement
Standard concentration (pg/ml) Volume of BSA 400 ^ig/ml (pi) Volume of water (pi)
200 400 0
160 320 80
120 240 160
100 200 200
80 160 240
40 80 320
20 40 360
0 0 400
2.5.3 Antibody Selection and Optimisation
2.5.3.1 Antibody Selection
Primary antibodies for R X Ra, H NF4a, GRa, PX R l, CARl and MB67 were obtained 
from Santa Cruz B iotechnology Inc. The species the antibody was raised in, the target 
peptide identity and the species identity are listed in table 2.16. The secondary 
antibodies goat anti-rabbit IgG-HRP (sc-2030) and donkey anti-goat IgG-HRP (sc- 
2033) were also obtained from Santa Cruz Biotechnology Inc. These secondary 
antibodies were selected because they were Cruz Marker™ compatible, recognising an 
epitope common to all the Cruz Marker™ molecular weight standards (sc-2035) 
allowing chemiluminescent detection o f standards as well as target protein.
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Table 2.16 Primaiy antibodies
Target
protein
Target sp ec ies S p ecies  
raised in
Antibody
type
Target peptide Doesn't cross  
react with
Catalog
number
CARl Rat, mouse Anti-goat Polyoionai mCARI carboxy terminus SC-8539
GRa Rat, mouse, human Anti-rabbit Polycionai hGRa carboxy terminus GRP SC-1002
HNF4a Rat, mouse, human Anti-goat Poiycional hHNF4a carboxy terminus HNF4y SC-6556
MB67 Human Anti-goat Poiycionai hCAR carboxy terminus SC-8541
PXRl Rat, mouse, human Anti-goat Poiycional Unique domain of mPXR1 PXR2 SC-7737
RXRa Rat, mouse, human Anti-rabbit Poiycionai hRXRa amino terminus RXRP &y SC-553
Showing the species the antibody was raised in and the species and peptide the 
antibody was raised to.
2.5.S.2 Antibody Optimisation
The PX R l antibody was optimised using a dot blot technique. This allowed multiple 
variables o f  protein and antibody concentration to be tested simultaneously. A dot blot 
was prepared placing 7 replicate dilutions (0, 1, 5, 10, 25 & 50 pg) o f a H4IIEC3 
nuclear extract horizontally across the blot. The samples had previously been mixed
with an equal volume o f load dye and denatured at 95 °C for 5 minutes. The protein 
was drawn onto the PVDF membrane for 30 minutes. The blot was cut into strips 
containing one o f each protein concentration. Each strip was incubated with a 
different dilution o f primary PX R l antibody, either 1/25000, 1/20000, 1/15000, 
1/10000, 1/5000, 1/2000 or 1/1000, in antibody buffer for 1 hour. The membranes 
were then washed three times in 10 ml o f wash buffer and then incubated with a 
1/2000 dilution o f anti-goat secondary antibody in antibody buffer for 1 hour. The 
membranes were washed three times with 10 ml o f wash buffer and then detected 
with ECL+ plus chemiluminescent detection reagent. The dot o f greatest intensity was 
selected as the optimum protein and antibody concentration.
For the other primary antibodies, strips o f dot blot loaded with 10 pg o f protein, 
prepared as above, were tested with the same range o f primary antibody 
concentrations and the dot o f greatest intensity was selected as optimum antibody 
concentration as shown in table 2.17. However for MB67, the primary antibody for 
human CAR, HepG2 nuclear and cytoplasmic protein extracts were tested. The rat 
CARl antibody was also tested with H4IIEC3 cytoplasmic protein extracts because 
CAR is known to translocate to the nucleus and so may be present in the cytoplasm 
also.
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Table 2.17 Optimum antibody concentrations
Target protein Primary antibody dilution Secondary antibody dilution
CAR1 1/5000 1/2000
GRa 1/20000 1/2000
HNF4a 1/25000 1/2000
MB67 1/5000 1/2000
PXR1 1/10000 1/2000
RXRa 1/25000 1/2000
2.S.3.3 Testing Antibody Specificity
Recombinant PXR protein was prepared using the quick coupled transcription /
translation system (Promega LI 170) and the pSG5-hPXR plasmid (shown in appendix 
9.1.7). The pSG5-hPXR plasmid DNA was kindly donated by Anna Phillips 
(University o f  Surrey). One microgram o f  hPXR plasmid was added to the T]qT®
reaction mixture described in table 2.18 and the reaction was incubated at 30 °C for 90 
minutes. The Transcend™ non-radioactive translation detection system (Promega 
L5070) was used to detect the synthesised hPXR protein as follows.
Five microlitres o f the newly synthesised hPXR protein was added to an equal volume 
o f pyronin Y load dye, denatured at 95 °C for 5 minutes and electrophoresed on an 
SDS-polyacrylamide gel at 180 V for 1 hour (Section 2.5.4). Five microlitres o f T%qT®
T7 quick mastermix was electrophoresed as a control and 5 pi o f Kaleidoscope 
prestained standards (BioRad, 161-0324) were also electrophoresed. The proteins 
were transferred onto PVDF membrane at 200 V for 1 hour, with cooling from frozen 
buffer blocks and constant stirring (Section 2.5.5.1). The protocol for colorimetric 
detection in the Transcend™ non-radioactive translation detection system technical 
manual was followed.
Five, ten and fifteen microlitres o f the IiPXR recombinant protein and 10 pi o f the 
hRX Ra and hG R a recombinant proteins (kindly prepared by Vincent Bombail, 
University o f Surrey, following the method described above) were subject to SDS- 
PAGE (section 2.5.4), western blotting (section 2.5.5) and immunodetection (section 
2.5.6) with their respective primary and secondary antibodies.
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Table 2.18 Volumes for T ^T  quick coupled transcription / translation system  
reaction mixture
R eagen ts V olum e (|il)
TNT'  ^T7 Quick master mix 40
Methionine (1 mM) 1
Plasmid (1 ^g) 2
Transcend™ Biotln-Lysyl-tRNA 1
Nuclease-free water 6
2.5.4 SPS-polvacrvlamide Gel Electrophoresis
2.5.4.1 Gel Preparation
The gels were run using a Mini-PROTEAN II electrophoresis cell (Bio-Rad). A
12.5 % total acrylamide gel was used to resolve the proteins (15-75 kDa in weight). 
The components o f the resolving gel from table 2.19 were mixed and the solution 
immediately poured between the glass gel plates. Before the gel polymerised 1 ml o f  
M illiQ water was applied to the top o f the resolving gel, to prevent oxygen inhibiting 
polymerisation and to produce a flat interface between the resolving and stacking 
gels.
Table 2.19 Volumes of reagents to prepare a 12.5 % acrylamide resolving gel
R eagent V olum e
30 % acrylamide / 0.8 % bisacrylamide (37.5:1) mix 4.2 ml
Water 3.2 ml
1.5 MTris-HCi (pH 8.8) 2.5 ml
10 % SD S 0.1 ml
TEMED (0.05 %) 5 pi
10 % ammonium persulphate (0.05 %) 50 pi
Once the resolving gel had polymerised fully, approximately 30 minutes, the water 
was decanted off the surface o f the gel. The comb was inserted between the two glass 
plates. The 6 % acrylamide stacking gel was made up using the volumes in table 2.20 
and applied to the top o f the resolving gel. The stacking gel was allowed to 
polymerise for approximately 30 minutes.
1 0 1
Table 2.20 Volumes of reagents to prepare a 6 % acrylamide stacking gel
R eagent V olum e
30 % acrylamide / 0.8 % bisacrylamide (37.5:1) mix 2 ml
Water 5.5 ml
1.5 M Tris-HCl (pH 8.8) 2.5 ml
10 % SD S 0.1 ml
TEMED (0.05 %) 10 pi
10 % ammonium persulphate (0.05 %) 50 pi
2.5.4.2 Sample P reparation
Routinely 10 pg o f protein was run per lane. The protein sample to be run was made 
up to a minimum volume o f 5 pi with MilliQ water and then mixed with an equal 
volume o f loading buffer (1.2 ml 0.5 M  Tris-HCl pH 6.8, 1.92 ml 10 % SDS, 1.21 g 
glycerol, 0.48 ml p-mercaptoethanol, 0.6 ml 0.05 % (w/v) Pyronin Y and 4.8 ml 
MilliQ water). The samples were denatured at 95 °C for 5 minutes in the Peltier 
thermal cycler and then placed on ice. Two microlitres o f Cruz Marker^” Molecular 
Weight standards (Santa Cruz sc-2035) were loaded in the first well o f  the gel and the 
samples were loaded into the remaining wells. Two microlitres was found to be the 
optimum loading concentration of molecular weight standards from a range of 
concentrations loaded onto an SDS-PAGE gel and Western blotted to identify the 
clearest intensity molecular weight marker bands.
2.5.4.3 Gel E lectrophoresis
The gels were run in electrophoresis buffer (25 mM Tris base pH 8.3, 192 mM 
glycine and 0.1 % SDS) at a constant 180 volts until the pyronin Y front had run off 
the end o f the gel, approximately 1 hour.
2.5.5 W estern Blotting
2.5.5.1 E lectrophoretic T ran sfer
SDS-PAGE gels were electro-blotted to transfer protein onto polyvinylidene 
difluoride membrane (PVDF, Hybond-P, Amersham Life Science) using a tank blotter 
(Bio-Rad). PVDF membrane was first wetted in 100 % methanol prior to blotting.
The blot was constructed in the blotting cassette immersed in transfer buffer (25 mM 
Tris-base pH 8.3, 192 mM glycine and 20 % methanol).
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Two layers o f filter paper were placed on top o f a fibre pad. After electrophoresis, the 
gel plates were separated and the gel placed on top o f the filter paper. The wetted 
PVDF membrane was gently lowered on top o f the gel, avoiding air bubbles which 
could result in localised areas o f poor transfer, and two pieces o f  filter paper and a 
fibre pad were placed on top o f  the membrane and the blotting cassette was closed.
The blotting cassette was placed with the membrane on the anode side into the 
blotting tank filled with chilled transfer buffer. The blot was electrophoresed 
overnight at a constant current o f 0.1 Amps. The blotted gel was subject to Coomassie 
staining to show that no detectable protein bands were present on the gel after 
blotting. This involved soaking the gel in staining solution (0.25 % Coomassie Blue 
R-250, 40 % methanol and 10 % acetic acid) with gentle agitation for 1 hour.
The gel was then transferred through several changes o f destain solution (30 % 
methanol and 10 % acetic acid) and visualised on a light box.
2,5.5,2 Blocking of PVDF membranes
The membrane was incubated in blocking buffer (10 % healthy eating (low fat) milk 
powder in TBS) for 1 hour at room temperature on a Denley Spiramix 5 roller. Excess 
blocking solution was removed by washing three times in 10 ml o f wash buffer 
(20 mM Tris-HCl pH 7.5, 500 mM NaCl and 0.1 % Tween 20).
2.5.6 Immunodetection
2.5.6.1 Incubation with Antibodies
The blocked membrane was incubated in antibody buffer (20 mM Tris-HCL pH 7.5, 
500 mM NaCl, 5 % healthy eating milk powder and 0 .1%  Tween 20) containing the 
appropriate dilution o f the primary antibody for 1 hour on a Denley Spiramix 5 roller. 
The dilution o f each primary antibody was determined by optimisation experiments 
described in section 2.5.3.2. The membrane was washed three times with 10 mis o f 
wash buffer. The washed membrane was incubated for 1 hour in antibody buffer 
containing a dilution o f the secondary antibody.
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The secondary antibodies used were Cruz marker compatible so they also recognised 
an epitope on the Cruz Marker™ MW standards. The membrane was then washed 
three times with 10 mis o f  wash buffer.
2.5.6 2 Chemiluminescent Detection
This method used a Lumigen PS-3 based kit, ECL+ Plus Western blotting reagents 
(Amersham), for the chemiluminescent detection o f  HRP, as illustrated in diagram 
2.2. The kit was used in accordance with the manufacturer's protocol. The blot was 
incubated with a 40:1 m ixture o f  detection reagent A and B, to a final volume o f  
0.1 ml/cm^ for 5 minutes at room temperature. The excess detection reagent was 
drained o ff and the membrane was exposed to Polaroid 667 film in a polaroid camera.
Figure 2.2 Diagram to illustrate the method of chemiluminescent detection
LUMIGEN PS-3
Secondary Ab
epitope
HRP
+ peroxide HRP
Acridinium
buffer
"MW s t d s ^  peroxide V
Excited product
Protein
Secondary Ab
Primary Ab
LIGHT
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2.6 The Effects of Xenobiotics on the Expression of CYP3A and 
Nuclear Receptors mRNA Characterised bv Real Time PCR
As outlined in section 2.4 there are many methods for determining quantities o f 
mRNA species in cells. The most recent advance is real time PCR, where the kinetics 
o f  the early amplification phase are observed and used directly for the quantification 
o f sample DNA (Heid et al., 1996). This method has previously been used to measure 
expression o f nuclear receptors, such as R X R a and nuclear coregulators such as 
SRC-1 (Graham et al., 2000, Lehmann et al., 2001). An example o f the high 
sensitivity o f this technology is provided by Funkhouser et al. (2001) who detected 
one human cell transplanted in 10000 mouse cells. Real time PCR technology has also 
been used to measure the induction o f CYP3A1 and other CYP450 mRNAs, by 
phénobarbital and hydrocortisone in primary rat hepatocytes, the similarity o f  this 
work to this project indicates the suitability o f the assay to detect CYP3 A mRNA 
expression in hepatoma cell lines (Burczynski et al., 2001).
Earlier methods determined the amount o f PCR product after the amplification 
reaction, so-called end point assays, by measuring ethidium bromide or Sybr green 
staining intensities on agarose gels. The development o f new nucleic acid detection 
chemistries now enable closed tube detection, which offers a decreased risk o f PCR 
contamination and higher throughput (Nurmi et al., 2000). Real time PCR detection 
now uses either intercalating dyes as above or fluorescent labelled target specific 
probes such as TaqMan probes (exonuclease probes), hybridisation probes, molecular 
beacons (hairpin probes), cyclicons and scorpions (self-probing amplicons) (Bieche et 
al., 1998; Crockett and W ittwer, 2001; Kandimalla and Agrawal, 2000; Kutyavin et 
al., 2001; Mullah et al., 1998). Fluorescence is monitored at each cycle, at a set 
temperature, allowing the kinetics o f product formation to be followed and thus the 
initial amount o f template present can be estimated. The technique utilises a rapid 
thermocycler with online fluorescent detection, such as the commercially available 
LightCycler or the 7700 and 7900 ABI Prism sequence detection systems, enabling 
the fluorescent spectra o f all 96 wells o f the thermal cycler to be measured 
continuously during PCR amplification (Burczynski et al., 2001).
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The expense o f the instmmentation is the main disadvantage o f real time PCR 
technology, along with the expense o f probe synthesis.
TaqMan real time PCR is based on the 5’ nuclease assay o f Holland et al. (1991).
Dual labelled fluorogenic hybridisation probes, hybridise to the template DNA. When 
hybridised, the fluorescence o f the reporter dye (FAM) covalently linked to the 5’ end 
o f the probe is quenched by fluorescence resonance energy transfer by the quencher 
dye (TAMRA) on the 3’ end o f the probe (Stryer, 1978; Mullah et al., 1998). Taq 
DNA polymerase has 5’ to 3’ exonuclease activity that allows it to cleave terminal 
nucleotides o f double stranded DNA. During the polymerisation stage o f PCR, the 
Taq polymerase cleaves the reporter dye from the probe, thus distancing the reporter 
dye from the quencher dye and so increasing the peak fluorescence emission (Bieche 
et al., 1998). The ABI Prism 7900 sequence detection system (7900) collects the 
emission from each sample using a charge-coupled-device (CCD) (Heid et al., 1996).
The SDS software normalises the fluorescence signal by dividing the emission 
intensity o f the reporter dye by the emission intensity o f a reference dye (ROX), 
included in the TaqMan universal mastermix, to obtain a ratio known as Rn for a 
given reaction tube at the end o f each thermal cycle (Mullah et al., 1998). Rn is 
proportional to the amount o f PCR product generated up to that point in time. A 
baseline Rn value is produced by measuring the fluorescence between cycles 3 and 
15, unless the amplification curve growth begins before cycle 15, when the baseline is 
adjusted (ABI Prism® 7900HT sequence detection user manual). A threshold (Th) 
above the baseline is set, the default value for the SDS software is the average 
standard deviation o f Rn within the baseline region, multiplied by an adjustable factor 
(ABI Prism® 7900HT sequence detection user manual). This was adjusted manually 
(unless stated) to a value o f 0.02 in this project, so that the Th was in the exponential 
phase o f the log scale amplification plot. The threshold cycle (Ct) is the fractional 
cycle number at which Rn crosses the Th (Heid et al., 1996).
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The target gene copy number in unknown samples is quantified by the SDS software 
calculating Ct and using a standard curve to determine the starting copy number. An 
external standard curve prepared from dilutions o f genomic DNA, amplified in 
different wells than the unknown samples, was used (Bieche et al., 1998). The 
amplification plots shift to the left, giving lower Ct values as the input target increases 
(Heid et al., 1996). An external standard curve can be used as long as the 
amplification efficiency is 100 % (W ilhelm et al., 2000). Amplicons designed and 
optimised according to ABI guidelines (table 2.23) have amplification efficiencies 
approaching 100 %. The amplification efficiency o f the reaction was checked 
throughout the experiments by making sure the slopes o f the standard curves were 
close to the theoretical optimum o f -3.32 (Yin et al., 2001). At any given cycle within 
the exponential phase, the amount o f product is proportional to the initial number o f 
template copies by equation 1 (Leutenegger et al., 2001).
I f  the amplification efficiency is 100 % equation 1 transforms to equation 2. I f  c 
represents 1 thermal cycle then equation 2 transforms to form equation 3 showing that 
each cycle in the PCR reaction corresponds to double the amount o f product and so 
therefore a change in Ct o f 1 must indicate a two fold difference in template 
concentration (Leutenegger et al., 2001, ABI Prism® 7900HT sequence detection user 
manual).
Equation 1 : Nc = N(1 + E)c Where Nc -  product concentration at any cycle
Equation 2: Nc = N(2)c N  = initial concentration o f target template
Equation 3: Nc = N (2)l = 2N E = efficiency o f the system, c = cycle number
2.6.1 Hepatoma Cell Culture
HepG2 (passage 9) and FaO and H4IIEC3 (passage 10) hepatoma cells were cultured 
2in 75 cm vented culture flasks following the method described in section 2.2.
107
2.6.2 Xenobiotic T reatm ent
The HepG2, FaO and H4IIEC3 cell lines were treated with a range o f  xenobiotics at a 
range o f concentrations that incorporated both pharmacological and physiological 
levels. The cells were dosed 24 hours after passage.
Doses o f xenobiotics were 0.01, 0.1, 1, 10 and 50 pM dexamethasone (Sigma D4902), 
0.1, 1,5, 10 and 50 pM rifampicin (Sigma R3501) and PCN (Sigma P0543) and 1, 10, 
50, 100 and 200 pM phénobarbital (Sigma P5178).
The medium for dosing was prepared by adding 0.1 % o f the corresponding lOOOX 
stock o f xenobiotic, prepared as shown in table 2.21 to produce the pM dose. DCC 
treated FCS was used in preparing the medium for xenobiotic dosing.
In addition to three flasks o f each cell type being treated with each xenobiotic dose, 
three flasks o f each cell type were dosed with medium containing 0.1 % o f the 
appropriate vehicle for each xenobiotic, DMSO for dexamethasone, rifampicin and 
PCN and DEPC treated water for phénobarbital. Also twelve flasks o f each cell type 
were left untreated to provide basal levels.
Twenty millilitres o f the appropriate dose medium was added to each flask and the 
cells were incubated at 37 °C in 4 % CO^ for 48 hours prior to total RNA extraction. 
Table 2.21 P reparation  of the xenobiotic doses
Stock Concentration Mass of Di*ug Volume of solvent
100 niM Dexamethasone 5.89 mg 150 pi DMSO
100 mM Rifampicin 16.46 mg 200 pi DMSO
100 mM PCN 6.83 mg 200 pi DMSO
200 mM Phénobarbital 25.4 mg 500 pi Water
Dose
concentration
Vol of Dex 
stock (pi)
Vol of 
DMSO (pi)
Vol of Rif or 
PCN stock (pi)
Vol of 
DMSO (pi)
Vol of PB 
stock (pi)
Vol of 
water (pi)
100 mM ' 100 100
50 mM 100 100 125 125 50 150
10 mM 20 180 30 270 10 190
5 mM 15 285
1 mM 2 198 3 297 1 199
0.1 mM 1 999 1 999
0.01 mM 1 9999
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2.6.3 Total RNA Extraction
Total RNA was extracted from the cell lines using RNeasy Midiprep kits
7(QIAGEN). The manufacturer's protocol for isolation o f total RNA from 5x10 -  
1x10^ animal cells was followed. The cells were harvested by the trypsinization 
method for cell grown in a monolayer from the manufacturer's protocol. The cells 
were lysed in the presence o f  a highly denaturing guanidine isothiocyanate (GITC) 
containing buffer, which inactivated RNases to ensure isolation o f  intact RNA.
The cell lysates were homogenised by passing through a 21 gauge needle ten times.
The homogenised lysate was added to the RNeasy midi spin column where the total 
RNA bound to the silica gel membrane and the contaminants were washed away. The 
RNA was eluted from the membrane using two 250 pi aliquots o f RNase-free water. 
All the centrifugation during the extraction procedure was performed at 3300 xg. The 
RNA was stored at -4  °C before concentrations were determined.
2.6.4 Measurement of the quality and concentration of total RNA
2.6.4.1 Measurement of RNA quality
Ten microlitres o f each total RNA extract was combined with 2.5 pi o f Orange G load 
dye and the samples were electrophoresed on 2 % agarose gels containing ethidium 
bromide (Section 2.1.12.1). The RNA was considered good quality if the ribosomal 
bands were sharp with the 28S ribosomal band appearing twice as intense as the 18S 
RNA band. I f  the ribosomal bands appeared as a smear o f smaller sized RNAs, the 
RNA was likely to have suffered degradation during preparation. High molecular 
weight bands were considered a sign o f  DNA contamination.
2.6.4.2 Spectrophotometric measurement of RNA concentration
The concentration o f total RNA was measured by spectrophotomery as described in 
section 2.1.13. The DNA calculator also provided an estimate o f the purity o f RNA 
with respect to contaminants that absorb in the UV, such as proteins, in the form of 
the ratio o f the readings at 260 nm and 280 nm (A2 6 0 /A2 8 0 ). Pure RNA had an 
A2 6 0 /A2 8 0  ratio o f 1.9 -  2.1 in 10 mM Tris-Cl pH 7.5, however the total RNA was 
eluted in water which is not buffered, so the ratio could vary with pH (W ilfinger et al., 
1997).
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2.6.4.S Rib0 Green RNA Quantitation Assay
RiboGreen™RNA quantitation reagent is a fluorescent nucleic acid stain for 
quantitating RNA in solution with a sensitivity exceeding that o f UV absorbance 
determination by 1000 fold (Molecular probes product information M PI 1490). The 
RiboGreen™ RNA quantitation kit (Molecular Probes, R -11490) was used following a 
scaled down version o f the high range assay method from the manufacturer's protocol, 
optimised by GlaxoSmithKline Mechanism and Extrapolation Technologies, DMPK 
group.
A IxTE working solution was prepared by diluting the concentrated buffer 20 fold 
w ith DEPC treated water (Ambion, 9915G). This was used to dilute the provided 
100 pg/ml ribosomal RNA standard, oïE.coli origin, 100 fold to produce 1000 ng/ml 
RNA solution.
A standard curve was prepared in the final column o f a Costar 3595 96 well cell 
culture cluster plate (Corning Incorporated) as follows. One hundred microlitres o f the 
1000 ng/ml RNA standard was aliquotted into the first two wells. One hundred 
microlitres o f IxTE was aliquotted into the second and the remaining empty wells o f 
the final column. Doubling dilutions o f standard were made by transferring 100 pi o f 
the contents o f the second well into the third well and so on until the 7th well, when 
the excess 100 pi was discarded to leave the final well as a buffer blank. This 
provided a dilution series o f RNA from 1000 ng/ml to 15.62 ng/ml.
The samples were prepared in the remaining 11 columns o f the 96 well plate as 
follows. The spectrophotometric DNA concentrations were used as a guide to dilute 
the total RNA extracts to approximately 2.5 pg/ml. Five micro litres o f these dilutions 
were added to 95 pi o f IxTE buffer in the 96 well plate. These dilutions positioned 
the samples centrally within the RiboGreen™ assay standard curve with 
concentrations o f approximately 125 ng/ml.
The RiboGreen™ RNA quantitation reagent was diluted 200 fold w ith Ix TE buffer. 
Care was taken to protect the reagent from light to avoid photodegradation.
1 1 0
One hundred microlitres o f diluted probe was added to each well and the plate was 
mixed. The fluorescence was measured using a Polarstar galaxy fluorescent plate 
reader and FLUOstar galaxy software version 4.11-0 (bmg labtechnologies). Sample 
concentrations were calculated using the standard curve and accounting for the 
dilution factors.
2.6.5 DNase trea tm en t and cDNA synthesis
The total RNA samples from each cell type were used to produce two 96 well cDNA 
plates, one o f each o f the real time PCR plate layouts shown in figure 2.3. For each 
RNA sample, an RT and a no RT cDNA reaction was prepared. The no RT reactions 
did not contain reverse transcriptase nor dNTP mix, so no cDNA could be made. Also 
on the plate were two NTC reactions, which contained no total RNA to show that the 
RT-PCR mastermix was free from contamination. The total RNA extracts were 
treated with DNase before cDNA synthesis to remove any contaminating DNA.
2.6.5.1 DNase trea tm en t
Total RNA samples were diluted to 10 pg/ml using the RiboGreen™ quantitation 
results. One hundred microlitres o f 10 pg/ml RNA was aliquotted per well o f  a skirted 
Thermo-Fast® 96 well plate (Abgene, AB-0800). One microlitre o f DNase I (RNase 
free 2 U/pl, Ambion, 2222) was added to each well and the plate was sealed using 
adhesive PCR film (Abgene, AB-0558). The plate was incubated at 37 °C for 10 
m inutes and then 75 C for 5 minutes in an Eppendorf mastercycler. The plate was 
centrifuged at 5600 xg to collect the contents in the bottom of the wells.
2.6.5.2 cDNA synthesis
The plates containing the DNase I treated total RNA were used to produce on well o f 
cDNA per RNA sample. One microlitre o f 01igo(dT)i2-i8 primer (Life Technologies, 
Gibco BRL^, 18418-012) was added to the RT and NTC wells, while 1 pi o f  DEPC 
treated water was added to the NoRT wells. One hundred microlitres o f DEPC 
treated water was added to the NTC wells, instead o f total RNA. The plates were 
heated to 70 °C for 10 minutes in the mastercycler and then cooled on ice for 5
minutes. The plates were centrifuged at 4 °C and 2500 xg for 1 minute.
I l l
Bulk buffer mixes were prepared using the volumes from table 2.22 and 8 pi o f the 
appropriate bulk mix was added to each well and mixed. The plates were incubated at 
42 °C for 50 minutes and then at 70 °C for 15 minutes in the mastercycler. The plate 
was centrifuged at 4 C and 2500 xg for 1 m inute before the plate was stored at -20
2.6.6 Real Time PC R
2.6.6.1 P rim er and P robe Design and O ptim isation
Primers and probes were designed by GlaxoSmithKline for rat CYP3A2, CYP3A23, 
CYP3A9 and CYP3A18, human CYP3A4, CYP3A5 and CYP3A7 and rat and human 
P actin, GAPDH, PXR, CAR, G Ra, HNF4o, COUP-TFI, RX Ra, RXRp and RXRy 
using the Primer Express software. The Primer Express software designs primers 
using the guidelines in table 2.23 with the optimum conditions o f 50 °C for 40 cycles. 
This avoided the need for numerous optimisation experiments. The primers and 
probes are shown in table 2.24.
Primers were supplied lyophilised by Sigma-Genosys and were diluted to a 1 mM 
stock concentration with DEPC water. A 10 |u.M working solution was prepared by 
diluting 5 pi primer stock 100 fold with DEPC water. The working primers were split 
into aliquots o f  250 pi, in presterilized DNase and RNase free microtubes (Axygen 
Scientific Inc., MCT-175-C-S) to m inimise contamination and any freeze-thawing 
effects. The aliquots and stock were stored at -2 0  °C.
Probes were supplied ready to use with a 5’-Fluor label o f  6-FAM, by Perkin Elmer 
Applied Biosystems (UK). The probes were split into 200 pi aliquots, in microtubes 
as above, to minimise contamination and freeze-thawing effects. The aliquots were 
stored at -2 0  ”c .
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2.6.6.2 Genomic DNA standards
Rat genom ic DNA was supplied by Bioline (DNAROlOO) at 200 ng/jj.1, which 
according to the theory in appendix 9.3 contained 2.4 x 10  ^ single stranded copies/p.1. 
The rat genomic DNA stock was sheared by passing through a 25 gauge needle 10 to 
20 times. The rat genomic DNA was diluted one in twelve with DEPC treated water
to provide a standard containing 1 x 1 0  single stranded copies/ 5 jj.1. The 1 x 1 0 ” 
standard was used to prepare 1 x 10^, 1 x 10^, 1 x 10  ^ and 1x10^ standards by a 
dilution o f  100 p.1 o f  standard in 900 p.1 o f  DEPC treated water.
The human genomic DNA standards were prepared in the same way as above but the 
human genomic DNA was supplied by Promega (G3041, Lot 112010) at 223 ng/pl
which contained 2.676 x 10 single stranded copies/p.1. Therefore the human genomic 
DNA was sheared and diluted one in 13.38 with DEPC treated water to provide a 1 x 
10^ single stranded copies/ 5 pi standard.
2.6.6.3 Real Time Polymerase Chain Reactions
A bulk mix was prepared for each 96 well TaqMan reaction plate using the volumes 
from table 2.25. Twenty microlitres o f bulk mix was aliquoted into each well o f a 96 
well optical reaction plate (ABI Prism, Applied Biosystems, 43067377). Five 
microlitres o f the cDNA prepared or 5 pi o f the appropriate genomic standard were 
added to the optical reaction plate in accordance with the plate layout in figure 2.5. 
The 10 standard had 5 pi o f DEPC treated water added as a buffer blank. There were 
two reaction plates per cell type per target gene.
Table 2.25 Volumes of reagents for 96 TaqMan reactions
C om p on en ts V olum e per well (pi) V olum e per 96 w ell plate (pi)
Forward primer (10 pM) 1 110
R everse primer (10 pM) 1 110
Probe (5 pmol/pl) 0.5 55
DEPC water 5 550
TaqMan universal PCR Mastermix 12.5 1375
(PE Applied Biosystem s, 4304437)
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When the H4IIEC3 A plates containing extracts from cell treated with dexamethasone 
and rifampicin were prepared, UT^ was replaced by a 1 x 10  ^ standard and the 
respective no RT with a buffer blank because the H4IIEC3 UT^ sample was lost 
during transportation to GlaxoSmithKline.
The contents o f the reaction plate were mixed and the plate was firmly sealed with an 
optical adhesive cover (ABI Prism, PE Biosystems, 4311971). The plate was
centrifuged at 2500 xg and 4 for 1 minute in the 4K15C centrifuge. The plate was 
loaded into the ABI Prism 7900HT sequence detection system (Applied Bio systems) 
and the appropriate plate template opened. The plate template informs the system o f 
the plate layout, so Karen 1 template was used for A plates and Karen 2 template was 
used for B plates, the reaction volume o f 25 pi and the thermal cycler conditions 
shown in table 2.26. The plate format was saved and the reaction run.
Table 2.26 Thermal cycler conditions for the TaqMan real time PCR
Stage 1 50 X 2 minutes 1 cycle
Stage 2 95 X 10 minutes 1 cycle Taq polymerase activating step
Stage 3 95 X  
60 X
10 minutes 
1 minute
40 cycles Dénaturation step
Combined annealing / extension step
Once completed, the run was analysed with a threshold o f 0.020, unless the 
background was too high and the threshold was manually adjusted to the lowest value 
above background. This analysis provides Ct values and uses the standard curve 
produced during the reaction to calculate the copies o f RNA per well from these 
values. The analysed data was exported for further analysis which involved 
calculation o f the number o f copies o f mRNA detected /ng total RNA and 
normalisation o f  this by subtraction o f the noRT values. An average normalised value 
was calculated for the number o f copies o f mRNA detected per ng total RNA in the 
triplicate samples using equation 1. This was used to calculate fold induction values, 
comparing cells treated with xenobiotic to the corresponding vehicle, using 
equation 2.
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Equation 1:
M ean (copies o f mRNA detected per ng total RNA in triplicate RT samples)
Mean (copies o f mRNA detected per ng total RNA in triplicate noRT samples)
Equation 2:
Normalised mean copies o f mRNA detected in drug treated samples/ng total RNA 
Normalised mean copies o f mRNA detected in vehicle treated samples/ng total RNA
2.6.7 Statistical Analysis of Real Time PCR Results
The results were analysed for significant differences, intra and inter cell line, due to 
xenobiotic dosing, using a one factor ANOVA with Bonn Feronni all means post hoc 
test (InStat® version 3.05, GraphPad Software Inc.). Trends observed were tested for 
significance using linear or log linear regression. (InStat® version 3.05, GraphPad 
Software Inc.). Principal component analysis (PCA) was also performed on the results 
both on mRNA levels o f the receptors and on receptor ratios calculated from latin 
square tables using the Multi Variate Statistical Package (MSVP version 3.12f, 
Kovach Computing Services).
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3 Results of the Investigation into the Functional Induction of 
CYP3A Using Reporter Gene Constructs
Species differences in the induction response o f CYP3A genes to xenobiotics are 
proposed to be due, in part, to host cell differences (Barwick et al., 1996). These host 
cell effects were investigated functionally by trans-species transfections o f human and 
rat CYP3 A promoter driven reporter genes into human HepG2 and rat FaO and 
H4IIEC3 cells. An alkaline phosphatase reporter gene driven by 1 kb o f CYP3A4 5’ 
flanking region had previously been developed and used in an optimised reporter gene 
assay in HepG2 cells (El-Sankary, 2000; Ogg, 1998; W illiams, 1997). Thus described 
in this chapter, the corresponding rat CYP3A23 reporter gene was developed by 
amplification o f 1.6 kb o f the CYP3A23 5’ flanking region and cloned into an alkaline 
phosphatase reporter gene. Methods o f transfection into the three hepatoma cell lines 
were optimised and the induction o f the reporter gene activities in the cells treated 
with known CYP3A inducers was measured. Ogg et al., 1999 and El-Sankary et al., 
2001 showed that co-transfection o f a glucocorticoid receptor (hGR) expression 
plasmid enhanced induction o f the CYP3 A4-CMV-pSPAP construct, therefore co­
transfection o f hGR with the CYP3 A promoter driven reporter gene constructs was 
also performed.
3.1 CYP3A23 Promoter Driven Reporter Gene Construct 
Development
3.1.1 Isolation of CYP3A23 5* flanking region
The region -11 to -1616 bp o f the CYP3A23 5’ flanking region was amplified using 
the primers CYP3A23 A and B, an annealing temperature of 60 °C for 35 cycles and 
male Wistar rat liver genomic DNA as a template (Section 2.1.1 and 2.1.3). The 
signal obtained was approximately 1600 bp, which agreed with the expected size o f 
1606 bp (Figure 3.1).
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Figure 3.1 Amplification of the 5’ flanking region of CYP3A23 using an 
annealing temperature of 60
Marker 
sizes in 
bp
10000
1600 bp 
fragment of 
CYP3A23 5’ 
flanking region
The region -11 t o -1616 bp of the CYP3A23 5’ flanking region was amplified by 
PCR at 60°C for 35 cycles from male Wistar rat liver. The signal obtained agreed with 
the expected size o f 1606 bp. M = 1 Kb DNA Ladder, 3A23 = CYP3A23 5’-flanking 
region
3.1.2 Cloning and sequencing of CYP3A23 5’ flanking region
The 1606 bp amplified region o f CYP3A23 was cloned into the pCR®-TOPO-vector, 
as described in section 2.1.4. The transformed E. coli cells were rapidly screened by 
phenol chloroform lysis and the lysates separated on 1 % agarose gel (Ohyama et al., 
1997). Eight clones with larger plasmid bands than in lysate from cells containing 
control plasmid were identified. Diagnostic restriction enzyme digests with BamHI of 
these 8 clones were used to identify two clones (A and C) containing correctly 
orientated inserts that produced fragments of 1497 and 4006 bp. The rest o f the clones 
appeared to contain inserts with reverse orientation, producing fragment sizes o f 182 
and 5321 bp (Figure 3.2).
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Figure 3.2 Restriction digests to identify the orientation of CYP3A23 inserts in
the TOPO-vector
M A B C D E F G H M
Marker
sizes in
Restriction digests were performed with BamHI on eight TOPO-TA clones (A-H) 
inserted with 1.6 kb o f the CYP3A22 5’ flanking region. Two clones (A and C) 
containing correctly orientated inserts, that produced fragments o f 1497 and 4006 bp, 
were identified. The rest o f the clones appeared to contain inserts with reverse 
orientation, producing fragment sizes o f 182 and 5321 bp. M = 1 Kb DNA Ladder.
Automated sequencing o f the two correctly orientated inserts was carried out using 
the M13 primers, plus an internal primer (KES3A23MID; Section 2.1.2). The 
sequences showed a high sequence similarity to CYP3A23 but low identity with 
CYP3A2 5’ flanking region sequences using the Gene Jockey software (Biosoft). The 
sequences were compared to known sequences using the BLAST search facility in the 
National Institute o f Health (NIH) GenBank Database website 
(http://www.ncbi.nlm.nih.gov/cgi-bin/BLAST7nph-newblast). This identified a match 
with the Burger et al. (1992) sequence to which the primers were designed (Table
3.1). The matches for each sequencing reaction were not 100 % identical, due to 
sequencing artefacts, which became more abundant as the reaction progressed further 
from the priming site. The use of a third primer (KES3A23MID) designed to start 
sequencing where errors began with the M l3 primers, removed these errors. Sequence 
results with the different primers were aligned and sequencing artefacts eliminated, 
confirming 100% identity o f the inserts with the CYP3A23 5’ flanking region.
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3.1,3 Subcloning of CYP3A23 5* flanking region into pSEAP reporter gene 
vector
Restriction digests were carried out using the enzymes Xho I and Spe I with
CYP3A23-TOPO (clone A) and Xho I and Nhe I with pSV40-SEAP midiprepped
DNA (Section 2.1.5 and 2.1.7) The digested CYP3A23 and pSEAP bands o f 1600 bp
and 5000 bp respectively, seen in figure 3.3, were cut from the gel and purified
(Section 2.1.7.1). The CYP3A23 fragment was ligated into the pSEAP vector and
transformed into TOPI OF’ E. coli cells (Section 2.1.8).
Figure 3.3 Restriction digest of pSEAP and CYP3A23-TOPO to prepare 
fragments for ligation
M 1 2 3 4
Marker 
sizes in
Cut pSEAP 
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fragment
bp
3000
1000
TOPO
Vector
CYP3A23 
insert 
1600 bp
Restriction digest o f the TOPO cloned CYP3A23 5’ (3) flanking region with Xho I 
and Spe I cut the CYP3A23 insert from the TOPO-TA vector, preparing it for ligation 
into the pSV40-SEAP vector (1) which was digested with Xho I and Nhe I. The 
digests were electrophoresed on a 1 % agarose gel alongside undigested CYP3A23- 
TOPO (4) and pSV40-SEAP (2). The digested DNA fragments were extracted from 
the agarose and used for ligation to form CYP3A23-SV40-pSEAP. M = 1 Kb DNA 
ladder
The transformed E. coli cells were rapidly screened by phenol chloroform lysis and 
the lysates separated on 1 % agarose gel (Ohyama et al., 1997). Two clones (T and I) 
with larger plasmid bands than in lysate from cells containing control plasmid were 
identified. Both clones (T and I) were subject to PCR using the original CYP3A23 
primers (KES3A23A and B, Section 2.1.2) and inserts were amplified (Figure 3.4).
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Figure 3.4 Confirmation of CYP3A23 promoter insertion by amplification
Marker M l  2 3  4 5 6 7 8  9 10 M
CYP3A23-SV40-pSEAP clones (T and I) were subject to PCR using the original 
CYP3A23 primers (KES3A23A and B, Section 2.1.2) to identify whether they 
contained CYP3A23 5’ flanking region insert. Five reactions were performed with 
each clone and all amplified a signal that agreed with the expected size o f 1606 bp. M 
= 1 Kb DNA ladder, 1-4 + 9 = Clone T, 5-8 + 10 = Clone I
D iagnostic restriction digests confirmed that the two clones (T and I) contained 
correctly orientated inserts because they produced fragments o f 1754 & 4776 bp and 
1614 & 4656 bp with Apa I & Hind III or EcoRI respectively (Figure 3.5).
The plasmid DNA of the CYP3 A23-SV40-pSEAP (clone T) was sent to 
GlaxoSmithKline for sequencing using the pSEAP primers and the sequences were 
analysed using the Gene Jockey software and the BLAST search facility as described 
in section 3.1.11. The sequences showed a high sequence similarity to CYP3A23 
using Gene Jockey and a BLAST search identified a match with the Burger et al. 
(1992) sequence to which the primers were originally designed, and other CYP3A1 
sequences (Table 3.1).
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Figure 3.5 Restriction digest to confirm the orientation of CYP3A23 insert in
pSEAP
A Restriction digest using Apa I and Hind III
Marker M A B T C sizes in 
bp
3000
1000
D E F G I H M
SSSSK Uncut plasmids 
4776 bp
1754 bp
B Restriction digest using EcoRI
Marker M
sizes in
bp
3000 g
1000
C.'.X V Uncut plasmids 4656 bp
1614 bp
Restriction digests were performed with Apa I & Hind III or EcoRI on 10 CYP3A23- 
SV40-pSEAP clones. Two clones (T and I), previously identified as containing 1.6 kb 
inserts o f the CYP3A23 5’ flanking region by PCR, contained correctly orientated 
inserts and thus produced fragments of 1754 & 4776 bp and 1614 & 4656 bp. The rest 
o f the clones (A-H) did not appear to contain inserts. M = 1 Kb DNA Ladder.
3.2 Optimisation of Transfection Methods
3.2.1 Optimisation of transfection into human HepG2 cells
The initial calcium phosphate method used was an adaptation o f the method presented 
in section 2.3.2. The precipitate was made up to the volume o f 1 ml with IxTE and 
diluted to 30 ml with 28 ml of medium and 120 pi was added to each well. This 
method only applied 0.2 pg DNA per well (refer to table 3.2).
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Table 3.2 Methods for calcium phosphate transfection
Method Initial Ogg et al., 1999 Optimised
Calcium chloride 100 pi 100 pi 100 pi
DNA 25 pg/ml 25 pg/ml 25 pg/ml
Tris EDTA buffer Up to 1 ml (x l) Up to 1 ml (xO.l) Up to 1 ml (xO.l)
2x HEPES buffered saline 1 ml 1 ml 1 ml
Media 28 ml 4.6 ml 4.5 ml
Volume per well 120 pi 40 pi 80 pi
DNA added per well 0.2 pg 0.3 pg 0.62 pg
Three protocols for producing a calcium phosphate transfection mix were used during 
the optimisation o f transfection into HepG2 cells. The calcium phosphate precipitates 
were produced in the same way, yet the volume o f medium in which the precipitate 
was diluted differed between the three methods and the volume o f transfections mix 
per well and thus DNA per well differed. The second method was published by Ogg 
et al. (1999) while the optimised method was published by El-Sankary et al. (2000). 
The calcium chloride, DNA and tris EDTA buffer were mixed and then 2 x HBS was 
added and the mixture incubated for 1 min on ice, before the addition o f medium and 
transfer onto the cells.
The Lumicount™ luminometer was used to measure the chemiluminescence produced 
by alkaline phosphatase activating StarLight^"' chemiluminescent substrate. An 
indication o f transfection efficiency was obtained by recording the automatic gain 
levels used by the Lumicount™ luminometer while alkaline phosphatase activity was 
measured, with lower gain values indicating an increased efficiency. Using the initial 
calcium phosphate precipitation method, the transfection efficiency appeared high, 
with gain readings o f approximately 1 on a scale o f 1 to 32. However when the cells 
were treated with a variety o f drugs (5 |aM PCN, 5 pM & 50 pM  dexamethasone, 50 
pM  rifampicin), no notable fold induction values (i.e. greater than two) o f CYP3A4- 
CMV-pSPAP were observed (refer to appendix 9.4 for raw data).
However induction was observed with the CYP3A23 promoter driven reporter gene 
construct. Fold induction values o f 5.2 and 4.2 (without hGR) in the presence o f 50 
pM  dexamethasone treatment o f the CYP3 A23-SV40-pSEAP constmct were 
obtained.
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Fold induction values o f 2.4 without hGR and 4.1 with hGR with 50 pM  rifampicin 
treatment and 8.1 with hGR due to 10 pM  rifampicin were also observed for the 
CYP3A23 promoter driven reporter gene construct (Table 3.3).
T able 3.3 Fold induction values for the CYP3A23 p rom oter driven alkaline 
phosphatase rep o rte r gene construct in H epG 2 cells
Dose (pM ) CYP3A23 CYP3A23 + 
hG R
PCN 5 0.37 n.d.
PCN 5 0.22 n.d.
Dex 5 1.08 1.27
Dex 50 5.23 1.07
R if 50 2.35 4.10
Dex 50 4.20 1.25
R if 50 0.38 1.23
HepG2 cells were transfected with CYP3A23-SV40-pSEAP, w ith or without the 
glucocorticoid receptor (hGR). Basal alkaline phosphatase activity, in relative light 
units, was measured 24 hours after transfection using a chemiluminescent substrate. 
The cells were then incubated with xenobiotic for 48 hours and then dosed alkaline 
phosphatase activity measured. Fold induction was calculated based upon the average 
o f eight replicate wells, using the equation (dosed 3A:dosed control)(vehicle 3 A: 
vehicle control), where control is the pSV40-SEAP plasmid. Bold type indicates 
notable fold induction values greater than 2. n.d. represents not determined.
Alternate methods o f calcium phosphate precipitate transfection were assessed using 
the parameters detailed in table 3.2. These two methods were compared with the 
initial method to transfect CYP3 A4-CMV-pSPAP into HepG2 cells dosed with either 
50pM dexamethasone or rifampicin. All three methods produced notable fold 
induction values with 50 pM  rifampicin, in the second experiment, o f 7.8, 2.3 and 3.8. 
The transfection method o f Ogg et al. (1999) also produced a notable fold induction 
o f  2.2 with 50 pM  dexamethasone in the second experiment, as can be seen in Figure 
3.6.
127
From these results and consistently reproducible statistically significant specific 
chemical effects^ or notable fold induction values obtained in our laboratory by other 
PhD students using the “optimised” method, it was decided to use the alternate 
‘optimised’ calcium phosphate transfection method, using 0 .62pg DNA per well.
Figure 3.6 Fold Induction of CYP3A4-CMV-pSPAP, using different calcium 
phosphate transfection methods
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HepG2 cells were transfected with pCMV-SPAP and CYP3A4-CMV-pSPAP using 
three methods that transfected 0.2, 0.3 and 0.62pg o f plasmid into the cells. The cells 
were treated with 50pM dexamethasone or rifampicin in two separate experiments 
and the chemiluminescence was used to calculate fold induction, based upon the mean 
o f eight replicates. ♦ Notable fold induction values greater than 2. Initial, Ogg et al. 
and Optimised transfection conditions were as defined in table 3.2.
Various commercially available transfection reagents were tested using pCMV-SPAP 
in an attempt to increase the efficiency o f  the system. The methods tested were the 
optimised calcium phosphate precipitation method, Dosper, DOTAP, Effectene, 
Superfect, TfxlO, Tfx50 and TransFast following the manufacturer’s instructions 
(section 2.3) to transfect the same pCMV-SPAP preparation into cells seeded in a 96 
well plate.
' Specific chemical effect is defined as the change in gaie expression due to chemical action on the 
regi(Mi of DNA undCT study in the reporter gene construct removing any non-chemical effects.
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Relative light units (chemiluminescence) were measured on day 3. Figure 3.7 shows 
that calcium phosphate produced the most efficient transfection in terms o f relative 
light units, so the calcium phosphate precipitate method was continued to be used 
even though the cells appeared somewhat compromised (small and slow growing) by 
the procedure.
Figure 3.7 Comparison of transfection methods of pCMV-SPAP reporter gene 
construct in HepG2 cells
10000
I I
CaP04 Dosper TfxlO Tfx50 TransFast Superfect Effectene DOTAP
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HepG2 cells seeded in a 96 well plate were transfected with the same pCMV-SPAP 
reporter gene construct DNA preparation (70 % supercoiled) by a range o f 
commercially available transfection reagents. The chemiluminescence was measured 
24 hours after transfection. The mean chemiluminescence fi-om eight wells, in relative 
light units is presented on the figure. The error bars represent standard error o f the 
mean.
3.2.2 Optimisation of transfection into rat H4IIEC3 cells
Initial transfections o f  H411EC3 cells using CYP3A4-CMV-pSPAP used the initial 
calcium phosphate precipitate transfection method and were dosed with 5 pM  PCN. 
These experiments produced very high gain levels, indicating poor transfection 
efficiency.
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Several adaptations to this method were tested, including glycerol shock (Hur and 
Edenburg, 1995) and the inclusion o f 15 % glycerol in the media (Wilson and Smith, 
1997). Gain levels consistently indicated poor transfection efficiencies and so various 
commercially available transfection reagents were tested using pCMV-SPAP and the 
RLUs measured on day 3. The calcium phosphate precipitate, SuperFect, Effectene 
and DOSPER appeared to produce almost the same RLUs as the non-transfected cells, 
indicating failure o f transfection. However the RLU values for the Tfx-10, Tfic-50 and 
TransFast methods indicated successful transfections (Figure 3.8). The TransFast 
method was therefore chosen as an optimised method for H411EC3 transfection.
Figure 3.8 Comparison of transfection methods of pCMV-SPAP reporter gene 
construct in H4IIEC3 cells
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H411EC3 cells were transfected with pCMV-SPAP reporter gene construct by a range 
o f  commercially available transfection reagents. The chemiluminescence was 
measured 24 hours after transfection. The mean chemiluminescence from eight wells, 
in relative light units is presented on the figure. The error bars represent standard error 
o f  the mean.
3.2.3 Optimisation of transfection into rat FaO cells
In order to avoid introducing a third transfection technique, the optimised calcium 
phosphate precipitate method and optimised TransFast method were tested on FaO 
cells using pCMV-SPAP.
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The results in Figure 3.9 show that FaO cells that were calcium phosphate transfected 
with pCMV-SPAP produced approximately the same RLUs as the non-transfected or 
DNA-free transfected cells. TransFast produced thirty times the alkaline phosphatase 
activity levels, leading to this being selected.
Figure 3.9 Optimisation o f transfection methods of pCMV-SPAP reporter gene 
construct in FaO cells
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FaO cells were transfected with pCMV-SPAP reporter gene construct by calcium 
phosphate precipitation and TransFast methods. The chemiluminescence was 
measured 24 hours after transfection. The mean chemiluminescence from eight wells, 
in relative light units is presented on the figure. The error bars represent standard error 
o f  the mean.
3.3 Functionality of the CYP3A23 construct
The functionality o f  the construct was demonstrated by the fold induction values 
greater than two that were obtained during transfection optimisation when human 
hepatoma cells (HepG2) were dosed with 5 or 50 pM  dexamethasone or 10 or 50 pM 
rifampicin (for example the results shown in table 3.3). Notable fold induction values 
were also obtained when rat hepatoma cells (H411EC3) were dosed with 10 pM 
dexamethasone. As explained in section 2.3.10, fold induction values greater than 2 
were considered notable because previously it had been shown that there was a good 
correlation between statistical significant SCE values and fold induction values 
greater than two (Dr. N. Plant, personal communication).
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3.4 Activation of CYP3A Reporter Gene Constructs by 50 uM 
Dexamethasone
Five experiments were performed using the optimised transfection procedures to 
transfect both the CYP3A4-CMV-pSPAP and CYP3A23-SV40-pSEAP constructs 
into the three cell lines, human HepG2 cells and H4IIEC3 and FaO rat cells, dosed 
with 50 pM  dexamethasone.
The first experiment compared fold induction values from CYP3A4 and CYP3A23 
promoter driven reporter gene constructs in HepG2 and H4IIEC3 cells. Only 
CYP3A4-CMV-pSPAP, in HepG2 cells, produced a notable fold induction value o f 
3.75 (without hGR), but CYP3A23-SV40-pSEAP in HepG2 and CYP3 A4-CMV- 
pSPAP in H4IIEC3 cells produced notable inductions o f 3.48 and 2.51 with pSG5- 
hGR. The CYP3 A4-CMV-pSPAP cotransfected with pSG5-hGR into HepG2 cells 
produced a very low fold induction value and as such is assumed to be an anomalous 
result due to problems with the CYP3A4-CMV-pSPAP / pSG5-hGR transfection 
mixture (Figure 3.10).
I f  it were assumed that the CYP3A4-CMV-pSPAP fold induction was enhanced by 
pSG5-hGR cotransfection in a similar proportion to in the H4IIEC3 cells, this would 
be comparable to the results reported by Ogg et al. (1999). From this, a pattern 
appears to emerge, where the CYP3A4 promoter driven reporter gene activity is 
induced by 50 pM  dexamethasone in HepG2 cells, but not in H4IIEC3 cells unless 
pSG5-hGR is cotransfected. The CYP3A23 promoter driven reporter gene activity is 
induced by 50 pM  dexamethasone in HepG2 cells when pSG5-hGR is cotransfected 
but not in the H4IIEC3 cells. However the gain level for the CYP3A23 promoter 
driven reporter gene construct transfection into H4IIEC3 cells was 32 indicating a 
poor transfection efficiency, which may explain the low fold induction value. It would 
appear that dexamethasone is a more potent inducer o f CYP3 A4-CMV-pSPAP 
activity than CYP3 A23-SV40-pSEAP activity. The CYP3A promoter driven reporter 
gene activities are lower in H4IIEC3 cells than in HepG2 cells.
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Figure 3.10 Fold Induction of CYP3A promoter driven reporter gene constructs
with 50 pM Dexamethasone Treatment
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Both HepG2 and H4IIEC3 cells were separately transfected with CYP3 A4-CMV- 
pSPAP and CYP3A23-SV40-pSEAP and their respective controls pCMV-SPAP and 
pSV40-SEAP, with or without cotransfection o f the pSG5-hGR plasmid. The 
chemiluminescence was measured before and after 48 hour 50 pM  dexamethasone 
treatment. From this the fold induction was calculated, based upon the average o f 
eight replicate wells. ♦ indicates notable fold induction values, greater than 2.
Further results, ft"om repetition o f  the experiment above, were variable, however 
notable induction o f  CYP3A4 promoter driven reporter gene activity (without hGR) in 
HepG2 and H4IIEC3 cells (2.86, 2.12 and 2.03 respectively) and CYP3A23 promoter 
driven reporter gene activity (without hGR) in HepG2 cells (10.9) was observed 
(Table 3.4). The failure to repeat the patterns observed in the above experiment may 
be due to poor transfection efficiencies, thus the results for both the CYP3A4-CMV- 
pSPAP and the CYP3A23-SV40-pSEAP constructs were not conclusive due to lack 
o f reproducibility.
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Table 3.4 Fold Induction of CYP3A Promoter Driven Reporter Constructs by
50 pM Dexamethasone
Experiment Reporter gene HepG2 H41IEC3 FaO
Cotransfection -hGR + hGR - hGR + hGR -hGR + hGR
1 3A4 0.65 1.14 2.03 1.23
3A23 10.9 1.58 1.65 0.77
2 3A4 2.86 1.37 1.07 0.87 1.32 1.11
3A23 0.23 1.44 1.23 0.77 1.49 0.43
3 3A4 2.11 1.14
3A23 0.65 1.17
4 3A4 0.91 1.34
3A23 1.07 0.8
Four trans-species transfections o f CYP3A4-CMV-pSPAP and CYP3A23-SV40- 
pSEAP and their respective control plasmids were performed in rat and human 
hepatoma cell lines seeded in 96 well plates. The first two experiments included co­
transfections o f  the pSG5-hGR expression plasmid. The latter two experiments only 
used HepG2 and FaO cell lines, without hGR co-transfection. The chemiluminescence 
was measured before and after 48 hour incubation with 50 pM  dexamethasone. From 
this the fold induction was calculated, based upon the average o f eight replicate wells. 
Bold type indicates notable fold induction values greater than 2. Blank cells indicate 
where transfections were not performed.
3.5 Discussion
3.5.1 CYP3A23-SV40-idSFAP  R epo rter Gene C onstruct Developm ent
The CYP3A23 5’ flanking region has been successfully isolated and cloned. The 
sequencing results suggested that the insert shared 100 % identity with the CYP3A1 5’ 
flanking region sequence published by Burger et al. (1992), which was the sequence 
to  which the primers were designed. The high identity with all CYP3A1 published 
sequences supports this. Interestingly, the CYP3 A23-SV40-pSEAP clone shared 99 % 
identity with CYP3A23, which supports the suggestion that the Burger et al. (1992) 
sequence previously identified as CYP3AJ, is in fact CYP3A23 (Huss et al., 1996). 
However because CYP3A1 and CYP3A23 have been used interchangeably for many 
years and until the nomenclature committee makes a definite decision, the situation 
remains unclear. The aim o f my study was to isolate and investigate the regulation o f 
rat CYP3A and CYP3A23 is the major form o f CYP3A in rat liver. While reviewing 
the literature on CYP3A1 and CYP3A23 in section 1.2.4.3, it would appear that I have 
isolated CYP3A23 5’ flanking region.
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3.5.2 CYP3A Assay Quality
3.5.2.1 HepG2 Assay Quality
During the optimisation o f the calcium phosphate precipitate method in HepG2 cells, 
the transfection efficiency was consistently high. Unfortunately, notable fold 
induction values for the reporter gene constructs were variable, especially with the 
CYP3 A4-CMV-pSPAP construct. I was unable to reproduce the results published by 
Ogg et al. (1999) for transfections o f CYP3 A4-CMV-pSPAP in HepG2 cells dosed 
w ith PCN (1.23 fold induction with 10 pM), dexamethasone (3.5 fold induction with 
50 pM ) or rifampicin (2.43 fold induction with 50 pM). Ogg et al. (1999) observed an 
increase in fold induction from -3 .5  to -9  when pSG5-hGR was cotransfected in 
HepG2 cells dosed with 50 pM  dexamethasone, whereas I observed no enhancement 
and often a decrease. This led me to attempt to discover and rectify the methods 
relating to reproducibility problems.
There is no way o f determ ining whether a plasmid DNA preparation is functional or 
not until a transfection experiment is performed, and even then the evidence may not 
be conclusive. My early DNA preparations were very low in concentration and so 
larger volumes had to be used in the transfection mixtures which may be responsible 
for the low fold induction values, due either to poor transfection efficiency or an 
increased volume o f impurities. Transfection efficiency can be adversely effected by 
endotoxin contamination, which is why the QIAGEN endofree DNA preparation kits 
were used (Weber et al., 1995; Weber et al., 1996). However there were no methods 
available to me to check for endotoxin levels within the preparations.
Wafaa El-Sankary (Molecular Toxicology, University o f Surrey) optimised the DNA 
preparation method and higher DNA concentrations were gained and simultaneously 
the fold induction values appeared to improve (El-Sankary, 2000). So poor DNA 
preparation could lead to increased endotoxin concentration, poor transfection 
efficiency, decreased AP activity or even cytotoxicity. It would therefore be 
advantageous to find a method to standardise DNA preparation quality. A trial 
observation o f DNA preparation spectrophotometric profiles at 200-400 nm did not 
show any difference between good and poor preparations.
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Increasing the concentration o f DNA within the transfection mixture did not appear to 
increase the fold induction value as might be expected. For example, a 0.2 pg DNA 
transfection produced a fold induction value o f 7.8 with 50 pM  rifampicin, whereas 
0.62 pg o f DNA produced only a 3.8 fold induction. Ogg et al. (1999) noted that 
cotransfection o f pSG5-hGR enhanced dexamethasone induction o f CYP3 A4-CMV- 
pSPAP activity, however when pSG5-hGR was cotransfected, it often caused a 
decrease in the fold induction values. This was originally believed to  be a problem 
with the pSG5-hGR DNA preparation, but numerous preparations o f  the pSG5-hGR 
plasm id produced the same results. It may be that cotransfection o f two plasmids 
decreases the transfection efficiency. This would be logical because W ilson et al. 
(1995) and Jordan et al. (1996) state that DNA concentration affects the transfection 
efficiency, and there is a third more DNA in the transfection mixture when pSG5- 
hGR is cotransfected. However DNA concentration did not appear to have an effect 
on transfection efficiency in my experiments with single plasm ids (refer to section 
3.2.1, figure 3.6). It may be possible that GR sequestered the inducer, preventing 
CYP3 A induction or competed within the cell for the machinery o f protein synthesis 
meaning less AP was produced, but this is unlikely and contradicts the findings o f 
Ogg et al. (1999).
The transfection mixture for each plasmid is prepared separately, and this often leads 
to a particular construct, showing higher basal AP activity than another. This is 
evident in appendix 9.5. It has been shown that successful calcium phosphate 
transfection depends on the fineness o f the precipitate (Jordan et al., 1996). Thus a 
slight difference in transfection mixture may mean comparison o f a successfully 
transfected plasmid to an unsuccessfully transfected plasmid. Construct to construct 
variability is also effected by plasm id size. Larger constructs are more difficult to 
transfect, however this factor should have been eliminated by the CYP3A23 promoter 
driven reporter gene construct being produced with an insert o f 1606 bp, which is 
similar to the insert size o f the CYP3A4-CMV-pSPAP construct.
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Once the calcium phosphate precipitate method had been optimised, I noticed high 
well to well variation, as much as ten fold different (refer to raw results in appendix
9.6.1). In order to minimise this variation, precipitates were stirred vigorously with a 
pipette to avoid the precipitate settling before pipetting each column with a 
multichannel pipetter. However this did not reduce the variability (refer to raw results 
in appendix 9.6.2). Well to well variability was much less when the TransFast method 
was used to transfect H4IIEC3 cells, which required single pipetting (refer to raw 
results in appendix 9.6.3). Thus single pipetting was also used for the calcium 
phosphate precipitation method to transfect HepG2 cells, but this failed to reduce the 
well to well variability (refer to raw results in appendix 9.6.4). This variability is 
more likely to be due to precipitate distribution within the medium, rather than 
pipetting problems. However this is an area that requires further consideration in the 
future because the relative light units measured did not produce statistically 
significant specific chemical effect values.
However significant SCEs (p<0.05) were observed by El-Sankary et al, (2001), using 
the same CYP3 A4-CMV-pSPAP reporter gene construct, transfected by the calcium 
phosphate precipitation method, for rifampicin concentrations > 1 0  pM  and 
dexamethasone concentrations > 3 0  pM. This is indicative that the problems reported 
within this section with regards to reporter gene inducibility are due to the high well 
to well variability observed.
In an attempt to reduce variability, a range o f commercially available transfection 
reagents including TransFast were used to transfect the pCMV-SPAP construct into 
HepG2 cells. However the calcium phosphate precipitation method produced eight 
fold higher relative light units compared to the other reagents, with Dosper and 
DOTAP being the next effective. Therefore the calcium phosphate method was the 
most effective for transfecting HepG2 cells.
I observed that cells transfected by the optimised calcium phosphate precipitate 
method appeared small and slow grow ing in comparison to non-transfected cells (data 
not shown). This was attributed to an overload o f calcium phosphate, as a heavy 
precipitate was observed.
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This appeared to comprom ise the cells, affecting their response to xenobiotics. The 
effect o f the precipitate was exam ined by the addition o f different dilutions o f the 
optimised calcium phosphate precipitate. I observed that the less dilute the precipitate, 
the smaller and more slow grow ing the cells appeared (data not shown). The 
concentration o f the precipitate, however had no effect on induction o f the CYP3A 
reporter gene construct activity, as notable fold inductions by 50 |aM rifampicin were 
not observed in any o f the transfected cells (data not shown).
Calcium levels within cells are highly regulated under normal circumstances 
(Berridge, 1995; Clapham, 1995; Ferris and Synder, 1992; Pozzan et al., 1994). The 
influx o f  calcium either into the cells environment or into the cells themselves, may 
disrupt this balance or cause stress on the cells in maintaining the balance. Calcium is 
able to up regulate the Ca^^ binding protein, calreticulin, which is able to inhibit 
steroid, thyroid, vitamin D 3  and retinoid receptor subfamily activity by inhibiting their 
DNA binding activity by direct protein protein interactions (Nguyen et al., 1996; 
Shago et al., 1997; Wheeler et a l, 1995; Winrow et a l, 1995). Therefore the lack o f 
induction o f CYP3 A promoter driven reporter gene activity in HepG 2  cells 
transfected by the calcium phosphate precipitate method may be due to up regulation 
o f calreticulin, which may interfere with PXR/RXRa and CARTRXRa heterodimers 
as well as G R a and VDR regulation o f CYP3A induction.
Transfections require an actively dividing cell population, which may not have been 
true when the cells were split and 2.4 x 10"^  cells seeded per well in 96 well plates on 
the same day, as many o f the cells would have ceased division due to contact 
inhibition. Splitting the cells one day and seeding out the following day was tried, 
however this did not appear to cause any difference to the fold induction values. The 
age o f the cells did not have an effect on the fold induction levels, although cells were 
not used over passage number 16, because Ogg et al. (1999) described a change in 
HepG2 cell morphology and decreased inducibility of CYP3A4 promoter driven 
reporter gene activity after this.
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Ogg et al. (1999) and El-Sankary et al. (2000, 2001) did not encounter the problems 
w ith transfections into the HepG2 cell line, which were encountered here in. There 
may be a subtle difference in timing or technique that has gone unnoticed by my 
scrutiny but leads to the formation o f a dense calcium phosphate precipitate, that is 
enhanced by hGR cotransfection, or the presence o f any additional DNA. The dense 
calcium phosphate precipitate then compromises the cells, either by directly causing 
changes in their morphology, growth and survival or by sensitising the cells to the 
xenobiotic. It may be that although no obvious cytotoxicity was observed w ith the 
high xenobiotic concentrations, internally the cells are stressed and unable to respond 
to xenobiotic.
3.5.2.2 H 4IIEC3 and FaO  Assay Q uality
The only published method for H4IIEC3 transfection was the glycerol shock calcium 
precipitate method using 15 % by Hur and Edenburg (1995). However this method 
did not appear to work when tested, possibly due to a difference in fineness o f the 
precipitate (Section 3.2.2). Wilson and Smith (1997) suggested that placing 6 % 
glycerol into the medium improved transfection by either, allowing equilibration to 
produce osmotic effects on subcellular compartments important in promoting DNA 
transport to the nucleus, or due to glycerol effects on the cell membranes. However 
the use o f glycerol containing medium did not produce any better transfection results 
in H4IIEC3 cells, but this may have been due to 15 % glycerol being used instead o f 
6 %, as this may have caused disruptive osmotic effects. The TransFast method was 
selected as the most efficient method from the commercially available reagents tested.
The problems found w ith transfection o f H4IIEC3 cells led to the consideration o f 
alternative rat hepatoma cell lines. FaO cell lines were selected because they were 
known to be used frequently, unlike H4IIEC3 cells and they could be transfected by 
the TransFast transfection method (Chevalier and Roberts, 1999; Passilly et al., 1996; 
Passilly et al., 1999). Because two rat cell lines were being considered, it would be an 
improvement to also study two human hepatoma cell lines, then any differences 
observed between the species could be pinpointed to the species rather than to a 
problem with the cell line.
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A second human cell line HuH7 was selected for testing, because it is frequently used 
in industry, however they were not obtained until after completion o f this project but 
are being used for further work in this area by other PhD students (Pascussi et al., 
1999).
3.5.3 Functionality of the CYP3A23-SV40-pSEAP Construct
The CYP3A23 promoter driven reporter construct has shown notable fold induction 
values in both HepG2 and H4IIEC3 cells when dosed with dexamethasone and in 
HepG2 cells when dosed w ith rifampicin. This would be expected because one o f the 
most characteristic species differences between rat and human CYP3A induction, is 
that rat CYP3A is not inducible by rifampicin (Kocarek et al., 1995; Williams et al., 
1994). Bai*wick et al. (1996) suggests this is due to differences between host cells, and 
this appears to be supported by the above results. However my data for rifampicin is 
inconclusive because induction o f the activity o f CYP3 A23-SV40-pSEAP and 
CYP3 A4-CMV-pSPAP by rifampicin was inconsistent. Induction o f  the activity o f 
both the CYP3A promoter driven reporter gene constructs in HepG2 cells in the same 
experiment was not observed and thus a complete induction profile for rifampicin was 
not obtained. The results do demonstrate that the CYP3A23-SV40-pSEAP construct 
is fully functional.
3.5.4 Suminaiw of the CYP3A Induction Systems
Thus in summary, the CYP3A4-CMV-pSPAP construct has been shown to be 
functional by Ogg et al. (1999) and El-Sankary et al. (2000, 2001). However the high 
well to well variability and construct to construct variability obseiwed during the 
calcium phosphate precipitate transfections into HepG2 prevents production o f 
reproducible fold induction and statistically significant SCE values. The 
CYP3A23-SV40“pSEAP construct activity could be induced by xenobiotics 
intermittently, which is probably due to variation in the quality o f the plasmid DNA 
preparations. The HepG2 cell line appeared to support induction o f CYP3 A promoter 
driven reporter gene constructs during this project and the work o f others such as Ogg 
et al. (1999) and El-Sankary et al. (2000, 2001). Again it is only the high variability o f 
response during calcium phosphate precipitate transfection that requires reduction.
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CYP3A promoter driven reporter gene constructs appeared non-responsive to 
xenobiotics in H4IIEC3 cells, even though their transfection efficiency was good. It is 
possible that H4IIEC3 cells are missing an essential receptor or activating factor 
involved in regulating CYP3A induction. The semiquantitative RT-PCR o f receptors 
helped to elucidate this, indicating that H4IIEC3 cells express the major receptors 
involved in regulating CYP3A induction, but at low levels (Section 4.5.1).
FaO cells appeared to be a prom ising rat hepatoma cell line, which could be 
transfected with high efficiency. However not enough transfections into this cell line 
were performed, to allow conclusions to be drawn about the responsiveness o f 
CYP3 A promoter driven reporter genes within these cells. We may encounter the 
same problems as w ith the H4IIEC3 cells, because FaO cells are derived from the 
H4IIEC3 cell line. However FaO cells are more commonly used within industry, and 
so appear to be the rat hepatoma cell line o f choice.
CYP3 A4 promoter driven reporter gene activity appeared to be induced better in 
HepG2 cells than CYP3 A23 promoter driven reporter gene activity by 50 p.M 
dexamethasone. Ten micromolar dexamethasone is reported to induce CYP3A7 
protein (3 fold) and mRNA (5 fold) in HepG2 cells and CYP3 A4 protein (2 fold) in 
primary human hepatocytes, whereas 50 mg/kg/d ay dexamethasone treatment induced 
CYP3 A1 protein over 600 fold and 6(3-testosterone hydroxylation activity up to 60 
fold in Sprague Dawley rat liver microsomes (Ghosal et al., 1996; Schuetz et al., 
1993a). Therefore from this it would appear dexamethasone is a more potent inducer 
o f rat CYP3A than human CYP3A. However as mentioned by Plant et al. (2000) care 
must be taken when fold induction values are compared between research groups 
because they may have been calculated using a different method and as such 
potentially giving vastly different results. For example within the data analysis for this 
section, a fold induction value o f 2.86 corresponded to a SCE o f 4, illustrating the 
difference in results even from models based on the same theoiy (Appendix 9.4). The 
dose o f 50 mg/kg/d ay for the rats may have provided a much greater dose to the cells 
than 50 dose we used.
141
Therefore the literature may not contradict my conclusion that CYP3 A4 promoter 
driven reporter gene activity is induced more potently than CYP3A23 promoter 
driven reporter gene activity in HepG2 cells. This again may be a host cell effect as 
the CYP3A23-SV40-pSEAP construct was induced in HepG2 cells, which may lack a 
regulatory factor present in rat liver that controlled the higher induction o f CYP3 A1 
protein and activity seen in vivo (Ghosal et al., 1996). For example, the effect o f hGR 
is important in induction o f CYP3A23 promoter driven reporter gene activity in 
HepG2 cells.
The role o f hGR in CYP3 A4-CMV-pSPAP induction by dexamethasone in HepG2 
cells can not be interpreted because the value was so low. If  it is assumed that the 
CYP3A4-CMV-pSPAP fold induction was enhanced by hGR cotransfection in a 
similar proportion to in the H4IIEC3 cells, this would compare to the results produced 
by Ogg et al.(1999). From this a pattern emerges, where CYP3A4 promoter driven 
reporter gene activity is induced by 50 pM dexamethasone in HepG2 cells, but not in 
H4IIEC3 cells unless hGR is added, whereas CYP3A23 promoter driven SEAP 
activity is induced in HepG2 cells with the aid o f hGR but not in H4IIEC3 cells.
In conclusion, dexamethasone is a more potent inducer o f CYP3 A4 than CYP3A23 
promoter driven reporter gene constmct activity in HepG2 cells. H4IIEC3 cells 
support much lower CYP3A promoter driven reporter gene activity than the HepG2 
cells. FaO cells supported induction o f CYP3 A4 promoter driven SEAP activity but 
not CYP3A23 promoter driven SEAP activity.
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4 Results of Cell Characterisation at the mRNA level
During the trans-species transfections o f CYP3 A promoter driven reporter gene 
constructs, it was observed that as well as species differences in the response o f the 
constructs to xenobiotics, differences between cell lines o f the same species (FaO and 
H4IIEC3) also occurred. To examine if  the receptor complement o f the cells was 
responsible for this variation in response, the mRNA levels o f the major receptors 
involved in CYP3 A regulation in the hepatoma cell lines were measured by semi­
quantitative RT-PCR. The mRNA levels o f the receptors in the hepatoma cell lines 
were compared to those measured in rat and human liver.
4.1 Primer Design and Optimisation
4.1.1 Primer Design
Initial rat and human primers were designed to nucleotide sequences found in the 
NCBI GenBank database. The accession numbers are shown in table 4.1 and primers 
shown in table 2.9.
Table 4.1 The Accession Numbers for the NCBI GenBank sequences used to 
design primers for RT-PCR
Target Sequence Accession number
Human Rat
CYP3A M18907 X96721
PXR AF061056 AF151377
GRa MI0901 M14053
CAR XM 042458 AF133095
CAR NM 005122
RXRa NM 002957 NM 012805
RXRP M81766
RXRy AF059312
ERa X03635 NMO12689
ERa NM 000125
ER(i AB006589 NMO12754
HNF4a Z49825 X57133
HNF4y Z49826 X57133
GAPDH XM 033269 NM 017008
Albumin
uyuool 
XM 031320 NM 134326
P Actin XM 037235 NM 031144
c database was searched for the cDNA sequenThe NCBI GenBanl 
genes to be detected by RT-PCR. The accession numbers for the sequences are 
presented above. The sequences were used to design primers. Blank cells indicate 
target gene sequences to which primers were not designed
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The primers for human CYP3A (detected both CYP3A4 and CYP3 A7), GAPDH, 
G Ra, PXR, RXRa^^^ and SRC-1 were obtained from DR. M. N. Vahaditi (University 
o f Surrey) and had previously been optimised using an annealing temperature o f 
58 °C (55 for PXR). The albumin primers designed originally by Dr. J. Rockett 
(University o f Surrey) to the rat sequence, were not species specific and were thus 
used to amplify human albumin also. The primers designed to the human H N F4a and 
HNP4y sequences, also bound to the rat HNF4 sequence and so both were used to 
amplify rat HNF4. Originally the only published rat RXR sequence (RXRy) was used 
to design primers for rat RXR.
When the rat R X R a sequence was published, new primers were designed (RXRa^^^). 
Primers to amplify rat GAPDH were published by ‘t Hoen et al. (2000). Primers to 
amplify human p actin were published by Donato et al. (1998).
4.1.2 O ptim isation of the ra t prim ers
Several reactions were performed for each primer pair before optimal reaction 
conditions were determined, which are shown in table 2.14 (Section 2.4.2.3). 
Complete details o f  the parameters for each reaction and the results can be found in 
appendix 9.7. The initial parameters producing clear signals, o f the expected sizes, for 
albumin, CAR, CYP3A23, E R a, ERp, GRa, HNEda and PXR were an annealing 
temperature o f 55 °C for 35 cycles using 100 ng of mRNA extracted from FaO cells 
and Ready to Go RT-PCR beads (Section 2.4.2.3), as shown in figure 4.1. However 
when E R a  and ERP primers were used in repeat reactions only rat liver mRNA 
produced a signal with E R a (Figure 4.1). Using an annealing temperature o f 57 °C for 
35 cycles produced signals w ith both the primer pairs for E R a and ERP, but repetitive 
reactions to determine the log linear phase (section 2.4.3) produced no signals. It 
appears that E R a and ERp were present at the limits o f detection o f the RT-PCR 
method and were therefore not pursued further.
Two human RXRa primer pairs were used, superscript numbering distinguishes the two pairs. 
RXRa^^  ^refers to tlie second human RXRa primer pair as described in section 2.4.2, table 2.10.
Two rat RXRa primer pairs were used, superscript numbering distinguishes llie two pairs. RXRa '^  ^
refers to tlie first rat RXRa primer pair as described in section 2.4.2, table 2.10.
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The HNF4y primer pair could not be optimised to produce a signal (Figure 4.1). The 
rat RXRa^^^ primers were optimised to produce a clear signal with an annealing 
temperature o f 58 °C (Figure 4.1). The rat GAPDH primers were published by ‘t Hoen 
et al. (2000) to produce optimum signal with an annealing temperature o f 52 °C for 18 
cycles (Figure 4.1).
Figure 4.1 Initial Optimisation of Rat Primers 
Marker
sizes iK b  CYP GAP 1 Kb
Marker 3A23 GRa PXR CAR ERB HNF4aHNF4v ALB ACT ERa RXRa '^  ^ DH Marker
10000
Primers for rat CYP3A23, GRa, PXR, CAR, ERp, HNF4a, and ALB (album in) 
produced clear signals o f the correct size with an annealing temperature o f 55 °C with 
FaO mRNA. An annealing temperature o f 55 °C was also optimum for rat E R a and 
ACT (P actin) using rat liver as a template. Primers for rat RXRa^^^and GAPDH 
produced optimum signals with annealing temperatures o f 58 °C and 52 °C 
respectively, using rat liver as a template.
4.1.3 Optimisation of the human primers
Several reactions were performed for each primer pair before the optimal reaction 
conditions were determined, which are shown in table 2.14 (Section 2.4.2.3). Details 
o f  the parameters for each reaction and the results can be found in appendix 9.7. 
Initially the human primer pairs were optimised using 100 ng o f mRNA extracted 
from HepG2 cells and the Access RT-PCR kits (due to a distribution failure o f the 
Ready to Go RT-PCR beads).
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The initial parameters o f 55 °C for 40 cycles produced clear signals o f the expected 
sizes for albumin, ERP, GAPDH, H N F4a and PXR but not for RXRa^^^ CAR^‘\  
ERa^^\ G R a and SRC-1, as shown in figure 4.2. No signal was obtained with 
RXRa^^^ primers so this primer pair was replaced with the RXRa^^^ primer pair. The 
HNF4y primer pair could not be optimised to produce a signal (Figure 4.2).
A  signal was obtained using the ERa^^^ primers w ith an annealing temperature o f 
60 ®C for 40 cycles, however repetitive reactions to determine the log linear phase 
(section 2.4.3) produced no signals so new primers were designed.
The ERa^^^ primers amplified two products with an annealing temperature o f 58 ®C, 
neither o f which were the correct size and so E R a was not pursued further. New 
primers were also designed for CAR^^^and produced a double-banded signal when 
amplified with an annealing temperature o f 58 ®C (Figure 4.2). The bottom band 
appeared to be the correct size.
Dr. M. N. Vahaditi (University o f Surrey) used an annealing temperature o f 58 ®C 
w ith the primers he donated and after 45 cycles, clear signals o f the correct size were 
obtained for the CYP3A, GRa, and SRC-1 primers using 100 ng o f  mRNA extracted 
from HepG2 cells (Figure 4.2). The R X R a primers produced a double-banded 
signal, with the larger band, the correct size. The human p actin primers were 
published by Donato et al. (1998) to produce optimum signal with an annealing 
temperature o f 58 °C for 27 cycles (Figure 4.2).
(') ®  Two rat RXRa and human RXRa, CAR and ERa primer pairs were used, superscript numbering 
distinguishes between tlie two pairs. For example RXRa '^  ^refers to tlie first rat RXRa primer pair as 
described in section 2.4.2, table 2.10.
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Marker
Figure 4.2 Initial Optimisation of Human Primers
1 Kb CYP
Marker PXR GAPDH RXRa^ ^^  SRCl 3 A GRa ACT CAR^ ^^  ERp HNF4aHNF4y ALB
n n n
Primers for human PXR, ERp, HNF4a, GAPDH and ALB (albumin) produced clear 
signals o f  the correct size with an annealing temperature o f 55 °C and HepG2 mRNA. 
An annealing temperature o f 58 °C was also optimum for human CYP3 A, GRa, 
SRC-1 RXRa^^^ and ACT (P actin) using rat liver as a template and human CAR^^  ^
using human liver poly A^ mRNA
4.2 Determination of the log phase
Log phase experiments were performed on all primer pairs under their optimal 
conditions. Figures 4.3, 4.4 and 4.5 show selected examples o f log phase experiments 
for rat GAPDH, CYP3A23 and human CAR, respectively. Figure 4.6 illustrates the 
linear log relationship between increasing cycle number and amount o f RT-PCR 
product for the 3 examples. The log phase experiments for rat E R a and ERp using an 
annealing temperature o f 57 °C for 21 to 35 cycles showed no signal and identified 
requirement for reoptimisation of the signal. The log phase experiments for human 
E R a using an annealing temperature o f 60 °C for 18 to 36 cycles, showed no signal 
and identified requirement for reoptimisation o f the signal. The mid exponential phase 
cycle numbers are shown in table 2.13, in section 2.4.3.
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Figure 4.3 Rat GAPDH Amplification from a Linear Log Phase Experiment.
M arker^îj4 22 24 26 28 30 32 34 36 38 40 M
sizes 
in bp
3000
1000
750
500
250
Even sequential cycle numbers from 22 to 40 were used to produce the log phase. A 
1 Kb ladder was also run on the gel (M). The mid-exponential cycle number 26 was 
used for the sem i-quantitative RT-PCR.
Figure 4.4 Rat CYP3A23 Amplification from a Linear Log Phase Experiment.
Markeij^ 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Msizes
Sequential cycle numbers from 11 to 30 were used to produce the log phase. A 1 Kb 
ladder was also run on the gel (M). The mid-exponential cycle number 16 was used 
for the semi-quantitative RT-PCR
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Figure 4.5 Human CAR Amplification from a Linear Log Phase Experiment.
M 22 24 26 28 30 32 34 36 38 40 MMarker 
sizes in 
bp
3000
1000
750
500
250
Even sequential cycle numbers from 22 to 40 were used to produce the log phase. A 
1 Kb ladder was also run on the gel (M). The mid-exponential cycle number 28 was 
used for the sem i-quantitative RT-PCR. The signals were double banded, w ith the 
smaller band the correct size.
Figure 4.6 A Graph to show the log linear relationship between cycle number 
and amplification of rat CYP3A23, rat GAPDH and human CAR.___________
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The cycle numbers selected, by eye from band intensity on agarose gels, are circled in red. 
The densitometric measurement o f  band intensity shown in this figure was used to check 
that selected cycle numbers were before the amplification plateaus. Individual data points 
are from 1 determ ination o f  band intensity.
4.3 Optimisation of mRNA concentration for RT-PCR
There is also a linear log relationship between the initial mRNA concentration in the 
RT-PCR reaction and the amount o f  RT-PCR product. The amount o f  human liver 
poly A^ mRNA to be used in RT-PCR was optimised by Dr. M. N. Vahaditi 
(University o f  Surrey) to be 1 ng per reaction. To optimise the rat liver mRNA 
concentration that was to be used, six RT-PCRs were prepared using the albumin 
primer pair and Ready to Go RT-PCR beads. Each reaction contained a different 
mRNA concentration o f  1, 10, 50, 100, 150 and 200 ng.
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The signal intensity increased w ith increasing mRNA concentration (Figure 4.7). 
Densitometric measurement o f  signal intensity indicated that 100 ng rat liver mRNA 
was before the plateau o f  the log linear relationship, as shown in figure 4.8. Therefore 
100 ng rat liver mRNA was used per reaction. One hundred nanograms o f  FaO, 
H4IIEC3 and HepG2 mRNA was also used because reactions using this concentration 
showed that the signals fi-om the cell lines were less than that fi-om rat liver, indicating 
that the mRNAs were not at saturating concentrations.
Figure 4.7 Dependency o f Amplification with Rat Liver mRNA Concentration.
Marker  M 1 10 50 100 150 200 ne mRNA M
sizes in 
bp
1000
750
500
250
mRNA concentrations fi-om 1 to 200 ng were used in RT-PCR reactions, producing 
the log phase. A 1 Kb ladder was also run on the gel (M). The 1 OOng reaction was 
used for the semi-quantitative RT-PCR.
Figure 4.8 Relationship between initial rat liver mRNA concentration and signal 
intensity for rat albumin.
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mRNA concentrations fi-om 1 to 200 ng were used in RT-PCR reactions. The signal 
intensity was measured by densitometry and shows a relationship between mRNA 
concentration and signal intensity.
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4.4 Analysis of RT-PCR Products
Prior to quantitation experiments, amplified products were cloned and identity with 
the target sequence confirmed using the BLAST search facility in the National 
Institute o f Health (NIH) GeiiBanlc database website. Table 4.2 shows that all the RT- 
PCR products match the sequence for the intended target, confirming that 
amplification o f the target gene had occurred.
The human RXRa^^^ primer pair produced a double-banded signal with the larger 
band, the correct size, whereas the human CAR primers produced a double band 
where the smaller band was the correct size. Fifty microlitres o f these two RT-PCR 
products were run on 2 % low melting point agarose gels containing ethidium 
bromide and all four bands were extracted using a Promega Wizard PCR preparation 
kit (Section 2.1.6.2) and sent for sequencing to GlaxoSmithKline. The larger RXRa^^^ 
RT-PCR product and both the signals produced by the human CAR primers matched 
with their target genes, as shown in table 4.2.
4.5 Verification of human ERg primer specificity
Repeated attempts to sequence the two human E R a RT-PCR products did not 
produce results, possibly due to their low concentration, indicated by their low signal 
intensity on 2 % agarose gels containing ethidium bromide. Therefore human E R a 
plasm id DNA was used as a template to test the specificity o f the human E R a 
primers, to determine whether the intermittent RT-PCR products observed were due 
to failure in priming or to levels o f  E R a mRNA being below the detection level o f 
RT-PCR in HepG2 cells and human liver poly A'*’ mRNA.
The human ERa-pSG5 plasm id was extracted from competent Kcoli cells by the 
miniprep method (Section 2.1.10). Both the human E R a primer pairs were used in 
PCRs using human ERa-pSG5 as template DNA, with annealing temperatures o f 60 
and 58 °C respectively for 40 cycles. Figure 4.9 shows the human ERa^^^ primer pair 
did not produce a signal but human ERa^^^ primers produced a signal o f 
approximately 290 bp, thus confirming the functionality and specificity o f the second 
human E R a primer pair.
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Table 4.2 Sequence analysis of the RT-PCR products for target genes
RT-PCR product Prim ers Match S core id entities
Rat CAR rCAR A NM 022941 60 46/53 (86%)
Rat CAR rCAR B NM_022941 121 63/64 (98%)
Rat CYP3A23 M13R NM_013105 626 316/316 (100%)
Rat CYP3A23 M13R NM_013105 626 316/316 (100%)
Rat GRa M13R NM_012576 733 370/370 (100%)
Rat HNF4a M13R D10554 658 338/340 (99%)
Rat HNF4a M13R D10554 652 337/340 (99%)
Rat HNF4a M13R D10554 644 336/340 (98%)
Rat PXR rPXR A AF151377 153 161/186 (86%)
Rat PXR rPXRB AF151377 165 132/148 (89%)
Rat RXRa rRXRa (1) A NM012805 519 326/347 (93%)
Rat RXRa rRXRa (1) B NM012805 242 204/231 (88%)
Human CAR (large) hCAR (2) A NM 005122 295 161/166 (96%)
Human CAR (large) hCAR (2) B NM 005122 157 133/150 (88%)
Human CAR (small) hCAR (2) A NM 005122 157 133/150(88% )
Human CAR (small) hCAR (2) B NM_005122 422 220/221 (99%)
Human CYP3A hCYP3A A NM 017460 396 224/233 (96%)
Human CYP3A hCYP3A B NM_017460 256 143/147 (97%)
Human ER|3 tiERp A AB006589 603 366/390 (93%)
Human ERp hER|3 B AB006589 658 387/409 (94%)
Human GRa hG R aA M10901 678 372/386 (96%)
Human GRa hG R aB XM_003838 87.7 70/77 (90%)
Human HNp4a hHNF4a A XM_009514 462 268/280 (95%)
Human PXR hPXR A AF061056 394 325/373 (87%)
Human PXR hPXR B AF061056 79.8 97/114 (85%)
Human RXRa (large) hRXRa (2) B XM 011778 490 283/294 (96%)
Human RXRa (large) hRXRa (2) A XM 005440 654 335/337 (99%)
Human RXRa (large) hRXRa (2) B XM 011778 283 167/178 (93%)
Human RXRa (large) hRXRa (2) A XM 005440 597 309/313 (98%)
Human RXRa (large) hRXRa (2) B XM 005440 634 334/338 (98%)
Human RXRa (small) hRXRa (2) A XM_011778 107 62/66 (93%)
Human SRC-1 hSRC-1 A U90661 103 148/187 (79%)
Human SRC-1 hSRC-1 B AJ000882 99.6 137/167 (82%)
Amplified products were cloned, sequenced with the target specific primers and 
identity with the target sequence confirmed using the BLAST search facility in the 
National Institute o f Health (NIH) GenBank database website. All the RT-PCR 
products match the sequence for the intended target, confirming that amplification o f 
the target gene had occurred.
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Figure 4.9 Amplification of Human ERa-pSG5 to Test The Specificity of the 
Human ER a Primer Pairs rERa rERp hERa '^  ^ hERa^ ^^Marker 
sizes in 
bp
1000
750
500
M
250
Both ERa^*^ and ERa^^^ were used to amplify human ERa-pSG5 by PCR with 
annealing temperatures o f 60 and 58 °C respectively for 40 cycles. The rat E R a and p 
primers were also tested using ERa-pSG5 as a template, but no signal was produced.
This indicates that the failure to amplify E R a from HepG2 cells and human liver poly 
A"^  mRNA with the hERa^^^ primers was due to low template concentration, indicating 
that E R a is expressed below the RT-PCR limit of detection.
4.6 Quantitation Results
4.6.1 Rat Quantitation Results
mRNA levels o f  rat CAR, CYP3A23, GRa, HNF4a and PXR were all quantified by 
RT-PCR, in comparison with the standards albumin and act in, using FaO, H4IIEC3 or 
rat liver mRNA as templates. Triplicate reactions were carried out for all 
amplification reactions. Where multiple mRNA extracts were used, inter experiment 
variability was < 9 %.
The target gene RT-PCR products from each reaction were electrophoresed once with 
the corresponding albumin and P actin products on 2 % agarose gels stained with 
SYBR Green. P actin, albumin, CAR, CYP3A23, GRa, H N F4a and PXR transcripts 
were detected in rat liver, p actin, albumin, CAR, GRa, H NF4a and PXR transcripts 
were detected in FaO cells and P actin, CAR, G R a and PXR transcripts were detected 
in H4IIEC3 cells (Figure 4.10).
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A table o f raw data from the individual experiments can be found in appendix 9.8.
The rat RXRa^^^ and rat GAPDH primers were not optimised until after the 
sem i-quantitative RT-PCRs had been performed, therefore the RT-PCR products o f 
these primer pairs were electrophoresed on a 2 % agarose gel containing ethidium 
bromide, with the P actin RT-PCR product from the previous third reaction. The 
intensity o f the P actin RT-PCR product from the earlier electrophoresis was divided 
by the intensity o f the same product when electrophoresed with RXRa^^^ and GAPDH 
to calculate the difference in intensity between the two gels. This produced a 
normalisation factor, which was then used to multiply the signal intensity o f  the rat 
RXRa^^^ and GAPDH signals, to allow comparisons between the other receptors 
mRNA levels as measured on the third gel.
The mean ratios o f target gene to albumin or p actin intensity were calculated from 
the triplicate amplifications, however the lack of signal in H4IIEC3 cells w ith the 
albumin primer pair illustrated the differing concentrations o f control genes in the 
different cell types, when quantitation relied on the concentration o f control genes to 
be stable. Accordingly receptor levels were compared by normalising to per ng of 
mRNA and are shown in figure 4.10.
The statistical differences between FaO cells and rat liver and H4IIEC3 cells were 
analysed using a one way ANOVA with Bonferroni Dunn post hoc test. The 
differences between PXR mRNA expression in FaO cells compared to that in 
H4IIEC3 cells or in rat liver, were significant with p values < 0.05 and 0.01 
respectively. R X R a was expressed at significantly lower levels in FaO cells than in 
H4IIEC3 cells, with a p value < 0.001. Rat liver showed no R X R a signal, but high 
levels were observed in FaO and H411EC3 cells, thus indicating a highly significant 
difference. The rat hepatoma cell lines showed no CYP3A23 signal but rat liver did, 
indicating a highly significant difference in CYP3A23 expression (Figure 4.10).
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Figure 4.10 Semi-quantitative RT-PCR Results Comparing Rat Liver, FaO and 
H4IIEC3 cells.
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Each RT-PCR reaction was performed in triplicate using multiple FaO and H4IIEC3 
mRNA extracts but a single rat liver mRNA extract, except for the RX Ra RT-PCR, 
which was only performed once. The signal intensity was averaged and normalised to 
per nanogram o f  mRNA. Error bars represent the standard error o f  the mean. 
Statistical analysis using the 1 factor ANOVA with Bon Ferroni / Dunn post hoc tests 
on an n=3 showed that FaO PXR is significantly different from H4IIEC3 PXR at a 
level o f  0.0343 (*p<0.05) and from rat liver PXR at a level o f 0.007 (**p<0.01). FaO 
R X Ra is significantly different from H4IIEC3 RX Ra at a level o f  0.0003
(***p<0.001).
4.6.2 Human Quantitation Results
The transcripts o f  human CAR, CYP3A, ERp, G Ra, HNF4a, PXR, RXRa^^^ and 
SRC-1 were all quantified in comparison w ith the housekeeping standards albumin, 
p actin and GAPDH by RT-PCR using HepG2 mRNA extracts or human liver poly 
A^ mRNA as templates and Ready to Go RT-PCR beads. Reactions were performed 
in triplicate using the same human liver poly A^ mRNA sample but different HepG2 
mRNA extracts, from the same flask o f  passage 11 cells.
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The target gene RT-PCR products from the triplicate experiments were each 
electrophoresed once with the corresponding albumin, 3 actin and GAPDH 
housekeeping standards on 2 % agarose gels containing ethidium bromide. A 
reproduction o f the first gel is shown in figure 4.11.
Figure 4.11 A Representative Semi-quantitative RT-PCR Using Human Primers 
and HepG2 (A) or Human Liver (B) mRNA.
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The RT-PCR products were sized using the 1Kb ladder CYP3A 293 bp, Actin 452 bp, 
CAR 263 bp, G R a 494 bp. Albumin 450 bp, SRC-1 450 bp, PXR 442 bp, RX Ra 
492 bp and GAPDH 426 bp. ERp did not produce a signal.
The primers for ERp produced no signals with any o f the mRNA types. H N F4a was 
only amplified from HepG2 extracts, not human liver poly A  ^ mRNA, in only one o f 
the three experiments. A signal was gained for albumin from human liver poly A^ 
mRNA in only one of the triplicate reactions. CYP3A was amplified from HepG2 
mRNA extracts in only one o f the triplicate reactions. A table o f raw data from the 
individual experiments can be found in appendix 9.8.
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Receptor levels were normalised to per nanogram o f  mRNA and the results shown in 
figure 4.12. The statistical differences between HepG2 cells and human liver were 
analysed using a paired t test. There were significantly higher levels o f  G Ra, PXR 
and SRC-1 in human liver compared to HepG2 cells. CAR and R X Ra were not quite 
significantly different in HepG2 cells to human liver. H NF4a could not be tested for 
significance because it was only detected in HepG2 cells. CYP3A mRNA could not 
be tested for significance because it was only detected in one reaction.
Figure 4.12 Semi-quantitative RT-PCR Results Comparing Human Liver and 
HepG2 cells.
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Each RT-PCR reaction was performed in triplicate using the same human liver poly 
A+ mRNA sample and multiple HepG2 mRNA extracts. The signal intensity was 
averaged and normalised to per nanogram o f mRNA. Error bars represent the standard 
error o f the mean. Statistical analysis using the paired t-test on an n=3 showed that 
human liver expressed significantly greater levels o f  the G R a, PXR and SRC-1 than 
HepG2 cells where * represents a p value less than 0.05 and **p<0.01.
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4.7 Principal Component Analysis
4.7.1 Principal Component Analysis on Receptor luRNA Levels
PGA is a technique for reducing the dimensionality o f  datasets for compression or 
recognition purposes (Calvo et al., 2000). Principal component analysis can be used to 
identify key variables or groups o f  variables that control the system under study. The 
dimensional reduction also perm its graphical representation o f  the data, in the form o f 
case scores, in this situation allovying relationships between the cell lines and their 
liver counterparts to be drawn. In essence it clusters similar factors, thus indicating 
patterns w ithin datasets, PGA was used to compare receptor mRNA levels between 
cell lines and their liver counterparts and to indicate any similarities in receptor 
mRNA profiles. The figure o f  PGA case scores is shown as figure 4.13. There was 
little clustering and only the HepG2 cells were close to rat liver. Mainly, the three 
ligand activated receptors; PXR , GAR and R X R a determ ined vaiiance between the 
cell types w ith percentage variances o f 24, 25 and 37 % respectively.
Figure 4.13 Principal Component Analysis on Receptor mRNA Levels in Rat 
and Human Cell Lines and Liver
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PGA compares the hepatoma cell lines w ith their liver counterparts and airanges them 
according to similarities in their receptor mRNA levels.
158
4.7.2 Principal Component Analysis on Relative Abundance o f Receptors
Latin square tables were produced to calculate the abundance o f  each receptor 
compared to the other receptors in the form o f  receptor ratios. This adaptation o f 
Graeco-Latin square analysis was performed for each cell type with the semi- 
quantitative RT-PCR results. The names o f  the receptors were used to label the 
columns o f  a table and the rows in the same table. Equations were inserted into the 
table so that the level o f  mRNA o f  the receptor, heading the column, was divided by 
the mRNA level o f  the receptor heading the row, thus providing ratios o f  the mRNA 
levels o f  each receptor divided by every other receptor. PCA was used to analyse 
these ratios. Figure 4.14 shows that human liver, rat liver and HepG2 mRNA 
clustered together while H4IIEC3 mRNAs were segregated. The major variables 
according to percentage variance were H N F4a:RX Ra and CAR:RXRa; 28 and 23 % 
respectively.
Figure 4.14 Principal Component Analysis on the Relative Abundance of 
Receptor mRNA.
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PCA compares the hepatoma cell lines w ith their liver counterparts and arranges them 
according to similarities in their ratios o f  receptor mRNA levels.
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4.8 Investigation of RXR Expression in Rat Liver by RT-PCR.
During sem i-quantitative RT-PCR, R X R a was not amplified using rat liver as a 
template, but it was amplified in the rat hepatoma cell lines using the same primer pair 
(RXRa^^^). Ulven et al. (1998) published primer pairs used to detect rat RXRa^^\
P and 7 , designed to the mouse nucleotide sequences. These primer pairs were used to 
set up RT-PCR reactions w ith Ready to Go RT-PCR beads and 100 ng per reaction o f 
two rat liver mRNA extracts used for previous RT-PCR experiments. The cycle 
parameters were an annealing temperature o f 55 °C for 30 cycles. Rat P actin was also 
amplified from each mRNA extract. Reactions were also set up w ithout mRNA with 
the RXR primers as negative controls. As seen in figure 4.15 the first mRNA extract 
only produced a low intensity signal with the R X R a primer pair whereas the second 
mRNA extract produced intense signals for R X Ra, p and y o f the expected sizes o f 
165, 175 and 191 bp respectively. P actin was only detected in the second extract. No 
signals were detected in the negative controls.
The three RXR RT-PCR products from the second mRNA extract were sent for 
automated sequencing with the target specific primers to GlaxoSmithKline. 
Comparison to known sequences using the NIH GenBank BLAST search facility 
matched the R X R a product to rat R X R a mRNA (L06482). However the proposed 
RXRp product was identified as rat thrombin mRNA (M81397) and the proposed 
RXRy product was identified to rat transferrin mRNA (M27966), as shown in table
4.3. The RXR primers o f  Ulven et al (1998) were designed using the mouse cDNA 
sequences because the rat RXR sequences were not available. Table 4.3 also shows 
that the sequences o f  the transcripts matched the mouse R X Ra, P and y sequences to 
which the primers had been designed. Despite the failure to amplify RXRp and y, this 
experiment showed the presence o f R X R a in rat liver, confirming that the absence of 
R X R a in the previous sem i-quantitative RT-PCR experiments was anomalous. 
However the previous PCAs could not be repeated to include the mRNA levels o f  
R X R a in the rat liver that were measured here, because the mid exponential cycle 
number had not been determined.
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Also no previous RT-PCR products were available to normalise this rat liver 
R X R a signal to allow comparison with the signals from the products on the previous 
gels.
Figure 4.15 Amplification of Rat RXRs by RT-PCR using an annealing 
temperature of 55 ®C.
Marker mRNA extract 1 mRNA extract 2 Negative controlsRXRa RXRB RXRv RXRa RXRB RXRv
The intense signals for RX Ra, P and y o f the expected sizes o f 165, 175 and 191 base 
pairs respectively were produced from the second rat liver mRNA extract. Negative 
controls were RT-PCR reactions set-up without mRNA, with the RXR primers.
Table 4.3 The results of sequence analysis on the rat liver RXR RT-PCR  
products.
RT-PCR product Primers Match S core Identities
Rat RXRa rRXRa (2) L06482 rRXRa 273 154/159 (96 %)
NM_011305 mRXRa 233 149/159 (93 %)
Rat RXRp rRXRp M81397 r thrombin 265 138/143 (96 %)
NM _011306 mRXRp 41 20/20 (100 %)
Rat RXRy rRXRy M27966 r transferrin 171/171 (100 %)
NM_009107 mRXRy 44.3 22/22 (100 %)
Amplified RXR products were cloned, sequenced with the target specific primers and 
identity with the target sequence confirmed using the BLAST search facility in the 
National Institute of Health (NIH) GenBank database website.
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4,9 Discussion
4.9.1 Semi-quantitative RT-PCR Methodology
Sem i-quantitative RT-PCR was used rather than quantitative competitive RT-PCR 
because the latter method requires an internal control containing the same primer sites 
as the target sequence, allow ing them to be co-amplified (Gilliland et al., 1990). The 
design o f PCR mimics or adaptation o f homologous sequences would have been very 
time consum ing and expensive. Optimisation o f the co-amplification reactions would 
also have been beyond the scope o f the project due to the large number o f target genes 
that were selected for analysis in the two species. Other absolute mRNA quantitation 
methods such as RNase protection assays, which avoided such lengthy optimisation 
procedures, could have been used. However RT-PCR was considered more sensitive 
in the detection o f  low abundance mRNAs and because the mRNA levels were being 
used to compare between the cell lines and their liver counterparts, a relative rather 
than absolute measurement o f mRNA was sufficient.
The control genes albumin, p actin and GAPDH were selected as internal standards 
for the sem i-quantitative RT-PCR procedure. They could have been amplified in the 
same reaction to the target sequence, however quantitation must be performed in the 
exponential phase o f  amplification and the reported high expression o f these control 
genes would generate lower exponential phases than most o f the target genes (Kellogg 
et al., 1990; Zimmermann and Mannhalter, 1996). This dictated amplification o f the 
standards in different reactions to the target sequences.
Horikoshi et al. (1992) predicted that if  an internal standard is expressed at the same 
level in two samples, the ratio o f PCR products generated from the target and standard 
should indicate the relative expression level o f  the target mRNA in those samples.
This meant that for comparison between cell lines, an internal standard that was 
expressed at the same level in all cell types would be required.
Because the levels o f control genes were not known in the three cell lines, three 
different control genes were examined, such that the most appropriate standard could 
be chosen.
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Album in was not expressed in the H4IIEC3 cell line, which raised difficulties in 
normalising the data to the control genes because it established the differing 
concentrations o f  these genes in the different cell lines. Other examples o f  this 
included albumin expression which was half the level in FaO cells compared to rat 
liver, whereas |3 actin was one and two thirds o f  the levels in H4IIEC3 cells in rat 
liver and FaO cells and (3 actin expression in HepG2 cells was double that in the 
human liver. A  clear illustration o f how the differences in standard expression skewed 
the sem i-quantitative results was shown by PXR and G R a levels, which were 
significantly different in FaO cells and rat liver when albumin:receptor ratios were 
tested, but not significantly different when actin:receptor ratios were tested (data not 
shown).
As the same volume o f each reaction was loaded onto the gels and the initial 
concentration o f mRNA template added to the reaction was known, it was decided to 
analyse the results in terms o f  per ng mRNA added to avoid skewed results due to 
control genes. This method has been favoured previously within the molecular 
toxicology laboratory (University o f  Surrey) as the debate as to which control gene is 
preferable continues in the literature (Enmark et a l, 1997; Lau et a l, 1998). Very few 
people have used RT-PCR to compare between cell types or species, and those who 
have done so have been qualitative rather than quantitative (Lau et a l , 1999). Those 
that have used control genes reported no difference in expression levels, but obvious 
differences were observed in, for example, the Moore et a l (1998) publication, which 
used GAPDH as a control gene even though the levels varied in both the tissues and 
the cell lines they tested. The per ng o f mRNA method did not take into account any 
difference in the intensity o f the rat and human signals due to their electrophoresis on 
separate gels, such as post reaction analysis errors including differences in gel 
loading, gel quality and photography. However the rat and human reactions used 
species specific primer pairs with different optimum annealing temperatures and mid 
exponential phase cycle numbers, which may have had different amplification 
efficiencies. Thus comparison between the rat and human RT-PCR results should be 
considered in relative, rather than absolute terms.
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M ore adequate controls for gel to gel variation would have been to electrophorese 
both human and rat RT-PCR products on the same gel or to run a selection o f RT- 
PCR products from the other species on the sem i-quantitative gels as controls. 
However the experiment as it stands, measures mRNA indirectly by a non- 
quantitative method and as such could not be used to quantitate absolute receptor 
levels, but was indicative o f  receptor mRNA profiles.
The sem i-quantitative RT-PCR reactions used album in as a positive control with 
which all mRNA extracts were tested, except for the H4IIEC3 extracts, when (3 actin 
was used. At the same time, a reverse transcriptase negative reaction was performed 
to test for the presence o f genom ic DNA contamination. The primer sets were 
designed to span intron / exon boundaries, when the relevant information was 
available, such that any genomic contamination would produce a different sized band 
to that originating from mRNA.
It would have been preferable to include an RT negative and an RNA negative during 
each sem i-quantitative experiment to indicate if  any genomic contamination had 
occurred during the use o f the RNA sample or during RT-PCR set-up. However the 
large number o f target genes and mRNA samples and the use o f  Ready to Go RT- 
PCR beads made this difficult. Instead, before a reaction set-up, the bench and 
pipettes were cleaned w ith ethanol and the pipettes UV irradiated, dedicated RT-PCR 
reagents were used, including mRNA previously identified as genom ic DNA free by 
gel electrophoresis and RT negative PCR, in order to reduce the risk o f  contam ination 
from the surroundings or sample manipulation.
Each mRNA sample should have been amplified in triplicate, however due to the 
small volume and concentration o f mRNA we were able to extract from the hepatoma 
cell lines, this was not possible. For the first two rat reactions, the same FaO mRNA 
sample was used whereas the third reactions used a different FaO mRNA sample. The 
second and third rat reactions used the same H4IIEC3 mRNA sample whereas the 
first reactions used a different one. However all three sets o f reactions used the same 
rat liver sample.
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This use o f the same and different samples allowed an approximation o f experimental 
error o f  30 % and o f the differences due to biological sources o f 8.5 % for the rat 
sem i-quantitative RT-PCR reactions. All three human sem i-quantitative RT-PCR 
reactions used the same human liver poly A^ mRNA sample but different HepG2 
mRNA extracts. However the HepG2 mRNA extracts were all from the same flask o f 
passage 11 cells and were extracted simultaneously, so differences due to biological 
sources should have been minimal. The analysis o f  additional samples was not 
possible due to difficulties w ith the supply o f  mRNA extraction kits and difficulties in 
extracting high quality mRNA from the hepatoma cell lines.
4.9.2 Primer design and optimisation
Initially the human CYP3 A primers obtained by Dr. M, N. Vahaditi were reported to 
be CYP3A4 specific. However during the use o f the primers, it was discovered that 
they were found to detect both CYP3A4 and CYP3A7, The identity between CYP3A4 
and forms CYP3A5, CYP3A7 and CYP3A43 cDNAs are 83, 95 and 75 % 
respectively, therefore designing primers specifically to one form is difficult. It was 
advantageous that the CYP3A primers also detected CYP3A7 as it is the major 
CYP3A mRNA expressed in HepG2 cells (Schuetz et al., 1993a). Dr. M. N  Vahaditi 
(University o f  Surrey) performed sem i-quantitative RT-PCR with form specific 
primers and found the CYP3 A mRNA expression in HepG2 cells as being only 
CYP3A7 mRNA. This, in association with my real time PCR o f the human CYP3A 
mRNA forms negated the requirement to redesign the CYP3A4 primers to be specific.
The only rat RXR nucleotide sequence published when the primers were designed 
was a partial RXRy sequence. Primers were designed to this sequence in the hope, 
they would also detect R X Ra, however primer design was limited due to the small 
area o f sequence available, therefore it was no surprise when neither R X R a or RXRy 
were detected. The first human R X R a primers were then used to try and detect rat 
R X R a but no signal was obtained with these primers from either rat or human mRNA 
templates, indicating poor primer design or lack o f optimisation. A second human 
R X R a and a specific rat R X R a primer produced signals o f the correct size, indicating 
the lack o f  signal with the other primer pairs were false negative results.
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The HNF4y primer pair could not be optimised to produce signals using either human 
or rat mRNA as a template, suggesting that HNF4y may not be expressed in liver.
This confirmed the lack o f HNF4y expression in liver observed by Drewes et al. 
(1996).
Optimisation o f the RT-PCR signals proved difficult for many o f  the target genes.
One reason may have been inefficient primer design as already mentioned. The 
optimisation reactions were performed on a trial and error basis until a strong signal 
was obtained, except in the cases where published reaction parameters were available. 
However repetition o f some reactions using optimised conditions, such as the E R a 
reactions, produced dramatically different (un-optimised) results. This illustrates the 
problems with primer design and optimisation procedures, which are still largely 
empirical and must be worked out experimentally. Even with primer design 
programmes there is no guarantee o f success because the programmes cannot predict 
if  the primer chosen will bind to other genes or if  pseudogenes or alternatively spliced 
mRNAs are present. The differences may also be explained by pipetting inaccuracies, 
but reactions were prepared using a master-m ix to minimise the inaccuracies 
introduced by pipetting small volumes.
The choice to use rat liver mRNA for the rat and HepG2 mRNA for the human primer 
optimisation was made initially because rat liver was expected to contain a high 
concentration o f mRNA with a complete complement of receptors, whereas HepG2 
mRNA was less expensive than the commercially acquired poly A^ human liver 
mRNA. This was advantageous for the optimisation reactions, although most primer 
pairs were tested with all their species specific mRNA extracts before use in 
sem i-quantitative RT-PCR. However the human liver poly A^ mRNA was used to 
optimise the hCAR primer as Sueyoshi et al. (1999) reported that HepG2 cells do not 
express CAR. The rat liver mRNA concentration was identified using the albumin 
primers and this concentration o f 100 ng was shown to be in the exponential phase o f 
the RT-PCR reaction.
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This RT-PCR reaction using FaO, H4IIEC3 and HepG2 mRNA at 100 ng indicated 
that the signals obtained from the cell lines were lower than those in rat liver and 
therefore the mRNAs were unlikely to be at saturating concentrations in the cell lines. 
However some o f the other primer pairs produced signals from the cell lines, greater 
than those from rat liver. Therefore it would have improved my experimental design 
to optimise the mRNA concentration for each cell type.
The use o f only one mRNA type for the linear log phase, may have led to the use o f 
cycle numbers that were either too low to amplify genes in the other samples or too 
high, no longer amplifying genes in the exponential phase. It would therefore have 
improved my experimental design to test the optimised conditions and the mid 
exponential cycle number on all o f the mRNAs for each species. It is hoped however 
that cycle numbers mid exponential phase allowed the signal to remain in the log 
phase despite any fluctuations in the mRNA levels o f the genes.
The rat E R a  and ERp primers produced signals intermittently with rat liver and FaO 
mRNA but not H4IIEC3 mRNA, suggesting that the estrogen receptors were at the 
detection limit o f the RT-PCR technique.
The initial human E R a  primers produced intermittent signals and the second human 
E R a  primers amplified two products o f incorrect size. However when tested using a 
human E R a  plasmid, a clear signal o f the coiTect size was only produced by the 
second E R a primers confirming that the second primers were functional. This also 
indicated that E R a  is expressed at a low level in HepG2 cells, or is mutated, thus 
explaining the different signal sizes. The human ERp primers also produced 
intermittent signals, which were confirmed as ERp by sequencing, suggesting that 
ERP was also expressed at the limit o f detection. This confirmed the work o f M oore 
et al. (1998) who did not detect ERp in HepG2 cells.
The human R X R a and CAR primers each amplified two products, one o f the correct 
size and one smaller and one larger respectively.
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Sequencing indicated that the smaller R X R a product and the larger CAR product 
were 99 and 97 % similar to their respective targets. The mouse CAR gene is 
transcribed into two forms, the abundant mCARl and inactive mCAR2, a truncated 
splice variant (Choi et ah, 1997). Until now only one transcriptionally active form o f 
human CAR has been reported but there may be a splice variant in which the primers 
bind to a different region than in the known CAR, thus producing a larger product. 
Baes et al. (1994) observed 3 different sized (1.7 kb, 2.1 kb & 2.9 kb) mRNA species 
o f  MB67 (human CAR), thus supporting this. However the existence o f a splice 
variant could not be confirmed by sequencing the RT-PCR products. It is possible that 
the smaller sized R X R a signal is a splice variant, although none have been reported to 
date. Or it could be due to cross specificity o f  the primers w ith the other RXR family 
members, although no binding with the human RXRP or y sequences were observed 
using Vector NTI or the NIH Blast search facility.
4.9.3 Gene expression
4.9.3.1 Rat CYP3A23 and nuclear receptor expression
The reduced mRNA levels o f  most o f  the receptors within the H4IIEC3 cell line 
provides an explanation for their low responsiveness when used in the CYP3 A 
reporter gene assays. Clayton et al. (1985) reported substantially different albumin 
expression levels in several rat hepatoma cell lines indicating a changed phenotype, as 
album in is said to be a liver specific differentiation marker (Bayly et ah, 1993). 
Therefore the lack of, or undetectable levels of, albumin in H4IIEC3 cells suggests 
they have an extremely changed phenotype compared to adult hepatocytes and this is 
supported by the literature (Gudas and Hankinson, 1987). The FaO cells are derived 
from the H4IIEC3 cell line, but display a liver specific phenotype, including the 
highest expression o f albumin in five rat hepatoma cell lines exam ined by Bayly et al. 
(1993). FaO cells have a transcription rate similar to primary rat hepatocyte cultures, 
however this transcription rate is only 1 to 30 % o f the transcription rate o f in vivo rat 
liver (Clayton et ah, 1985).
It is notable that HNF4 was only detected in one reaction with rat liver but at higher 
levels than the level in the hepatoma cell lines.
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This lack o f HNF4 in the rat liver is believed to be anomalous because HNF4 is a 
liver enriched transcription factor (Cereghini, 1996). Therefore the levels at which 
HNF4 was detected is more likely to be correct than the absence. The lack o f 
detection may be due to poor primer design or incorrect optimisation.
The lack o f  CYP3A23 mRNA in both hepatoma cell lines suggests disruption to the 
CYP3A basal expression pathway. This could in turn explain why H4IIEC3 cells 
could not support the induction o f CYP3 A promoter driven reporter genes. It also 
predicts possible problems in the use o f FaO cells for reporter gene experiments in the 
future.
Huss and Kasper (1998) stated that site A, (-85 to -110) in the CYP3A23 proximal 5’ 
flanking region, binds HNF4. Mutation in this region decreased the induction o f 
promoter driven reporter gene activity response for dexamethasone from 15 to 2 fold 
and was accompanied by a 40 to 60 % drop in basal luciferase activity. Therefore the 
low level HNF4 expression in the rat hepatoma cell lines may be responsible for their 
low basal expression o f CYP3A23 mRNA.
The poor induction o f alkaline phosphatase activity in the cell lines during the 
CYP3 A promoter driven reporter gene assays could also be due to the low HNF4 
levels because HNF4 is essential for the lull induction response to glucocorticoids 
(Huss and Kasper, 1998). The low HNF4 levels were another indicator o f departure 
from adult hepatocyte phenotype in the hepatoma cell lines.
FaO cells contained significantly higher levels o f PXR mRNA than rat liver or 
H4IIEC3 cells w ith p values < 0.007 and 0.0343 respectively. This pattern was also 
true for CAR, although the differences were not statistically significant. Sara Lucas 
(Personal communication 2001, University o f  Aberdeen) found that PXR mRNA was 
present at equal levels in rat liver and freshly isolated hepatocytes for up to 48 hours, 
but after 66 hours in culture, PXR mRNA was increased 6 fold in primary rat 
hepatocytes. This indicates that PXR levels increase during hepatocyte phenotypic 
change, because primary hepatocytes become less differentiated during culture and 
hepatoma cell lines have an altered phenotype to liver.
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If, as Pascussi et al. (2000a, b) and Huss and Kasper (2000) state, that maximal 
CYP3 A23 mRNA induction requires a GR-dependent increase o f PXR and R X R a 
expression, FaO cells appear a hopeful prospect for future CYP3A promoter driven 
reporter gene induction assays as they also contained high G R a levels. It is these 
G R a levels that may be responsible for the higher PXR and CAR mRNA levels in 
FaO cells. However G R a is expressed at almost the same levels in H4IIEC3 cells and 
rat liver and therefore does not explain the higher expression o f PXR in the H4IIEC3 
cells.
R X R a was expressed at significantly higher levels in H4IIEC3 cells than FaO cells 
(p < 0.0003). Using the initial rat R X R a primers, no R X R a was detected in rat liver. 
This may be an anomalous result because the rat R X R a RT-PCR was only performed 
once, so the primers may not have been optimised correctly. The high levels o f 
R X R a in the hepatoma cell lines compared to the other receptors may be due to post 
amplification effects as the products were mn on a separate gel. The signal intensity 
o f R X R a was normalised by repeating the electrophoresis o f the previous (3 actin 
product from the third experiment on the same gel and then using the intensity o f this 
product to calculate the difference in intensity between the new R X R a gel and the gel 
from the third experiment. Thus the R X R a signal intensity was adjusted accordingly 
to allow comparison w ith the previous samples.
There was however, the possibility that R X R a was expressed at levels below the 
detection limit in rat liver and thus other RXR forms may have replaced it. It has been 
shown that RXRp is capable o f compensating for most o f R X R a’s functions in 
R X R a null mice (Krezel et al., 1996). To determine R X R a expression in rat liver, 
primers for RX Ra, P and y published by Ulven et al. (1998) were examined in this 
project. These primers had been designed to the mouse RXR nucleotide sequences 
because those for rat were not available. Two rat liver mRNA extracts were tested 
w ith the 3 RXR form primer pairs; the first mRNA produced only a faint signal for 
R X R a alone, whereas the second mRNA produced strong signals for the 3 RXR 
forms o f  the correct sizes. The signal intensity decreased from R X R a > RXRP > 
RXRy.
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However sequencing o f the products indicated that the R X R a primers had amplified 
R X R a but that the RXRp primers had amplified rat thrombin and RXRy primers had 
amplified rat transferrin. This demonstrates the problems o f  assum ing similarity 
between the species and the need for sequencing to confirm that the specific target is 
amplified. Fragments o f 20 and 22 bp in length, respectively, were matched 100 % 
with mouse RXRp and y, indicating that the primers would amplify the mouse forms 
that they were designed to. This also disputes the description by Ulven et al. (1998) 
that RXRp was expressed in all rat liver cell types whereas RXRy is expressed at low 
levels in parenchymal, kupffer and endothelial cells but not stellate cells. Despite the 
problems w ith target specificity I was able to answer my initial question o f whether 
R X R a was expressed in the rat liver, which it was. Lyn Rosenbrier (Personal 
communication, University o f Manchester) encountered the same problem with lack 
o f R X R a expression in rat liver. However she too was able to detect R X R a with 
further primer optimisation, therefore it would appear that the rat R X R a sequence 
contains areas which are difficult for primers to anneal to. Therefore care should be 
taken when designing primers and amplifying R X R a in rats.
4.9.3.2 H um an CYP3A and nuclear receptor expression 
There were significantly higher levels o f G Ra, PXR and SRC-1 in human liver 
compared to in HepG2 cells. The differences in the mRNA levels o f  CAR and R X R a 
in HepG2 cells to in human liver were not quite significant. As in rat liver, the lack o f 
H NF4a, a liver enriched transcription factor, in human liver was surprising, however 
the same primer pair, designed to the human H N F4a sequence was used for both 
human and rat RT-PCR. Therefore it may be that the primers detect a splice variant or 
mutated HNF4 in the cell lines w ith greater amplification efficiency than in human or 
rat liver. Alternatively, the primers were optimised using mRNA from the hepatoma 
cell lines and the conditions selected may have been inefficient for amplification 
using liver mRNA. Whereas HNF4 is believed to be responsible for the basal 
expression o f rat CYP3A, the HNF4 element is not conserved in the CYP3A4 or 
CYP3A7 genes (Saito et al., 2001). This supports the expression o f  CYP3A mRNA in 
the human liver and HepG2 cells, even in the absence or low abundance o f HNF4a.
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The low levels o f CYP3 A mRNA in HepG2 cells suggests a disruption to the CYP3A 
basal pathway, which may in turn explain their poor support o f induction o f the 
CYP3 A4 promoter driven reporter gene. It has been suggested that hepatoma cell 
lines revert to foetal enzyme expression, in which case HepG2 cells would express 
CYP3A7 mRNA. This is supported by my TaqMan® work (discussed in section 6), 
the work o f Dr. M. N. Vahaditi (personal communication, University o f  Surrey) and 
by Schuetz et al. (1993a). Kelly and Darlington (1989) reported that HepG2 cells 
show a foetal hepatic phenotype, such as increased synthesis o f  a-fetoprotein, foetal 
albumin and pyruvate kinase, therefore suggesting they possess the transcription 
factors necessary for the gene expression seen in the foetus. Therefore it was highly 
likely that CYP3A7, the foetal CYP3A, would be the major CYP3 A mRNA expressed 
in HepG2 cells. Even the combination o f CYP3A7 and CYP3 A4 mRNA expression 
shows a low expression in HepG2 cells. Kelly and Darlington (1989) also reported 
HepG2 cells had a lower expression o f  albumin and the RT-PCR results support this, 
as poly A"*" human liver mRNA produced a signal 100 times as intense as that in 
HepG2 cells for albumin.
Whereas the levels o f  the receptors in HepG2 cells were much lower than in human 
liver, all the receptors were expressed, indicating that no major component o f the 
CYP3A induction pathway was missing. It was surprising to identify PCR signals for 
CAR in HepG2 cells because Sueyoshi et al. (1999) suggested that HepG2 cells 
lacked CAR because they could not detect CYP2B6 mRNA expression unless CAR 
was either stably or transiently transfected into HepG2 cells. However 
Muangmoonchai et al. (2001) found constitutively active CAR in HepG2 cells, 
suggesting that it is the low abundance o f CAR protein and mRNA that makes 
detection o f these molecules difficult. The lack o f CYP2B6 mRNA expression is 
more likely to be due to lack o f transcription factors involved in the basal expression, 
rather than CAR, which is involved in induction.
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4.9 3.3 Comparison of human and rat nuclear receptor levels.
The receptor levels in the human liver, were the highest out o f all the mRNA types 
tested and were 5 to 7 fold higher than rat liver levels. The receptor levels in the 
HepG2 cells were the lowest out o f all the mRNA types tested, even compared to the 
rat hepatoma cell lines. In order to compare the receptor mRNA levels between the 
cell lines and their liver counterparts, principal component analysis was performed to 
indicate any similarities in receptor mRNA profiles. There was no clustering o f 
HepG2 cells and human liver, which matched the differences in the basal expression 
levels o f  CYP3 A mRNA between the two. This did not explain however, why HepG2 
cells m imic in vivo CYP3A induction responses in reporter gene assays such as those 
mentioned earlier in this report and those by Ogg et al. (1999) and El-Sankary et al. 
(2000, 2001). PCA did indicate that it was mainly the ligand activated receptors, 
PXR, CAR and G R a determ ined the variance between the cell types. R X R a was also 
indicated as a key variable, however this is likely to be due to the anomalous lack o f 
detection o f R X R a mRNA in rat liver.
Recently there has been an expansion o f evidence o f nuclear receptor crosstalk with 
PXR and CAR competing for the same binding sites, ligands and heterodimerisation 
partner R X R a (Bertilsson et al., 2001; Moore et al., 2000; Smirlis et al., 2001; 
Sueyoshi et al., 1999; Xie et al., 2000b). Also o f importance is the co-operativity o f 
G R a regulating the expression o f PXR, CAR and RX Ra, and thus potentiating the 
CYP3A induction response, and the interaction o f these receptors with the same 
coactivator SRC-1 (Huss and Kasper, 2000; Forman et al., 1998; Kino et al., 1999; 
Masuyama et al., 2001; Pascussi et ai., 2000a, b). Therefore it may be the relative 
abundance o f the nuclear receptors that determines the CYP3A induction profile and 
not the individual receptor levels.
PCA analysis for trends in the relative abundance o f the receptor mRNAs 
demonstrated a cluster o f human liver and HepG2 receptor profiles, indicating that 
differences in CYP3A induction responses are due in part, to the relative receptor 
abundance rather than the amount.
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The H4IIEC3 cells were dissociated from the other mRNA types, corresponding with 
their non-responsiveness in my in vitro CYP3 A promoter driven reporter gene assays 
and this may be due to their high level o f change from adult hepatocyte phenotype. 
FaO cells clustered closer to their liver counterpart, supporting the suggestion that 
FaO cells are more differentiated than H4IIEC3 cells and are able to support induction 
o f CYP3 A promoter driven reporter gene constructs. Rat liver clustered together with 
human liver and HepG2 cells, yet rat liver has a distinctly different CYP3A induction 
profile to  human liver. CYP3A regulation is complex and it is likely to  involve nuclear 
receptors, coactivators, corepressors and both ubiquitous and liver enriched 
transcription factors. For example, Shibata et al. (1997) suggests that activation of 
gene transcription may depend on the relative ratio of coactivators and corepressors in 
the cell. The sem i-quantitative RT-PCR only measured the relative abundance o f five 
major receptors and one coactivator mRNAs. If  the target genes exam ined were 
widened, rat liver may move from its cluster with human liver and move closer to the 
rat cell lines, as one o f the major rat regulatory factors may be absent from this 
analysis. R X R a mRNA was not detected in rat liver during the sem i-quantitative RT- 
PCR experiments, but later experiments showed R X R a mRNA to be expressed in rat 
liver. Therefore inclusion o f R X R a mRNA levels in the PCA may cause rat liver to 
cluster more closely w ith the rat hepatoma cell lines.
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5 Results of Cell Characterisation at the Protein Level
The sem i-quantitative RT-PCR results suggested that CYP3A response to xenobiotics 
is determined, in part, by the relative abundance of nuclear receptors. However 
mRNA requires translation into proteins before the receptors can exert their effects. 
Therefore if the mRNA levels did not exactly correspond to the levels of expressed 
proteins; the relative abundance of the receptors would be different at a protein and 
thus a functional level. Hence the protein levels of the receptors, in protein extracts 
from the hepatoma cell lines, were measured by Western blotting, using a highly 
sensitive chemiluminescent detection system.
5.1 Optimisation of Western Blotting
A dot blot was used to determ ine optimum protein concentration used for Western 
blotting (section 2.5.3.2) and ten micrograms of H4IIEC3 protein was shown to 
produce optimum chemiluminescence. Simultaneously, a range of PXR 1 antibody 
dilutions from 1/1000 to 1/25000 were tested as described in section 2.5.3.2. The 
1/10000 PX R l antibody dilution produced the optimum chemiluminsecent signal 
when combined with a 1/2000 dilution of secondary antibody. Therefore a 1/2000 
dilution of secondary antibody was selected for use in all the Western blots. The 
primary antibodies for CA Rl, G Ra, HNF4a, MB67 and R X R a were also tested at 
differing dilutions to select the concentration to be used for the Western blots. The 
optimum antibody concentrations that produced the greatest chemiluminscence are 
shown in table 2.16.
5.2 Antibody Specificity
A recombinant PXR protein was produced from the pSG5-hPXR plasm id using the 
TnT® quick coupled transcription /  translation system as described in methods section
2.5.3.3. The protein appeared to be the correct size during colorimetric detection 
compared to Kaleidoscope molecular weight standards. Five, ten and fifteen 
m icrolitres of this protein, plus 5 jxl of a human PXR recombinant protein donated by 
M iss A. Phillips (University of Surrey) were electrophoresed and Western blotted.
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The blot image is shown in figure 5.1, where the brightest bands, indicated with an 
arrow, were the correct size of 49 kDa for human PXR, according to the Cruz 
Marker™ molecular weight standards.
Figure 5.1 Western Blotting of Recombinant PXR Protein to Test Antibody 
Specificity
AP I KES
5 15 |il lOpl 5^1 M
Recombinant 
PXR signal, 
49 kDa
Marker
sizes in
Five microlitres of recombinant PXR donated by M iss A. Phillips (AP) and a range of 
volumes of recombinant PXR made by myself (KES) were electrophoresed and 
Western blotted as shown above. PXR protein was 49 kDa in size, indicated by an 
arrow. M represents Cruz Markers™ molecular weight standards.
Mr. V. Bombail (University of Surrey) donated recombinant human R X R a and 
G R a proteins. Ten microlitres of each were electrophoresed on SDS/PAGE gels, 
accompanied by a selection of protein extracts from H4IIEC3, FaO and HepG2 cells. 
The blot image for R X R a is shown in figure 5.2, with clear signals observed for the 
H4IIEC3 protein extracts, but no signal from the recombinant RXRa. The blot image 
for G R a is shown in figure 5.3, with a clear signal of the correct size from the 
recombinant G R a, but no signal from the cell line protein extracts. The primary 
antibodies for CAR, MB67 (hCAR) and H N F4a could not be tested for specificity 
due to unavailability of rat CAR, human CAR and rat and human H N F4a plasmids.
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Figure 5.2 Western Blotting of Recombinant RXRa Protein to Test Antibody 
Specificity
1 2 3 4 RXRa M M^ker sizein kDa
RXRa signal, 
50 kDa in size
Ten microlitres of recombinant R X R a donated by Mr. V. Bombail and 10 pg of 4 
separate cytoplasm ic protein extracts from H4IIEC3 cells (1-4) were electrophoresed 
and Western blotted as shown above. R X R a protein was 50 kDa in size, indicated by 
an arrow. M represents Cruz Markers™ molecular weight standards.
Figure 5.3 The Western Blot of Recombinant G R a Protein to Test Antibody 
Specificity
1 2 3 GRa M
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Recombinant 
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in size ™
Ten microlitres of recombinant G R a donated by Mr. V. Bombail and 10 pg of 3 
separate cytoplasm ic protein extracts from FaO (1) and HepG2 cells (2-3) were 
electrophoresed and Western blotted as shown above. G R a protein was 94 kDa in 
size, indicated by an arrow. M represents Cruz Markers™ molecular weight standards.
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5,3 Measuring the Expression of Receptors in Hepatoma Cell Lines 
by Western Blotting
5.3.1 PXR
The antibodies used for Western blotting of the receptors were not chosen because 
they were known to be good, but because they were the only ones available in most 
cases. For PXR, signals were obtained in two different Western blots from H4IIEC3 
nuclear or cytoplasm ic protein extracts but not for HepG2 or FaO protein extracts. A 
reproduction of one of these blots is shown in figure 5.4. However the bands of 34 
kDa were not the correct size because the recombinant protein results and literature 
report a size of 49 kDa for PXR protein. Three further Western blots were incubated 
with the PXRl antibody but the bands observed in HepG2 and H4IIEC3 protein 
extracts were also incorrect in size. Thus Western blotting with the PXRl antibody 
was unsuccessful.
Figure 5.4 Western Blot to Examine PXR Expression in Hepatoma Cell Lines
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sizes in kDa 
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Ten micrograms of nuclear (N) and cytoplasmic (C) protein extracts from separate 
extractions from FaO (IN ), H4IIEC3 (2C, 3N & 6N) and HepG2 cells (4C & 5N) 
were electrophoresed and Western blotted as shown above. PXR protein was expected 
to be 49 kDa in size but the bands were 34 kDa as indicated by an arrow. M 
represents Cruz Markers™ molecular weight standards.
5.3.2 R XRa
R X R a signals were obtained in three different Western blots from FaO, H4IIEC3 and 
HepG2 cells, in both nuclear and cytoplasm ic protein extracts. The antibody appeared 
to detect proteins of the correct size of 50 kDa as shown in figure 5.5.
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The signal intensity was measured by densitometry and normalised to a selected 
molecular weight standard signal, to allow comparisons between blot images of 
different exposures. The results are presented per jig of protein in table 5.1.
Figure 5.5 Western Blot to Examine RX R a Expression in Hepatoma Cell Lines
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Ten micrograms of nuclear (N) and cytoplasm ic (C) protein extracts from separate 
extractions from FaO (7N) H4IIEC3 (2C, 4C, 5C & 6C) and HepG2 cells (1C & 3C ) 
were electrophoresed and Western blotted as shown above. R X R a protein was 
50 kDa in size indicated by an arrow. M represents Cruz Markers™ molecular weight 
standards.
5.3.3 G R a
Signals for G R a were inconsistent. A possible G R a signal was observed on the first 
Western blot from an FaO cytoplasm ic protein extract, however the molecular weight 
markers were unclear and so the size could not be confirmed (data not shown). 
Signals were not observed in further experiments with other FaO protein extracts. A 
low intensity signal from an HepG2 cytoplasmic extract was observed on another 
G R a Western blot, which was the correct size of 94 kDa (data not shown). However 
in two further experiments, signals were not observed from HepG2 protein extracts 
(data not shown). The G R a signals observed from FaO and HepG2 protein extracts 
were measured by densitometry, manipulated as above and shown in table 5.1. 
Signals for G R a were not observed in experiments with H4IIEC3 protein extracts.
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5.3.4 HNF4g
H N F4a signals were observed from H4IIEC3 nuclear and cytoplasm ic protein 
extracts and FlepG2 and FaO cytoplasm ic protein extracts, but again the molecular 
markers were unclear so the signals could not be sized (data not shown).
In a second blot (data not shown), signals of the correct size of 51 kDa were measured 
from H4IIEC3 and HepG2 cytoplasm ic protein extracts, as shown in table 5.1.
5.3.5 CAR
The primary antibody for CAR was reported to be rat and mouse specific therefore it 
was only used with FaO and H4IIEC3 protein extracts. Out of four Western blots, 
signals were only observed in one from H4IIEC3 cytoplasmic protein extracts. The 
signals were of low intensity as shown in figure 5.6, but appeared to be the correct 
size of 39 kDa. The signal intensity of these bands were measured and presented in 
table 5.1. The primary antibody for human CAR or MB67 was only used with HepG2 
protein extracts but no signals were observed on any of the four Western blots, 
indicating a poor antibody or need for further optimisation (data not shown).
Figure 5.6 Western Blot to Examine CAR Expression in Hepatoma Cell Lines
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Ten micrograms of separate cytoplasm ic (C) protein extracts from H4IIEC3 (1-4) 
were electrophoresed and Western blotted as shown above. CAR protein was 39 kDa 
in size indicated by an arrow. M represents Cruz Markers™ molecular weight 
standards.
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Table 5.1 The Expression Levels of Receptor Protein /  pg protein
Protein Extract R X R a  
(U/fig pr)
G Ra  
(U/|Xg pr)
H N F4a  
(U/pg pr)
CAR 
(U/pg pr)
FaO Nuclear 12.1 n.d. n.d. n.d.
FaO Cytoplasmic 49.3 392.0 13.2 n.d.
HepG2 Nuclear 2.1 n.d. n.d. X
HepG2 Cytoplasmic 1 9.4 n.d. 15.8 X
HepG2 Cytoplasmic 2 5.7 n.d. n.d. X
HepG2 Cytoplasmic 3 0.5 0.5 4.6 X
HepG2 Cytoplasmic 4 17.3 n.d. 1.2 X
H4IIEC3 Nuclear n.d. n.d. 4.1 n.d.
H4IIEC3 Cytoplasmic 1 2.8 n.d. n.d. n.d.
H4IIEC3 Cytoplasmic 2 7.2 n.d. 3.4 0.3
H4IIEC3 Cytoplasmic 3 0.7 n.d. 25.2 n.d.
H4IIEC3 Cytoplasmic 4 3.1 n.d. 0.3 0.8
H4IIEC3 Cytoplasmic 5 0.7 n.d. 19.2 n.d.
H4IIEC3 Cytoplasmic 6 1.7 n.d. 0.1 n.d.
The signal intensities of RXRa, G R a and 3N F4a were measured in 6 nuclear and
cytoplasmic protein extracts of three separate hepatoma cell lines and, of CAR in 6 
nuclear and cytoplasm ic protein extracts of rat hepatoma cell lines only, normalised 
between the W estern blots and presented here as arbitrary units per m icrogram of 
protein. Protein extracts were tested initially with R X R a and H N F4a antibodies and 
if no signal was detected with at least one of the antibodies, it was concluded that the 
levels of receptor protein were too low to detect by Western blotting and the extracts 
are not included above. X indicates protein extracts that were not tested with the 
respective antibody, n.d. represents protein extracts that did not produce signals when 
incubated with the respective antibody. Each data point represents the densitometric 
measurement of one signal.
G R a and CAR produced inconsistent results, which made comparison of the receptor 
protein levels in the three hepatoma cell lines difficult. These receptors may be 
expressed at the limit of detection because the signals observed were of low intensity.
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Statistical analysis by a one way ANOVA with Bonferroni all means post hoc test 
showed no significant differences between R X R a and H N F4a in HepG2 and 
H4IIEC3 cytoplasm ic protein extracts and CAR in H4IIEC3 cytoplasm ic protein 
extracts, using the data points measured from separate protein extracts.
The expression of G R a in all the protein extracts and the expression of all four 
receptors in nuclear extracts of the three cell types and in the cytoplasm ic extracts of 
FaO cells could not be analysed for statistical significance due to the lack of replicate 
values. Therefore the lack of significance and the difficulty in comparing the cell 
types receptor expression at a protein level appears to be due to the wide variability in 
signal intensity between the different protein extracts, even from the same cell type. 
The relative abundance of the receptors in the different cell types could not be 
analysed at a protein level, again due to the variation in detection of receptors 
between the samples.
5.4 Comparison of mRNA and Protein Receptor and Transcription 
Factor Levels
There appears to be no relationship between mRNA and protein levels, even in terms 
of which receptor was expressed at the highest levels. For example in H4IIEC3 cells, 
R X R a is the highest expressed receptor in terms of mRNA but H N F4a is the highest 
in terms of protein. This is again likely to be due to the inconsistency and variability 
in the Western blot results and will be considered further in the discussion in section 
5.5.
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5.5 Discussion
5.5.1 Measurement of protein expression methodology
The protein levels of the 5 major receptors were exam ined in the hepatoma cell lines, 
not in rat liver or human liver due to the difficulty in obtaining human liver for protein 
extraction. The protein extracts were centrifuged to separate nuclear and cytosolic 
fractions because some of the nuclear receptors such as PXR reside in the nucleus, 
whereas others such as CAR and G R a reside in the cytoplasm and translocate to the 
nucleus upon ligand exposure (Beato, 1989; Kawamoto et al., 1999; Kliewer et al., 
1998; Moore et al., 2000).
The experimental procedure may have been improved by analysis of the total protein 
extract as well, because the total protein levels of receptors were required to compare 
w ith mRNA levels and there may be leakage between fractions.
The nuclear fractions, even after homogenisation and resuspension of the nuclear 
pellet, were thick and viscous making pipetting difficult especially with small 
volumes, therefore introducing errors in the protein concentration loaded onto the gel 
and possibly altering the electrophoresis profile of the proteins. Proteins can 
precipitate in the absence of SDS, therefore resuspension in 1 ml of SDS lysis buffer 
may have been too low an SDS concentration thus allowing the nuclear proteins to 
precipitate. However the viscosity of the nuclear fractions was most likely due to their 
high DNA concentrations. This viscosity may have been avoided if the lysate had 
been passed through a 21 gauge needle to shear any DNA, as suggested in the Santa 
Cruz Biotechnology Inc. research applications document.
The modified Lowry method of determ ining protein concentration was selected 
because the modifications made the assay less sensitive to interfering buffer 
components and more sensitive to low levels of protein (Stoscheck, 1990). Under 
alkaline conditions Cu^ "*" forms a complex w ith the peptide bonds of proteins and is 
reduced to Cu^. The Cu^, as well as the R groups of tyrosine, tryptophan and cysteine 
residues can react with the Folin reagent, which is slowly reduced to produce a blue 
colour.
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The proteins will therefore produce different colour intensities depending on their 
tyrosine and tryptophan content. This is disadvantageous because different proteins 
produce different absorbances and thus unless the same protein as that being assayed 
is used as the standard, the protein values obtained are relative rather than actual. BSA 
was used as a standard because although it was not the protein being assayed, it has 
been commonly used as a protein standard and therefore made my protein 
concentrations readily comparable with those already published (Stoscheck, 1990).
5.5.2 Antibody optimisation
The antibodies used for immunodetection were obtained from Santa Cruz 
B iotechnology Inc. because they were the only commercial suppliers of primary 
antibodies for the orphan receptors PXR and CAR. The secondary antibodies were 
also obtained from Santa Cruz, so that Cruz Markers™ could be used. Cmz Markers™ 
contain an epitope that is detected by the Santa Cruz secondary antibodies. Images of 
the molecular weight markers appeared on the gel photograph with the receptor 
signals, rather than having to compare colourmetric markers on the blotting 
membrane with detected bands on a photograph. Accurate sizing of the protein signals 
was difficult with Cruz Markers™ because the intensity of the molecular weight 
marker signals was variable, sometimes being so intense that the bands merged to 
form a smear, (e.g. figure 5.3). The concentration of markers loaded onto the gels was 
recommended by the manufacturer, however the signals were often either too intense 
or too weak to allow comparisons with signals of unknown sizes. My own 
optimisation experiment agreed with the manufacturer’s suggestion but the signals 
were not consistent across the Western blots performed.
Three of the Santa Cruz primary antibodies were tested for their target specificity and 
functionality using recombinant proteins of their targets PXR, R X R a and G Ra . The 
PXRl antibody detected a correct sized PXR recombinant protein, however the signal 
was not distinct, especially at higher concentrations of the recombinant protein 
mixture, indicating a lack of specificity for the PXRl antibody. This may be due to 
overloading of the gel with proteins, because the protein concentration of the 
recombinant reaction mixtures was not known.
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Also the TnT® quick coupled transcription /  translation system used rabbit 
reticulocyte lysate to produce the recombinant protein, causing the final recombinant 
protein solution to be dark coloured and viscous and thus may have interfered with the 
immunodetection.
The R X R a recombinant protein did not produce a signal whereas the cytoplasm ic 
H4IIEC3 protein extracts run along side produced signals of the correct size. The 
pSVL-hRXRa plasmid used for production of the R X R a recombinant protein had 
been used previously to produce R X R a protein for use in co-immunoprecipitation 
assays, which had not produced any results (personal communication, Miss A. 
Phillips, University of Surrey). This indicates that there may be a problem with the 
R X R a plasmid. The G R a recombinant protein was detected at the correct size with 
the G R a antibody, thus confirming the target specificity and functionality of this 
primary antibody.
5.5.3 Nuclear receptor protein expression
5.5.3.1 PXR
Despite the functionality and specificity of the PX Rl primary antibody, signals were 
interm ittently obtained from H4IIEC3 and HepG2 protein fractions of the incorrect 
size, 34 kDa instead of 49 kDa. It is possible that this is evidence of PXR2, although 
the antibody is reported to be PX R l specific by the manufacturer. This could be an 
indication that hepatoma cell lines express the splice variant inactive PXR form in 
preference to the active PXR form. However personal communication with Cliff 
Rowe (University of Aberdeen) and Lyn Rosenbrier (University of Manchester) 
suggests that the PX R l antibody from Santa Cruz B iotechnology Inc. is either not 
functional or impossible to optimise using protein extracts from rat liver and primary 
rat hepatocytes.
Matthew Wright (personal communication, University of Aberdeen) suggests that the 
human PXR antibody from Santa Cmz Biotechnology Inc. that detects both PX Rl 
and 2 produced a clear single band, therefore future researchers may be better using 
that antibody rather than the multispecies PXRl antibody used here.
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5.5.3.2 G R a
Despite the apparent functionality and specificity of the G R a primary antibody, 
correct sized signals were only obtained in one cytoplasm ic FaO protein extract and 
one HepG2 cytoplasm ic protein extract on separate gels. In order for the two signals 
to be compared by densitometry, a control was required to allow normalisation 
between the two gels. The 23 kDa molecular weight marker was used to normalise 
signals on each of the gels, the reasons for which are discussed in section 5.5.4. The 
results suggested that G R a is expressed at much higher protein levels in FaO 
cytoplasm than in HepG2 cytoplasm , where the latter appears to be at the limit of 
detection, because it was only detected in one out of four HepG2 cytoplasm ic 
extracts. However only one FaO cytoplasm ic extract was tested for G R a expression 
so these results are by no means conclusive. G R a protein was not detected in 
H4IIEC3 protein extracts. The fact that G R a was only detected in cytoplasm ic 
extracts supports the theory that it is retained in the cytoplasm in a complex with heat 
shock proteins and only translocates to the nucleus in the presence of a ligand (Beato, 
1989).
In compaiison to the mRNA levels of G R a measured by semi-quantitative RT-PCR, 
G R a mRNA was also expressed at higher levels in FaO cells than HepG2 cells, by 
approximately 20 fold. However the difference in protein levels was over 800 fold 
indicating that mRNA levels may not correspond directly to protein levels, especially 
as G R a mRNA in H4IIEC3 cells was approximately half that in FaO cells but the 
G R a protein was not detected at all in H4IIEC3 protein extracts. However the 
interm ittent detection of G R a made analysis of the results invalid.
5.5.3.3 R X R a
Although confirmation of the specificity of the R X R a antibody could not be obtained 
by using a recombinant protein, all the protein extracts except the H4IIEC3 nuclear 
fractions produced signals of the correct size when incubated with the R X R a primary 
antibody. The densitometric measurement of the signal intensity indicates overall that 
R X R a levels were higher in the cytoplasm ic than the nuclear fraction for all three cell 
types.
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However the protein levels were highly variable between the cytoplasm ic fractions 
within a cell type, making it difficult for conclusions to be drawn. For example,
R X R a protein expression in HepG2 and H4IIEC3 cytoplasm ic fractions ranged from 
0.5 to 17.3 and 0.7 to 7.2 U /pg protein, respectively. This wide variability meant there 
were no statistically significant differences between R X R a expression in HepG2 and 
H4IIEC3 cytoplasm ic protein extracts.
Comparison to mRNA levels was difficult, again due to the wide variability, but 
overall the protein expression profile for R X R a is FaO > HepG2 > H4IIEC3. This is 
in contrast to the mRNA expression levels of R X R a where the expression profile is 
H4IIEC3 > FaO > HepG2, again indicating that mRNA levels may not correspond to 
protein levels.
S.5.3.4 CAR
The primary antibodies for detection of rat CAR, human CAR and H N F4a could not 
be tested for specificity due to the lack of expression plasmids for production of 
recombinant proteins. However Dr. S. Kliewer (personal communication, 
GlaxoSm ithKline, RTF, USA) has a rat CAR expression plasmid and so in future 
testing of the rat CAR primary antibody functionality and specificity could be 
performed. Western blots for CAR only produced signals of the correct size with 
H4IIEC3 cytoplasm ic protein fractions. The intensity of the signals was very low, 
indicating that the interm ittent detection of CAR, in two out of six H4IIEC3 
cytoplasmic fractions, could be due to CAR being expressed at the limits of detection 
of the immunodetection technique. This supports the suggestion that mRNA levels are 
not directly related to protein levels because FaO cells expressed CAR mRNA at 
higher levels than H4IIEC3 cells, yet CAR protein was not detected in FaO protein 
extracts. Cliff Rowe (personal communication. University of Aberdeen) suggested 
that the Santa Cruz rat CAR antibody was poor because he was unable to produce 
signals using protein extracts from rat liver or primary rat hepatocytes, which may 
explain the interm ittent detection of CAR protein in the rat hepatoma cell lines.
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The MB67 primary antibody for detecting human CAR could not be optimised and 
did not produce any signals using HepG2 protein extracts, which indicates that this 
antibody may also be non-functional, or that CAR protein is expressed at extremely 
low levels or not at all in HepG2 cells. The latter explanation is supported by 
Sueyoshi et al. (1999) who were unable to achieve CYP2B6 expression in HepG2 
cells unless CAR was either stably or transiently transfected into the cells. However 
CAR mRNA was detected in HepG2 cells in my studies at similar low levels to the 
other nuclear receptors RX Ra , H N F4a and G Ra, which were all detected at a protein 
level. Therefore the lack of CAR activity in the transfection experiments of Sueyoshi 
et al. (1999) may be due to a lack of protein, indicating that the translation rate of 
CAR in HepG2 cells may be lower than for the other nuclear receptors.
5.53.5 H N F4a
H N F4a signals of the correct size were detected in the cytoplasm ic protein extracts of 
the three hepatoma cell lines and the nuclear extracts of H4IIEC3 cells. Again a wide 
variation in the H N F4a protein levels between cytoplasm ic extracts from the same 
cell line was observed with expression levels ranging from not detected to 15.8 and
25.2 U/jLig protein for HepG2 and H4IIEC3 extracts respectively. The possible reasons 
for this variability are discussed below. Overall H N F4a appeared to be expressed at 
higher levels in the cytoplasm than in the nuclear protein fractions, especially in FaO 
and HepG2 cells when it was not detected in nuclear fractions. In the case of H N F4a 
expression, the protein pattern followed that seen in mRNA with the profile FaO > 
H4IIEC3 > HepG2. However while the protein levels in FaO and H4IIEC3 cells were 
approximately 2 fold the mRNA levels, in the HepG2 cells the protein levels were 10 
fold the mRNA levels.
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5.5.4 Sources of variability in Western blotting
The variability in signals between fractions from the same cell type could be due to 
differences in extraction efficiency, although the protein extractions were all 
performed at the same time, or due to post extraction effects such as differences in gel 
loading (already commented on with respect to nuclear fractions), gel quality and 
transfer efficiency, although these effects should have been negligible, as the samples 
were electrophoresed on the same gel in many cases. Non-homogenous backgrounds 
on the Western blots may have effected the densitometric measurement. Despite the 
use of a PVDF membrane, which is reported to have low background staining, some 
of the blots had high chemiluminescence in areas (Pluskal et al., 1986). The higher 
background would have been included in the densitometric measurement of signal 
intensity, therefore resulting in an anomalously high signal compared to others on the 
blot. The incidence of high background signals may have been reduced if  TBS-Tween 
and not just TBS had been used in the initial blocking solution (Miss. M. Coulson, 
University of Surrey, personal communication).
The final source of variation may have been the normalisation control. The 23 kDa 
molecular weight marker was selected as a control for normalisation between the 
photographs of Western blots that had different exposure times. However I have 
already mentioned that the signals from the molecular weight markers were very 
variable and therefore this may have skewed the normalisation. This may explain why 
analysis of the same protein extract more than once did not produce the same results 
(data not shown). Originally a sample was selected to run on all the gels as a control 
but this sample did not produce signals with some of the primary antibodies, thus 
eliminating it from use. Therefore the only alternative was to use one of the molecular 
weight marker bands which appeared on every gel. If a control protein extract had 
been run on every gel, two (a human and a rat) would have been required due to the 
use of species specific antibodies and this would have negated the comparison of 
protein levels between the species.
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6 Results of the Investigation into the Effects of Xenobiotics on the 
Expression of CYP3A and Nuclear Receptor mRNA bv Real Time 
PCR.
The semi-quantitative RT-PCR results suggest that relative abundance of receptors 
partially determ ined the host cell effects observed during the trans-species 
transfections of CYP3A promoter driven reporter genes. Xenobiotics can alter 
receptor levels, thus altering their relative abundance, which could effect the 
induction of CYP3A genes. Real time PCR was therefore used to measure the mRNA 
expression of rat and human CYP3A forms and a selection of nuclear receptors, both 
basally and after a range of dose concentrations of dexamethasone, rifampicin, PCN 
and phénobarbital in the 3 cell lines previously used for transfections.
6.1 Basal CYP3A mRNA Expression
Total RNA was extracted from 4 x 10^ untreated HepG2, H4IIEC3 and FaO cells. 
One m icrogram of each total RNA was used to synthesise cDNA, 5 jiil of which was 
used for each TaqMan® reaction using the primers and probes for rat CYP3A2, 
CYP3A9, CYP3A18, CYP3A23 and human CYP3A4 and CYP3A7. The expression 
levels of CYP3A mRNAs in FaO and H4IIEC3 cells are shown in figures 6.1 and 6.2 
respectively. CYP3A18 mRNA was expressed at significantly higher levels than the 
other CYP3A forms in FaO and H4IIEC3 cells. CYP3A7 mRNA was the major 
CYP3A expressed in HepG2 cells (figure 6.3). CYP3A5 mRNA expression was not 
measured in HepG2 cells because target specific primers and probes could not be 
designed that did not interact with the other CYP3A forms.
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Figure 6.1 Basal expression levels of CYP3A mRNAs in the FaO cell line.
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The values are given as copies o f  mRNA detected per nanogram o f  total RNA. The 
values were normalised by the subtraction o f  No RT values for the same RNA extract 
and then the twelve results were averaged. Error bars represent the standard error o f 
the mean for n=12. Significance o f  CYP3A mRNA levels compared to CYP3A18 
levels were calculated by a one way ANOVA w ith Bonferroni all means post hoc test 
where * represents p < 0.05, ** p < 0.01.
Figure 6.2 Basal expression levels of CYP3A mRNAs in the H4IIEC3 
cell line.
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The values are given as copies o f  mRNA detected per nanogram o f  total RNA. The 
values were normalised by the subtraction o f  No RT values for the same RNA extract 
and then the twelve results were averaged. Error bars represent the standard error o f 
the mean for n=12. Significance o f  CYP3A mRNA levels compared to CYP3A18 
levels were calculated by a one way ANOVA w ith Bonferroni all means post hoc test 
where *** represents p < 0.001.
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Figure 6.3 Basal expression levels of CYP3A mRNAs in the HepG2 cell line.
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The values are given as copies o f  mRNA detected per nanogram o f total RNA. The 
values were normalised by the subtraction o f  No RT values for the same RNA extract 
and then the twelve results were averaged. Error bars represent the standard error o f 
the mean for n=12. The difference between the expression o f  CYP3A4 and CYP3A7 
mRNAs was not significant when tested with a Welch corrected t-test.
6.2 Basal Expression of nuclear receptor mRNAs
Total RNA was extracted from 4 x 1 0 *  untreated HepG2, H4IIEC3 and FaO cells.
One m icrogram o f  each total RNA was used to synthesise cDNA, 5 pi o f  which was 
used for each TaqMan® reaction using the primers and probes for rat and human CAR, 
COUPTFI, G Ra, HNF4a, PXR, RXRa, p and y. The basal expression levels o f  
nuclear receptors in FaO and H4IIEC3 cells are shown in figure 6.4. Figure 6.5 shows 
the basal expression levels in HepG2 cells. PXR was the major nuclear receptor 
mRNA expressed, o f  those measured, in FaO and H4IIEC3 cells but the least 
expressed in HepG2 cells. R X R a mRNA was expressed at significantly lower levels 
in FaO and H4IIEC3 cells than in HepG2 cells w ith p < 0.01 calculated by one way 
ANOVA w ith Bonferroni, all means post hoc test. COUPTFI mRNA was also 
expressed at significantly lower levels in FaO and H4IIEC3 cells than in HepG2 cells 
w ith p < 0.001 and p < 0.01 respectively.
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Figure 6.4 Basal expression levels o f nuclear receptor mRNAs in the FaO and 
H4IIEC3 cell lines.
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The values are given as copies o f  mRNA detected per nanogram o f  total RNA. The 
values were normalised by the subtraction o f  No RT values for the same RNA extract 
and then the twelve results were averaged. Error bars represent the standard error o f  
the mean for n=12.
Figure 6.5 Basal expression levels o f nuclear receptor mRNAs in the 
HepG2 cell line.
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The values are given as copies o f  mRNA detected per nano gram o f total RNA. The 
values were normalised by the subtraction o f  No RT values for the same RNA extract 
and then the twelve results were averaged. Error bars represent the standard error o f 
the mean for n=12.
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6.3 The effects of xenobiotics on CYP3A and nuclear receptor mRNA 
expression in FaO cells
6.3.1 The Effects of Dexamethsone on mRNA expression in FaO cells.
Total RNA was extracted from 1x10^  FaO cells that had been treated with DMSG 
and 0.01 pM, 0.1 |iM , 1 |iM , 10 jiM and 50 pM  dexamethasone. One microgram of 
each total RNA was used to synthesise cDNA, 5 jiil of which was used for each 
TaqMan® reaction using the primers and probes for rat CYP3A2, CYP3A9,
CYP3A18 and CYP3A23. The levels of CYP3A mRNAs in FaO cells are shown in 
figure 6.6. Fifty m icromolar dexamethasone caused a statistically significant increase 
in CYP3A23 mRNA compared to the levels in cells treated with DMSO (p < 0.001, 
One way ANOVA with Bonferroni, all means post hoc test) corresponding to an 
induction of 327 fold, as shown in figure 6.7, indicating that induction of CYP3A23 
mRNA is concentration dependent. Fold induction was calculated by dividing the 
mean copies of mRNA detected /  ng total RNA in cells treated with dexamethasone 
with copies of mRNA detected / ng total RNA in cells treated with DMSO.
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Figure 6.6 CYP3A mRNA expression levels in FaO cells after dexamethasone
treatment.
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each concentration o f  dexamethasone 
were averaged. Error bars represent the standard error o f the mean for n=3. The 
significant difference in CYP3A23 mRNA expression levels in 50 pM  
dexamethasone treated cells compared to expression levels in cells treated with 
DMSO (p < 0.001) is represented by*** and was calculated by a one way ANOVA 
w ith Bonferroni all means post hoc test. UT = untreated cells
Figure 6.7 Induction o f CYP3A23 mRNA by dexamethasone in FaO cells
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The values are given as fold induction, calculated from mean normalised copies o f 
mRNA detected / ng total RNA in cells treated with dexamethasone (n = 3) divided 
by mean normalised copies o f  mRNA detected / ng total RNA in cells treated with
DMSO (n = 3) Represents a trendline indicating the concentration dependent
induction o f  CYP3A23 mRNA by dexamethasone, linear regression showed this trend 
to be significant * p < 0.0469.
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Five micro litres o f  each cDNA was used for each TaqMan® reaction using the primers 
and probes for rat CAR, COUPTFI, G Ra, HNF4, PXR, RXRa, (3 and y. There were 
no significant differences in the mRNA levels o f  the nuclear receptors due to 
dexamethasone treatment according to a one way ANOVA w ith Bonferroni all means 
post hoc test, as shown in figure 6.8.
Figure 6.8 Nuclear receptor mRNA expression levels in FaO cells 
after dexamethasone treatment.
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f  
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  dexamethasone were 
averaged. Error bars represent the standard error o f the mean for n=3. Dexamethasone 
did not significantly change nuclear receptor mRNA levels according to analysis by 
one way ANOVA with Bonferroni all means post hoc test, nd = not detected.
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6.3.2 The Effects of Rifampicin on mRNA expression in FaO cells.
Five microlitres of cDNA synthesised from total RNA extracted from 1x10^  FaO 
cells that had been treated with DMSO and 0.1 |oM, 1 |xM, 5 |iM, 10 |iM  and 50 jiM 
rifampicin, were used for each TaqMan® reaction using the rat CYP3A and nuclear 
receptor primers and probes. Analysis by one way ANOVA with Bonferroni all 
means post hoc test showed there were no statistically significant changes in the 
expression levels of CYP3A and nuclear receptor mRNAs due to rifampicin treatment 
in FaO cells, as shown in figures 6.9 and 6.10.
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Figure 6.9 CYF3A mRNA expression levels in FaO cells after rifampicin 
treatment.
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f No RT values for the 
same RNA extract and then the three results for each dose o f  rifampicin were 
averaged. Error bars represent the standard error o f  the mean for n=3. Statistical 
analysis by one way ANOVA with Bonferroni post hoc test showed no significant 
changes in CYP3 A mRNA expression by rifampicin. UT = untreated cells
Figure 6.10 Nuclear receptor mRNA expression levels in FaO cells 
after rifampicin treatment.
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  rifampicin were 
averaged. Error bars represent the standard error o f  the mean for n=3. Statistical 
analysis by one way ANOVA with Bonferroni post hoc test showed no significant 
changes in nuclear receptor mRNA expression by rifampicin. UT = untreated cells.
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6.3.3 The Effects o f PCN on mRNA expression in FaO cells
Five microlitres of cDNA synthesised from total RNA extracted from 1 x10^  FaO 
cells that had been treated with DMSO and 0.1 |iM , 1 pM, 5 |XM, 10 |liM  and 50 jxM 
PCN were used for each TaqMan® reaction using the rat primers and probes. Ten 
micromolar PCN caused a statistically significant increase in the expression levels of 
CYP3A2 and CYP3A23 mRNAs compared to in DMSO treated cells (p<0.01, 
P<0.001 respectively) according to a one way ANOVA with Bonferroni post hoc test. 
PCN thus caused a bell shaped induction profile with maximal induction by 10 pM  of 
209 fold and 57 fold for CYP3A23 and CYP3A2 mRNA respectively. The mRNA 
levels are shown in figure 6.11 and the fold induction in figure 6.12. There were no 
statistically significant changes in the expression levels of the nuclear receptor 
mRNAs due to PCN treatment according to a one way ANOVA with Bonferroni post 
hoc test (data not shown).
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Figure 6.11 CYP3A mRNA expression levels in FaO cells after PCN
treatment.
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  PCN were averaged. 
Error bars represent the standard error o f  the mean for n=3. One way ANOVA with 
Bonferroni post hoc test showed significance o f  CYP3A2 and CYP3A23 mRNA 
expression levels in 10 pM  PCN treated cells compared to expression levels in cells 
treated with DMSO, which are represented by ** p < 0.01 and ***p< 0.001. nd = not 
detected. UT = untreated cells.
Figure 6.12 Induction o f CYP3A2 and CYP3A23 mRNA by PCN in FaO cells
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The values are given as fold induction, calculated from mean normalised copies o f  
mRNA detected / ng total RNA in cells treated with PCN (n = 3) divided by mean 
normalised copies o f  mRNA detected / ng total RNA in cells treated with DMSO 
(n = 3). Linear regression showed the trend was significant (3A23 **p<0.0036, 3A2 
*p<0.0277) w ithout the 50 pM  inductions included.
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6.3.4 The Effects o f Phénobarbital on mRNA expression in FaO cells
Five microlitres of cDNA synthesised from total RNA extracted from 1x10^  FaO 
cells that had been treated with water and 1 ^M , 10 |iM, 50 jlM, 100 jxM and 200 |xM 
phénobarbital were used for each TaqMan® reaction using the rat primers and probes. 
One way ANOVA with Bonferroni all means post hoc test showed there were no 
statistically significant changes in expression levels of CYP3A and nuclear receptor 
mRNAs due to phénobarbital treatment, as shown in figures 6.13 and 6.14. However 
when fold induction was calculated, the values demonstrated a trend, increasing after 
the higher dose of 200 jiiM phénobarbital (data not shown).
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Figure 6.13 CYF3A mRNA expression levels in FaO cells after 
_______ phénobarbital treatment._______________________
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The values are given as mean normalised copies o f mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  phénobarbital were 
averaged. Error bars represent the standard error o f  the mean for n=3. Analysis by one 
way ANOVA with Bonferroni all means post hoc test showed no significant changes 
in CYP3A mRNA expression due to phénobarbital. UT = untreated cells.
Figure 6.14 Nuclear receptor mRNA expression levels in FaO cells
________ after phénobarbital treatment.______________________________
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  phénobarbital were 
averaged. Error bars represent the standard error o f  the mean for n=3. Analysis by one 
way ANOVA with Bonferroni all means post hoc test showed no significant changes 
in nuclear receptor mRNA expression due to phénobarbital. UT = untreated cells.
202
6.3.5 Principal Component Analysis of the effects of xenobiotics in FaO cells
Principal component analysis is used to identify key variables or groups of variables 
that control the system under study. In this case, the nuclear receptor mRNA 
expression in FaO cells was analysed to identify the relative importance of each 
receptor (variable) during xenobiotic treatment. During treatment w ith each of the 
xenobiotics, PXR mRNA contributed the largest proportion of the variance in the 
mRNA levels. Pascussi et al. (2000a) suggest that dexamethasone can potentiate 
induction of CYP3A by inducing PXR expression via G Ra. Therefore the levels of 
PXR available to activate CYP3A, may determ ine CYP3A induction profiles. The 
PCA variable loadings (a measure of the relative importance of each variable in the 
PCA axis) showed HNF4 and CAR mRNA levels to also be relatively important 
during dexamethasone and rifampicin treatment respectively.
The semi-quantitative reverse transcription PCR experiments led to the conclusion 
that relative receptor mRNA abundance may be responsible in part, for the species 
differences observed in CYP3A induction. Therefore one of the aims of the real time 
PCR experiments was to investigate whether treating cells with xenobiotics would 
change their basal receptor mRNA ratios. Latin square tables were used to calculate 
the ratio of each receptor compared to the every other receptor, for each xenobiotic. 
RXRymRNA levels were not included in the analysis because it was present at the 
limit of detection for TaqMan analysis and thus was not consistently detected and 
could have prejudiced the results. PCA on the receptor mRNA ratios indicated that the 
largest proportion of the variance in relative receptor mRNA abundance was 
contributed by the PXR:RXRp mRNA ratio during treatment with xenobiotics. The 
PCA variable loadings showed the PXR:CAR and PXR:COUPTFI mRNA ratios to 
also be relatively important during dexamethasone treatment, whereas the 
HNF4a:RXRp mRNA ratio was relatively important during rifampicin treatment. 
However during phénobarbital treatment, the proportion of variance in relative 
receptor mRNA abundance was evenly attributed to PXR:RXRp, PXR:RX Ra and 
PXR:COUPTFI mRNA ratios and to a lesser extent the PX R :G Ra ratio.
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6.4 The Effects of xenobiotics on CYP3A and nuclear receptor 
mRNA expression in H4IIEC3 cells
6.4.1 The Effects o f D exam ethasone on mRNA expression in H 4IIEC 3 cells.
Total RNA was extracted from 1x10^  H4IIEC3 cells that had been treated with 
DMSO and 0.01 |iM , 0.1 ^M , 1 |LiM, 10 jiiM and 50 |iM  dexamethasone. One 
microgram of each total RNA was used to synthesise cDNA, 5 jO,l of which was used 
for each TaqMan® reaction using the primers and probes for rat CYP3A2, CYP3A9, 
CYP3A18 and CYP3A23. One way ANOVA with Bonferroni post hoc test showed 
that there were no statistically significant changes in the expression levels of the 
CYP3A mRNAs due to dexamethasone treatment of H4IIEC3 cells. The levels of 
CYP3A mRNAs are shown in figure 6.15.
Five microlitres of each cDNA was used for each TaqMan reaction using the primers 
and probes for rat CAR, COUPTFI, G Ra, HNF4, PXR, RXRa, P and y. The levels of 
these nuclear receptor mRNAs are shown in figure 6.16. One way ANOVA with 
Bonferroni post hoc test showed there were no statistically significant changes in the 
mRNA expression levels of the nuclear receptors due to dexamethasone treatment of 
H4IIEC3 cells.
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Figure 6.15 CYP3A mRNA expression levels in H4IIEC3 cells after
dexamethasone treatment.
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  dexamethasone were 
averaged. Error bars represent the standard error o f  the mean for n=3. One way 
ANOVA with Bonferroni all means post hoc test showed no significant changes in 
CYP3A mRNA levels due to dexamethasone treatment, nd = not detected. UT = 
untreated cells.
Figure 6.16 Nuclear receptor mRNA expression levels in H4IIEC3 
cells after dexamethasone treatment.
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  dexamethasone were 
averaged. Error bars represent the standard error o f the mean for n=3. One way 
ANOVA with Bonferroni all means post hoc test showed no significant changes in 
nuclear receptor mRNA levels due to dexamethasone treatment, nd = not detected. 
UT = untreated cells.
205
6.4.2 The Effects of Rifampicin on mRNA Expression in H4IIEC3 Cells.
Five micro litres o f  cDNA synthesised from total RNA extracted from 1x10*
H4IIEC3 cells that had been treated with DMSO and 0.1 pM, 1 pM, 5 pM, 10 pM  
and 50 pM  rifampicin were used for each TaqMan® reaction using the rat primers and 
probes. One way ANOVA with Bonferroni all means post hoc test showed there were 
no statistically significant changes in the expression o f  CYP3A mRNAs due to 
rifampicin treatment, as shown in figure 6.17.
Five and fifty m icromolar rifampicin caused a statistically significant increase in the 
expression level o f  PXR mRNA compared to in DMSO treated H4IIEC3 cells (p < 
0.05 and p < 0.001) according to one way ANOVA w ith Bonferroni all means post 
hoc test analysis, as shown in figure 6.18. This concentration dependent trend in the 
induction o f  PXR by rifampicin is shovm in figure 6.19, where only 10 pM  rifampicin 
does not fit the trendline, corresponding to its failure to significantly change PXR 
mRNA levels. HNF4 mRNA was also significantly increased by 5 pM  and 0.1 pM 
rifampicin compared to vehicle treated levels (p<0.05), as shown in figure 6.18. 
Figure 6.17 CYP3A mRNA expression levels in H4IIEC3 cells after rifampicin 
treatment.
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f No RT values for the 
same RNA extract and then the three results for each dose o f  rifampicin were 
averaged. Error bars represent the standard error o f  the mean for n=3. Rifampicin 
caused no significant changes in CYP3A mRNA expression according to one way 
ANOVA w ith Bonferroni post hoc test analysis. UT = untreated cells.
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Figure 6.18 Nuclear receptor mRNA expression levels in H4IIEC3 cells after 
rifampicin treatment.
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  rifampicin were 
averaged. Error bars represent the standard error o f  the mean for n=3. The statistically 
significant difference in the expression o f  PXR and HNF4 in cells treated w ith 
rifampicin compared to cells treated with DMSO, as measured by one way ANOVA 
with Bonferroni all means post hoc test, is represented by * p < 0.05 and *** p < 
0.001. UT = untreated cells.
Figure 6.19 Induction of PXR mRNA by rifampicin in H4IIEC3 cells
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The values are given as fold induction, calculated from mean normalised copies o f  
mRNA detected / ng total RNA in cells treated w ith rifampicin (n = 3) divided by 
mean normalised copies o f  mRNA detected / ng total RNA in cells treated with
DMSO (n = 3 ). Represents a trendline indicating the dose dependent induction
o f PXR by rifampicin. Linear regression showed the trend to be significant *p<0.0308
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6.4.3 The Effects o f PCN on mRNA Expression in H4IIEC3 Cells*
Five microlitres of cDNA synthesised from total RNA extracted from 1x10^  
H4IIEC3 cells that had been treated with DMSO and 0.1 |LiM, 1 pM , 5 jiiM, 10 jj.M 
and 50 pM  PCN were used for each TaqMan® reaction using the rat primers and 
probes. One way ANOVA with Bonferroni all means post hoc test showed there were 
no statistically significant changes in the expression levels of CYP3A or nuclear 
receptor mRNAs due to PCN dosing, as shown in figures 6.20 and 6.21.
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Figure 6.20 CYP3A mRNA expression levels in H4IIEC3 cells after PCN
treatment.
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The values are given as mean normalised copies o f mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  PCN were averaged. 
Error bars represent the standard error o f  the mean for n=3. There were no significant 
changes in CYP3A mRNA levels due to PCN treatment according to one way 
ANOVA w ith Bonferroni all means post hoc test, nd = not detected. UT = untreated 
cells.
Figure 6.21 Nuclear receptor mRNA expression levels in H41IEC3 
cells after PCN treatment.
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The values are given as mean normalised copies o f mRNA detected per nanogram of 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  PCN were averaged. 
Error bars represent the standard error o f  the mean for n=3. There were no significant 
changes in nuclear receptor mRNA levels due to PCN treatment according to one way 
ANOVA w ith Bonferroni all means post hoc test. UT = untreated cells.
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6.4.4 The Effects of phénobarbital on mRNA Expression in H4I1EC3 Cells.
Five microlitres of cDNA synthesised from total RNA extracted from 1x10^  
H4IÏEC3 cells that had been treated w ith water and 1 |jlM, 10 jxM, 50 |iM , 100 |iM  
and 200 pM  phénobarbital were used for each TaqMan® reaction using the rat primers 
and probes. One way ANOVA with Bonferroni all means post hoc test showed there 
were no statistically significant changes in the expression levels of any o f the target 
mRNAs due to phénobarbital treatment, as shown in figures 6.22 and 6.33.
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Figure 6.22 CYP3A mRNA expression levels in H4IIEC3 cells after
_________ phénobarbital treatment.___________________________
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f No RT values for the 
same RNA extract and then the three results for each dose o f  phénobarbital were 
averaged. Error bars represent the standard error o f  the mean for n=3. There were no 
significant changes in CYP3 A mRNA expression due to phénobarbital treatment 
according to one way ANOVA w ith Bonferroni all means post hoc test analysis. UT = 
untreated cells.
Figure 6.23 Nuclear receptor mRNA expression levels in H4IIEC3 cells after 
phénobarbital treatment.
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The values are given as mean normalised copies o f mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  phénobarbital were 
averaged. Error bars represent the standard error o f  the mean for n=3. One way 
ANOVA with Bonferroni all means post hoc test showed there were no significant 
changes in nuclear receptor mRNA levels due to phénobarbital treatment. UT = 
untreated cells.
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6.4.5 Principal Component Analysis of the effects of xenobiotics in H4IIEC3 cells
Principal component analysis is used to identify key variables or groups of variables 
that control the system under study. In this case, the nuclear receptor mRNA 
expression in H4IIEC3 cells was analysed to identify the relative importance of each 
receptor (variable) during xenobiotic treatment. During treatment w ith each of the 
xenobiotics, PXR mRNA contributed the largest proportion of the variance in the 
nuclear receptor mRNA levels. Thus, like xenobiotic treatment of FaO cells, the 
levels of PXR available to activate CYP3A, may determ ine CYP3A induction profiles 
in H4IIEC3 cells. The PCA variable loadings (a measure of the relative importance of 
each variable in the PCA axis) showed the levels of HNF4 mRNA to also be 
relatively important during dexamethasone, rifampicin and PCN treatment. In 
addition R X R a and RXRp mRNA levels were relatively important during 
dexamethasone treatment, whereas R X R a and G R a mRNA levels were relatively 
important during rifampicin treatment. However during treatment w ith phénobarbital, 
the proportion of variance (10 % for each receptor) in receptor mRNA levels was 
additionally attributed to RXRp and G R a mRNA .
Latin square tables were used to calculate the ratio of each receptor mRNA compared 
to that of every other receptor, for each xenobiotic. RXRy mRNA levels were not 
included because they were present at the limit of detection for TaqMan analysis and 
so may have prejudiced the PCA results if included. PCA of these receptor mRNA 
ratios indicated that the PXR:RXRp mRNA ratio contributed the largest proportion of 
the vaiiance in the relative receptor mRNA ratios during treatment w ith xenobiotics. 
The PCA variable loadings showed the RXRa: RXRP and HNF4:RXRp mRNA ratios 
to also be relatively important during dexamethasone and PCN treatment respectively. 
However during phénobarbital treatment, the proportion of variance in relative 
receptor mRNA abundance was evenly attributed to PXR:RXRp, CAR:RXRp, 
HNF4:RXRp, RX Ra:RX Rp and PXR:GRa. This suggests that the mRNA abundance 
of no one receptor, relative to the others, is more important during phénobarbital 
treatment of H4IIEC3 cells.
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6.5 The Effects of xenobiotics on CYP3A and nuclear receptor 
mRNA expression in HepG2 cells.
6.5.1 The Effects of Dexamethasone on mRNA expression in HepG2 cells.
Total RNA was extracted from 1x10* HepG2 cells that had been treated with DMSO 
and 0.01 pM, 0.1 pM, 1 pM, 10 pM  and 50 pM  dexamethasone. One microgram o f 
each total RNA was used to synthesise cDNA, 5 pi o f  which was used for each 
TaqMan® reaction using the primers and probes for human CYP3A4 and CYP3 A7. 
One way ANOVA with Bonferroni all means post hoc test showed there were no 
statistically significant differences in the expression o f  CYP3 A mRNAs due to 
dexamethasone treatment as shown in figure 6.24.
Figure 6.24 CYP3A mRNA expression levels in HepG2 cells after dexamethasone 
treatment.
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  dexamethasone were 
averaged. Error bars represent the standard error o f the mean for n=3. One way 
ANOVA with Bonferroni all means post hoc test showed there were no significant 
changes in CYP3A mRNA levels due to dexamethasone treatment. UT = untreated 
cells.
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Five micro litres o f  each cDNA were used for each TaqMan® reaction using the 
primers and probes for the human nuclear receptors. The levels o f  these mRNAs are 
shown in graph 6.25. Data was analysed for statistically significant changes in mRNA 
levels using a one way ANOVA with Bonferroni all means post hoc test. Fifty 
micro molar dexamethasone caused a statistically significant increase in H N F4a 
mRNA compared the levels in HepG2 cells treated with vehicle (p < 0.001). This 
appears to fit a concentration dependent trend in HNF4a mRNA induction by 
dexamethasone as shown in figure 6.26. The levels o f  RX Ra and p mRNA in HepG2 
cells treated with 0.01 pM  dexamethasone were significantly higher than those in 
DMSO treated cells (p < 0.01 and p < 0.05, respectively. Figure 6.25), corresponding 
to 3 and 4 fold inductions (data not shown).
Figure 6.25 Nuclear receptor mRNA expression levels in HepG2 cells after 
dexamethasone treatment.
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f  
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  dexamethasone were 
averaged. Error bars represent the standard error o f  the mean for n=3. The statistically 
significant differences in the expression o f  H NF4a, RX Ra and RXRp mRNA in cells 
treated with dexamethasone compared to in cell treated with DMSO, as measured by a 
one way ANOVA with Bonferroni all means post hoc test, are represented by * p < 
0.05, ** p < 0.01, *** p < 0.001. UT = untreated cells.
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Figure 6.26 Induction of HNF4a mRNA by dexamethasone in HepG2 cells
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The values are given as fold induction, calculated from mean normalised copies o f  
mRNA detected / ng total RNA in cells treated with dexamethasone (n = 3) divided 
by mean normalised copies o f  mRNA detected / ng total RNA in cells treated with 
DMSO (n = 3). Represents a trendline indicating the dose dependent induction
o f  H N F4a mRNA by dexamethasone. Log linear regression showed the trend was 
significant *p<0.0268.
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6.5.2 The Effects of Rifampicin on mRNA Expression in HepG2 Cells
Five micro litres o f  cDNA synthesised from total RNA extracted froml x 10* HepG2 
cells that had been treated with DMSO and 0.1 pM, 1 pM, 5 pM, 10 pM and 50 pM 
rifampicin were used for each TaqMan® reaction using the human primers and probes. 
One way ANOVA with Bonferroni all means post hoc tests showed there were no 
statistically significant changes in expression o f  CYP3A mRNAs due to rifampicin 
treatment, as shown in figure 6.27. However 5, 10 and 50 pM  rifampicin caused 
statistically significant changes in the expression o f  CAR, COUPTFI, RX Ra and 
RXRP mRNAs compared to in vehicle treated cells, as shown in figure 6.28. The 
significant increase o f  COUPTFI mRNA due to 5 pM  rifampicin corresponded to a 
168 fold induction.
Figure 6.27 CYP3A mRNA expression levels in HepG2 cells after rifampicin 
treatment.
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  rifampicin were 
averaged. Error bars represent the standard error o f  the mean for n=3. There were no 
significant changes in CYP3A mRNA levels due to rifampicin according to one way 
ANOVA w ith Bonferroni all means post hoc test analysis. However linear regression 
on the CYP3A7 mRNA levels showed a significant deviation from zero slope, * 
p<0.0144. UT = untreated cells.
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Figure 6.28 Nuclear receptor mRNA expression levels in HepG2 cells after
___________ rifampicin treatment._____________________________________
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  rifampicin were 
averaged. Error bars represent the standard error o f  the mean for n=3. The statistically 
significant changes in CAR, COUPTFI, R X R a and RXRp mRNA levels due to 
treatment with rifampicin, as measured by one way ANOVA with Bonferroni all 
means post hoc test, are represented by ** p < 0.01 and *** p < 0.001. UT = 
untreated cells.
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6.5,3 The Effects of PCN on mRNA Expression in HepG2 Cells
Five micro litres o f  cDNA synthesised from total RNA extracted from 1x10* HepG2 
cells that had been treated with DMSO and 0.1 pM, 1 pM, 5 pM, 10 pM and 50 pM 
PCN were used for each TaqMan® reaction using the human primers and probes.
The mRNA levels o f  CYP3A4 and CYP3A7 showed a trend to increase with 
increasing PCN dose up to seven fold higher in HepG2 cells treated with 50 pM  PCN 
relative to levels in HepG2 cells treated w ith vehicle, but this increase was not 
statistically significant when analysed by one way ANOVA with Bonferroni all 
means post hoc test, as shown in figure 6.29.
Graph 6.29 Induction of CYP3A mRNA forms by PCN in HepG2 cells______
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The values are given as fold induction, calculated from mean normalised copies o f  
mRNA detected / ng total RNA in cells treated w ith PCN (n = 3) divided by mean 
normalised copies o f  mRNA detected / ng total RNA in cells treated with DMSO
(n = 3 ) . ------- Represents a trendline indicating a dose dependent increase in
induction o f  CYP3A7 mRNA in HepG2 cells by PCN. Log linear regression showed 
the trend to be significant for CYP3A7 mRNA level, * p<0.0215.
One way ANOVA w ith Bonferroni all mean post hoc test showed that fifty 
m icromolar PCN caused significant increases in the expression o f  CAR (p < 0.001), 
RX Ra (p < 0.001) and RXRp (p < 0.05) mRNAs compared to in cells treated with 
DMSO, reflecting inductions o f  3 to 4 fold. Ten micro molar PCN, also caused a 
statistically significant increase in R X R a mRNA (p <0.01) compared to in vehicle 
treated HepG2 cells, as shown in figure 6.30.
218
The induction by the higher PCN doses (10 and 50 pM) indicates a dose dependent 
trend for CAR, RX Ra and RXRp mRNAs, as shown in figure 6.31.
Figure 6.30 Nuclear receptor mRNA expression levels in HepG2 cells after PCN 
treatment.
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  PCN were averaged. The 
error bars represent the standard error o f  the mean for n=3. One way ANOVA with 
Bonferroni all means post hoc test showed a significant difference in the expression o f 
CAR, RX Ra and RXRp in cells treated with PCN compared to in cells treated with 
DMSO is represented by * p < 0.05, ** p < 0.01, *** p < 0.001. UT = untreated cells.
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Figure 6.31 Induction of nuclear receptor mRNAs by 5,10 and 50 pM PCN in 
HepG2 cells
4 .5 
4
3.5 
3
2 .5 
2
1.5 
1
0.5
0
RXRa
T re n d lin e
RXRa
PCN (uM)
The values are given as fold induction, calculated from mean normalised copies o f  
mRNA detected / ng total RNA in cells treated with PCN (n = 3) divided by mean 
normalised copies o f  mRNA detected / ng total RNA in cells treated with DMSO
(n = 3). ------- Represent trendlines indicating a dose dependent increase in induction
o f  CAR, RX Ra and RXRp mRNAs in HepG2 cells by PCN. Linear regression 
analysis showed that the CAR (* p<0.0129), RX Ra (* p<0 .0411) and RXRp (** 
p<0.0045) trends were significant.
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6.5.4 The Effects of Phénobarbital on mRNA Expression in HepG2 Cells
Five microlitres of cDNA synthesised from total RNA extracted from 1 x 10* HepG2 
cells that had been treated with water and 1 pM, 10 pM, 50 pM, 100 pM  and 200 pM 
PCN were used for each TaqMan® reaction using the human primers and probes. One 
way ANOVA with Bonferroni all means post hoc test showed there were no 
statistically significant changes in taiget mRNA expression due to phénobarbital 
treatment as shown in figures 6.32 and 6.33.
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Figure 6.32 CYP3A mRNA expression levels in HepG2 cells after phénobarbital 
treatment.
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The values are given as mean normalised copies o f  mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f phénobarbital were 
averaged. The error bars represent the standard error o f  the mean for n=3. There were 
no significant changes in CYP3 A mRNA levels due to phénobarbital treatment 
according to one way ANOVA w ith Bonferroni all means post hoc test analysis. UT = 
untreated cells.
Figure 6.33 Nuclear receptor mRNA expression levels in HepG2 cells after 
phénobarbital treatment.
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The values are given as mean normalised copies o f mRNA detected per nanogram o f 
total RNA. The values were normalised by the subtraction o f  No RT values for the 
same RNA extract and then the three results for each dose o f  phénobarbital were 
averaged. The error bars represent the standard error o f the mean for n=3. There were 
no significant changes in nuclear receptor mRNA levels due to phénobarbital 
treatment according to one way ANOVA w ith Bonferroni all means post hoc test 
analysis, nd = not detected. UT = untreated cells.
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6.5.5 Principal Component Analysis of the effects of xenobiotics in HepG2 cells
Principal component analysis is used to identify key variables or groups of variables 
that control the system under study. In this case, the nuclear receptor mRNA 
expression in HepG2 cells was analysed to identify the relative importance of each 
receptor (variable) during xenobiotic treatment. During treatment with each of the 
xenobiotics, COUPTFI and R X R a mRNA contributed the largest proportion of the 
variance in the nuclear receptor mRNA levels. Thus, unlike xenobiotic treatment of 
the rat hepatoma cell lines, the mRNA levels of PXR heterodimerisation partner 
R X R a and accessory factors such as C O U PTFI, may determ ine CYP3A induction 
profiles in HepG2 cells.
Latin square tables were used to calculate the ratio of each receptor mRNA compared 
to that of every other receptor, for each xenobiotic. RXRy mRNA levels were not 
included because they were present at the limit of detection for TaqMan analysis and 
so may have prejudiced the PCA results if included. PCA of these receptor mRNA 
ratios indicated that the COUPTFI:RXRp and RXRaiRXRg mRNA ratios contributed 
the largest proportion of the variance in the relative receptor mRNA ratios during 
treatment w ith the xenobiotics. In addition the PCA variable loadings (a measure of 
the relative importance of each variable in the PCA axis) showed the 
CAR:HNF4a mRNA ratios to also be relatively important during dexamethasone and 
PCN treatment.
223
6.6 Comparison of the effects of xenobiotics on FaO. H4IIEC3 and 
HepG2 cell lines.
HepG2 cells contained significantly different mRNA levels of CAR (p < 0.05), R X R a 
(p < 0.001) and RXRp (p < 0.001) compared to the rat hepatoma cell lines when 
treated with 0.01 pM  dexamethasone. H N F4a mRNA levels were significantly 
different, p < 0.001 in HepG2 cells compared to the rat hepatoma cell lines when 
treated with 50 pM  dexamethasone. FaO cells contained significantly different levels 
of R X R a mRNA (p < 0.05) compared to H4IIEC3 cells after 50 pM  dexamethasone 
treatment.
Rifampicin caused varying statistically significant differences in HepG2, FaO and 
H4IIEC3 cells depending on the dose. Five and fifty micromolar rifampicin caused 
highly significant differences in the levels of CAR, COUPTFI, R X R a and 
RXRp mRNAs in HepG2 cells compared to in the rat hepatoma cell lines. However 
50 pM  rifampicin caused a significant difference in PXR mRNA levels in H4IIEC3 
cells compared to in FaO and HepG2 cells, p < 0.001. Ten micromolar rifampicin 
caused a significant difference in COUPTFI and R X R a mRNA expression levels in 
HepG2 cells compared to in FaO and H4IIEC3 cell lines, p < 0.01.
PCN caused significantly significant differences in receptor mRNA levels in HepG2 
cells compared to the rat hepatoma cell lines. For example 50 pM  PCN produced 
significant differences in G R a (p < 0.05), CAR (p < 0.001), R X R a (p < 0.001) and 
RXRp (p < 0.001) mRNAs. COUPTFI was expressed at significantly different mRNA 
levels in HepG2 cells treated with 5 and 10 pM  PCN with p < 0.05 and 0.01 
respectively, compared to FaO and H4IIEC3 cells. Ten micromolar PCN also caused 
significant differences in the levels of CAR and R X R a mRNAs in HepG2 cells 
compared to in the rat hepatoma cell lines, with p < 0.01 and 0.001 respectively.
There was also a significantly higher expression of CAR mRNA in FaO cells than in 
H4IIEC3 cells after DMSO treatment with a p < 0.05 according to a one way 
ANOVA with Bonferroni all means post hoc test.
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There were no statistically significant differences in the expression of the target 
mRNAs due to phénobarbital treatment. The differences observed indicate that human 
hepatoma cell lines respond differently to xenobiotics than rat hepatoma cell lines.
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6.7 Discussion
6.7.1 Real Time PCR M ethodology
In order to look at a wider range of receptors at a range of xenobiotic doses, real time 
PCR was selected because it allowed the flexibility of looking at a large number of 
samples and /  or many genes in the same experiment (Freeman et al., 1999). The 
technique is rapid and less labour intensive than semi-quantitative RT-PCR especially 
with the lack of primer optimisation and linear log phase experiments, which also 
makes the technique more accurate and reliable due to the reproducibility of the initial 
exponential phase (Bieche et al., 1998; Held et al., 1996; Nurm i et al., 2000). Real 
time PCR is more specific than semi-quantitative RT-PCR because it requires 
hybridisation of both primers and a probe (Bieche et al., 1998). Quantitative mRNA 
levels can be measured even at low copy number without the use of internal standards 
or control genes due to the external standard curve and wide dynamic range. The main 
disadvantages of the technique are the expensive instrumentation and the complicated 
fluorogenic probe design. However these problems were eliminated in this project by 
the generosity of the DMPK department of GlaxoSm ithKline (GSK). A TaqMan® 
assay for rat CYP3A forms and PXR mRNA expression in primary rat hepatocytes 
had already been developed by this department and so the real time PCR work 
performed in this latter project on hepatoma cell lines was based on their optimised 
methodology (Baldwin et al., 2001).
Total RNA was extracted from the hepatoma cell lines using the QIAGEN RNeasy® 
total RNA extraction kit. Before the experiment commenced, a trial of three 
commercial total RNA extraction kits was performed; S V Total RNA isolation 
system (Promega), RNeasy® m idiprep kit (QIAGEN) and Biol RNA-XCell™ 
(Biogene). This highlighted the importance of testing kits rather than relying on 
colleague recommendations, because the Biogene kit had been used previously in the 
molecular toxicology laboratory (University of Surrey) for the extraction of total 
RNA from rat tissues, however it was unable to extract RNA from the hepatoma cell 
lines (data not shown). Both the Promega and QIAGEN kits extracted high quality 
RNA from the hepatoma cell lines but the QIAGEN yield was higher and therefore 
became the method of choice.
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This method did not incorporate a DNase treatment step, so this was performed after 
measurement of RNA concentration. Paul Murdock (personal communication, GSK) 
mentioned that the DNase can also break down ribosomal RNA and can halve its 
levels during treatment, whereas increased concentrations of DNase, greater than the 
2 units per pg RNA that I utilised, could degrade the poly A"*" signal as well. Therefore 
the RNA concentration measured may not have been accurate if any degradation had 
occurred during DNase treatment. However the same amount of DNase was added to 
each sample and therefore degradation should have occurred to the same degree in 
each sample, if at all.
The total RNA concentration was measured by two methods, the first by UV 
absorbance and the second using the RiboGreen™ RNA quantitation assay, which is 
reported to be a 1000 fold more sensitive (Molecular Probes RiboGreen™ RNA 
quantitation kit technical information). A comparison was made between the two 
methods and the results appeared varied. Overall, at concentrations < 300 pg/ml 
spectrophotometry produced higher results than the RiboGreen™ assay, but at 
concentrations > 300 pg/ml spectrophotometry produced lower results than the 
RiboGreen™ assay. The RiboGreen assay results were used to determ ine the amount 
of RNA to use in the TaqMan® reactions due to its reported higher sensitivity. 
Absorbance can be affected by pH and the samples were diluted in water not buffer, 
therefore the basis for calculation of RNA concentration may not have been accurate 
(W ilfinger et al., 1997).
A standard curve of genom ic DNA specific to the species being tested was used, 
providing a range from 10  ^copies /5 pi to 10 copies of DNA /5 pi. The use of a 
genomic standard curve required primers and probes that bound within one exon, 
otherwise the standards were not amplified. This occurred with the first CYP3A4 
primers tested, because the forward primer and the probe hybridised to exon 12 and 
the reverse primer hybridised to exon 13. The cDNA samples produced signals during 
real time PCR because the total RNA template lacked introns, however the genomic 
DNA standards contained introns and therefore the standards did not produce signals. 
The first CYP3A4 primer pair therefore had to be redesigned (data not shown).
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The real time PCR quantitation theory is based on the fact that a PCR reaction of 
100 % amplification efficiency will double the amount of PCR products w ith each 
cycle (Leutenegger et al., 2001). The efficiency of amplification of the TaqMan® 
reactions was determ ined by the slope of the standard curve, which was considered to 
correspond to 100 % amplification efficiency if it was close to the theoretical 
optimum of -3 .32  (Yin et al., 2001). However it is unlikely that the quantity of 
mRNA calculated by TaqMan® is an accurate reflection of the actual number of 
mRNA molecules present in the sample.
TaqMan® quantitation theory does not take into account the efficiency of the RNA 
extraction from the cell lines, or the efficiency of cDNA synthesis during the reverse 
transcription step. The reverse transcription step of any RT-PCR is the source of most 
variability because the reverse transcriptase enzyme is sensitive to salts, alcohols or 
phenol remaining from the RNA isolation (Freeman et al., 1999). Even the base 
sequence of the RNA can affect the reverse transcriptase amplification efficiency of a 
given RNA molecule, thus resulting in inter-tube and inter-experimental variation 
(Nurmi et al., 2000). TaqMan® theory also does not account for differences in the 
efficiency of amplification between the cDNA samples and the genomic standards. 
There may have been differences between the amplification efficiency of the human 
and rat genom ic standards. Therefore it may have been better to use a different source 
of DNA for the standard curves, such as dilutions of plasmid. However it has been 
reported that there is bigger variation between different plasm id dilutions than 
between batches of commercially purchased genomic DNA (Paul Murdock, personal 
communication, GSK). In order to reduce variation between standard curves and to 
allow for comparison between the TaqMan® reactions, the threshold was set at a 
default of 0.02, which produced a standard curve close to the theoretical optimum. 
However in experiments where a threshold (Th) of 0.02 produced a non optimum 
standard curve, the Th was altered until a suitable curve was obtained, thus taking into 
account the different amplification efficiency of those reactions.
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During the reverse transcription step, a no RT reaction for each sample was prepared 
by the replacement of dNTPs and the reverse transcriptase with water. No RT 
reactions for each sample were included in each TaqMan® reaction and they usually 
had low copy numbers of < 10, which proved that no genom ic contam ination was 
present in the RNA sample. Because the same cDNA samples were being used for 
each gene, an adaptation to the experimental design would have been to only include 
no RT reactions for each sample for a couple of genes to show there was no genomic 
contam ination and that it was not gene dependent. This would have allowed more 
samples to be analysed per 96 well plate and therefore decrease the total assay time. 
Also included in each TaqMan® plate were two no-template controls in which buffer 
replaced template cDNA. This control was meant to be used to subtract any 
fluorescence not related to the PCR amplification, however signal was not detected in 
the NTC.
For some of the low abundance genes, swings between positive and negative copy 
numbers of mRNA were observed during xenobiotic dosing (for example figure 6.16 
RXRp). This is due to the basal mRNA levels of these genes being at the limit of 
detection. If the RT reaction contained no detectable cDNA, its fluoresence should be 
equal to that of the NoRT. However slight variations in fluoresence between the two 
reactions would be encountered. Therefore when the NoRT fluorescence was 
subtracted from the RT fluorescence, negative values could be produced. Thus 
negative copies of mRNA were represented as non detected in the figures. It is 
possible that increasing the template cDNA concentration would eliminate such 
discrepancies by raising the control levels, but this may lead to saturating cDNA 
concentrations, which would have no additional effect.
Three flasks of each cell line were treated with each dose and the total RNA extracted 
from the individual flasks. The 3 RNA extracts per cell line, per xenobiotic dose 
formed the triplicate samples for the TaqMan® reactions. This introduced more 
biological and experimental errors than would have been encountered if only one 
extract per dose per cell type had been prepared and that had been amplified in 
triplicate, because the 3 flasks of cells were dosed and extracted separately.
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Therefore the large errors sometimes encountered within the triplicates will have been 
introduced at these stages.
TaqMan® only measured each transcript in each sample once due to the time 
constraints of the large number of samples being considered. It would have improved 
the experimental procedure to have amplified each sample in triplicate and measured 
each target mRNA in triplicate. This may also have made some of the trends observed 
significant. However TaqMan® has been shown to be highly reproducible and so the 
lack of these controls should not negatively affect the accuracy of my results (Yin et 
al., 2001).
6.7.2 Basal CYP3A mRNA Expression in Hepatoma Cell lines
6.7.2.1 Basal CYP3A mRNA expression in rat hepatoma cell lines
The CYP3A mRNA expression profile in both FaO and H4IIEC3 cells was CYP3A18 
> CYP3A9 > CYP3A2 > CYP3A23 but the levels in H4IIEC3 cells were at least 10 
fold lower. CYP3A18 mRNA in male and CYP3A9 mRNA in female rat liver were 
expressed at approximately the same levels when measured by RT-PCR normalised to 
18S ribosomal RNA, suggesting that they compensate for the lack of the other in the 
opposing sexes (Mahnke et al., 1997). Therefore the high expression levels of both 
these forms in the rat hepatoma cell lines may result in increased CYP3A metabolic 
activity, de Waziers et al. (1992) reported that the high CYP3A protein levels they 
detected in FaO cells were due to CYP3A2 because they used a CYP3A1/2 antibody, 
but the results of this project suggest it was more likely to be CYP3A9 or CYP3A18 
protein, or a combination of both.
CYP3A2 has been reported as the major CYP3A in male rat liver at all stages of 
development (Kawai et al., 2000; Xu et al., 2001). This suggests that during the shift 
from rat adult hepatocyte phenotype to the phenotype in the hepatoma cell lines, the 
levels of CYP3A9 mRNA and CYP3A18 mRNA are increased. The low levels of 
CYP3A23 mRNA as detected by TaqMan®, may explain why CYP3A23 mRNA was 
not detected in the semi-quantitative RT-PCR experiments, as the levels may have 
been below the detection limit of this technique.
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6,1,22 Basal expression of CYP3A mRNA in a human hepatoma cell line
In HepG2 cells, CYP3A7 mRNA was expressed at over 6 fold the levels of CYP3A4 
mRNA, an indication that HepG2 cells have adapted to express a foetal phenotype, as 
CYP3A7 is expressed mainly in foetal liver (Kitida et al., 1985; Schuetz et al., 1994). 
Kelly and Darlington (1989) have previously suggested the foetal phenotype of 
HepG2 cells. Schuetz et al. (1993a) only detected CYP3A7 mRNA and protein in 
HepG2 cells even after treatment with known inducers, suggesting that the levels of 
CYP3A4 mRNA were so low that the northern blotting method of Schuetz et al. 
(1993a) was not sensitive enough to detect them. Saito et al (2001) used HepG2 cells 
as a foetal model for investigating CYP3A7 regulation. They suggested that CYP3A7 
gene activation is partially regulated by Specificity protein 1 or 3 (Spl or 3), 
recognising a distal NF-kB like element in the CYP3A7 5’ flanking region. This is 
supported by the fact that Spl levels are elevated in foetal livers compared to in 
adults, but are down regulated during term inal differentiation of hepatocytes (Leggett 
et al., 1995; Saffer et al., 1991). Therefore if HepG2 cells are dedifferentiated like the 
rat hepatoma cell lines, they may contain elevated Spl levels.
Saito et al., (2001) also reported that HNF3p could activate the CYP3A7 proximal 
promoter driven reporter gene in a co-operative manner with the aforementioned 
distal enhancer. The HNF3 family, especially HNF3p are expressed during 
development and the foetal phenotype of the HepG2 cells may mean HNF3 levels are 
elevated (Cereghini, 1996).
Saito et al. (2001) also postulated that the lower level of CYP3A4 mRNA expression 
in HepG2 cells may be due to the interference of N Fl with Y Y l (a transcriptional 
repressor) causing transcriptional activation of CYP3A4 to be repressed due to low 
prenatal N Fl expression (Chaudhry et al., 1997; Puzianowska-Kuznicka and Shi, 
1996). It has also been proposed that U SFl binds to the E box in the CYP3A4 
proximal promoter and that this binding is increased by C/EBPa, which is reported to 
be high in mature hepatocytes but low in hepatoma cells such as HepG2 cells 
(Friedman et al., 1989; Saito et al., 2001; Timchenko et al., 1995).
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Therefore the combination of low N Fl and C /EBPa expression in HepG2 cells maybe 
responsible for the low CYP3A4 mRNA expression.
The levels of CYP3A5 mRNA in HepG2 cells could not be measured as 2 sets of 
primers and probes were designed but neither worked, due to design across an intron 
or cross hybridisation of one of the primers with CYP3A4 mRNA. The close 
sequence identity of the 3 forms has made specific primer design very difficult for 
both TaqMan® and semi-quantitative RT-PCR. A third CYP3A5 primer and probe set 
has been tested by GlaxoSm ithKline but was not optimised in time for inclusion in 
this project.
Iwano et al. (2001) suggest that the expression mechanism of the CYP3A5 gene 
appears different to that of other CYP3A genes, but they were able to express 
CYP3A5 promoter driven reporter genes in HepG2 cells, suggesting that the factors 
regulating CYP3A5 expression are present in HepG2 cells. However Schuetz et al. 
(1993a) were unable to detect CYP3A5 mRNA or protein in HepG2 cells by Northern 
blot or immunoblot analysis.
6.7.3 Basal Nuclear Receptor mRNA Expression in Hepatoma Cell Lines
PXR was the lowest expressed nuclear receptor mRNA in HepG2 cells but was the 
highest mRNA in FaO and H4IIEC3 cells (6 fold difference). However again the 
magnitude of PXR mRNA expression in H4IIEC3 cells was lower than in FaO cells. 
These results match those obtained by semi-quantitative RT-PCR when the rat 
hepatoma cell lines expressed PXR as the highest receptor mRNA. CAR mRNA was 
expressed at lower levels than PXR mRNA in FaO and H4IIEC3 cells but it was 
expressed at much higher levels in HepG2 cells. G R a mRNA was expressed at low 
levels in all 3 cell types. R X R a and COUPTFl mRNAs were expressed at similar 
levels to G R a mRNA in rat hepatoma cell lines, which was at significantly lower 
levels than in HepG2 cells.
RXRp mRNA was expressed at higher levels in the HepG2 cells compared to the rat 
hepatoma cell lines, whereas RXRy mRNA was barely detectable in all the cell lines.
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It is notable that FaO cells expressed RXRp mRNA at a higher level than 
R X R a mRNA, whereas the literature predicts R X R a is always the most abundant of 
the 3 forms in the liver (Mangelsdorf et al., 1992). This may indicate an alteration in 
the pathways regulating RXR mRNA expression in FaO cells and could impact on 
CYP3A induction.
The high level of R X R a mRNA in HepG2 cells could be due to the number of cells 
in the culture because the levels of R X R a mRNA have been shown to increase in 
Hep3B cells as they reach confluence (Wan et al., 1998). However if this was the only 
regulatory influence, the R X R a mRNA levels in H4IIEC3 cells should be extremely 
high due to the rapid growth of these cells.
COUPTFl was the highest expressed receptor mRNA in the HepG2 cells. COUPTF is 
known to be an important receptor in regulating development demonstrated by the 
lethality in COUPTF null mice (Pereira et al., 1995; Pipaôn et al., 1999; Qiu et al., 
1994). The enhanced COUPTFl mRNA levels in HepG2 cells therefore could 
contribute to the foetal phenotype and may play a role in CYP3A7 expression.
HNF4 was the second major receptor mRNA in the rat hepatoma cell lines, but the 
levels in HepG2 cells were even higher. The high levels of HNF4 mRNA in the FaO 
and H4IIEC3 cells made it surprising that CYP3A23 and CYP3A2 basal mRNA 
expression was so low. HNF4 is proposed to regulate CYP3A23 and CYP3A2 
expression both basally and for maximum glucocorticoid induction (Huss et al., 1996, 
1999; Huss and Kasper, 1998). However accompanying the HNF4 binding site is an E 
box to which U SFl binds in CYP3A23 but not in CYP3A2 proximal promoters, 
therefore initiating the in vivo higher basal activity of CYP3A23 (Huss et al., 1999). 
The lower expression of CYP3A23 than CYP3A2 mRNA may indicate reduced levels 
or lack of U SFl in the rat hepatoma cell lines. C /EBPa has been shown to increase 
U SFl binding to an E box in the CYP3A4 promoter. If the same occurs in the 
CYP3A23 promoter in rat hepatoma cell lines, which have low C /EB Pa expression, 
the CYP3A23 mRNA expression may therefore be low (Friedman et al., 1989; Saito 
et al., 2001; Timchenko et al., 1995).
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Therefore the basal CYP3A and nuclear receptor mRNA levels in the different cell 
lines were not the same, even in cell lines from the same species. Overall HepG2 cells 
expressed mRNA at much greater levels than the rat hepatoma cell lines, which 
contradicts the observations from the semi-quantitative RT-PCR work, when HepG2 
cells had dramatically lower mRNA expression compared to FaO and H4IIEC3 cells. 
This difference may be due to different extraction methods (total RNA versus poly A'*' 
mRNA), differing efficiencies of the reverse transcriptase step (oligo dT primed 
versus target specific primers) or different amplification efficiencies of the TaqMan® 
versus the semi-quantitative RT-PCR primers.
6.7.4 The Effects o f Dexamethasone on CYP3A and Nuclear Receptor mRNA 
Expression
6.7.4.1 In rat hepatoma cell lines
CYP3A23 mRNA was induced up to 327 fold by 50 pM dexamethasone, so that 
CYP3A23 mRNA levels were significantly increased compared to the untreated, 
vehicle treated or lower dexamethasone doses. The increase in CYP3A23 mRNA 
caused it to replace CYP3A18 and CYP3A9 as the highest expressed CYP3A mRNA 
in FaO cells. Mahnke et al. (1997) predicted that dexamethasone was the most 
effective inducer of CYP3A18 mRNA in male rats, inducing approximately 7 fold. 
However ‘t Hoen et al., (2000) reported that 10 pM  dexamethasone treatment did not 
restore the CYP3A18 mRNA expression in rat primary hepatocytes, which is closer to 
the lack of change in CYP3A18 mRNA expression in FaO cells after dexamethasone 
treatment observed here. This indicates that there may be an alteration in the 
regulation of CYP3A18 mRNA expression in vitro, possibly due to changes in 
nuclear receptor or transcription factor expression due to movement away from the 
adult hepatocyte phenotype.
CYP3A9 mRNA was only induced 2 fold by dexamethasone in rats o f both sexes 
according to Mahnke et al. (1997), but this is also in contrast to the lack of significant 
induction of CYP3A9 mRNA observed in FaO cells. However the rats were dosed 
with 100 mg/kg for 3 days, which may have been at a circulatory level greater than 
the dexamethasone doses used here and the mRNA levels were calculated normalised 
to p actin, therefore a direct comparison can not be made (Mahnke e t al., 1997).
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Dexamethasone has been reported to induce CYP3A23 mRNA over 10 fold and 
CYP3A2 mRNA two fold in male rat liver, whereas in primary hepatocytes 
CYP3A23 mRNA levels increased 45 fold and CYP3A2 mRNA 4 fold after 10 pM 
dexamethasone treatment ( ‘t Hoen et al., 2000; Mahnke et al., 1997). In my project 
CYP3A23 mRNA was induced 160 fold whereas CYP3A2 mRNA levels were not 
significantly changed by 10 pM  dexamethasone, supporting the lower inducibility of 
CYP3A2 mRNA compared to CYP3A23 mRNA by dexamethasone, previously 
shown.
By contrast, de Waziers et al. (1992) reported that 0.1 pM dexamethasone decreased 
the amounts of CYP3A mRNA significantly in FaO cells after 48 hours treatment, but 
it is unclear which CYP3A mRNA foi*m was being measured. The different method of 
Northern blotting may explain the differences in the results, or their comparison to 
untreated cells as opposed to those treated with vehicle. In my project FaO cells were 
cultured in a 1:1 mixture of FIO Ham’s nutrient mix and DMEM media with 5 % 
charcoal stripped FCS, whereas de W aziers et al. (1992) used modified Ham’s F12 
medium containing 5 % FCS. Therefore it is possible that the difference in media and 
/ or the presence of a factor in the non-charcoal stripped FCS may have caused the 
decrease in CYP3A mRNA.
Therefore FaO cells do not appear to m imic rat liver in terms of their basal CYP3A 
mRNA expression or their induction profiles. In FaO cells, dexamethasone produced 
an almost concentration dependent increase in CYP3A23 mRNA. Only 10 pM 
dexamethasone deviated from the dose dependent trend, but that dose also had 
reduced PXR mRNA levels in FaO cells, which may mean that the dose is anomalous 
due to the xenobiotic not being homogeneously suspended in solution. It may be that 
the situation in primary hepatocytes where dexamethasone is required to maintain an 
in vivo CYP3A mRNA expression profile is also true for FaO cells.
The induction of CYP3A23 mRNA by dexamethasone was not observed in H4IIEC3 
cells, which may be due to the lower basal levels of CYP3A mRNA in H4IIEC3 cells 
compared to FaO cells.
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This indicates that H4IIEC3 cells may not support induction of CYP3A promoter 
driven reporter gene assays, which corresponds to the lack of induction in the 
functional assays discussed in section 3.
There were no significant changes in receptor levels to explain CYP3A mRNA 
induction, however it must be noted that induction of receptors does not correlate with 
activation, therefore the receptors could be involved in the CYP3A mRNA induction 
even though there were no changes in their expression.
6.7.4.2 HepG2 human hepatoma cell line
CYP3A4 mRNA was expressed at very low levels in HepG2 cells and its levels were 
not changed by increasing doses of dexamethasone up to 50 pM . CYP3A7 was the 
major CYP3A mRNA in HepG2 cells and appeared to increase in a concentration 
dependent manner due to dexamethasone, although this increase was not significant. 
Schuetz et al. (1993a) reported a concentration dependent induction of CYP3A7 
mRNA and protein in HepG2 cells with a 2.69 fold induction by 10 pM 
dexamethasone treatment for 48 hours, which is similar to the non-significant 2.9 fold 
induction of CYP3A7 mRNA by 10 pM dexamethasone observed in my experiments. 
However it is difficult to make direct comparisons of fold induction values as they can 
be calculated in different ways.
Fukuda et al. (1992) also measured the expression of CYP3A3 mRNA (their primers 
also bound to CYP3A4 and CYP3A7 mRNA when tested using the NIH Blast search 
facility) in HepG2 cells and found its levels to be very low but inducible by 100 pM 
dexamethasone. Therefore it is possible that the dose of 50 pM  dexamethasone used 
in this experiment is not high enough to produce a significant induction of CYP3A7 
mRNA in HepG2 cells.
H N F4a mRNA exhibited an almost concentration response relationship with 
increasing doses of dexamethasone, up to a 21 fold induction by 50 pM  
dexamethasone, a highly statistically significant increase in H N F4a mRNA.
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Therefore it is possible that, although Saito et al. (2001) suggest that HNF4 may not 
be involved in the constitutive expression of CYP3A7 and CYP3A4 as they lack the 
HNF4 binding site located in site A of rat CYP3A forms, H N F4a may still be 
involved in regulating human CYP3A mRNA induction by dexamethasone. It is 
possible that H N F4a potentiates the induction response controlled by PXR therefore 
leading to induction of CYP3A7 mRNA by 50 pM dexamethasone. This idea is 
supported by the observed down regulation of CYP3A4 and CYP3A5 mRNA in 
primary human hepatocytes transfected w ith HNF4 antisense RNA (Jover et al., 
2001).
The target mRNA levels appeared to increase due to 0.01 pM  dexamethasone 
treatment, including significant increases in R X R a and P mRNA levels. However the 
control genes GAPDH and p actin mRNA were also increased so this was likely to be 
an anomalous result due to dexamethasone not being homogeneously suspended in 
solution or stress to the cells treated with this concentration, such as reduced CO 2  
availability.
6.T.4.3 Comparison of the effects of dexamethasone in rat and human hepatoma 
cell lines
When comparing the cell lines to each other, HepG2 cells response to 0.01 pM 
dexamethasone was statistically significantly different than that of FaO and H4IIEC3 
cells with respect to CAR, R X R a and RXRP mRNA levels. This supports the 
indications that the results at this dose in HepG2 cells were anomalous. HepG2 cells 
also had significantly different HNF4 mRNA levels compared to FaO or H4IIEC3 
cells after dosing with 50 pM  dexamethasone. However, R X R a mRNA levels were 
significantly higher in H4IIEC3 cells compared to FaO cells after 50 pM 
dexamethasone treatment. Dexamethasone treatment reversed the FaO RXR profile 
such that R X R a mRNA was greater than RXRp mRNA, however R X R a mRNA 
remained expressed at higher levels in H4IIEC3 cells, indicating that R X R a is not a 
limiting factor in CYP3A23 induction by dexamethasone. This indicates that the 
effects of dexamethasone only differ in the cell lines at the higher concentrations.
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6.7.5 The Effects of Rifampicin on CYP3A and Nuclear Receptor mRNAs
6.7.5.1 Rat hepatoma cell lines
Rifampicin caused no significant changes in CYP3A and nuclear receptor mRNA 
expression in FaO cells. This was expected because the most noted species difference 
in CYP3A induction is that rifampicin induces human but not rat CYP3A forms, 
partially due to failure of rifampicin to activate rat PXR (Jones et al., 2000; Kocarek 
et al., 1995). In fact, rifampicin treatment appeared to cause a decrease in most of the 
transcripts in FaO cells.
There were also no significant changes in CYP3A mRNA in H4IIEC3 cells due to 
rifampicin. However PXR mRNA was significantly induced in a concentration- 
dependent manner up to 30 fold by 50 pM  rifampicin. To my knowledge, this is the 
first time that rifampicin has been observed to increase PXR mRNA. Only 10 pM 
rifampicin did not maintain the concentration dependent profile of PXR mRNA 
induction. However at this concentration the levels of the other nuclear receptor 
mRNAs appeared to decrease, indicating an anomaly, which could be due to the 
xenobiotic not being homogeneously suspended in solution. 0.1 and 5 pM  rifampicin 
also significantly induced HNF4 mRNA, but this induction did not potentiate CYP3A 
mRNA expression. This suggests that the role of HNF4 in induction of CYP3A by 
glucocorticoids is not effective for other xenobiotics, or that the mechanism of 
potentiation requires an interaction or co-operation between HNF4 and activated PXR 
(Huss et al., 1999).
The difference in induction of PXR mRNA between FaO and H4IIEC3 cells, may 
indicate changes in the PXR regulatory pathway due to dedifferentiation, therefore 
H4IIEC3 cells may have a more foetal or tumourogenic receptor profile due to their 
shift from the adult liver phenotype. This has already been suggested at a basal 
mRNA level during the discussion of the semi-quantitative RT-PCR, as PXR mRNA 
levels have been observed to be higher in both rat hepatoma cell lines and in primary 
rat hepatocytes during culture when they begin to dedifferentiate (Sara Lucas, 
personal communication. University of Aberdeen). These TaqMan® results indicate 
that the induction pathway of PXR mRNA may also be altered by dedifferentiation.
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6.7.5.2 Human hepatoma cell line
Surprisingly, in HepG2 cells, rifampicin did not significantly change CYP3A7 and 
CYP3A4 mRNA levels, but there appeared to be a trend to increase at the higher 
doses of 5 to 50 pM, with CYP3A7 mRNA at higher levels than CYP3A4 mRNA. 
CAR, R X R a and RXRp mRNA followed a similar induction trend. Induction of 
R X R a mRNA peaked after 50 pM rifampicin treatment, increasing 47 fold and 
coinciding with peak CYP3A mRNA expression in HepG2 cells. COUPTFl mRNA 
was significantly induced to a maximum of 170 fold by 5 pM rifampicin and declined 
in a concentration dependent manner across the higher concentrations.
If COUPTFl plays a repressive or negative regulatory role in CYP3A expression, the 
decline of COUPTF mRNA would correspond to the apparent increase of CYP3A7 
mRNA by rifampicin indicating that the increasing concentrations of rifampicin may 
gradually release CYP3A7 repression.
It was surprising that rifampicin was not a good inducer of CYP3A7 mRNA in 
HepG2 cells because rifampicin has been considered a potent human CYP3A inducer 
(Williams et al., 1994). Also Schuetz et al. (1993a) reported that 10 pM  rifampicin 
induced CYP3A7 mRNA 5 fold in HepG2 cells, although this induction was not 
supported by statistics. This indicates that CYP3A7 mRNA has a different induction 
profile to CYP3A4 mRNA and the induction of CYP3A4 mRNA is not supported in 
HepG2 cells, due to the low basal mRNA expression and lack of transcription factors 
such as N Fl (Saito et al 2001). The apparent increase in CYP3A7 mRNA at higher 
concentrations of rifampicin may be due to relief from COUPTFl repression, although 
Rodrigues et al. (2001) proposed COUPTF to act positively in the regulation of a rat 
CYP3A promoter driven reporter gene in HuH7 cells (a human hepatoma cell line). 
The induction of CAR and R X R a mRNA at the higher doses may be responsible for 
the apparent increase in CYP3A7 mRNA. CAR may replace the role of PXR in 
HepG2 cells because PXR mRNA is expressed at such low levels. CA R/RXRa 
heterodimers have been reported to activate CYP3A7 via the XREM but PXR usually 
dominates the regulation of CYP3A (Bertillsson et al., 2001; Moore et al., 2000).
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PXR may not be the dominant regulator of CYP3A7 or may not be dom inant in 
HepG2 cells due to its low level of expression.
6,1,53 Comparison of the effects of rifampicin in rat and human hepatoma cell 
lines
Comparison of the three cell lines indicated that 5 to 50 pM rifampicin significantly 
altered COUPTFl and R X R a mRNAs in HepG2 cells compared to in the rat 
hepatoma cell lines. CAR and RXRp mRNAs were also significantly altered by 5 and 
50 |iM  rifampicin in HepG2 cells compared to FaO and H4IIEC3 cells. Whereas in 
H4IIEC3 cells dosed with 50 |xM rifampicin, PXR mRNA was significantly altered 
compared to in FaO or HepG2 cells. The significant changes of at least 4 nuclear 
receptors at a mRNA level in HepG2 cells by rifampicin, compared to only one in the 
rat hepatoma cell lines suggests an additional mechanism for the difference in the 
response of human and rat liver to rifampicin.
6.7.6 The Effects of PCN on CYP3A and Nuclear Receptor mRNA Expression
6,1,6,1 Rat hepatoma cell lines
In FaO cells, PCN caused a bell shaped concentration dependent induction profile that 
peaked for CYP3A23 and CYP3A2 mRNA with a significant increase due to 10 pM 
PCN. The decrease in mRNA levels by 50 pM  PCN may be due to saturation of the 
regulatory pathway or the high concentration of the dose compromising the FaO cells, 
such as cytotoxicity. There were no changes in nuclear receptor expression, which 
suggests that the receptor mRNA levels present are sufficient to support induction of 
CYP3A23 and CYP3A2 mRNAs by PCN. In basal FaO cells, the PXR mRNA 
expression was the highest out of the receptors tested and PCN is believed to activate 
PXR and thus cause CYP3A induction in rats, therefore the TaqMan® results appear to 
support this mechanism of CYP3A induction.
The lack of CYP3A9 mRNA induction matches with the only slight increase in 
CYP3A9 mRNA observed in both male and female Sprague Dawley rat liver when 
treated with PCN (dose not stated, Mahnke et al., 1997).
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However CYP3A1 protein was induced 250 fold and CYP3A2 protein was induced 
25 fold by PCN in Wistar rat hepatic microsomes, supporting my results that 
CYP3A23 was more inducible than CYP3A2 by PCN.
The induction of CYP3A23 and CYP3A2 mRNAs observed in FaO cells by PCN was 
not observed in H4IIEC3 cells. There were no significant changes in CYP3A mRNA 
levels and whereas CYP3A23 and CYP3A2 mRNAs replaced CYP3A18 and 
CYP3A9 as the major CYP3A mRNA forms in FaO cells after PCN treatment, 
CYP3A18 mRNA remained the major form in H4IIEC3 cells. The levels of 
CYP3A18 mRNA appeared to increase with increasing PCN dose but the increase 
was not significant. This suggests that only a very high dose of PCN would be able to 
cause significant induction of CYP3A mRNA in H4IIEC3 cells. This may be true for 
all the xenobiotics tested because PCN, dexamethasone and rifampicin failed to cause 
significant changes in CYP3A mRNA expression. This may indicate that the mRNA 
levels of nuclear receptors in H4IIEC3 cells are too low to support CYP3A mRNA 
induction as suggested by the CYP3A promoter driven reporter gene assays in section 
3. After both rifampicin and PCN treatment in H4IIEC3 cells, CYP3A18 mRNA 
retained its position as the highest expressed CYP3A mRNA, whereas in FaO cells 
CYP3A18 mRNA only remained the highest expressed CYP3A mRNA forms after 
rifampicin treatment. This suggests that the expression of a nuclear receptor or 
transcription factor involved in the differential expression of CYP3A mRNA forms 
may be lacking or overexpressed in H4IIEC3 cells, thus causing CYP3A18 mRNA to 
be dominant.
PCN treatment in H4IIEC3 cells appeared to increase PXR and HNF4 mRNA at the 
high concentration of 50 |iM , although the difference was not significant. As PCN is 
believed to act via PXR, and HNF4 is required for maximal glucocorticoid 
responsiveness, it is possible that these two factors also act co-operatively in 
regulating PCN induction of CYP3A mRNA in H4IIEC3 cells (Huss et al., 1999; 
Kliewer et al., 1998).
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6.T.6.2 Human hepatoma cell line
In HepG2 cells, CYP3A4 and CYP3A7 mRNAs showed a trend to increase with 
increasing PCN dose, but this increase was not statistically significant. This is 
supported by the results of Schuetz et al. (1993a) who reported that PCN failed to 
induce CYP3A7 protein or mRNA in HepG2 cells. As with rifampicin, which also 
showed a trend of increasing CYP3A mRNA expression with increasing dose, CAR, 
R X R a and RXR|3 mRNAs were significantly induced by higher PCN doses. This 
again suggests the possibility of CAR replacing PXR in the regulation of CYP3A7 in 
HepG2 cells.
CAR may bind in preference to the ER 6  in the CYP3A7 promoter or it may just 
compensate for the low levels of PXR mRNA in HepG2 cells. The coincident 
induction of R X R a and p mRNAs, which can both interact w ith CAR, suggests a new 
regulatory mechanism for CFPiA 7 by PCN, indicating that CAR does not only 
regulate CYP3A in response to barbituates such as phénobarbital (Moore et al., 2000; 
Smirlis et al., 2001).
6.7 6.3 Comparison of the effects of PCN in rat and human hepatoma cell lines
When the levels of nuclear receptors were compared between the 3 cell lines exposed 
to PCN, HepG2 had statistically significant levels of G Ra, CAR, R X R a and 
RXRp mRNAs compared to FaO and H4IIEC3 cells treated with 10 and 50 jxM PCN. 
This added further support to the role of CAR/RXR heterodimers in the regulation of 
CYP3A in HepG2 cells. The induction of CAR and RXR mRNAs may be regulated by 
G R a, which is known to control PXR, R X R a and CAR mRNA expression in 
response to glucocorticoids (Pascussi et al., 2000 a, b).
Five and ten m icromolar PCN also showed statistically significant differences in the 
mRNA levels of COUPTFl in HepG2 cells compared to in FaO or H4IIEC3 cells.
This suggests that COUPTFl may also have a role to play in CYP3A regulation but 
that by 50 |xM this role had been removed, therefore COUPTFl may be acting as a 
negative regulator o f CYP3A7 in HepG2 cells, whose repression is relieved by high 
doses of PCN.
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A possible mechanism for this repression is that COUPTFl heterodimerises with 
R X R a when its expression is high, whereas when the COUPTFl mRNA levels begin 
to decrease after 50 |xM PCN treatment, the levels of CAR and RXR mRNAs are still 
high therefore CAR/RXR heterodimers become dominant.
6.7.7 The Effects of Phénobarbital on CYP3A and Nuclear Receptor mRNA  
Expression
6.7.7.1 In rat hepatoma cell lines
There were no statistically significant changes in CYP3A and nuclear receptor mRNA 
expression due to phénobarbital in FaO cells, however the CYP3A mRNA forms 
appeared to increase when 200 |xM phénobarbital was used. The errors encountered at 
the 2 0 0  pM  dose were quite large, possibly explaining why the increase was not 
significant.
It was known that a higher dose of phénobarbital would be required to induce CYP3A 
mRNA than the other inducers, which was why a maximum dose of 200 pM rather 
than 50 pM was selected (Kocarek et al., 1990). It may be that this dose was too low 
to cause significant CYP3A mRNA induction. However there is a lot of evidence that 
indicates that cell lines are non-responsive to phénobarbital (Muangmoonchai et al., 
2001; Sueyoshi and Negishi, 2001; Waxman and Azaroff, 1992). Despite this, 
phénobarbital was used in this experiment because phénobarbital had induced 
CYP3A4 promoter driven alkaline phosphatase activity in HepG2 cells 16.9 fold 
(SCE) and therefore its effects on nuclear receptor mRNA levels were still relevant 
(El-Sankary et al., 2001).
After 200 pM  phénobarbital treatment HNF4, COUPTFl and RXR(3 mRNAs 
appeared to increase but the increase was not significant. This again suggests that 
HNF4 may potentiate CYP3A induction. It is interesting to note that CYP3A2 mRNA 
appeared to be increased more than CYP3A23 mRNA by 200 pM  phénobarbital, 
which may correspond to the higher COUPTFl mRNA levels because COUPTF was 
shown to have a higher affinity for site 6 pA-C in the CYP3A2 promoter than in the 
CYP3A23 promoter (Huss et al., 1999).
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This difference in affinity was proposed to be due to 2 base pair mismatches and to be 
responsible for the lower inducibility of CYP3A2 compared to CYP3A23 promoter 
driven reporter gene constructs by glucocorticoids (Huss et al., 1999). Phénobarbital 
may act via an alternate regulatory pathway that is potentiated by COUPTFl, rather 
than competed out by it. COUPTFl may co-operate with HNF4 in a similar manner to 
that observed during transactivation of the HNFl gene (McNair et al., 2000).
In H4IIEC3 cells, phénobarbital again did not cause any significant changes in 
CYP3A and nuclear receptor mRNA expression. The 10 pM  dose of phénobarbital 
appeared to increase the CYP3A mRNAs but the errors were very large for this dose 
and many of the nuclear receptors were also observed to increase. This indicates that 
the results may be anomalous due to effects other than those by the drug, such as 
stress on the cells or phénobarbital not being homogeneously suspended in solution. 
This was supported by the increase of GAPDH mRNA, a control gene, indicating that 
the cells were compromised. At the higher doses of 50 to 200 pM  phénobarbital, PXR 
and HNF4 mRNA appeared increased compared to controls although this increase 
was not statistically significant.
The two rat cell lines indicated that phénobarbital does not induce CYP3A mRNA, 
even at doses of 200 pM  phénobarbital. This is in contrast to the response to 
phénobarbital in vivo where 0 . 1 % phénobarbital was the best in vivo inducer of 
CYP3A9 mRNA, compared to clotrimazole, dexamethasone and PCN, and marginally 
induced CYP3A18 mRNA levels. This supports the previous evidence that 
transformed cell lines are not phénobarbital responsive (Muangmoonchai et al., 2001; 
Sueyoshi and Negishi, 2001; Waxman and Azaroff, 1992).
6.7.T.2 Human hepatoma cell line
Phénobarbital also did not cause significant changes in CYP3A and nuclear receptor 
mRNA expression in HepG2 cells, which suggests that the concentrations of 
phénobarbital may have been too low to cause a measurable effect.
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Schuetz et al., (1993a) reported that 1 mM phénobarbital induced CYP3A7 protein
1.6 fold and mRNA 2 fold in HepG2 cells but they did not report whether these 
inductions were statistically significant. Therefore a 5 fold higher dose than the 
highest concentration tested in my project caused only a small induction of CYP3A7 
mRNA in HepG2 cells according to Schuetz et al. (1993a).
6,1,13 Comparison of the effects of phénobarbital in rat and human hepatoma 
cell lines
The lack of response in the three cell lines to phénobarbital, is reflected in the lack of 
significant changes in mRNA expression between the cell lines. It has been suggested 
that phénobarbital triggers the translocation of CAR to the nucleus without interacting 
with the receptor and that this receptor mediates barbituate activation of CYP3A via 
the DR3 and ER 6  elements in the CYP3A23 and CYP3A4 promoters (Kawamoto et 
al., 1999; Moore et al., 2000; Sm irlis et al., 2001). Muangmoonchai et al. (2001) 
reported that CAR was constitutively active in the nuclei of HepG2 cells. If this is the 
case for all hepatoma cell lines, then the proposed role of phénobarbital in CAR 
translocation would be redundant. Phénobarbital would not initiate CAR translocation 
to the nucleus and therefore no further increase in CYP3A mRNA expression would 
be expected after phénobarbital adm inistration. This was suggested by 
Muangmoonchai et al. (2001), who observed no further activation of a PBRE driven 
reporter gene construct in HepG2, HeLa and CV-1 cells, after phénobarbital 
treatment.
However, El-Sankary et al. (2001) measured an Imax (SCE) of 16.9 for phénobarbital 
induction of the CYP3A4-CMV-pSPAP reporter gene construct in HepG2 cells, and 
of 41.3 when hGR/hPXR were cotransfected. The increased induction by 
cotransfection of hGR and hPXR may be due to the increased levels of PXR taking 
over from CAR as the receptor regulating phénobarbital induction of CYP3A due to 
the large concentration of PXR after cotransfection. PXR has been shown to activate 
the CYP3A4-XREM in response to phénobarbital when cotransfected into HepG2 
cells (Goodwin et al., 1999a).
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The specific chemical effect of 16.9 on CYP3A4 promoter driven reporter gene 
activity by phénobarbital w ithout exogenous receptors, may reflect a slight increase in 
activated CAR and / or PXR, amplified by the internal enhancer of the construct, 
CMV.
6.7.8 Principal Component Analysis of the Effects of Xenobiotics on CYP3A and 
Nuclear Receptor mRNA Expression in Hepatoma Cell Lines
6.7.8.1 FaO
In FaO cells, CYP3A9 mRNA is the major variable during dexamethasone, rifampicin 
and PCN treatment. This does not mean that CYP3A9 was the most inducible of the 
rat CYP3A mRNA forms in FaO cells but that it varied the most across the doses, 
which is true when the mRNA expression levels are considered. The CYP3A9 mRNA 
levels increase and decrease but not significantly for any of the xenobiotic 
concentrations tested. However overall CYP3A9 mRNA undergoes the most change. 
The cumulative variability was spread between the CYP3A mRNA forms for 
phénobarbital, possibly because phénobarbital did not cause any induction of CYP3A 
mRNA in FaO cells, or because phénobarbital is the most potent inducer of CYP3A9 
mRNA out of the xenobiotics tested according to Mahnke et al. (1997) and therefore 
phénobarbital may bring CYP3A9 mRNA in line with the other forms.
PXR mRNA is the major cumulative variable for all the doses for FaO cells, which 
indicates that the level of PXR may be important in determ ining the induction of 
CYP3A in FaO cells, especially because it is the highest expressed nuclear receptor 
mRNA. Pascussi et al. (2000a) suggest that dexamethasone can potentiate the 
induction of CYP3A by inducing PXR expression via G Ra. Therefore the levels of 
PXR available to activateClT3A may change due to xenobiotic treatment, thus 
determ ining the CYP3A induction profile. Binomial analysis of the PXR mRNA levels 
measured by real time PCR, suggests that the probability that the increase in PXR 
mRNA levels, across all the dexamethasone concentrations compared to control, is 
determ ined by chance is 1 in 32.
During dexamethasone treatment, HNF4 mRNA levels were also relatively important.
246
This provides support for the statement by Huss et al. (1999) that HNF4 is required 
for both basal and maximal glucocorticoid induced expression of CYP3A23. During 
rifampicin treatment CAR mRNA levels were also relatively important, which may 
indicate a role for CAR in CYP3A regulation in FaO cells. CYP3A mRNA is not 
significantly induced by rifampicin (CYP3A mRNA levels appeared to decrease 
slightly), and CAR may be responsible for this repression, possibly by sequestering 
coactivators required to maintain CYP3A mRNA expression.
Receptor mRNA ratios were considered a factor wherein the xenobiotics tested 
caused changes in the relative receptor abundance and thus had an impact on CYP3A 
regulation. PCA of the receptor mRNA ratios indicated that PXR:RXRp was 
responsible for the largest proportion of the variance during treatment with the 4 
xenobiotics. This again indicates that the levels of PXR mRNA relative to the other 
receptors are important in determ ining the induction of CYP3A in FaO cells. 
Therefore PXR may be the major regulator of CYP3A. The role of RXRP mRNA in 
ratio variability could be due to RXRp heterodimerising with PXR. I have been 
unable to locate any evidence for this heterodimerisation, but Wan et al. (2000) 
reports that all the RXR forms are able to heterodimerise with any of the class 2 
receptors, which include PXR
If heterodimerisation does occur, the complex may have a lower efficacy than 
PXR/RXRa heterodimers, as observed with RAR/RXRp heterodimers in the 
activation of the rat C R B PII gene (Hallenbeck et al., 1996). In m ice with non­
functional RX Ra, expression of CYP2B10 and CYP3A1 mRNA is decreased 10 and 
4 fold respectively, indicating that RXRp may be able to compensate for a lack of 
R X R a but not to the same extent (Wan et al., 2000; Krezel et al., 1996). This may be 
because the RXRp heterodimers require 9-cis retinoic acid to act in a permissive 
manner, whereas R X R a can act independently of its cognate ligand. The 
permissiveness of RXRP is suggested because gene activation by 
PPAR/RXRp heterodimers is often synergistically increased by 9-cis retinoic acid 
(Baes et al., 1995; Keller et al., 1993).
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An alternate possibility is RXRp competing with R X R a to heterodimerise with 
COUPTFl, thus relieving the COUPTF repression at site C of rat CYP3A genes and 
releasing R X R a to form more PXR/RXRa heterodimers (Huss et al., 1999; Kliewer 
et al., 1992). This may also then relieve COUPTF repression of HNF4, allowing 
HNF4 to control basal expression of rat CYP3A as well as induction (Huss et al.,
1999; Qiu et al., 1996; Yanai et al., 1999). The HNF4/RXRP mRNA ratio was also 
relatively important during to rifampicin treatment in FaO cells.
The PXR:CAR mRNA ratio is relatively important during dexamethasone treatment 
in FaO cells, which was expected because Pascussi et al. (2000a, b) reported that both 
PXR and CAR can be induced by dexamethasone, although no significant induction 
was observed in the FaO cells by dexamethasone during my real time PCR 
experiments. However PCA identifies key variables that control the system under 
study, therefore any slight differences in the mRNA levels of either or both of the 
receptors, significant or not, could disrupt the balance of receptors and thus affect the 
CYP3A induction profile.
During phénobarbital treatment, PXR:RX Ra and PXR:RXRP mRNA ratios were 
relatively important variables in FaO cells. It would be expected that the ratios of 
these receptors would be important because PXR/RXRa heterodimers regulate 
CYP3A induction and therefore if the R X R a or PXR levels decrease, induction may 
decrease due to lack of heterodimers or vice versa.
The PXR:COUPTFl mRNA ratio was also relatively important in controlling the 
system during phénobarbital treatment of FaO cells. Huss et al. (1999) reported that 
COUPTFl and PXR/RX Ra heterodimers compete for the same binding site in 
DexRE-2 and therefore alterations in the relative amounts of these receptors may 
change the receptor binding profile of DexRE-2, thus altering the regulation of 
CYP3A induction. According to Rodrigues et al. (2001), transcriptional activation of a 
CYP3A1 promoter driven reporter gene construct by PXR increases when 
cotransfected with a COUPTFl expression plasmid in human HuH7 cells treated with 
glucocorticoids.
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They suggest that dynam ic heterodimers of PXR/COUPTFI regulate adult but not 
immature CYP3A induction and that this is impaired by cotransfection of a R X R a 
expression plasmid, thus contradicting the model proposed by Huss et al. (1999). 
Either way, the ratios of PXR:RXRa and PXR:COUPTFl mRNAs would be 
determ ining factors in the regulation of CYP3A expression and induction.
6.7.S.2 H4IIEC3
CYP3A18 and CYP3A23 mRNA contributed the largest proportion of the variance in 
mRNA levels in H4IIEC3 cells due to dexamethasone, rifampicin and PCN treatment, 
which may be due to the high level of CYP3A18 mRNA expression, which was often 
overtaken by CYP3A23 mRNA expression after xenobiotic treatment.
As in FaO cells, the even spread of cumulative variability of the CYP3A mRNA 
forms after phénobarbital treatment is likely to be due to the failure of phénobarbital 
to change their mRNA expression.
As with FaO cells, PXR mRNA levels were identified as key in the response to all of 
the xenobiotics. The HNF4 mRNA levels were relatively important during 
dexamethasone, rifampicin and PCN treatment. Again this supports the statement of 
Huss et al. (1999) that HNF4 is required for maximal glucocorticoid induction of 
CYP3A23. It also suggests that HNF4 may also potentiate induction by non­
glucocorticoid inducers, such as PCN.
During dexamethasone treatment, R X R a and |3 mRNA levels were relatively 
important. It has been shown previously that dexamethasone up regulates R X R a 
mRNA in 3 different rat hepatoma cell lines, whereas RXRp is unaltered (Wan et al., 
1994). Therefore the mRNA levels of RXRa, which acts as a heterodimerisation 
partner for the other nuclear receptors, were expected to be important, even though 
significant differences were not observed for individual doses of dexamethasone in 
the TaqMan® experiments in H4IIEC3 cells.
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In H4IIEC3 cells the basal expression levels of RXRp mRNA were low and in 3 out 
of the 5 dexamethasone concentrations, RXRp mRNA was not detected, suggesting 
that dexamethasone can also change RXRp mRNA levels. Again RXRP may compete 
with R X R a for heterodimerisation with the nuclear receptors, thus changes in its 
expression could alter CYP3A regulation.
During rifampicin treatment R X R a and G R a mRNA levels were relatively important, 
in contrast to CAR in FaO cells. The role of G R a in induction of CYP3A by 
rifampicin has not been clearly defined with suggestions that rifampicin acts via G R a 
or acts via PXR, the latter appearing most likely now (Jones et al., 2000). However 
G R a is believed to be responsible for regulating the expression of PXR, CAR and 
RX Ra, so variation in G R a mRNA levels due to rifampicin treatment may affect 
CYP3A regulation indirectly by altering the expression of the other nuclear receptors 
(Pascussi et al., 2000a, b). The mRNA levels of G R a may also play a role via the 
distal enhancer in the CYP3A1 gene, described by Periera et al. (1998).
This may also be where G R a mRNA levels become important for phénobarbital, 
along with RXRp mRNA, which can co-operate with CAR, the major regulator of 
CYP3A induction by barbituates (Moore et al., 2000). The lack of importance of 
HNF4 mRNA levels during phénobarbital treatment, unlike the other xenobiotics, in 
H4IIEC3 cells, may indicate that HNF4 is unable to potentiate phénobarbital 
induction of CYP3A.
As in FaO cells, PXR:RXRP mRNA ratios were the key factor controlling the 
response of H4IIEC3 cells during xenobiotic treatment. The RX Ra:RX Rp mRNA 
ratio is relatively important during dexamethasone treatment, which may again be due 
to the competition of RXRp with R X R a and the possible induction of R X R a mRNA 
by dexamethasone.
During PCN treatment, the HNF4:RXRp mRNA ratio is relatively important, 
indicating that HNF4 mRNA levels may partially determine CYP3A induction by 
PCN, possibly by potentiating the induction through PXR.
250
The proportion of variance in relative receptor mRNA abundance was evenly 
attributed between the ratios during phénobarbital treatment of H4IIEC3 cells. This 
may be due to the non-responsiveness of hepatoma cell lines to phénobarbital, so no 
receptor can be identified as controlling the response. However, this may also indicate 
that the regulation of CYP3A by phénobarbital in both rat hepatoma cell lines is 
different from the other xenobiotics that were tested, involving a disrupted regulatory 
pathway or key receptors that were not measured here in.
6,7.S3 HepG2
In HepG2 cells, CYP3A7 mRNA contributed the largest proportion of variance during 
xenobiotic treatment due to it being the major CYP3A mRNA expressed, and thus 
induced, in this cell line.
The largest proportion of variance was attributed to COUPTFI and R X R a mRNAs, in 
terms of individual mRNA levels and in ratios to RXRp, in the response of HepG2 
cells to xenobiotics. CYP3A4 and CYP3A7 have putative COUPTF binding sites in 
their distal enhancer regions, adjacent to two PXR response elements (an imperfect 
DR3 and an ER 6 ). It is unclear however what role COUPTF plays in the 
responsiveness of human CYP3A to inducers.
Quattrochi and Guzelian (2001) suggest that COUPTF may interact with PXR, along 
with H N F4a to produce a highly active transcriptional complex. Rodrigues et al. 
(2 0 0 1 ) support this theory because they reported that transcriptional activation of a 
CYP3A1 promoter driven reporter gene by PXR was increased when cotransfected 
with COUPTFI in HuH7 cells treated with glucocorticoids. Therefore Rodrigues et al. 
(2001) propose that dynam ic heterodimers of PXR:COUPTFI regulate adult CYP3A1 
induction. However no direct interaction of PXR and COUPTFI has been shown, 
therefore the binding of COUPTFI homodimers and PXR/RXRa at DexRE-1 and -2 , 
could be stimulating CYP3A1 induction. In this case overexpressing RXRa, which 
impairs CYP3A1 promoter driven reporter gene activation, could sequester COUPTF 
from its response element by form ing heterodimers (Kliewer et al., 1992).
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It has not been reported that COUP-TF and PXR bind co-operatively to DNA but it 
has been shown that they bind to adjacent sites in the rat CYP3A 5’ flanking regions 
and therefore it is possible that this binding is co-operative.
Co-operative binding rather than heterodimerisation would appear to be the most 
logical suggestion for COUPTFI and PXR interaction in the CYP3A4 and CYP3A7 
distal enhancers because of the adjacent COUPTF and PXR binding motifs. Either 
way, COUPTF appears to be acting positively on the expression of a CYP3A1 
promoter driven reporter gene in HuH7 cells, whereas Ogino et al. (1999) and Huss et 
al. (1999) suggested that COUPTF suppressed CYP3A23 and CYP3A2 expression in 
Cos-1 and H4IIEC3 cells. The differences observed in the regulation of rat CYP3A by 
COUPTF may be due to the different cell types, because it has previously been shown 
that COUPTF can be differentially regulated in different cell types by the same 
stimuli (Qiu et al., 1994; Soosaar et al., 1996). The difference between the cell types 
may be due to levels of coactivators and corepressors that interact with COUPTF such 
as SMRT and NCoR. The basis of this investigation is that the species differences in 
CYP3A regulation are due in part to host cell effects, therefore it is likely that CYP3A1 
is regulated in a human manner in HuH7 cells and therefore that COUPTFI acts as a 
positive regulator of CYP3A4 and CYP3A7 expression.
In whatever way COUPTF, PXR and R X R a interact, the HepG2 PCA results 
indicate that COUPTF and R X R a are the key nuclear receptors controlling the 
response of HepG2 cells to xenobiotics. This indicates that the heterodimerisation 
partner and accessory factor levels are more important than PXR availability in 
human CYP3A regulation, such that the induction of PXR may not affect CYP3A 
regulation, as its the levels of heterodimerisation partners and accessory factors such 
as R X R a and COUPTFI that are more important. In rats however, PXR is the 
dominant variable and this may indicate a species difference making induction of 
PXR in rats more important in relation to CYP3A induction than in humans.
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The relative importance of RXRp in the receptor mRNA ratios could be due to RXRP 
heterodimerising with PXR to form a lower activity complex or a perm issive 
heterodimer as mentioned earlier. These heterodimers would compete for binding to 
the PXRE, or RXRp could compete with R X R a to bind COUPTF, preventing 
COUPTF action on human CYP3A genes. Another possibility is that RXRp competes 
for coactivators and / or corepressors required by RXRa. This may alter whether 
PXR/RXRa transactivates the CYP3A genes. Therefore the ratios of RX Ra, p and 
COUPTF may be important in terms of available coactivators to interact in the 
transactivating complex of human CYP3A genes.
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7 Discussion
7.1 Investigation Design and Development
Many methods have been used to investigate CYP3A regulation, including in vivo 
exam ination of CYP3A activity. This has included the exam ination of various rat 
strains and clinical investigations in humans, and in vitro exam ination of CYP3A 
mRNA and protein expression and activity in primary hepatocyte cultures or 
established hepatoma cell lines (Ferro et al., 1993; Lee et al., 1995; Li et al., 1995; 
Sonderfan et al., 1987).
Barw ick et al. (1996) proposed that the host cellular environment, in addition to gene 
structure, dictates the pattern of CYP3A inducibility. Hence the method of study may 
influence the end result of an induction assay. To decide upon the most relevant 
model it is necessary to exam ine these host differences. To achieve this aim, 
investigating these host cell effects on CYP3A induction, reporter gene constructs 
containing the CYP3A23 and CYP3A4 5’ flanking regions were trans-species 
transfected into human HepG2 and rat H4IIEC3 and FaO hepatoma cell lines. This 
appears to be the most suitable method for exam ining both human and rat CYP3A 
regulation. Although recently Xie et al. (2000a) has produced mPXR null mice that 
express human PXR, as an in vivo adaptation of this method. As predicted by Barwick 
et al. (1996), host cellular effects were observed in this study with the CYP3A23 
reporter gene construct being induced by rifampicin in HepG2 cells but not in the rat 
hepatoma cell lines. Rifampicin is a known potent inducer of human CYP3A4 but not 
rat CYP3A23 in vivo (Kocarek et al., 1995).
Differences between cell lines of the same species were also observed in my study. 
H4IIEC3 cells supported very low induction whereas FaO cells could support 
substantial induction of CYP3A promoter driven reporter gene activity. This raised a 
potential problem with the reporter gene assay, which made the assumption that the 
hepatoma cell lines would contain a similar receptor complement as rat or human 
liver, thus producing comparable induction profiles to those seen in vivo.
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For example, induction of CYP3A4 promoter driven alkaline phosphatase activity by 
xenobiotics tested by Ogg et al. (1999) and El-Sankary et al. (2000) in HepG2 cells, 
reflected CYP3A induction in vivo. Therefore the receptors to support such induction 
in the liver should be present in the cell lines to activate the same promoter. To 
exam ine if the receptor complement was responsible for this variation in response 
between the cell lines, the mRNA levels of the major receptors involved in CYP3A 
regulation were measured by semi-quantitative RT-PCR.
My results have demonstrated that the hepatoma cell lines did not express similar 
receptor complement profiles as the in vivo adult hepatic phenotype. However mRNA 
levels may not exactly correspond to the levels of expressed proteins in all cases and 
hence the protein levels of the receptors were also measured by Western blotting. The 
Western blotting method was a lengthy 2 day procedure in comparison to the 3 hours 
of RT-PCR and the results it produced were not reproducible and were dependent on 
the availability of specific antibodies. This study indicated why mRNA levels were 
originally selected for measurement and why they are so often considered rather than 
proteins. It appears that while genomics has forged ahead to become a widely used 
research area, proteom ics has lagged behind, in desperate need for technical 
advancement, such as low titre antibodies.
The observation that the hepatoma cell lines did not precisely resemble their liver 
counterparts in terms of CYP3A and nuclear receptor mRNA expression, led to the 
exam ination of their endogenous CYP3A mRNA expression and induction profiles by 
real time PCR.
The 96 well format of the TaqMan® assay and the lack of optimisation and log phase 
experiments for primers and probes designed using the Primer Express software, 
made real time PCR the method of choice for measuring the expression of CYP3A 
forms and nuclear receptor mRNAs in the 3 hepatoma cell lines and how these 
profiles are regulated by xenobiotic exposure. The TaqMan® assay could be 
automated, thus taking only 72 hours (including the 48 hour exposure of cells to 
xenobiotic) whereas the reporter gene assays took over 5 days to perform and lacked 
the reproducibility of TaqMan® measurements.
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However TaqMan® only measured induction of the CYP3 A forms and the nuclear 
receptor mRNA levels and so could not functionally identify which of the receptors 
were regulating any CYP3A induction, unlike the co-transfection of receptor plasm ids 
in the reporter gene assay.
Accordingly a selection of 4 in vitro techniques were used to elucidate the host cell 
effects on CYP3A induction in hepatoma cell lines. Each technique used in isolation 
offers distinct advantages and disadvantages, and in combination provides a complete 
exam ination of the receptor dependency of CYP3A gene expression regulation.
7.2 CYP3A Induction by Dexamethasone in Human and Rat Cell 
Lines.
The reporter gene assays suggested that 50 |iiM dexamethasone was a more potent 
inducer of CYP3A4 than CYP3A23 promoter driven reporter gene activity in HepG2 
cells. However literature reports suggest that CYP3A23 protein is induced more than 
CYP3A4 protein by dexamethasone in vivo. (Ghosal et al., 1996; Schuetz et al., 
1993a). This indicates a host cell effect, possibly a regulatory factor present in rat 
liver but absent, or at lower levels in HepG2 cells, controls CYP3A23 induction by 
dexamethasone. Measurement of induction of endogenous CYP3A mRNA in the 
hepatoma cell lines by real time PCR contrasted with the reporter gene assay results 
because CYP3A23 mRNA was induced by 50 pM  dexamethasone in FaO cells but 
neither CYP3A4 or CYP3A7 mRNAs were induced in HepG2 cells. This again 
indicates the presence of a rat specific factor determ ining CYP3A23 induction by 
dexamethasone. FaO cells contained high basal expression levels of PXR mRNA 
compared to HepG2 cells in both semi-quantitative RT-PCR and real time PCR 
measurements. This supports the role of this factor in CYP3A23 induction in vivo and 
suggests that low PXR mRNA expression may be responsible for the lack of 
endogenous CYP3A mRNA induction observed in HepG2 cells. However the 
induction of the CYP3A4 promoter driven reporter gene activity in HepG2 cells by 
dexamethasone suggests that PXR is expressed at high enough levels to induce 
CYP3A4, or that another receptor, such as CAR, can replace the role of PXR, as 
suggested by the TaqMan® results.
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This is supported by the reported reciprocal activation of CAR and PXR in cultured 
primary hepatocytes, transgenic mice and reporter gene assays (Moore et al,, 2000; 
Sm iiiis et al., 2001; Xie et al., 2000b).
Co-transfection of human G R a potentiated induction of the CYP3A23 promoter 
driven reporter gene activity in HepG2 cells by dexamethasone. As G R a is believed 
to regulate PXR and CAR expression due to glucocorticoids, human G R a may induce 
PXR to levels capable of inducing CYP3A23 in HepG2 cells (Pascussi et al., 2000a, 
b). However PXR mRNA levels were not significantly changed by dexamethasone 
treatment in HepG2 cells, but H N F4a mRNA was significantly induced by 50 pM  
dexamethasone and H N F4a has been reported to regulate rat CYP3A basal expression 
and be required for maximal glucocorticoid response (Huss et al., 1999). Alternatively 
a PXR-independent, GR-dependent activation pathway may exist, as suggested by 
Pereira et al. (1998).
The host cellular environmental effects as first observed by Barw ick et al. (1996), are 
more complex than the simple conclusion drawn from the fact that rifampicin does 
not induce rat CYP3A and does not activate rat PXR, but does activate human PXR, 
resulting in human CYP3A induction. This identifies the need for cell characterisation 
in combination with reporter gene assays to elucidate the factors determ ining these 
host cell effects.
7.3 Cell Characterisation
Cell characterisation by semi-quantitative RT-PCR demonstrated that the 
levels of receptor mRNAs in rat liver did not resemble that in human liver, thus 
questioning how good a model the rat is for screening drugs for induction. This 
difference was expected because there are notable species differences in CYP3A 
induction including a-Napthoflavone, which induces human CYP3A4 but inhibits rat 
CYP3A activity (Barw ick et al., 1996; Zhao and Ishizaki, 1997). However the levels 
of receptor mRNAs in hepatoma cell lines did not resemble their liver counterparts 
either, thus questioning how good a model they would be for screening drugs for 
induction.
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The large body of literature using cell lines as a model system must offset such a 
statement. Indeed presence of all the receptors suggests that hepatoma cell lines 
would be suitable for use as tools or hosts, to transfect in components of the CYP3A 
regulatory system and observe the results. The low expression of CYP3A and the 
nuclear receptor mRNAs would be difficult to use to measure endogenous CYP3A 
induction in hepatoma cell lines, thus requiring the use of reporter gene assays and 
their deviation from adult hepatic phenotype would have to be considered when 
interpreting results. The level of shift of the hepatoma cells away from the adult 
hepatocyte phenotype would also impact on their ability to support CYP3A induction. 
For example, the foetal phenotype of the HepG2 cells may subtly change the CYP3A 
induction observed, because CYP3A7 has a lower catalytic activity than CYP3A4 and 
therefore if it is a metabolite of a drug that causes the induction, this effect would be 
lower in HepG2 cells (Wrighton, 2001).
The regulation of CYP3A expression and induction is a complex process, involving a 
large degree of nuclear receptor cross-talk. For example, PXR, CAR and COUPTFI 
will compete for the same binding sites, ligands and the ubiquitous heterodimerisation 
partner R X R a in cell based assays (Goodwin et al., 1999a; Huss et al., 1999; Kliewer 
et al., 1992; Moore et al., 2000; Sm irlis et al., 2001). A hypothesis to encompass such 
cross-talk, and to explain the relative usefulness of hepatoma cell-based models where 
absolute receptor levels do not mimic the in vivo situation is exam ined in this thesis. It 
may be the relative abundance of the nuclear receptors that determ ines the CYP3A 
response profile and not the absolute receptor levels. My PCA showed that while 
receptor mRNA levels varied widely, the relative abundance of receptors in HepG2 
cells and human liver closely resemble each other, indicating that relative receptor 
levels may be a deteimining factor in species specific responses to xenobiotics.
The investigation of protein expression within the three hepatoma cell lines was 
performed in an attempt to determ ine whether the relative receptor abundance 
observed at the mRNA level was conserved at the protein level. If the overall 
translation efficiency of one protein was higher than another, or its protein was 
stabilised and less likely to be degraded, the relative abundance of the receptors at a 
protein level would be different to that at an RNA level.
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If this were the case then the profile observed by PCA on the mRNA receptor ratios in 
relation to CYP3A induction may be altered to either support or disprove the 
hypothesis that relative receptor levels may be a determ ining factor in species 
responses to xenobiotics. However due to inconsistent and variable W estern blot 
results, confirmation of the similarities observed in mRNA could not be obtained at 
the protein level. Although the protein work did not support the hypothesis as hoped, 
it did not disprove it, because although in most cases the mRNA levels did not appear 
to correspond to the protein levels, this is most likely due to the poor reproducibility 
and variability of the results. Hence the presented data support the hypothesis that 
relative receptor expression levels are key to determining CYP3A responsiveness, 
although with the caveat that this has not been confirmed at the protein level.
7.4 Investigation of Endogenous CYP3A niRNA Expression and 
Induction in Hepatoma Cell Lines bv Real Time PCR
If, as suggested by sem i-quantitative RT-PCR, relative receptor abundance is an 
important factor in determ ining a cells ability to support xenobiotic induction of 
reporter gene activity driven by CYP3A promoters, the basal relative receptor 
abundance may be altered by xenobiotics, such as induction of PXR, CAR and R X R a 
expression by glucocorticoids, impacting on the cells ability to support CYP3A 
induction (Pascussi et al., 2000a, b).
The semi-quantitative RT-PCR work focused on only 5 regulators of CYP3A 
induction but regulation of CYP3A is complex and is likely to involve nuclear 
receptors, coactivators, corepressors and both ubiquitously and liver enriched 
transcription factors. For example in the PCA of the relative receptor ratios, rat liver 
was similar to human liver and HepG2 cells in relative receptor abundance, but it is 
known that rat liver has a different CYP3A induction profile to human liver (Kocarek 
et al., 1995; W illiams et al., 1994; Wrighton et al., 1985). The similarity could be due 
to the lack of a major induction regulator of rat CYP3A in the investigation. TaqMan® 
was used to exam ine the endogenous mRNA expression of a wider range of nuclear 
receptors to try and identify their role in CYP3A induction and to see how treatment 
with xenobiotics effected their relative receptor ratios.
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TaqMan® also allowed the measurement of basal and induced expression mRNA 
levels of CYP3A forms to try and identify any differences between hepatoma cell 
lines and their liver counterparts.
PXR and CAR were selected for investigation because they are believed to be the 
major regulators of CYP3A induction by PCN, rifampicin, phénobarbital and other 
xenobiotics (Bertilsson et al., 2001; Moore et al., 2000; Sm irlis et al., 2001; Wei et al., 
2000; X ie et al., 2000a, b). R X R a was measured because it is the ubiquitous 
heterodimerisation partner of PXR, CAR and other nuclear receptors (Keller et al.,
1993). The other RXRs, (3 and y  were measured due to the proposed functional 
redundancy between the RXRs, which indicated that these forms may also 
heterodimerise with PXR and CAR (Krezel et al., 1996). G R a expression was 
exam ined because it is believed to be involved in CYP3A induction either directly via 
GREs such as those in the distal CYP3A1 enhancer or indirectly by regulating the 
expression of PXR and CAR (Pascussi et al., 2000a, b; Pereira et al., 1998). HNF4 
was investigated because it is proposed to be required for basal rat CYP3A expression 
and maximal glucocorticoid induction response (Huss et al., 1999). Finally COUPTFI 
was selected because it is acts as a transcriptional repressor of CYP3A23 and 
CYP3A2 promoter driven reporter gene activity (Huss et al., 1999).
CYP3A18 and CYP3A7 were the major CYP3A mRNA forms in rat and human 
hepatoma cell lines respectively, indicating a deviation from the adult hepatic 
phenotype in the cell lines.
In the rat hepatoma cell lines PXR was the highest expressed nuclear receptor mRNA, 
out of those tested and was indicated by PCA to be the major variable both in terms of 
absolute basal levels and in terms of receptor ratios with RXRp. This indicates that 
the levels of PXR may be important in determ ining the induction of CYP3A in FaO 
and H4IIEC3 cells.
CYP3A23 mRNA was induced by 50 jiM dexamethasone (327 fold) and 10 jiiM PCN 
(209 fold), whereas CYP3A2 mRNA was induced 57 fold by 10 p,M PCN.
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No statistically significant changes in nuclear receptor mRNA levels accompanied 
these inductions in FaO cells, suggesting that the receptor complement available was 
sufficient to support induction of CYP3A mRNA. If PXR is responsible for regulating 
CYP3A mRNA induction, its high basal mRNA expression levels would appear to 
support this. It is notable that Pascussi et al. (2000a, b) reported induction of PXR, 
CAR and R X R a mRNA by 100 nM dexamethasone in primary human hepatocytes, in 
contrast to the lack of induction observed in FaO cells, suggesting that these nuclear 
receptors may not be regulated in a classical glucocorticoid controlled manner. 
However Zhang et al. (1999) observed accumulation of rat PXR mRNA in rat liver by 
dexamethasone, suggesting that this is not a species difference but that the 
glucocorticoid regulatory pathway may be disrupted in rat hepatoma cell lines.
H4IIEC3 cells did not support induction of the mRNA of CYP3A forms or CYP3A 
promoter driven reporter gene activity by the xenobiotics tested in the real time PCR 
experiments and reporter gene assays. However all the nuclear receptor and CYP3A 
mRNAs were expressed, in almost the same profile as the FaO cells, which do support 
induction of CYP3A23 and CYP3A2 mRNA in real time PCR experiments. The lack 
of induction of CYP3A mRNA or CYP3A promoter driven reporter gene activity in 
H4IIEC3 cells appears to be due to the low basal mRNA expression levels of the 
nuclear receptors, which were at least 2-3 fold lower than in the FaO cells. The 
receptors may be too low to activate CYP3A genes to a level that can be measured as 
an induction, especially as the basal CYP3A mRNA levels were also 10 fold lower in 
H4IIEC3 cells compared to in FaO cells. From this the previous hypothesis develops 
to state that CYP3A inducibility is dependent upon the receptor ratios, providing a 
threshold abundance of these receptors is exceeded.
A major secondary variable in mRNA levels in FaO cells treated with dexamethasone 
and H4IIEC3 cells, treated with dexamethasone, rifampicin or PCN, was HNF4.
This supported the proposal of Huss et al. (1999) that HNF4 regulates basal CYP3A 
expression and is required for maximal induction of CYP3A by glucocorticoids. This 
potentiation role of HNF4 in the response of CYP3A to glucocorticoids, may also be 
active in increasing the response to other CYP3A inducers, such as PCN and 
rifampicin, according to the real time PCR results.
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Induction by rifampicin or phénobarbital was not observed in the rat hepatoma cell 
lines. The lack of induction by rifampicin was expected because the most noted 
species difference in CYP3A induction is that rifampicin induces human but not rat 
CYP3A forms due to failure of rifampicin to activate rat PXR (Jones et al., 2000; 
Kocarek et al., 1995; W illiams et al., 1994). It is of interest that rifampicin caused a 
dose dependent induction of PXR mRNA in H4IIEC3 cells, which did not cause 
CYP3 A mRNA induction, as it is assumed that rifampicin did not activate this rat 
PXR. This also supports the conclusion that induction of a receptor mRNA does not 
correlate to activation of that receptor and therefore lack of receptor mRNA induction 
by a xenobiotic does not negate its involvement in regulating CYP3A induction.
Zhang et al. (1999) also observed induction of PXR mRNA by non-CTP3A inducers 
isoniazid and perfluorodecanoic acid, indicating that PXR activators are not 
necessarily involved in the positive control of PXR gene expression.
The lack of induction by phénobarbital in the rat or human cell lines may be due to 
the concentration of the doses being too low to activate the low levels of CAR, 
expressed in the cells lines, sufficiently to cause induction. However Muangmoonchai 
et al. (2001) report that CAR is constitutively active in HepG2 cells. Therefore it is 
more likely that in hepatoma cell lines, which are historically considered as non- 
phenobarbital responsive, CAR is constitutively active in the nucleus and thus 
phénobarbital is redundant in its role of initiating translocation of CAR, therefore no 
further activation of CYP3A transcription occurs (Kawamoto et al., 1999; 
Muangmoonchai et al., 2001; Sueyoshi and Negishi, 2001; Waxman and Azaroff, 
1992).
Dexamethasone failed to induce CYP3A mRNA in HepG2 cells, but H N F4a mRNA 
levels were increased in a dose-dependent manner, suggesting that H N F4a may 
potentiate human CYP3A induction by glucocorticoids as well as rat CYP3A (Huss et 
al., 1999). Rifampicin also failed to induce CYP3A mRNA in HepG2 cells, when it 
was expected to be a potent inducer (Williams et al., 1994). This indicates that the 
major CYP3A in HepG2 cells, CYP3A7, has a different mRNA induction profile to 
CYP3A4 and that induction of CYP3A4 mRNA is not supported in HepG2 cells, 
possibly due to the low level expression of PXR mRNA.
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However CAR mRNA was induced by rifampicin and therefore may replace the role 
of PXR in HepG2 cells in the regulation of CYP3A7. Reciprocal activation of CYP3A 
genes by PXR and CAR has previously been demonstrated (Sm irlis et al., 2001; Xie 
et al., 2000b). This was also suggested by induction of CAR mRNA by PCN, however 
again no induction of CYP3A mRNA was observed in HepG2 cells. It is possible that 
the low mRNA expression levels of PXR and the high expression of COUPTFI 
mRNA, which appears to act as a negative regulator, prevented induction of CYP3A 
mRNA at the doses used. The non-significant trends of increase in CYP3A mRNA 
that were observed after xenobiotic treatment may have been significant if higher 
concentrations were used. This suggests that either CYP3A7 mRNA has a lower 
inducibility than CYP3 A4 or that CAR requires greater concentrations of xenobiotic 
than PXR to be activated and thus trigger induction of CYP3A mRNA in HepG2 
cells. The latter is a plausible hypothesis as there are established differences in EC 5 0  
for these two receptors (Lehmann et al., 1998; Moore et al., 2000).
In the human hepatoma cell line, COUPTFI and R X R a were the major nuclear 
receptor mRNAs influencing variability in the response to xenobiotics, in terms of 
both individual receptor mRNA levels and RXRp ratios.
COUPTFI appeared to act as a negative regulator of human CYP3A mRNA 
expression in response to rifampicin and PCN because CYP3A mRNA expression 
increased as COUPTFI mRNA expression decreased in a dose dependent manner. 
However evidence points to a positive regulatory role for COUPTFI during 
glucocorticoid exposure, synergistically activating a CYP3A1 promoter driven 
reporter gene in HUH7 cells with PXR, possibly by heterodimerisation (Rodrigues et 
al., 2 0 0 1 ).
PCA indicated that the level of heterodimerisation partners and accessory factors were 
more important than PXR availability in CYP3A regulation, such that the induction of 
PXR may not affect CYP3A regulation, as it is the levels of additional receptors such 
as COUPTFI and R X R a that are more important. This is in contrast to the dominant 
role of PXR in rats and may indicate a species difference in comparison to human.
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7.5 Differences in CYP3A Regulation in Hepatoma Cell Lines 
Compared to their Liver Counterparts
As predicted by the semi-quantitative RT-PCR results, hepatoma cell lines do not 
resemble their liver counterparts in terms of absolute receptor levels. CYP3A mRNA 
basal expression and induction by xenobiotics in the cell lines was compared to in 
vivo profiles to see if there were any other differences.
The CYP3A mRNA expression profile in FaO and H4IIEC3 cells was CYP3A18 > 
CYP3A9 > CYP3A2 > CYP3A23, whereas in adult male rat liver the profile is 
CYP3A23 > CYP3A2 > CYP3A18 = CYP3A9 and in adult female rat liver is 
CYP3A23 > CYP3A9 > CYP3A18 > CYP3A2 (Mahnke et al., 1997). Therefore basal 
CYP3A mRNA expression in rat hepatoma cell lines was almost the reverse of that in 
Sprague Dawley rat liver. However CYP3A23 expression is not developmentally 
regulated therefore the decreased mRNA expression was not due to alteration of rat 
hepatoma cell lines to a foetal phenotype, like that observed in HepG2 cells (Kelly 
and Darlington, 1989; Mahnke et al., 1997; Schuetz et al., 1993a).
In contrast to the observed low HNF4 mRNA levels in rat hepatoma cell lines as 
assessed by semi-quantitative RT-PCR, real time PCR demonstrated that HNF4 
mRNA was the second highest expressed receptor in rat hepatoma cell lines. 
Therefore the low basal CYP3A23 mRNA expression could not be explained by lack 
of HNF4. The difference in CYP3A mRNA expression in vivo and in vitro may be 
due to a lack of hormonal regulation that up regulates CYP3 A mRNA in vivo. For 
example 50 (iM dexamethasone was able to change the CYP3A mRNA profile to that 
similar in rat liver by inducing CYP3A23 mRNA in FaO cells. To further exam ine 
this, it would be necessary to assay glucocorticoid hormone levels in FaO and in vivo 
liver cells.
As previously reported, HepG2 cells have a foetal phenotype expressing CYP3A7 
rather than CYP3A4 as the major CYP3A mRNA form, possibly due to elevated Spl 
and HNF3p levels and reduced N Fl and C /EBPa expression compared to human 
liver (Kelly and Darlington, 1989; Saito et al., 2001).
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The expression of CYP3A mRNA was not induced by any of the xenobiotics tested in 
H4IIEC3 cells. H4IIEC3 cells did not express albumin mRNA as measured by semi- 
quantitative RT-PCR indicating that the H4IIEC3 cells do not resemble rat liver. This 
shift from adult hepatic phenotype appears to decrease the expression of most of the 
nuclear receptor mRNAs, leading to the lack of induction of CYP3A mRNA. This 
data further confirms the unsuitability of H4IIEC3 cells for use in reporter gene 
assays to exam ine CYP3A regulation by xenobiotics.
In comparison, both dexamethasone and PCN induced CYP3A mRNA expression in 
FaO cells. Dexamethasone induced only CYP3A23 mRNA in FaO cells, whereas in 
rat liver dexamethasone markedly induces CYP3A18 mRNA and also induces 
CYP3A9 and CYP3A2 mRNAs (Mahnke et al., 1997). Therefore the induction by 
dexamethasone in FaO cells is different from that observed in rat liver. PCN induced 
CYP3A23 more than CYP3A2 mRNA in FaO cells, which resembles the response in 
rat liver where CYP3A1 activity was induced more than CYP3A2 and CYP3A9 
activity was not induced (Debri et al., 1995; Jayyosi et al., 1992; W ang et al., 1996).
Phénobarbital did not induce CYP3A mRNA in FaO cells, whereas Mahnke et al. 
(1997) state that phénobarbital was a good inducer of CYP3A9 mRNA in vivo and 
that CYP3A18 mRNA was marginally induced. CYP3A1 and CYP3A2 activity can 
also be induced by phénobarbital in vivo (Shimada and Guengerich, 1985). 
Rifampicin did not induce CYP3A mRNA in FaO cells. Although FaO cells have 
deviated from the adult hepatic phenotype, they still retain their species specific 
induction profile, such that rifampicin does not induce rat CYP3 A mRNA due to its 
inability to activate rat PXR (Jones et al., 2000; Kocarek et al., 1995).
Therefore FaO cells do not appear to m imic rat liver in terms of their basal CYP3A 
mRNA expression or their induction profiles for some xenobiotics. However both 
rifampicin and PCN, known to activate PXR, induction profiles are maintained 
suggesting the lack of additional factors involved in controlling dexamethasone and 
phénobarbital induction.
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The PXR:COUPTFI mRNA ratio was a major variable for both dexamethasone and 
phénobarbital, suggesting that COUPTFI may be one of the additional factors. 
COUPTFI is reported to compete with PXR for binding to the CYP3A23 promoter and 
therefore it may be differing COUPTFI mRNA levels between the FaO and rat liver 
cells that are in part responsible for the difference in induction profile.
There was no significant induction of CYP3A mRNA in HepG2 cells by any of the 
xenobiotics tested. Even rifampicin, which was identified by Williams et al. (1994) as 
the most potent inducer of 6 p-hydroxylation of testosterone in human hepatocytes. 
This indicates that the CYP3A regulatory pathway in HepG2 cells differs from that in 
human liver. There was evidence of trends with CYP3A7 mRNA increasing non- 
significantly due to PCN and rifampicin treatment, therefore HepG2 cells may require 
higher doses, which may indicate that CYP3A7 is less inducible than CYP3A4 
mRNA. In HepG2 cells, a factor may be missing such as N F l, thus repressing 
CYP3A4 mRNA induction (Saito et al., 2001). This is supported by the fact that 
CYP3A7 activity was unchanged by PCN treatment in human liver (Williams et al.,
1994). However dexamethasone and phénobarbital have been reported to induce 
CYP3A7 protein and activity therefore HepG2 cells do not support the induction of 
CYP3A7 mRNA in a foetal in vivo manner either (Pichard et al., 1989; Watkins et al., 
1985). This may be due to the low level of receptors in the cells or the dose used 
being too low.
The hepatoma cell lines do not show similar induction profiles of CYP3A mRNA to 
their liver counterparts but this is likely to be due to the changes in basal CYP3A 
expression.
7.6 Conclusions
The receptor mRNA levels in rat liver do not resemble those in human liver, 
supporting the species differences observed in CYP3A induction and suggesting that 
rats may be unsuitable as models for screening drugs for induction in man.
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The receptor mRNA levels in hepatoma cell lines do not resemble their liver 
counterparts and the cell lines do not have the same endogenous CYP3A mRNA 
expression or induction profiles as liver. CYP3A18 is the major CYP3A mRNA in rat 
hepatoma cell lines whereas CYP3A7 mRNA is the major form in HepG2 cells. 
H4IIEC3 cells did not support induction of CYP3A (either endogenous or exogenous) 
due to their low basal mRNA expression levels of nuclear receptors. HNF4 appears to 
potentiate induction of CYP3A mRNA by glucocorticoids in both rat and human cell 
lines and may expand this role to other inducers in rats. CAR appears to replace PXR 
as the major regulator of CYP3A7 mRNA induction in HepG2 cells.
HepG2 cells resemble human liver in terms of relative receptor levels, indicating that 
they determ ine the ability of HepG2 cells to m imic the in vivo CYP3A4 induction 
response in CYP3A promoter driven reporter gene assays. This suggests that relative 
abundance of receptors may be responsible, in part, for species differences. This is 
supported by the conclusion that in human CYP3A regulation, heterodimerisation 
partners or accessory factors, such as R X R a and COUPTFI, are more important than 
PXR availability. However, in rats, PXR is important in determ ining the induction of 
CYP3A mRNA, which is supported by its high levels in FaO cells.
In my original aims, I had hoped to increase our ability to evaluate induction data and 
aid design of further drag screens for induction. Recently PXR has become a central 
focus for developing new high throughput drug screens, but my project suggests that 
consideration of PXR alone when evaluating induction data with respect to humans 
may be ill advised.
7.7 Highlighted Areas for Further Research
Increasing the reproducibility of the CYP3A promoter driven reporter gene assays 
described here would create a useful tool in the investigation of species differences 
and host cell effects. Recently the Lipofectam ine plus transfection reagent (Gibco 
BRL) has been recommended as efficient in transfection of HepG2 cells (L. Moore, 
personal communication, GSK).
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Once reproducible transfections are achieved with the CYP3A23 and CYP3 A4 
promoter driven reporter gene constructs, the additional human hepatoma cell line 
HuH7, should also be included in future studies. Initial studies with these cells 
suggest they may present a superior model to HepG2 cells, although they also express 
CYP3A7 as the major CYP3A mRNA form (personal communication Dr. N. Plant; 
Saito et al., 2001). Reporter gene constructs of other CYP3A promoters such as 
CYP3A2 and CYP3A7 could be developed to try and identify any differences in their 
inducibility and the reasons for the differences. This would aid elucidation of the 
CYP3A response to xenobiotics in HepG2 cells, whether this is a more foetal 
(CYP3A7) than adult (CYP3A4) phenotype, due to the 5’ controlling elements of the 
respective genes or the cellular environment.
From the real time PCR work, it appears that CAR may replace PXR as the major 
regulator of CYP3A7 induction in HepG2 cells, presumably initiated by the low basal 
levels of PXR mRNA expression. Therefore the role of CAR in CYP3A7 regulation 
should be investigated. CAR can activate CYP3A through the ER 6  elements of 
CYP3A4 and CYP3A7 (Xie et al., 2000b). However, there may be differences in the 
nuclear receptor binding motifs in the CYP3A7 promoter that make CAR bind with 
higher affinity than PXR. This could be investigated by gel shift and supershift assays 
using the CYP3A7 promoter compared to the CYP3A4 promoter. The CYP3A9 and 
CYP3A18 promoters should also be investigated to identify putative response 
elements and to exam ine the differences observed in CYP3A mRNA expression in 
FaO and H4IIEC3 cells compared to in rat liver.
In addition to the CYP3A promoter driven reporter gene constructs, co-transfection 
with nuclear receptors such as PXR, CAR and RXRp may elucidate the roles of these 
receptors in CYP3A induction. By modulating the levels of these receptors this will 
identify whether one of the receptors is expressed at too low a level in the hepatoma 
cell lines to support the induction usually observed in vivo. This technique may also 
be used to investigate how over-expression of a receptor can dismpt the basal receptor 
ratios. An expansion of this would be to titrate receptor expression in the cell lines, 
thus altering basal ratios; ultimately to m imic the in vivo situation, both in terms of 
absolute and ratio levels of receptors.
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This would be difficult to achieve because during transfection of receptor plasm ids, 
the amount of DNA in the transfection mixture does not correspond to the amount that 
is transferred into the cell due to different transfection efficiencies. An alternate 
strategy would be to target a receptor at a high level such as COUPTFI mRNA in 
HepG2 cells, gradually knocking out expression by addition of increasing 
concentrations of COUPTFI antisense RNA. However in most cases, the receptor 
mRNA levels in hepatoma cells are lower than in their liver counterparts.
The role of COUPTF in CYP3A regulation should be investigated further in the 
different cell lines and in vivo. Xenobiotic treatment appears to influence the direction 
of COUPTF regulation on CYP3A expression. Furthermore it should be investigated 
whether COUPTF heterodimerises with PXR as suggested by Rodrigues et al. (2001) 
or works co-operatively with PXR on the CYP3A promoters. Rodrigues et al. (2001) 
have attempted to investigate this interaction by co-immunoprecipitation but lack of a 
good PXR antibody has prevented elucidation at this time.
The real time PCR studies should be repeated using freshly isolated rat and human 
hepatocytes as substitutes for rat and human liver, to allow comparisons between the 
cell lines and rat and human liver in terms of induction of CYP3A mRNA and relative 
receptor abundance. This will allow further assessment of the comparative usefulness 
of the different model systems.
The regulation of CYP3A is complex and it is likely that it involves more receptors 
and transcription factors than investigated here. Already mentioned in this report are 
U SFl, HNF3P, N Fl, S p l, Sp3, C /EB Pa and Y Y l, all of which have been proposed to 
regulate CYP3A4, CYP3A7, CYP3A23 and CYP3A2 differential expression (Huss et 
al., 1999; Ourlin et al., 1997; Saito et al., 2001).
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AP2 and Spl putative response elements are found in the CYP3A4 promoter 
(personal communication, V. Bombail; Saito et al., 2001). These latter transcription 
factors appear to work in conjunction with one another to bring the promoter and first 
intron in contact with each other, causing the intervening DNA to loop out, which is 
optimal for the binding of the rest of the transcriptional machinery (Carrillo et al., 
1999; Quinn et al., 1995; Vergeer et al., 2000; Yang et al., 1998). AP3, O ctl, E R a  
and ERp should also be considered because of the presence of their putative response 
elements in the CYP3A promoters (Burger et al., 1992; Hashimoto et al., 1993; 
Jounaidi et al., 1994). Therefore the TaqMan® investigation should be expanded to 
include analysis of the expression of these receptors in the hepatoma cell lines, for 
example to see whether HNF3 levels are elevated in HepG2 cells and thus are 
responsible for the increased CYP3A7 mRNA expression (Saito et al., 2001).
Shibata et al. (1997) proposed that activation of gene transcription may depend on the 
relative ratio of coactivators and corepressors. The major receptors exam ined here, 
can interact with a variety of coactivators and corepressors, some of which overlap in 
their interactions with the individual receptors, such as SRC-1, G RIPl, SMRT, SUG l, 
RIP140 and DBF (Masuyama et al., 2001; Moore et al., 2000; Muraoka et al., 1999; 
Ourlin et al. 1997; Pipaôn et al., 1999; Shibata et al., 1997; Sugiyama et al., 2000; 
Synold et al., 2001; Wang et al., 1998). Therefore nuclear receptors will compete to 
interact with them and the balance and availability of these coactivators and 
corepressors within the cellular environment may dictate the CYP3A regulatory 
pathway. The levels of coactivators and corepressors should therefore be measured in 
the hepatoma cell lines in comparison with their liver counterparts, as this may 
identify why, for example rifampicin is a potent inducer of human CYP3A4 activity 
in vivo but is not an inducer of endogenous CYP3A mRNA in HepG2 cells (W illiams 
et al., 1994). The levels of many coactivators and corepressors could be exam ined 
using a gene array or specific ones could be measured by TaqMan® basally and after 
xenobiotic dosing.
The mechanisms of CYP3A regulation are complex. The role of receptors is beginning 
to be clarified but there is much more to be learned, including from the investigations 
proposed above.
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9 Appendices 
9.1 Vector Maps
9.1.1 DCR®2.1-TOPO-vector (Invitrogen)
M13 reverse 
priming siteI îiilïil
i  pCR®2.1-T0P0
3.9 kb
Represents covalently-bound topoisomerase
9.1.2 DSV40-SEAP ICIontechl
MCSA
sv
0  ^ 5^V«
M C S B
pSEAP2-Promotef
Amp' 4.9 kb
SV40
\  OUÇ
GGTACCGAGCTCTTACGCGTGCTAGCCCGGGCTCGAGATCT
SEAP _I
AAGCUm & TCGCGAAmGCCCACCATSCTG
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9.1.3 p CMV-cSPAP
OR .CMV promoter
■SPAP
cDNApCMV-cSPAP5976bp
. / ■
SV40 t-intron & poly(A) sites
9.1.4 CYP3A4-CMV-CSPAP
ORI
Amp'^
p3A4-CMV-cSPAP 
7006 bp
CYP3A4 
(-1087 to -57)
- CMV 
promoter
SPAP cDNA
SV40 t-intron & poly(A) sites
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9.1.5 pSG5-hGR
Amp''
SV40 Promoter
intron
T7
pSG5-hGR 
7300 bp
hGR
cDNA
POLYA
ORI
9.1.6 pSGS-hERg
So il (1)
S V 4 0
E a r l y
p r o m o t e r T 7  ( 1 0 2 2 )
HEG0/pSG5
( S 8 9 5 b p )
GRF C
 Hindl.!.l....tt.9.7.W
 Xb«l (2194)S V 4 0  
Poly A Q l y  ( 8 3 4 0 0 )  ( 2 2 5 8 )
E c o R I  ( 2 8 6 2 )
Bpmtii mm
S a il  (3022)' Bgill (2874)
Donated by Professor P. Chambon, CNRS, INSERM, Université Louis Pasteur
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9.1.7 pSGS-hPXR
hPXR/pSG5
5387 bps
hPXR
•.Cd136H2249S«cl.2249Ba<nHt.236ü
Donated by Dr. S. Kliewer, GlaxoSmithKline, RTP, USA 
9.1.8 pSV L -hR X R a
B»aI (4940)
H ind tll (6324)
hRXRa/ pSVL
(6396 bp)
S«ll (3547)
CUI (3259)
BsmHI (3 0 3 0 )-  
Sacl (3024)
Sm al (3018)
•TAG (2 9 1 6 ) 
«II (29S2)
Xbal (2990) 
m al (2996)
«cl (3002)
e.tQRy....(.rMj
I n d l l l  ( 1 0 4 5 )
l a l  ( 1 4 9 8 )
ATG (1 5 3 0 ) 
Sir.al (1658) 
S a d  (1691)
all (2116)
all (2192) 
DamHI (2230) 
■BamHI (2383) 
flamMI (2497) 
Ball (2508)
Xbal (3012)
Donated by Professor P. Chambon, CNRS, INSERM, Université Louis Pasteur
308
9.2 Method for QIAGEN Endofree Maxiprep
A starter culture containing 5 ml LB (0.1 mg/ml Ampicillin) was innoculated with a 
stab from the plasmid glycerol stock. This was incubated for 16 hours at 37®C with 
vigorous shaking. A  maxiculture containing 250 ml LB (0.1 mg/ml Ampicillin) was 
innoculated w ith 0.5 ml o f  starter culture. This was incubated for 16 hours at 37 ®C 
w ith vigorous shaking. The bacterial cells were harvested by centrifugation at 
6000 X g for 30 min. at 4 °C. The supernatant was discarded and the pellet 
resuspended in 10 ml Buffer P I using a sterile disposable teat pipette. Ten millilitres 
o f  Buffer P2 was added and incubated at room temperature for 5 min. Ten millilitres 
o f chilled Buffer P3 was added to the lysate and poured immediately into the barrel o f 
the QlAfilter Cartridge. The lysate was incubated at room temperature in the cartridge 
for 10 min. The plunger was depressed, filtering the lysate into a 50 ml Beckman 
centrifuge tube. The lysate was mixed with 2.5 ml Buffer ER and incubated on ice for 
45 min. During this time, a QlAGEN-tip 500 was equilibrated by applying 10 ml 
Buffer QBT and allowing the column to empty by gravity flow. The lysate was added 
to the QIAGEN-tip after incubation on ice and allowed to enter the resin by gravity 
flow. The QIAGEN-tip was washed twice with 30 ml Buffer QC. The DNA was 
eluted into a 50 ml Beckman centrifuge tube with 15 ml Buffer QN. The DNA was 
precipitated with 10.5 ml room temperature isopropanol. This was centrifuged at 
15000 X g for 45 min at 4 °C. The supernatant was carefully decanted and the pellet 
was washed with 2.5 ml o f endotoxin-free, room temperature 70 % ethanol. The DNA 
was centrifuged at 15000 x g for 10 min at 4 °C. The pellet was left to air dry and then 
dissolved in 0.5 ml endotoxin-free Buffer TE.
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9.3 Genomic DNA Standards Calculation
9.3.1 Calculation o f the number o f single stranded copies per microlitres
The rat genome is 3 x 10^bp (human genome 3.22 x 10^bp) and the molecular weight 
o f  one base pair is approximately 660 g/1, so the molecular weight o f  the rat genome 
is
3 X  10^x660 = 2 x  10^^g/1
but the rat genome is diploid such that 1 genome = 2 copies, therefore a IM  solution 
o f the rat haploid genome contains 1 x lO^^g/1. (human haploid genome
1.06xl0^^g/I)
1 mole contains 6.02 x 10^  ^molecules according to Avogadro’s number, but DNA 
contains two single strands so each mole o f  the rat haploid genome contains 1.2 x 10^ "^  
single strands. Therefore a 1 M (1 x 10^^ g/1) solution contains 1.2 x 10^ '^  molecules, 
therefore a 1 g/1 or 1 pg/pl solution contains 1.2 x 10^ single stranded copies /pi. 
(1.13x10^^ ss/pl)
9.3.2 Calculation of the stock dilution
The stock needs to be diluted to 2 x  10"^  ss copies /  pi (or 1 x 10^ ss copies /  5 pi), so 5 
pi is used for the PCR reaction.
For example, if  Bioline rat genom ic DNA is supplied at 200 ng/pl = 0.2 pg/pl, then 
there is
0.2 X 1.2 X 10^ =2.4 X 10^ ss copies /  pi.
To get 2 x 10"^  ss copies /  pi, a 1 in 12 dilution would be performed (i.e. 100 pi 
genomic DNA diluted w ith 1100 p i PCR grade water).
9.3.3 Standard dilutions
A serial dilution was performed using the 1 x 10^/5 pi diluted stock o f  rat genomic 
DNA. The dilutions required were 10^, 1 0 \ 1 0 \ 10^ 1 0 \ 10° / 5 p i (i.e. 100 pi DNA 
dilution plus 900 p i PCR grade water). The dilutions were stored in 50 p i aliquots.
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9.7 Summary of RT-PCR Optimisation Experiments
Target Gene Annealing tem perature X Cycle number mRNA type Results
rGRa 55 30 Rat liver No band
60 30 Rat liver No band
55 40 Rat liver No band
60 40 Rat liver No band
50 45 Rat liver No band
62 46 Rat liver No band
55 35 Rat liver No band
50 35 Rat liver No band
60 35 Rat liver No band
65 35 Rat liver No band
55 35 FaO Strong signal
60 35 FaO No band
55 35 Rat liver No band
55 35 H4IIEC3 Strong signal
55 35 H4IIEC3 No band
55 35 H4IIEC3 Feint signal
55 35 Rat liver Strong signal
55 21-35 Rat liver Strong signals
55 21 Rat liver No band
55 21 FaO No band
55 21 H4IIEC3 Feint band
55 21 Rat Liver No band
55 21 FaO No band
55 21 H41IEC3 No band
55 21 Rat Liver Strong signal
55 21 FaO Strong signal
55 21 H4liEC3 Strong signal
rPXR 55 30 Rat liver No band
60 30 Rat liver No band
55 40 Rat liver No band
60 40 Rat liver No band
50 45 Rat liver No band
62 45 Rat liver No band
55 35 Rat liver No band
50 35 Rat liver No band
60 35 Rat liver No band
65 35 Rat liver No band
55 35 FaO Strong signal
60 35 FaO No band
55 35 Rat liver No band
55 35 H4ilEC3 Feint signal
55 35 H4ilEC3 No band
55 35 H4ÜEC3 Feint signal
55 36 Rat liver Strong signal
55 21-35 Rat liver Strong signals
55 21 Rat liver No band
55 21 FaO No band
55 21 H4ilEC3 No band
55 21 Rat Liver Feint signal
55 21 FaO No band
55 21 H4ÜEC3 No band
55 21 Rat Liver Strong signal
55 21 FaO Strong signal
55 21 H4ÜEC3 Strong signal
rCAR 55 30 Rat liver No band
60 30 Rat liver No band
55 40 Rat liver No band
60 40 Rat liver No band
50 45 Rat liver No band
62 45 Rat liver No band
55 35 Rat liver No band
50 35 Rat liver No band
60 35 Rat liver No band
65 35 Rat liver No band
55 35 FaO Strong signal
60 35 FaO Feint signal
55 35 Rat liver No band
55 35 H4IIEC3 No band
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Target Gene Annealing tem perature "C Cycle number mRNA type Results
rCAR 55 35 H4IIEC3 No band
55 35 H4ÎIEC3 No band
55 35 Rat liver Strong signal
65 21-35 Rat liver Strong signal with nonspecific bands
55 25 Rat liver No band
55 25 FaO No band
55 25 H4IIEC3 Nonspecific band
55 25 Rat Liver No band
55 25 FaO No band
55 25 H4IIEC3 No band
55 25 Rat Liver No band
55 25 FaO Strong signal
55 25 H4IIEC3 Strong signal
CYP3A23 55 30 Rat liver Strong signal
60 30 Rat liver Double banded signal
55 40 Rat liver Double banded signal
60 40 Rat liver Double banded signal
50 45 Rat liver Double banded signal
62 45 Rat liver Double banded signal
55 35 Rat liver Feint signal
50 35 Rat liver Feint double banded signal
60 35 Rat liver Feint signal
65 35 Rat liver Feint signal
55 35 FaO Strong signal
60 35 FaO No band
55 35 Rat liver Strong signal
55 35 H4IIEC3 No band
55 35 H4IIEC3 No band
55 35 H4IIEC3 No band
55 35 Rat liver Strong signal with nonspecific bands
55 11-30 Rat liver Strong signals
55 16 Rat liver No band
55 16 FaO Feiint band
55 16 H4IIEC3 No band
55 16 Rat Liver Feint band
55 16 FaO No band
55 16 H4IIEC3 No band
55 16 Rat Liver Strong signal
55 16 FaO No band
55 16 H4IIEC3 No band
rERix 55 30 Rat liver No band
60 30 Rat liver No band
55 40 Rat liver No band
60 40 Rat liver No band
50 45 Rat liver Nonspecific band
62 45 Rat liver Nonspecific band
55 35 Rat liver No band
SO 35 Rat liver No band
60 35 Rat Liver No band
65 35 Rat Liver No band
55 35 FaO No band
60 35 FaO No band
55 35 Rat liver No band
55 35 H41IEC3 No band
55 35 H4IIEC3 No band
55 35 H411EC3 No band
55 35 Rat Liver Non specific band
55 35 FaO No band
55 35 H4IIEC3 No band
55 35 Rat liver Feint signal with nonspecific bands
55 35 Rat liver Feint signal with strong nonspecific bands
55 40 Rat liver Feint signal with strong nonspecific bands
57 35 Rat liver Feint signal with strong nonspecific bands
57 21-35 Rat liver No bands
57 35 Rat Liver No band
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Target Gene Annealing tem perature "G Cycle number mRNA type Results
rERp 55 30 Rat liver No band
60 30 Rat liver No band
55 40 Rat liver No band
60 40 Rat liver No hand
50 45 Rat liver No band
62 45 Rat liver No band
55 35 Rat liver No band
50 35 Rat liver No band
60 35 Rat Liver No band
65 35 Rat Liver No band
55 35 FaO Strong signal with nonspecific bands
60 35 FaO No band
55 35 Rat liver No band
55 35 H4IIÊC3 Feint signal
55 35 H4liEC3 No band
55 35 H41IEC3 No band
55 35 Rat Liver No band
55 35 FaO No band
55 35 H4liEC3 No band
55 35 Rat liver No Band
57 35 Rat liver Feint signal
57 21-35 Rat liver No bands
57 35 Rat liver No band
rHNF4a 55 30 Rat liver No band
60 30 Rat liver No band
55 40 Rat liver No band
60 40 Rat liver No band
50 45 Rat liver No band
62 45 Rat liver No band
55 35 Rat liver No band
50 35 Rat liver No band
60 35 Rat liver No band
65 35 Rat liver No band
55 35 FaO Strong signal with nonspecific bands
60 35 FaO Feint signal
55 35 Rat liver No band
55 35 H4iiEC3 No band
55 35 H4iiEC3 No band
55 35 H4iiEC3 No band
55 35 Rat liver Feint signal
55 21-35 Rat liver Strong signal with nonspecific bands
55 22 Rat liver No band
55 22 FaO No band
55 22 H4iiEC3 No band
55 22 Rat Liver No band
55 22 FaO No band
55 22 H4iiEC3 No band
55 22 Rat Liver Strong signal
55 22 FaO No band
55 22 H4liEC3 No band
rHNF4y 55 30 Rat liver No band
60 30 Rat liver No band
55 40 Rat liver No band
60 40 Rat liver No band
50 45 Rat liver Non specific band
62 45 Rat liver No band
55 35 Rat liver No band
50 35 Rat liver No band
60 35 Rat liver No band
65 35 Rat liver No band
55 35 FaO No band
60 35 FaO No band
55 35 Rat liver No band
55 35 H4IIEC3 No band
55 35 H4IIEC3 No band
55 35 H4IIEC3 No band
55 35 Rat liver No band
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Target Gene Annealing tem perature "C Cycle number mRNA type Results
rat hR X R a" ' 55 30 Rat liver No band
60 30 Rat liver No band
55 40 Rat liver No band
60 40 Rat liver No band
50 45 Rat liver No band
62 45 Rat liver No band
55 35 Rat liver No band
50 35 Rat liver No band
60 35 Rat liver No band
65 35 Rat liver No band
rRXRa^" 58 45 Rat liver Strong signal
58 26-44 Rat liver Strong signals
28 26 Rat liver No band
28 26 FaO Strong signal
28 26 H41IEC3 Strong signal
rRXRa'" 55 30 Rat liver Strong sugnal
rR^Rp 55 30 Rat liver Strong signal
rRXRy 55 30 Rat liver Strong signal
rAlbumln 55 35 Rat liver Strong signal
50 35 Rat liver Strong signal
60 35 Rat liver Strong signal
65 35 Rat liver Strong signal
55 35 FaO Strong signal
60 35 FaO No band
55 35 Rat liver Strong signal
55 36 H4IIEC3 Strong signal
55 35 hH4ilEC3 Feint signal
55 35 Rat liver Strong signal
55 10-17 Rat liver Strong signals
55 35 FaO No band
55 35 H4IIEC3 Strong signal
55 35 Rat liver Strong signal
57 35 Rat liver Strong signal
55 13 Rat liver No band
55 13 FaO No band
55 13 H4IIEC3 No band
55 13 Rat liver Strong signal
55 13 H4IIEC3 No band
55 13 FaO No band
55 13 Rat liver Strong signal
55 13 H4IIEC3 No band
55 13 FaO No band
rActIn 55 20 Rat liver No band
55 20 FaO No band
55 20 H4I1EC3 No band
55 20 Rat liver Strong signal
55 20 H4I1EC3 Strong signal
55 20 FaO Strong signal
55 20 Rat liver Strong signal
55 20 H4IIEC3 Strong signal
55 20 FaO Strong signal
55 20 Rat liver Feint signal
55 20 FaO Strong signal
55 20 H4IIEC3 Strong signal
rOAPDH 58 45 Rat liver No band
52 45 Rat liver Strong signal
52 22-40 Rat Liver Strong signal with nonspecific bands
52 26 Rat liver Strong signal
52 26 FaO Strong signal
52 26 H4IIE03 Strong signal
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Target Gene Annealing tem perature "C Cycle number mRNA type Results
hCAR 55 35 Human liver No band
55 35 HepG2 No band
60 35 HepG2 No band
50 40 HepG2 No band
55 40 HepG2 No band
60 40 HepG2 No band
62 40 HepG2 No band
55 40 Human liver No band
60 40 Human liver No band
50 40 Human liver No band
62 45 Human liver No band
50 45 Human liver No band
50 45 HepG2 No band
55 45 Human liver No band
55 45 HepG2 No band
55 35 Human liver No band
55 35 HepG2 No band
58 45 Human liver No band
hCAR 58 45 HepG2 No band
60 45 Human liver No band
82 45 Human liver No band
hCAR'" 58 45 HepG2 Strong double band
52 45 HepG2 Strong double band
60 40 Human liver Strong double band
55 40 Human liver Strong double band
58 22-40 HepG2 Strong double bands
58 28 HepG2 Strong double bands
58 28 Human liver Strong double bands
hRXRa 55 35 Human liver No band
55 35 HepG2 No band
60 35 HepG2 No band
50 40 HepG2 Nonspecific signals
55 40 HepG2 Nonspecific signals
60 40 HepG2 No band
62 40 HepG2 No band
hRXRa*" 55 40 HepG2 Strong signal
55 40-22 HepG2 No bands
50 45 Human liver Strong signal
50 45 HepG2 No band
58 45 HepG2 Strong signal with feint nonspecifc bands
58 45 20-40 Strong signals
58 28 HepG2 Strong signal
58 28 Human liver Strong signal
hERa 55 35 Human liver No band
55 35 HepG2 No band
60 35 HepG2 No band
50 40 HepG2 No band
55 40 HepG2 No band
60 40 HepG2 Feint signal
60 21-38 HepG2 No bands
60 45 HepG2 No band
55 40 Human liver No band
60 40 Human liver No band
50 40 Human liver No band
62 45 Human liver No band
50 45 Human liver No band
50 45 HepG2 No band
55 45 Human liver No band
55 45 HepG2 No band
65 35 Human liver No band
55 35 HepG2 No band
58 45 Human liver No band
58 45 HepG2 No band
60 45 Human liver No band
62 45 Human liver No band
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Target Gene Annealing tem perature '‘C Cycle number mRNA type Results
hERa**'* 58 45 HepG2 Feint signal with strong nonspecific bands
60 40 HepG2 Nonspecific signals
55 40 HepG2 Nonspecific signals
52 40 HepG2 No bands
62 40 Human liver No bands
62 40 HepG2 No bands
62 40 Human liver No bands
hERp 55 35 Human liver No band
65 35 HepG2 No band
60 35 HepG2 No band
60 40 HepG2 No band
65 40 HepG2 Strong signal
65 18.36 HopG2 No bands
65 45 HepG2 No band
hERp 55 28-48 HepG2 Strong signals
65 30 HepG2 No band
65 30 Human liver No band
hHNF4a 65 35 Human liver No band
65 35 HepG2 No band
60 40 HepG2 Feint signal
65 40 HepG2 Strong signal
65 18-36 HepG2 Feint signals
65 24 HepG2 No band
55 24 Human liver No band
hHNF4y 65 35 Human liver Nonspecific band
55 35 HepG2 No band
60 40 HepG2 No band
55 40 HepG2 No band
60 40 HepG2 No band
62 40 HepG2 No band
hAlbumin 65 35 Human liver Strong signal
65 35 HepG2 Strong signal
60 35 HepG2 Strong signal
65 40 HepG2 Strong signal
60 40 HepG2 Strong signal
62 40 HepG2 . Strong signal
65 8-26 HepG2 No bands
65 45 HepG2 Strong signal
68 45 HepG2 Strong signal
68 12-32 HepG2 Strong signal
68 20 HepG2 Strong signal
58 20 Human liver Strong signal
hu rActln 65 35 HepG2 No band
hActIn 68 45 HepG2 Strong signal
62 45 HepG2 Strong signal
68 22-40 HepG2 Strong signals
68 20 HepG2 Strong signal
58 20 Human liver Strong signal
hGAPDH 65 40 HepG2 Strong signal
55 36-18 HepG2 Strong signal
65 24 HepG2 Strong signal
55 24 Human liver Strong signal
hPXR 55 40 HepG2 Strong signal
55 22-40 HepG2 Strong signals
65 30 HepG2 Strong signal
65 30 Human liver Strong signal
hCYP3A 55 40 HepG2 No band
60 40 HepG2 Strong signal
60 22-40 HepG2 No bands
50 45 Human Liver Strongsignal
50 45 HepG2 No band
58 45 HepG2 Strong signal
58 22-44 HepG2 No bands
68 22-44 HepG2 Feint signals
68 24-42 HepG2 Strong signals
58 24 HepG2 Strong signal
58 24 Human liver Strong signal
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Target Gene Annealing tem perature Cycle number mRNA type Results
hGRa 65 40 HepG2 Feint signal
60 40 HepG2 No band
50 40 HepG2 No band
62 45 Human liver No band
50 45 Human liver Nonspecific signals
50 45 HepG2 No band
55 45 Human liver No band
55 45 HepG2 No band
55 35 Human liver No band
55 35 HepG2 No band
58 45 Human liver Nonspecific signals
58 45 HepG2 No band
58 45 HepG2 Strong signal with nonspecific bands
58 20-40 HepG2 Strong signals
58 24 HepG2 Strong signal
58 24 Human liver Strong signal
hSRC-1 55 40 HepG2 No band
60 40 HepG2 Feint signal
62 45 Human liver Feint signal
60 46-28 HepG2 No bands
50 45 Human liver Feint signal
50 45 HepG2 Strong signal
58 45 HepG2 Strong signal
58 20-40 HepG2 Strong signals
58 28 HepG2 Strong signal
58 28 Human liver Strong signal
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9.8 Semi-quantitative RT-PCR Data
Raw  data  for the ra t sem i-quan titative R T-PC R  s
R X R a was amplified separately and normalised to actin from the third experiment, so 
the grey cells in the table indicate where experiments were not performed. Blank cells 
indicate where a signal was not detected. The note o f smlpk  indicates a small peak was 
measured by densitometry but was less than the detection limit for RT-PCR.
mRNA type PXR CAR HlsJF4a CYP3A23 M R S Albumin Actin
Rat Liver 3503 2119 2459 3073 591
H4IIEC3 2321 1935 1099 10069
FaO 3826 
1174
6511
79Q
1998 2065 1930 7551
H4IIEC3 1309 1202 888 562 3476
FaO 1328 2602 485 722 2357
Rat Liver 1691 1880 1941 Sm! pk 1596 3381 3895
H4IIEC3 3203 3645 2182 Sml pk 1012 13599 12753
FaO 4209 6519 1931 961 7911 1316 11099
Raw  da ta  for the hum an sem i-quan titative RT-PCR*s
Blank cells indicate where a signal was not detected.
mRNA ty p e (5Ra PXR CAR HFlP4a"' CYP3A RX Ra SRC-I GAPDH A lbum in Actin
Human Liver 79 157 185 141 130 88 121 80
HepG2 172 83 89 64 107 123 235 76 105
Human Liver 159 129 50 197 73 215 54 59
HepG2 44 74 103 70 91 179 242 51 153
Human Liver 86 101 72 83 82 90 145 50
HepG2 81 69 74 68 70 180 73 78
O 'r
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